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Abstract   V
ABSTRACT 
 
Among the large family of terpenoid natural products, sesterterpenoids form a small subclass. 
Nevertheless, due to the diversity of cyclization modes and oxidation processes in biosynthesis, a 
broad range of unique structures has been isolated within the last 50 years. Not surprisingly, these 
structurally intriguing frameworks have captured the attention of synthetic chemists, resulting is 
several elegant approaches (Chapter 1). One small family of sesterterpenoids represented by 
astellatol (I), YW 3548 (II), and retigeranic acid B (III, Scheme A) comprises a trans-hydrindane 
portion that is substituted with an angular methyl group and an iso-propyl residue. Although the 
daunting carbon backbones of the 15 members of this subclass and their interesting biological 
properties render these natural products attractive targets for total synthesis, only few reports have 
been reported in the literature. In total, only four successful total syntheses of retigeranic acid A, the 
C-18 epimer of retigeranic acid B (III), and six approaches toward this family of sesterterpenoids have 
been published. 
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Scheme A Divergent synthesis of three building blocks suitable for trans-hydrindane iso-propyl sesterterpenoids. 
 
In the course of this Ph.D. thesis, we envisioned accessing the structurally unique architectures of 
trans-hydrindane iso-propyl sesterterpenoids in order to evaluate their biological properties, gain 
insight into their biogenesis and confirm their relative and absolute configuration. Moreover, we 
aimed to access a total of eight natural products by a divergent approach utilizing the two versatile 
building blocks IV and VI. Chapter 2 describes our successful efforts in developing a practical and 
scalable route to the trans-hydrindanes IV and VI, starting from enantiopure diketone V. In these 
investigations, the focus was laid on the diastereoselective installation of the sterically congested 
trans-hydrindane portion. Moreover, we disclose the surprising outcome of a seemingly straight-
forward hydrogenation. This result culminated in an efficient synthesis of a third versatile building 
block VII, which was an important intermediate in Corey’s and Hudlicky’s total syntheses of 
retigeranic acid A. 
 
VI  Abstract 
 
Scheme B Retrosynthetic analysis of astellatol (I): key intermediates and model system X. 
 
In chapter 3, our current progress toward the total synthesis of the unique pentacarbocyclic backbone 
of astellatol (I) is described. We envisaged constructing this unique pentacarbocyclic architecture I by 
a biomimetic cationic cascade from tricycle VIII (Scheme B). The first part of this chapter details our 
strategy for installing the C-9 and C-10 stereogenic centers in alkene IX starting from building 
block IV. In addition, we also report our progress toward the synthesis of the strained 11-membered 
ring following three different routes, carried out on a model system X. Ultimately, preliminary results 
of a strategy to prepare the carbon framework of astellatol (I) via a [2+2]-cycloaddition are presented. 
 
 
Scheme C Retrosynthetic analysis of 18-epi-nitiol (XI).  
 
Chapter 4 features the synthetic program directed toward a synthesis of nitiol and its C-18 epimer XI. 
We envisaged accessing tricycle XI via a dienyne metathesis, the precursor of which should be 
merged from two building blocks XII and XIII by a Myers alkylation (Scheme C). This chapter 
describes a successful preparation of western portion XII and our progress toward the eastern 
fragment XIII, starting from trans-hydrindane building block VII. 
 
 
Scheme D Progress toward YW 3548 (II): efficient enantioselective synthesis of enol triflate XXI. 
 
Finally, chapter 5 outlines our progress en route to the potent GPI anchor inhibitor YW 3548 (II). 
Thereby, an asymmetric synthesis of a suitable western fragment enol triflate XIV was focused on, 
starting from simple building blocks XV, XVI and XVII (Scheme D). In addition, the ability of enol 
triflate XIV to engage in Pd-catalyzed cross coupling reactions is disclosed. 
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1 INTRODUCTION 
 
1.1 Terpenoids: Biosynthetic Origin and Inspiration for Chemists 
 
With over 35.000 members,[1] terpenoids* constitute the largest class of natural products and their 
physical and biological properties have been exploited by mankind throughout history. In the modern 
world, these small molecules have found a variety of applications ranging from odors for perfumery 
and cosmetic products to therapeutic agents.[2] While low-molecular weight molecules like 
citronellol (2) or menthol (3) are utilized in industry as fragrances,[3] several terpenoid natural products 
are used for the treatment of human diseases,[4] exemplified by the antimalarial compound 
artemisinin (4)[5] and the anticancer drug paclitaxel (5, Figure 1.1).[6] 
 
 
Figure 1.1 Molecular structures of isoprene (1), terpenoid odorants and terpenoid therapeutics for treating human diseases. 
 
Not surprisingly, the importance of these natural products has evoked a myriad of studies to gain 
insight into their biosynthesis, biological properties and function in Nature.[7] Early examples of these 
investigations were described in the pioneering works of Wallach[8] and Ruzicka,[9] who formulated 
the ‘isoprene rule’ stating that all terpenoids arise from a varying number of a fundamental C5 building 
block, isoprene (1). Upon further investigations propelled by the impressive contributions of Bloch[10] 
and Lynen,[11] it was established that isoprene (1) itself is not involved in the biogenesis of terpenoids. 
Instead, Nature employs two activated forms of isoprene (1) as key building blocks, namely 
isopentenyl pyrophosphate (IPP, 13) and dimethylallyl pyrophosphate (DMAPP, 14). Both 
compounds 13 and 14 in turn arise from two different pathways.[12] In the mevalonate pathway,[13] 
mevalonic acid (MVA, 11) is the key intermediate for the production of IPP (13) and DMAPP (14). In 
the process, a Claisen condensation of the enolate of acetyl-SCoA (6) with an enzyme-bound acetyl 
group (7) initially forms diketone 8 (Scheme 1.1) that in turn undergoes a stereospecific aldol reaction 
of the enolate derived from an enzyme-bound acetyl group (7). After hydrolysis of the attached 
enzyme, the thioester functionality of the thus generated acid 3-hydroxy-3-methylglutaryl-CoA (9) 
gets reduced to an aldehyde in mevaldic acid (10) by NADPH.  
                                                 
*  According to IUPAC, the term ‘terpenes’ comprises all pure hydrocarbons in this class of natural products, whereas 
‘terpenoids’ refers to further functionalized molecules, which are e.g. oxygenated. However, both terms are often used as 
synonyms. In this Ph.D. thesis only the term terpenoid(s) will be employed. 
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Scheme 1.1 Formation of IPP (13) and DMAPP (14) via the mevalonate pathway. 
 
Another NADPH mediated reduction leads to the formation of MVA (11), which is then transformed 
into IPP (13) commencing with the sequential phosphorylation of the primary alcohol to generate 
pyrophosphate 12. In the following enzyme mediated transformation, an adenosine triphosphate (ATP) 
assisted decarboxylation/elimination reaction ultimately furnishes IPP (13) that is transformed into 
DMAPP (14) by IPP isomerase via a stereospecific allylic isomerisation reaction removing the pro-R 
proton.  
The second, non-mevalonate pathway, also known as methylerythritol phosphate (MEP) pathway, 
involves intermediates from the glycolytic biosynthesis.[14] Reaction of pyruvic acid (15) with thiamin 
pyrophosphate (TPP) provides enamine 16 with loss of CO2. Subsequently, the latter intermediate 16 
nucleophilically attacks glyceraldehyde 3-phosphate (17) leading to the deoxy-xylulose 
derivative 18 (Scheme 1.2). 
 
 
Scheme 1.2 Biosynthetic formation of IPP (13) and DMAPP (14) via the MEP pathway.  
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This β-hydroxy ketone 18 undergoes a retro-aldol/aldol cascade in the presence of a reductoisomerase 
to form aldehyde 19, which is reduced to MEP (20) by NADPH in the same sequence. In the following 
transformations, the C-1 alcohol of the C5 compound 20 reacts with cytidine triphosphate (CTP) to 
form cytidine diphosphate (CDP) derivative 21. After phosphorylation of the tertiary alcohol, the 
resulting intermediate 22 produces cyclic phosphate 23 via an intramolecular hydrolysis that 
concomitantly releases cytidine monophosphate (CMP). Whereas these steps are well understood, the 
following processes still require investigations to clarify the mechanisms. However, it has been shown 
that the cyclic phosphate 23 is enzymatically transformed to primary alcohol 24, which is converted 
into both IPP (13) and DMAPP (14) by reductive processes, with a 5:1 to 4:1 preference for 
IPP (13).[12] 
 
Scheme 1.3 (a) Biosynthetic formation of geranyl pyrophosphate (27), the biosynthetic origin for all monoterpenoids. 
(b) Molecular structures of the mono- and bicarbocyclic monoterpenoids. 
 
In the course of the biogenesis of complex molecules, DMAPP (14) forms allylic cation 25, which is 
nucleophilically attacked by IPP (13, Scheme 1.3).[12] Subsequent stereospecific loss of the pro-R 
proton from the intermediate tertiary carbocation 26 generates geranyl pyrophosphate (27). This C10 
building block 27 is the basis of the formation of monoterpenoids via cationic cascades in the presence 
of terpenecyclases and subsequent oxidations, forming e.g. monocarbocyclic compounds like 
limonene (28) and carvone (29) or bicycles like camphor (30) and α-pinene (31).[15] 
 
 
Scheme 1.4 Biosynthetic production of farnesyl pyrophosphate (32), geranylgeranyl pyrophosphate (33) and geranylfarnesyl 
pyrophosphate (34), the precursors for sesquiterpenoids, diterpenoids and sesterterpenoids, respectively. 
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Following the same mechanism, another C5 chain elongation of geranyl pyrophosphate (27) with 
IPP (13) produces farnesyl pyrophosphate (32), while two elongations give rise to geranylgeranyl 
pyrophosphate (33, Scheme 1.4). Analogously to the biosynthesis of monoterpenoids, these two 
building blocks provide the basis of the generation of sesquiterpenoids and diterpenoids,[16] 
respectively. A fourth chain elongation with IPP (13) results in the formation of the C25 building block 
geranylfarnesyl pyrophosphate (34) that is the biosynthetic precursor for all members of the 
sesterterpenoid subclass (cf. Chapter 1.2). 
In contrast to the previously discussed C10−C25 terpenoids, the precursor for triterpenoids is not formed 
via an IPP (13) homologation, but by a complex dimerization process of two molecules of farnesyl 
pyrophosphate (32) leading to squalene (35, Scheme 1.5).[12] Further transformations, e.g. a selective 
epoxidation to 2,3-oxidosqualene (not shown), then set the stage for cationic epoxide opening 
cascades, resulting in the formation of penta- and tetracarbocyclic triterpenoids such as lanosterol (36). 
The latter compound 36 and other structurally related triterpenoids serve as precursors for steroids, i.e. 
cholesterol (39), through biosynthetic degradation under the loss of carbon atoms. Thus, from a more 
general perspective, steroids are classified as nor-triterpenoids. 
 
 
Scheme 1.5 Molecular structures of squalene (35) and (Z)-phytoene (37): biosynthetic precursors for tri- and tetraterpenoids 
like lanosterol (36), cholesterol (39) and β-carotene (38). 
 
Analogously to triterpenoids, tetraterpenoids are usually generated from C2 symmetric compounds like 
(Z)-phytoene (37), which in turn are formed through dimerization processes from geranylgeranyl 
pyrophosphate (34). The structural diversity of this subclass of terpenoids is mainly limited to the 
carotenoids[17] such as β-carotene (38) that play an important role in photosynthesis and in the vision 
process, and show anti-oxidant properties. Apart from these ‘classical’ subgroups, higher terpenoids 
and meroterpenoids are produced in Nature.[12] While the first subclass is rather rare, meroterpenoids 
are abundant and comprise, in addition to terpenoidal parts, structural elements in the carbon skeleton, 
which are derived from other sources, e.g. the acetate or the shikimate pathways.  
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From a synthetic point of view, the structural diversity of terpenoids, exhibiting a plethora of unique 
and intriguing architectures, combined with their broad range of biological activities has attracted 
synthetic chemists since the inception of organic chemistry.[18] Whereas a major goal of these efforts 
was certainly the production of substantial amounts of material for the evaluation of biological and/or 
therapeutic properties due to the small quantities being isolated, these programs have expanded the 
knowledge of chemical synthesis in the broadest sense. This is based on the fact that the pursued 
avenues often went hand in hand with the discovery of unknown reactivity (e.g. the Wagner-Meerwein 
rearrangement),[19] the development of new synthetic methodologies, their application in complex 
settings and mechanistic studies. In addition, important chemical principles such as retrosynthetic[20] 
and conformational[21] analysis were applied in early studies toward terpenoids.  
 
Figure 1.2 Molecular structures of selected bioactive terpenoids, recently accessed by total synthesis. 
 
Historically, the total synthesis of terpenoids dates back to the early 1900’s, at which time Komppa 
succeeded in the first industrial preparation of camphor (30).[22] In the further evolution of synthesis, 
the bioactivity of steroids and their application as drugs initiated extensive explorations towards an 
artificial production, accompanied by the discovery and application of synthetic transformations. For 
instance, these investigations involved an early example of a Diels-Alder reaction in a total synthesis 
by Woodward[23] and pioneering reports on (enantioselective) organocatalysis in the synthesis of 
Wieland-Miescher-ketone[24] and the Eder-Sauer-Wiechert-Hajos-Parrish ketone (cf. Chapter 2).[25] 
With the advent of modern analytical methods and a continuously expanding repertoire of synthetic 
tools, terpenoids of increasingly complexity were accessed over the last decades,[26] exemplified by the 
total syntheses of maoecrystal V (40, Yang, 2010),[27] yuanhuapin analog 41 (Wender, 2011),[28] and 
solanoeclepin A (42, Tanino, 2011).[29] Whereas the molecules depicted in Figure 1.2 are formed via 
diterpenoid or triterpenoid pathways, the subclass of sesterterpenoids with its C25 backbone also 
provides a high diversity of unique structures and determined biological profiles, rendering them 
attractive targets for total synthesis. Further information on this beautiful class of natural products will 
be provided in the next subchapter, thereby focusing on synthetic strategies and interesting key steps 
en route to complex molecules. 
 
8  THEORETICAL SECTION 
1.2 Sesterterpenoids: Challenging Targets for Total Synthesis 
 
Among the terpenoid family, sesterterpenoids form a small subclass with 965 isolated members[30a] 
that have been isolated from a variety of organisms, including fungi, lichens, plants, and marine 
sources such as sponges.[30−33] Their name is derived from the Latin word sester, meaning ‘two and a 
half’, which was also incorporated into sestertius, an ancient Roman coin. Sester is thus referring to 
the old nomenclature that terpenoids are assembled from C10 units. As discussed, the biosynthetic 
origin is based on IPP (13) and DMAPP (14) which generate the pentaprenyl C25 building block 
farnesylgeranyl pyrophosphate (34).[12] Subsequent cyclization via cationic intermediates, hydride- and 
methyl-shifts, late-stage oxidations and eventually loss of carbon atoms lead to a variety of structural 
architectures. This process will be discussed for the biosynthesis of astellatol (103, Chapter 3.1) in 
detail. Due to the broad range of structural features, a further classification into linear, mono-, di-, tri-, 
tetra- and pentacarbocyclic sesterterpenoids is common. In addition, three major subclasses have been 
found within the diversity of carbon backbones that were named as ophiobolins, cheilantanes and 
scalaranes, respectively (Figure 1.3). 
 
 
Figure 1.3 (a) Carbon scaffolds of the sesterterpenoid families named ophiobolins, cheilanthanes and scalaranes. 
(b) Molecular and X-ray structure of (+)-ophiobolin A (43, hydrogen atoms omitted for clarity). 
 
One member of the ophiobolins called (+)-ophiobolin A (43) was the first sesterterpenoid to be 
isolated in 1958 as a toxic agent to rice seedlings[34] and its structure was deduced from NMR studies 
and a X-ray structure analysis of a bromo-methoxy derivative (not shown).[35] Quite recently, the X-
ray structure of the ‘free’ (+)-ophiobolin A (43) was reported too.[36] In the following decades, more 
than 20 members of the tricarbocyclic ophiobolin family have been isolated, most of them exhibiting 
biological activities as inhibitors against fungi and bacteria as well as cytotoxins against cancer 
cells.[37] Another subclass of tricarbocyclic sesterterpenoids, the cheilanthanes, comprises about 
50 members that have been mostly isolated during the 1990’s from marine sources. Their occurrence, 
their broad range of biological activities and successful syntheses have been reviewed recently.[38] A 
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structurally related sesterterpenoid subclass is called the scalaranes. In contrast to the cheilathanes, 
these natural products bear an additional ring and thus contain a tetracarbocyclic carbon backbone. 
Similarly however, most scalarane compounds have been found in marine sources like sponges and 
reveal a promising spectrum of potential applications due to observed anti-feedant properties or strong 
cytotoxicity.[39] 
Despite the beautiful and often intriguing architectures of sesterterpenoids, the number of total 
syntheses remains in the dozens, many of those accessing cheilanthanes and scalaranes by semi-
synthetic approaches (cf. Scheme 1.14).[40] In the following text, a few examples of successfully 
prepared sesterterpenoids will be given, focusing on key steps to access complex molecules. This 
summary will be ordered by the numbering of carbocycles, while total syntheses of and approaches 
toward trans-hydrindane iso-propyl sesterterpenoid will be discussed in Chapter 1.3 in more detail. 
In 2009, the monocarbocyclic sesterterpenoid (−)-alotaketal (47)[41] was found to be a potent activator 
of the cAMP cell signaling, which is essential for a diverse range of cellular processes. Thus, new 
modulators such as (−)-alotaketal (47) or its derivatives might be used in treating heart failure, cancer, 
and neurodegenerative diseases.[42] In 2012, Yang and co-workers disclosed the first enantioselective 
route to (−)-alotaketal (47) (Scheme 1.6).[43] 
  
 
Scheme 1.6 Yang’s enantioselective synthesis of the cAMP signaling agonist (−)-alotaketal (47) via a SmI2 mediated 
intramolecular Barbier-type ketalization. 
 
Their strategy hinged on a SmI2-mediated coupling between two fragments 44 and 45, whereby the 
former compound 44 was accessed ex-chiral pool starting from (R)-carvone (29). Contrarily, the sole 
stereogenic center within allyl iodide 45 originated from a Nagao-Fujita aldol reaction, which is based 
on an Evans-type auxiliary. With both fragments in hand, the envisaged coupling efficiently delivered 
intermediate 46 as mixture of hemiacetal epimers. This key compound was then transformed to 
(−)-alotaketal (47) via desilylation, spiroketalization, oxidation and PMB deprotection. Later that year, 
the group of Dalby reported a second synthesis of (−)-alotaketal (47).[44] Their strategy was based on 
the same disconnection and similar building blocks, but preparing the fragment analogous to 
bicycle 44 by an alternative route. Both reports paved the way for further evaluation of biological 
properties of (−)-alotaketal A (47) and for the preparation of synthetic congeners. 
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In contrast to (−)-alotaketal A (47), the sesterterpenoid (−)-dysidiolide (53, Scheme 1.7) exhibits an 
additional carbocycle and this bicarbocyclic sesterterpenoid 53 has been a popular target at the turn of 
the millennium.[45] On the one hand, this was due to the fact that its octahydronaphthaline structure 
comprises two quaternary stereocenters and a bicyclic system, the large substituents of which 
interestingly adopt sterically disfavored pseudo-axial positions as proven by X-ray crystallography. On 
the other hand, (−)-dysidiolide (53) has been shown to inhibit growth of A-549 human lung carcinoma 
and P388 leukemia cell lines, thus making it a potential anti-cancer agent.[46] The resulting synthetic 
endeavors culminated in numerous approaches and successful total syntheses.[40] The key step of the 
routes of Corey[47] and Danishefsky[48] are presented in Scheme 1.7. 
 
Scheme 1.7 (a) Corey’s divergent enantioselective route to (−)-dysidiolide (53) featuring a bioinspired 1,2-Me shift. 
(b) Danishefsky’s convergent racemic synthesis of dysidiolide (53) demonstrating the power of the Diels-Alder reaction. 
 
In his enantioselective synthesis, Corey utilized a bioinspired key step to install the quaternary 
stereogenic center at C-15.[47] To this end, bicycle 49 was prepared in a lengthy sequence, starting 
from Wieland-Miescher ketone analog 48. Noteworthy, they introduced the correct relative 
configuration at C-6 via an enone reduction under Birch conditions with subsequent trapping of the 
formed enolate with allyl bromide. The intermediate 49 was then treated with gaseous BF3, resulting in 
the formation of a tertiary carbocation and triggering a 1,2-methyl shift (not shown). The newly 
generated tertiary carbocation, stabilized by a β-silyl effect underwent an ensuing regioselective 
elimination to afford intermediate 52. With the cyclic framework installed, (−)-dysidiolide (53) was 
finally prepared by a series of standard transformation, including a Rose-Bengal mediated oxidation of 
a furan to the butenolide moiety. Contrarily to this linear approach, Danishefsky and co-workers 
envisaged a more convergent, yet racemic synthesis.[48] Thereby, they impressively demonstrated the 
synthetic power of the Diels-Alder reaction to install quaternary stereogenic centers.[49] At first, the 
team quickly built up two reaction partners, dienophile 51 and diene 50, the quaternary center of 
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which was installed by an alkylation. Upon exposure to TMSOTf at low temperatures, the reaction 
partners smoothly underwent a Gassmann Diels-Alder reaction, furnishing the bicarbocyclic system 54 
after acetal cleavage with all stereogenic centers set. This compound was then easily transformed to 
the desired target 53. 
At around the same time, several research groups embarked on the total synthesis of another 
bicarbocyclic sesterterpenoid named (−)-terpestacin (56), an inhibitor of the formation of multinuclear 
cell bodies, which are part of the pathology of an HIV infection.[50] In contrast to both previously 
discussed natural products, almost all 25 carbon atoms are embedded in the two carbocycles, one of 
which is 15-membered. Attracted by those features, six research groups reported successful 
approaches toward terpestacin (56) and four key intermediates with the respective strategic 
disconnections on closing the 15-membered ring and installing the quaternary stereogenic center at 
C-1 are depicted in Scheme 1.8.  
The first asymmetric synthesis of (−)-terpestacin (56) has been accomplished by the group of Tatsuta 
in 1998.[51] In their strategy, they utilized the conformational bias of a tricyclic system, directing an 
allylation with a farnesly derived allylic chloride to install the requisite relative configuration at C-1 
(not shown). Further transformations set the stage for the key intramolecular HWE reaction, which 
formed macrocycle 55. Additional functional group manipulations finally gave rise to 
(−)-terpestacin (56). 
 
 
Scheme 1.8 Intermediates in the total syntheses of terpestacin (56) by the groups of Matsuda, Myers, Jamison and Trost, 
including comparison of key C−C bond forming reactions. 
 
In 2002, the group of Myers at Harvard University reported a more concise synthesis of 
(−)-terpestacin (56)[52] that was based on three diastereoselective allylation reactions. Initially, the 
group diastereoselectively prepared a cyclopentanone moiety via an alkylation protocol developed in 
the same laboratories (not shown). The conformational bias of the cyclic system then allowed for both 
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the stereocontrolled installation of the C-1 stereocenter as well as ring-closure in the presence of 
Masamune’s base LiN(SiMe2Ph)2 to form bicycle 57 in an efficient manner. 
Similarly, in 2003 the group of Jamison constructed the macrocycle of (−)-terpestacin (56) via an 
allylation, but setting the quaternary stereogenic center in terpestacin (56) last.[53] Previously they had 
chosen to prepare the precursor 58 by a Ni-catalyzed intramolecular coupling of an alkyne and a 
farnesyl derived aldehyde. In the following, an allylation closed the 15-membered ring and ketone 58 
underwent a regio- and diastereoselective methylation with NaH to generate the requisite 
configuration at C-1. Interestingly, this transformation only occurred in the presence of H2O, which 
prompted the authors to attribute this in situ effect to the production of finely dispersed NaOH. 
Yet another possibility to close the 15-membered macrocycle was presented by Trost and co-workers 
in 2007.[54] At first, a sequence consisting of a Pd-catalyzed asymmetric alkylation and a subsequent 
Claisen rearrangement installed the stereogenic quaternary center at C-1 (not shown). Thereafter, a 
series of transformation gave rise to a pentaene, setting the stage for the envisaged key step: a ring-
closing metathesis (RCM). In the event, subjection of the substrate to Grubbs 2nd generation 
metathesis catalyst closed the macrocycle 59 in moderate yield, but high (E)-selectivity. Further 
reaction conditions, including another AAA/Claisen sequence then furnished (−)-terpestacin (56). 
Since this report, the groups of Tius[55] and Qui[56] also disclosed a racemic and an enantioselective 
total synthesis, in 2007 and 2012 respectively. Similarly to the approach of Matsuda, both groups 
constructed the macrocycle via an intramolecular HWE reaction, whereas the C-1 quaternary 
stereogenic center was installed by enolate allylation chemistry (not shown). 
From 2010 on, a new family of sesterterpenoids called leucosceptroids has been isolated from the 
small tree Leucosceptrum canum, representing a rare example of sesterterpenoids from higher plant 
origin.[57] The 15 members of this subclass, represented by (+)-leucosceptroid B (64), have been found 
to possess anti-feedant and anti-fungal properties, prompting the authors to name this family ‘harbor 
defense sesterterpenoids’. 
 
 
Scheme 1.9 Liu’s asymmetric total synthesis of (+)-leucosceptroid B (64) via a Michael addition/aldol sequence and a 
tandem Lewis acid mediated deprotection/dihydrofuran formation. 
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Already one year later, in 2011, Horne and co-workers published a Diels-Alder approach to furnish the 
tricyclic skeleton of the leucosceptroids (not shown),[58] and in 2013, the group of Liu succeeded in the 
first enantioselective synthesis of (+)-leucosceptroid B (64, Scheme 1.9).[59] Utilizing a seven-step 
sequence consisting of a Michael addition, ozonolysis, aldol condensation and diastereoselective 
hydrogenation, they quickly built up bicyclic lactone 60, which was further elaborated to enyne 61 by 
standard transformations. Thereafter, the authors beautifully orchestrated two consecutive key steps to 
construct the tricarbocyclic backbone. First, a Michael-addition/aldol sequence with a methyl cuprate 
derived from MeMgBr and CuCN preferentially gave rise to (Z)-configured alkene (62, d.r. = 3.6:1). 
This was followed by a MOM deprotection in the presence of BF3·Et2O with concomitant formation of 
the dihydrofuran moiety and desilylation, furnishing tricycle 63. Finally, a nine-step sequence afforded 
(+)-leucosceptroid B (64). It is worth noting that the authors installed the stereochemistry at C-11 in 
the last step via epimerization leading to an approximately 1:1 mixture of (+)-leucosceptroid B (64) 
and its β-epimer (not shown). 
 
 
Scheme 1.10 Boeckman’s racemic synthesis of gascardic acid (68) featuring a highly diastereoselective Claisen 
rearrangement to install the second adjacent quaternary stereocenter.  
 
Around 30 years earlier, in 1979, the group of Boeckman published the first synthesis of a structurally 
complex sesterterpenoid[60] named gascardic acid (68). This tricarbocyclic compound 68 had been 
isolated already in 1960[61a] and despite further careful investigations,[61b] the relative stereochemistry 
was not clarified. Boeckman et al. commenced their synthesis with cyclopentenone 65, which was 
transformed to vinyl allyl ether 66 (obtained as a mixture of diastereomers at C-18), featuring a three-
component coupling (cuprate addition, enolate Michael addition, aldol condensation) as the key 
element (Scheme 1.10). Subjecting this compound 66 to elevated temperatures triggered a Claisen 
rearrangement to diastereoselectively set the quaternary stereoecenter in aldehyde 67. This example 
impressively demonstrated the power of intramolecular sigmatropic reactions to install stereocenters in 
sterically encumbered settings.[62] Further transformations including the separation of the 
diastereomers at C-18 provided Boeckman et al. with gascardic acid (68), which could now be 
assigned based on comparison of NMR spectroscopic data.[60a,63] 
As pointed out earlier, the family of the ophiobolins constitutes a larger subfamily of sesterterpenoid 
natural products. Not surprisingly, several research groups were attracted by their structural and 
biological profiles and these studies culminated in numerous publications.[64] As most of this work was 
carried out in the pre-metathesis era, the ophiobolins and related terpenoids provided an inspiration to 
study the synthesis of eight-membered rings.[65,66] Despite the enormous synthetic efforts undertaken, 
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only the groups of Kishi in 1989[67] and Nakada in 2011[68] succeeded in total syntheses of 
(+)-ophiobolin C (74)[69] and (+)-ophiobolin A (43),[35] respectively. 
 
 
Scheme 1.11 Kishi’s enantioselective route to (+)-ophiobolin C (74) constructing the central eight-membered ring via a 
Nozaki-Hiyama-Kishi reaction. 
 
As depicted in Scheme 1.11, Kishi addressed the problem of establishing the central eight-membered 
ring by a Nozaki-Hiyama-Kishi (NHK) reaction, a CrCl2 and NiCl2 mediated coupling between an 
aldehyde and a vinyl iodide.[67] Starting from camphor derivative 69, they therefore prepared 
aldehyde 70, which in turn was reacted with vinyl lithium 71. After reinstallation of the pivaloate, the 
resulting alcohol 72 was successfully carried on to the desired [5-8-5]-tricarbocyclic ring system found 
in allylic alcohol 73, constructing the allylic C−C bond via the aforementioned methodology. 
Ultimately, standard functional group interconversion provided access to (+)-ophiobolin C (74). 
 
 
Scheme 1.12 Nakada’s enantioselective synthesis of (+)-ophiobolin A (43) closing the central eight-membered ring by a 
ring-closing metathesis reaction. 
 
In contrast to Kishi’s synthesis, the group of Nakada exploited a more recent synthetic tool in 
constructing the eight-membered ring of (+)-ophiobolin A (43), namely a RCM reaction.[68] In order to 
prepare a feasible precursor, they converted acid 75 in a 16-step sequence to hemiacetal 76, which 
underwent an intramolecular Sakurai type allylation to effectively form the two adjacent stereocenters 
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in spiro compound 77 (Scheme 1.12). This intermediate 77 was further elaborated to diene 78 over a 
series of transformations, involving several protecting group manipulations as the RCM reaction 
proved to be sensitive to the steric environment at the reacting sites.[68b] Subjecting diene 78 to the 2nd 
generation Hoveyda-Grubbs catalyst (HGII) in refluxing toluene closed the macrocycle in diol 79, and 
an additional six-step protocol provided, at long last, (+)-ophiobolin A (43), more than 50 years after 
its isolation. 
The structurally related natural products (+)-ceroplastol I (86),[70] (+)-ceroplastol II (90)[71] and albolic 
acid (91)[72] have also been accessed by the groups of Boeckman,[73] Paquette[74] and Kato.[75] 
Analogously to the ophiobolins, the central feature of these total syntheses was the construction of the 
eight-membered ring (Scheme 1.13). The synthesis of Boeckman and co-workers commenced with 
racemic bicycle 80, which was further functionalized to ketone 81 bearing the requisite relative 
stereochemistry for a key Grob fragmentation.[73] As envisaged, subjection of tricycle 81 to NaOMe in 
refluxing MeOH triggered the formation of the eight-membered ring in diester 82 and subsequent 
manipulations afforded ceroplastol I (86).  
 
Me
H
H
H
OH
H
Me
(+)-ceroplastol I (86)O
Me O
O
H
O
H
84
H
MeO
O
O
Me
O
O
O
CHO H
H
Me
Me
H
OO
OPiv
H H
Me
Me
H
OPiv
HO OHTiCl4
Zn H
H
Me
Me
R
H
( )-ceroplastol II (90)
( )-albolic acid (91)
R = CH2OH
R = COOH
O O
O
H H
Me
H
H
H
COOMe
COOMeNaOMe
MeOH,
H Me
Me
H
O
OMs
COOMe
c) Kato (1988)
1) Tebbe
2) 200 °C
3) K2CO3
MeOH
80
b) Paquette (1993)
a) Boeckman (1989)
81 82
8583
87 88 89
17 steps
5 steps
14 steps
10 steps
prepared in
9 steps
22 steps 10 steps
 
Scheme 1.13 Successful approaches toward the ceroplastins: (a) Boeckman’s racemic synthesis of ceroplastol I (86). 
(b) Paquette’s asymmetric synthesis of (+)-ceroplastol I (86). (c) Kato’s enantioselective synthesis of (+)-ceroplastol II (90) 
and (+)-albolic acid (91). 
 
In an alternative line of investigations, Paquette’s group utilized a Claisen rearrangement to conduct a 
ring-expansion en route to the eight-membered ring.[74] To this end, they elaborated the enantiopure 
Eder-Sauer-Wiechert-Hajos-Parrish analog 83 to lactone 84, the carbonyl functionality of which was 
methylenated by treatment with Tebbe’s reagent. The resulting allyl vinyl ether rearranged at elevated 
temperatures and a following epimerization furnished the essential trans-ring junction in ketone 85. 
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Ultimately, further transformations including a 1,3-carbonyl transposition and a Michael 
addition/annulation protocol afforded the optically active natural product (+)-ceroplastol I (86).  
Another methodology to construct the [5-8-5]-tricarbocyclic architecture of the ceroplastins was 
presented by Kato and co-workers, which culminated in total syntheses of (+)-ceroplastol II (90) and 
(+)-albolic acid (91).[75] In the course of their synthetic studies, Kato et al. synthesized enantiopure 
enal 87 via an optical resolution. It should be noted that the authors employed the other enantiomer in 
the preparation of intermediate 88, thus making the resolution process not wasteful. In the ensuing key 
step, bisaldehyde 88 was exposed to a lower valent Ti species (prepared in situ from TiCl4 and Zn) 
resulting in a pinacol coupling and closing the eight-membered ring. With the carbon backbone in 
hand, the remaining protocol produced both sesterterpenoids via a diversification in the last step: 
saponification of an ethyl ester with NaOH gave rise to (+)-albolic acid (91), whereas reduction with 
LiAlH4 furnished (+)-ceroplastol II (90). 
 
 
Scheme 1.14 Molecular structures of the scalarane sesterterpenoids (−)-sesterstatin 4 (92) and (+)-scalarolide (94), both being 
semi-synthetically prepared starting from (−)-sclareol (93) in the 2010’s. 
 
The last subclass concerning the synthesis of sesterterpenoids being discussed in this section are the 
tetracarbocyclic members. Whereas such compounds in general are rare, one big family are the 
scalaranes (vide supra). Showing interesting biological properties, several of these members including 
(−)-sesterstatin 4 (92)[76] and (+)-scalarolide (94)[77] have been synthesized over the last years, often 
via a semi-synthetic route starting from the inexpensive chiral building bock (−)-sclareol (93, 
Scheme 1.14).[78,79]  
 
Scheme 1.15 Paquette’s asymmetric route to (−)-cerorubenic acid-III methyl ester (100) featuring an anionic oxy-Cope 
rearrangement and a free-radical cyclization to construct the tetracarbocyclic core. 
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In contrast to the scalaranes, cerorubenic acid-III methyl ester (100),[80] another tetracarbocyclic 
sesterterpenoid addressed by the group of Paquette, consists of an unique [8.4.1.0.0]pentadecane 
skeleton. After extensive efforts spanning over one decade,[81] the group finally disclosed the 
successful preparation of this daunting structure in 1998.[82] In these studies, they took advantage of 
two key steps: an anionic oxy-Cope rearrangement and a diastereoselective free-radical cyclization. 
Starting from enone 95, Paquette and co-workers prepared allylic alcohol 96 in several steps, three 
being an optical resolution and thus rendering their approach enantioselective (Scheme 1.15). In the 
following, the aforementioned anionic oxy-Cope rearrangement took place when heating diene 96 
with KHMDS in THF to reflux. The resulting ketone 97 already contained the bridgehead double bond 
and the cyclopropyl moiety found within the natural product 100. Notably, these moieties stayed intact 
throughout the whole synthesis, which eventually provided homo allylic iodide 98. This precursor for 
the second key step was then subjected to reductive radical conditions (Bu3SnH, AIBN), resulting in a 
6-exo-trig-cyclization to give tetracycle 99 with a good diastereoselectivity (d.r. = 4.9:1) at the side 
chain’s stereogenic center. With all stereogenic centers correctly set and the carbon backbone 
installed, simple chain elongation finally provided (−)-cerorubenic acid III methyl ester (100), 
constituting its first and sole preparation.[82] 
The total syntheses discussed in this chapter showcase how sesterterpenoid natural products have 
inspired organic chemists. Based on structurally unique architectures, a broad array of chemical tools, 
ranging from classical rearrangements to modern transition metal catalysis, has been employed to 
access the target molecules and provide the foundation for biological evaluation and derivatization.[40] 
Whereas this chapter detailed the properties of sesterterpenoids in general and gave a brief overview 
on synthetic progress toward this group of natural products, the next chapter will focus on a specific 
subclass, possessing a trans-hydrindane iso-propyl moiety.  
 
 
1.3 trans-Hydrindane iso-Propyl Sesterterpenoids: Introduction to the 
Subclass and Previous Synthetic Efforts 
 
Within the class of sesterterpenoids,[30] a limited number of compounds has been isolated that 
comprise a trans-hydrindane moiety with an angular methyl group. Moreover, these natural products 
feature an iso-propyl or an isopropenyl group at C-3 (IUPAC numbering), a substituent which either 
resides in a trans-relationship to the angular methyl group or in a cis-fashion (Figure 1.4). 
Additionally, differences have been found concerning the skeletal order, namely the connectivity to 
further carbon atoms on the six-membered ring. Whilst the trans-hydrindane portion in type B is fused 
at the C-4 and C-5 (IUPAC numbering) position often generating a third carbocycle, the carbon 
backbone of type A is connected to further carbon atoms at C-5 and C-6. 
  
18  THEORETICAL SECTION 
 
Figure 1.4 Classification of the carbon skeleton of trans-hydrindane iso-propyl sesterterpenoids into type A and type B, 
depending on their connectivity at the six-membered ring. 
 
In the following text, the 15 known members of this subclass will be introduced. It should be noted 
that some members are drawn as their unnatural enantiomers to facilitate comparison with the 
enantiomeric series in which the synthetic work of these Ph.D. studies was carried out (cf. 
Chapters 2−5). Furthermore, if no sign (dextrorotary or levorotary) of the optical rotation is given, the 
absolute configuration of the natural product has not been assigned to the best of our knowledge.  
The oldest member of the trans-hydrindane iso-propyl sesterterpenoids is named (−)-retigeranic 
acid A (101), which was isolated for the first time in 1965 and bears a triquinane motif in addition to 
the trans-hydrindane portion (Figure 1.5, depicted as its unnatural isomer).[83] It took seven years until, 
in 1972, its structure was finally elucidated[84] and in 1974 confirmed by X-ray crystallography as its 
p-bromophenyl amide derivative (Figure 1.5b).[85] During efforts to synthesize this intriguing structure, 
it was found by HPLC analysis that the crystallized structure refers only to the minor component of 
the isolated material.  
 
 
Figure 1.5 (a) Molecular structures of the type A trans-hydrindane iso-propyl sesterterpenoids (+)-retigeranic acid A (101), 
(+)-retigeranic acid B (102) and astellatol (103). (b) X-ray structures of the p-bromophenyl amide derivative of retigeranic 
acid A (101) and the dimer of retigeranic acid B (102, hydrogen atoms omitted for clarity).  
 
The obtained spectroscopic data suggested the major compound being epimeric to (−)-retigeranic 
acid A (101) and the synthetic endeavors by the groups of Corey,[86] Paquette,[87] Wender[88] and 
Hudlicky[89] (vide infra) excluded some potential diastereomers.[90,91] Subsequent X-ray analysis 
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unraveled the structure of (−)-retigeranic acid B (102) as the α-epimer at the iso-propyl 
residue (Figure 1.5a, depicted as its unnatural enantiomer).[92] In addition, it is noteworthy that 
retigeranic acid A (101) is unique amongst type A trans-hydrindane iso-propyl sesterterpenoids, as it 
is the only member featuring a trans-relationship between the iso-propyl residue and the angular 
methyl group in the hydrindane portion. Similarly to the retigeranic acids, the unparalleled 
pentacarbocyclic structure of astellatol (103), established by extensive NMR studies in the late 1980’s, 
exhibits only one oxygenated site, namely an alcohol functionality at the five-membered ring of the 
trans-hydrindane portion (Figure 1.5a).[93] As astellatol (103) has been one major target within our 
synthetic efforts, its isolation and structural features as well as the proposed biosynthesis will be 
detailed in Chapter 3.1.  
 
 
Figure 1.6 Molecular structures of type B trans-hydrindane iso-propyl sesterterpenoids (+)-variecolin (104), 
(−)-variecolol (105), (−)-variecolactone (106), (−)-variecoacetal A (107) and (−)-variecoacetal B (108) and X-ray structure of 
(+)-variecolin (104, hydrogen atoms omitted for clarity). 
 
Contrarily to astellatol’s (103) type A skeleton, the natural product (−)-variecolin (104, depicted as its 
unnatural enantiomer), isolated in 1991 from aspergillus variecolor, is a type B trans-hydrindane 
iso-propyl sesterterpenoid and (−)-variecolin (104) has been evaluated as an angiotensin II receptor 
binding inhibitor (Figure 1.6).[94,95] Its isolation has been accompanied by the congeners 
(−)-variecolol (105),[96] (−)-variecolactone (106),[96] (−)-variecoacetal A (107)[97] and 
(−)-variecoacetal B (108),[97] all possessing immunsuppresive activities and stemming from the same 
cyclization mode as (−)-variecolin (104), but from different oxidations mechanisms in biosynthesis. 
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Figure 1.7 Molecular structures of the type A trans-hydrindane iso-propyl sesterterpenoids variculanol (109) and 
nitiol (110), lacking the C5−C6 bond formation (IUPAC numbering for hydrindanes) during biosynthesis. 
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In 1991, the Merck laboratories in Basel isolated a different type of carbon backbone from the same 
cultures of apergillus variecolor and named the compound based after its origin (−)-variculanol (109, 
Figure 1.7).[98] However, this sesterterpenoid differed from the rest of the variecolin family in two 
aspects. Firstly, its skeleton rather resembles a type A trans-hydrindane iso-propyl sesterterpenoid, 
and, secondly, the six-membered ring of the trans-hydrindane has not been closed during biogenesis of 
variculanol (109) and thus no trans-hydrindane portion is present. Due to the structural similarity 
however, we still classify variculanol (109) as a type A trans-hydrindane iso-propyl sesterterpenoid. 
The only other member within this whole subclass lacking such a C−C bond formation is the 
tricarbocyclic compound nitiol (110), which has been isolated by the group of Kawahara in 1999.[99] 
Further details on this natural product 110 will be provided in Chapter 4.1. 
 
Figure 1.8 (a) Molecular and X-ray structure (hydrogen atoms omitted for clarity) of nitidasin (111). (b) Molecular structures 
of the GPI anchor inhibitors YW 3548 (112) and YW 3699 (113). 
 
Already two years before, in 1997, Kawahara and co-workers had identified another trans-hydrindane 
iso-propyl sesterterpenoid, nitidasin (111), and verified its structure by NMR studies and X-ray 
crystallography (Figure 1.8a).[100] Although nitidasin (111) was isolated from plants used in Peruvian 
folk medicine (‘Hercampuri’), the authors did not evaluate its biological activities. At around the same 
time, Wang and co-workers reported the intriguing structure of YW 3548 (112, Figure 1.8b). In the 
course of these studies, the authors elucidated the relative configuration of the tetracyclic backbone, 
while the relative stereochemistry at the heptanoate side chain could not be assigned.[101] Yang et al. 
additionally investigated the biological properties and found that YW 3548 (112) is a selective 
inhibitor of GPI anchoring biosynthesis in mammalian cells. These properties have also been 
evaluated for YW 3699 (113).[102] Further discussion on the biological background combined with a 
structural analysis can be found in Chapter 5.1.  
In the last decade, the structures of two more sesterterpenoids with the trans-hydrindane iso-propyl 
motif have been disclosed, one being the tricarbocyclic compound alborosin (114), which has been 
isolated by Kawahara and co-workers from gentinella alborosin in 2000 (Figure 1.9).[103] Although the 
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relative configuration of four stereogenic centers could not be assigned based on 2D NMR studies, it is 
reasonable to suggest that alborosin (114) is a degradation product of nitidasin (111) by an oxidative 
cleavage, and thus the missing stereoinformation might match those of the tetracarbocyclic natural 
product 111. 
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Figure 1.9 Molecular structure of the sesterterpenoids alborosin (114) and (+)-asperterpenoid A (115) and the X-ray structure 
of asperterpenoid A (co-crystallized with MeOH, hydrogen atoms omitted for clarity). 
 
Very recently, in February 2013, She et al. discovered a new type B skeleton while establishing the 
pentacarbocyclic structure of asperterpenoid A (115) by NMR techniques and X-ray 
crystallography (Figure 1.9).[104] The backbone of asperterpenoid A (115), isolated from aspergillus 
sp. 16-5c, is closely related to the one found in variecolin (104), comprising a [7.1.0]cyclooctane 
moiety instead of a regular cyclooctene ring and a different oxidation pattern. In addition to its 
daunting structural features, the authors determined a strong inhibitory activity against mycobacterium 
tuberculosis protein tyrosine phosphatase B. This enzyme facilitates host infections and thus inhibitors 
as asperterpenoid A (115) might emerge as potential drugs for the treatment of pulmonary 
tuberculosis. 
From a chemist’s perspective, the above presented natural products represent highly attractive targets 
for synthetic programs due to their structurally intriguing ring systems and their associated biological 
properties. Although most isolations date back more than one decade, a literature survey surprisingly 
revealed that only retigeranic acid A (101) has been successfully accessed by total synthesis. In 
addition, very few approaches toward the variecolin family, nitiol (110) and YW 3699 (113) have 
been described over the years.[40]  
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Scheme 1.16 The challenge in installing a trans-hydrindane moiety exemplified on reductions of the diketone 116 and its 
monoketal derivative 119. 
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The small number of endeavors might be explained by three major challenges associated with 
trans-hydrindane iso-propyl sesterterpenoids. On the one hand, it is a well-known problem to install a 
trans-ring junction in a hydrindane portion.[105] This is due to thermodynamic reasons, which usually 
favor the less strained cis-ring junction, exemplified by the hydrogenation of the Hajos-Parrish-Eder-
Sauer-Wiechert ketone (116, Scheme 1.16). Based on simple steric factors, one would assume that the 
angular methyl group shields the top face of the bicycle and thus directs the hydrogenation to occur 
from the bottom face to yield trans-fused ring system 118. However, only the cis-isomer 117 is 
formed under standard hydrogenation conditions.[106] Under classical thermodynamic conditions e.g. 
dissolving metal reduction, the same results were obtained when employing ketal protected 
derivative 119 to form exclusively cis-isomer 120.[106] The second problem, in particular related to the 
type A trans-hydrindane iso-propyl sesterterpenoids, is the sterically encumbered situation at the five-
membered ring, resulting in disfavored steric interactions between the angular methyl group and the 
iso-propyl substituent. If one solves these two problems, the last remaining hurdle is the appropriate 
construction of the fully substituted ring systems with several stereogenic centers and challenging 
oxidation patterns. Some groups have surmounted these challenges and their findings will be presented 
in the following text ordered by the time of appearance in the literature.[40] 
In 1985, the group of Corey at Harvard University succeeded in the first total synthesis of a trans-
hydrindane iso-propyl sesterterpenoid, namely retigeranic acid A (101, Scheme 1.17).[86] The approach 
initiated with the preparation of the trans-hydrindane portion starting from racemic melonal (121), 
which underwent a Robinson annulation with MVK (122) providing a cyclohexenone (not shown). 
 
 
Scheme 1.17 Corey’s racemic synthesis of retigeranic acid A (101) installing the trans-hydrindane iso-propyl portion by a 
Lewis acid-mediated conjugate addition of an electron-rich alkene and a substrate-directed hydrogenation. 
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Upon exposure to Et2AlCl, the Lewis acid triggered a Prins-type cyclization followed by two 
stereospecific 1,2-hydride shifts to generate indenone 123 that comprised the correct trans-relationship 
between the angular methyl group and the iso-propyl moiety. The next task to be solved was the 
installation of the trans-ring junction. As pointed out earlier, a direct hydrogenation of the double 
bond would rather produce the undesired cis-isomer (not shown). Thus, Corey and co-workers 
resorted to a substrate directed hydrogenation employing cationic Rh-catalyst 125.[86b] In order to 
execute this transformation, the ketone functionality within enone 123 was stereoselectively reduced 
and a subsequent Mitsunobu inversion/saponification protocol furnished the requisite alcohol 124, 
setting the stage for the envisaged hydrogenation. The desired transformation took place in the 
presence of catalyst 125 and elevated pressure of H2 (66 bar) to furnish trans-hydrindane 126. 
Thereafter, a series of transformations, including a Diels-Alder reaction to diastereoselectively install 
the C-2 and C-3 stereogenic centers, provided acid 127. Sequential treatment of intermediate 127 with 
(COCl)2 and Et3N generated an alkene-ketene intermediate, which cleanly underwent an 
intermolecular [2+2]-cycloaddition to install the third quaternary stereogenic center at C-10 in 
cyclobutanone 128. A ring expansion of the four-membered ring via a thio-pinacol rearrangement 
then yielded cyclopentanone 129, the α-methyl group of which was epimerized to the desired relative 
configuration. After a chemoselective hydrogenation of the less substituted double bond and 
deoxygenation of the carbonyl moiety, dihydroxylation of the remaining alkene was followed by 
Criegee-oxidation with Pb(OAc)4, aldol condensation in the presence of Al2O3 and Pinnick oxidation 
to finally furnish retigeranic acid A (101). 
At around the same time, Paquette and co-workers embarked on an enantioselective synthesis of 
(−)-retigeranic acid A (101) and they published their convergent approach in 1987.[87] The triquinane 
portion present in retigeranic acid A (101) was prepared starting from (+)-pulegone (130), which was 
transformed to diquinane 131 in a multistep sequence, including a Favorskii rearrangement to induce a 
ring contraction (Scheme 1.18). This was followed by a diastereoselective cuprate addition/aldol 
reaction protocol, and the thus installed alcohol was dehydrated via a Chugaev elimination generating 
the alkene in triquinane 132. After further functional group manipulations (Wolff-Kishner reduction, 
allylic oxidation), the group accessed enone 133, having a Michael-acceptor for the envisioned 
fragment union.[87c] For the preparation of the second building block, Paquette et al. once more turned 
to the chiral pool, starting from (−)-limonene (28), which was elaborated to allylic alcohol 134 
following a known protocol. An ensuing Wittig-Still rearrangement installed a cis-relationship 
between the angular methyl group and the iso-propyl substituent in alkene 135. Since the relative 
configuration of retigeranic acid B (102) was unknown at that time, Paquette unmasked the ketone 
functionality by ozonolysis and erased the stereoinformation at the iso-propyl moiety while installing a 
double bond that facilitated an allylic oxidation, giving rise to enone 136. Next, the authors prepared 
alkyl bromide 137 via a diastereoselective Michael addition with vinyl cuprate, Wolff-Kishner 
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reduction with concomitant silyl ether cleavage and subsequent bromination, only being effective 
under Mitsunobu-type reaction conditions. 
  
 
Scheme 1.18 Paquette’s enantioselective ex-chiral pool synthesis of (−)-retigeranic acid A (101) featuring a late-stage aldol-
condensation to install the trans-hydrindane moiety. 
 
The intermediate 137 incorporated the correct stereochemistry of all stereogenic centers at the five-
membered ring of the trans-hydrindane moiety and underwent exclusive 1,4-addition to the sterically 
congested enone 133 upon generation of the corresponding Grignard species. However, a drawback of 
this convergent approach was the poor selectivity observed in this step, providing the desired 
product 138 as the minor diastereomer (d.r. = 1:3) after ozonolysis. Unfortunately, the subsequent 
installation of the trans-hydrindane moiety by an intramolecular aldol condensation did not add to the 
overall efficiency of the synthesis as it required forcing conditions (piperidine, HOAc, 100 °C, not 
shown) and resulted in an epimerization at C-15, providing the trans-ring junction as minor 
diastereomer (d.r. = 1:4). This result once more emphasized the challenges associated with the 
preparation of trans-hydrindanes. At last, a five-step sequence gave rise to (−)-retigeranic 
acid A (101), constituting its first enantioselective synthesis. 
Only one year later, in 1988, the group of Hudlicky published a very elegant convergent and 
enantioselective route toward (−)-retigeranic acid A (101).[88] They converted (+)-menthene (139) to 
triene 140 in several steps, which then underwent an intramolecular inverse electron demand Diels-
Alder reaction (Scheme 1.19). After enol ether cleavage and Krapcho decarboxylation, trans-
hydrindanone 141 was obtained that has already been an intermediate in Corey’s synthesis, albeit in 
racemic form.[86] Thereafter, a straight-forward homologation/dibromination/monodebromination 
sequence furnished vinyl bromide 142, the corresponding vinylogous enolate of which underwent a 
clean fragment coupling with diquinane 131 prepared in analogy to Paquette’s approach.[87]  
 
1 Introduction  25 
 
Scheme 1.19 Hudlicky’s convergent synthesis of (−)-retigeranic acid A (101) installing the trans-hydrindane iso-propyl 
moiety via an intramolecular Diels-Alder reaction. 
 
With the resulting intermediate 143 in hand, the stage was set for the key step of their synthesis: a 
vinylcyclopropane rearrangement. Thus, subjecting intermediate 143 to flash vacuum pyrolysis 
conditions (FVP, 585 °C, 10−6 mm Hg) triggered the desired rearrangement and formed the 
pentacarbocyclic compound 144 in high yield and moderate diastereoselectivity (4:1 to 2:1 depending 
on the isomer used). With all stereogenic centers set and the complete carbon skeleton in place, 
Hudlicky et al. readily accessed (−)-retigeranic acid A (101) by sequential reduction, Barton-
McCombie deoxygenation and saponification in a longest linear sequence of 19 steps. 
In 1990, Wender and co-workers at Stanford University described another approach to (−)-retigeranic 
acid A (101),[89] taking advantage of a photochemical arene-alkene meta cycloaddition. For this 
purpose, six steps were required to convert compound 145 (prepared enantioselectively by enzymatic 
resolution) to alkene 146 (Scheme 1.20). The envisaged photoreaction proceeded efficiently to furnish 
the desired tetracycle 147, albeit as the minor isomer (1:2). However, it should be noted that this 
transformation rapidly built up structural complexity and the unwanted isomer could be recycled, thus 
raising the overall yield and providing grams of material.  
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Scheme 1.20 Wender’s enantioselective synthesis of (−)-retigeranic acid A (101) via a photochemical arene-alkene 
cycloaddition and a late-stage intramolecular Diels-Alder reaction to generate the trans-hydrindane portion. 
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Exposure of intermediate 147 to an acyl radical prepared photochemically from formamide (148) 
resulted in opening of the cyclopropane moiety and the installation of a triquinane system with 
appropriate functional groups, leading to alkene 149 after N-methylation. A three-step sequence 
including an allylic oxidation gave rise to a triene (not shown), which underwent a thermal Diels-
Alder reaction (250 °C, 22 h). This protocol installed the trans-hydrindane portion as the major 
isomer 150 along with two isomers (8.6:3:1, cis-hydrindane, one double bond regioisomer with cis-
hydrindane formed) in a moderate overall yield of 64%. As direct double-bond isomerization attempts 
remained unfruitful, Wender’s group had to utilize an indirect methodology to install a diene 
moiety (not shown), which was subsequently hydrogenated under high pressure to yield amide 151. 
Unfortunately, this transformation remained unselective despite enormous efforts and provided the 
desired diastereomer in a poor yield of 25%, thus being detrimental for the overall efficiency of the 
synthesis. Ultimately, a stepwise adjustment of the oxidation state furnished (−)-retigeranic acid (101), 
constituting its fourth and thus far last preparation. Since then, no reports on progress toward the 
retigeranic acids have been published. In addition, Wender’s synthesis constituted the last successful 
total synthesis of any member of the trans-hydrindane iso-propyl sesterterpenoids. However, some 
synthetic studies toward this subclass of sesterterpenoids appeared in literature and these synthetic 
strategies will be detailed in the following. 
 
 
Scheme 1.21 Pier’s racemic synthesis of 5-deoxyvariecolol (160) and 5-deoxyvariecolactone (161) via sequential ring 
annulation protocols, a late-stage C−H activation and an interesting epimerization to install the trans-hydrindane portion. 
 
In 1997, Piers and co-workers reported their synthetic efforts toward a racemic synthesis of 
variecolin (104)[107] and more advanced studies were provided by the Ph.D. thesis of S. D. Walker in 
2002. This work was also carried in the Piers laboratories and resulted in the preparation of 
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5-deoxyvariecolol (160) and 5-deoxyvariecolactone (161, Scheme 1.21).[108] Utilizing a cuprate 
addition/aldol condensation annulation protocol, they prepared bicycle (152) that in turn was exposed 
to an isopropylene cuprate in the presence of TMSCl, diastereoselectively affording 
cis-hydrindane 153 in high yield. Interestingly, a NaOMe promoted epimerization provided the 
corresponding trans-fused bicycle in good selectivity (d.r. = 11:1, not shown), which was further 
elaborated to vinyl stannane 154 by a sequential double alkylation, installing a second quaternary 
stereogenic center. In the following, iododestannylation gave rise to a vinyl iodide that upon exposure 
to n-BuLi underwent a ring closure under Barbier conditions to yield tricycle 155. A subsequent 
Dauben oxidation set the stage for a Birch SET reduction, favoring the requisite trans-junction within 
ketone 156 in moderate selectivity (d.r. = 2.2:1). Unfortunately, several steps were required to effect a 
1,2-oxygen transposition, an oxidative ring-expansion and an unsaturation to prepare the eight-
membered ring within enone 157, providing the substrate for a final annulation to yield tetracycle 158. 
All tasks remaining were to complete the preparation of the variecolin family’s common carbon 
skeleton by a one-carbon homologation and an ensuing adjustment of oxidation states. To this end, 
ketone 158 was converted to the corresponding enol triflate (not shown), which cleanly allowed for a 
Pd-catalyzed methoxy-carbonylation. Following reduction and a chemo- and diastereoselective 
hydrogenation of the exomethylene group in the presence of Pt/Al2O3, the group accessed allylic 
alcohol 159. The authors utilized this functional handle to effect a Pb(OAc)4 mediated C−H activation, 
resulting in the formation of 5-deoxyvariecolol (160) that was further oxidized to 
5-deoxyvariecolactone (161). Unluckily, material constraints prevented further investigations on the 
C-5 oxidation to access the corresponding natural products within Walker’s Ph.D. thesis, and no 
additional progress by the group of Piers has been published since then. 
At around the same time, in 2001, the laboratories of Molander disclosed an alternative approach 
toward the tetracyclic architecture of the variecolin family.[109] Initially, Molander and co-workers 
developed a route to the central eight-membered ring, hinging on a SmI2 promoted intramolecular 
cyclization of a primary chloride to a lactone. The group demonstrated the feasibility of the envisaged 
key step by subjecting chloride 162 to SmI2 and NiCl2 under photochemical reaction conditions and 
isolating tetracycle 163, hemiacetal moiety of which might be further elaborated (Scheme 1.22). In 
light of the obtained results, the authors were poised to explore this chemistry on a real system. To this 
end, they prepared enantiopure lactone 165 in a lengthy sequence, starting from commercially 
available racemic anhydride 164 and benefiting from an enzyme catalyzed desymmetrization. 
However, the following conversion to coupling partner 166 has not yet been accomplished. The 
synthesis of the second coupling partner commenced from enantiopure diketone 116, which was 
transformed into enone 167, being the substrate for the installation of the crucial trans-hydrindane 
pattern. In the event, exposure of bicycle 167 to NaBH4 in the presence of NiCl2 allowed for the 
preparation of the desired trans-ring junction, furnishing tricycle 168 in a modest yield of 52% after 
hydrogenolysis of the benzyl ether and concomitant ketal formation. 
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Scheme 1.22 Molander’s progress toward an enantioselective synthesis of (+)-variecolin (104): (a) Demonstration of the 
envisaged key step in a model system. (b) Prepared intermediate 165 en route to the alkyl iodide fragment 166. 
(c) Asymmetric preparation of trans-hydrindane 172 installing the trans-junction by a NiCl2-mediated reduction. 
 
Thereafter, protecting group- and redox-manipulations delivered the α,β-unsaturated ketone 169, 
which in turn was exposed to isopropenyl cuprate. This protocol gave rise to a single diastereomer 170 
that exhibits a cis-relationship between the angular methyl group and the newly installed substituent. 
After a Wolff-Kishner reduction, the undesired outcome of this reaction was easily corrected by an 
ozonolysis/epimerization/Wittig olefination sequence furnishing the thermodynamically more stable 
β-isomer 171. Finally, Molander et al. completed the synthesis of the second coupling partner 172 by 
two more steps, namely a Pd-catalyzed cleavage of the acetal and an ensuing Appel reaction to install 
the alkyl chloride. Although the authors refer to further investigations in their outlook, no reports 
toward a synthesis of alkyl iodide 166 and results on the fragment coupling have been published to 
date. 
Also in 2001, a first report of Dake et al. toward a total synthesis of nitiol (110) appeared in literature, 
followed by a full paper five years later.[110] The authors stated that “it is well established that reactions 
generating trans-hydrindanes bearing pendant methyl and iso-propyl groups almost exclusively result 
in a trans-relationship between the methyl and the iso-propyl groups”. Thus, Dake opted to use the 
conformational bias of a [3.3.0]cyclooctane system to diastereoselectively install this stereochemical 
setting. To this end, they enantioselectively prepared enyne 174 starting from geraniol-derived 
alcohol 173 via a Sharpless enantioselective epoxidation, TBS protection, a Lewis acid promoted 
silyloxy-epoxide rearrangement and standard Wittig olefination (Scheme 1.23). Subsequently, a 
Pauson-Khand reaction furnished a bicycle as the major diastereomer (d.r. = 6:1, not shown), the 
enone system of which was in turn reduced with L-Selectride®. The resulting lithium enolate was then 
intercepted with MeI giving rise to ketone 175, the precursor for the key Norrish fragmentation.[110a] 
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Scheme 1.23 Dake’s enantioselective approach toward nitiol (112) preparing two 1,22-dihydroxynitianes and installing the 
cis-relationship between the methyl and the iso-propyl group on the five-membered ring by a Norrish fragmentation. 
 
As envisaged, exposure of ketone 175 to photochemical reaction conditions installed the desired 
cis-relationship between the methyl and the iso-propyl group in cyclopentane 176 and the ester 
functionality was further manipulated to access vinyl stannane 177. The preparation of a second 
fragment, enol triflate 179, commenced with allylic ester 178 that was subsequently transformed to a 
cyclopentenone by a highly diastereoselective Ireland-Claisen rearrangement and a RCM (not shown). 
The authors noted that the steps of this sequence needed careful optimization to avoid epimerization of 
the carbonyl’s α-stereocenter, as the cis-relationship of the two adjacent substituents is 
thermodynamically disfavored due to steric reasons. At last, a 1,4-reduction affected by L-Selectride® 
and trapping of the generated enolate with PhNTf2 provided access to vinyl triflate 179. Next, both 
coupling partners 177 and 179 were merged by a Stille cross-coupling furnishing diene 180. This 
compound 180 served as a common intermediate for the exploration of several routes in order to close 
the macrocycle, the only effective one being a NHK reaction. Thereby, Dake et al. transformed 
diene 180 to aldehyde 181 that upon exposure to standard NHK conditions yielded allylic alcohol 182 
as a 1:1 mixture of diastereomers at C-1 (nitiol numbering). Unfortunately, all attempts to deoxygenate 
the obtained products 182 failed and thus no total synthesis of nitiol (110) has been accomplished so 
far.[110b] 
Apart from the previously discussed examples, only one more report dealing with an approach to a 
trans-hydrindane iso-propyl sesterterpenoids has been published. More precisely, Tori and co-workers 
pursued a RCM strategy to close the central eight-membered ring of YW 3699 (113) in 2009.[111] 
Along these lines, enone 183 was converted to aldehyde 184 in a six-step sequence, bearing the correct 
trans-substitution of the six-membered ring (Scheme 1.24).  
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Scheme 1.24 Tori’s racemic approach to YW 3699 (113) closing the central eight-membered ring via a RCM. 
 
The latter compound 184 was then reacted with racemic vinyl lithium species 185 that has been 
prepared by a Shapiro reaction from the corresponding trisylhydrazone and t-BuLi. A subsequent 
Dess-Martin periodinane (DMP) oxidation furnished both epimers of ketone 186, which served as a 
substrate for a nucleophilic epoxidation under Scheffer-Weitz conditions leading to a set of four 
diastereomers 187 in total (only one shown). Subjecting all obtained isomers independently to RCM 
reaction conditions (Grubbs II in refluxing CH2Cl2), Tori et al. found that only the depicted 
isomer 187 participated in an efficient ring closure in high yield to construct the trisubstituted alkene 
in ketone 188. Fortunately, this isomer 188 comprised the desired relative stereochemistry of all 
methines at the ring junctures and subsequent exposure to the Tebbe reagent cleanly afforded 
tricycle 189. However, these model studies have not yet addressed the installation of the 
trans-hydrindane system found within YW 3699 (113). As discussed, this portion represents a 
significant challenge for synthetic chemists due to the cis-relationship between the methyl group and 
the iso-propyl residue and the unusual oxidation pattern. Since this publication and despite their 
inspiring beautiful structures and interesting biological properties, no further reports on the class of 
trans-hydrindane iso-propyl sesterterpenoids have appeared in the literature.  
 
 
1.4 Project Objectives 
 
As discussed in the previous section, little synthetic endeavors on trans-hydrindane iso-propyl 
sesterterpenoids have been published over the last decades.[40] This is especially true for those 
members, the iso-propyl substituent of which resides in a cis-relationship to the angular methyl group 
in the trans-hydrindane moiety providing a challenging task to synthetic chemists: solely the reports 
by Dake toward a synthesis of nitiol (110) included such an achievement. However, one has to 
mention that this target 110 did not require the installation of a full trans-hydrindane motif due to the 
missing C5−C6 bond formation in biogenesis.[110] Inspired by the beauty and complexity of the 
structural architectures presented in Chapter 1.3 and attracted by the fascinating biological profile of 
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the type A trans-hydrindane iso-propyl sesterterpenoids, this Ph.D. thesis was aimed at exploring a 
divergent[112] and concise synthetic route to this subclass of terpenoid natural products. 
 
 
Scheme 1.25 The first major goal of this Ph.D. project: an enantioselective synthesis of two intermediates 190 and 191 en 
route to type A trans-hydrindane iso-propyl sesterterpenoids. 
 
More precisely, we aimed in the first place for the development of an enantioselective route to two 
versatile trans-hydrindane building blocks 190 and 191, resembling precursors for synthetic programs 
directed toward syntheses of type A trans-hydrindane iso-propyl sesterterpenoids (Scheme 1.25). In 
spite of the complexity of the target natural products, we further sought to access these building 
blocks 190 and 191 by a robust route applicable on multigram scale from a common intermediate, 
hence taking advantage of a diverse approach. Ideally, we opted for a reaction sequence starting from 
diketone 116[25] that is readily available in either enantiomeric series on large scale and has been 
employed previously in total syntheses.[113] As the conversion of diketone 116 into a trans-hydrindane 
system has been explored by a few research groups,[105] one formidable challenge in the preparation of 
building blocks 190 and 191 relies on a diastereoselective installation of the iso-propyl substituent, 
residing in a cis-relationship to the angular methyl group. If such an introduction was accomplished, it 
would essentially constitute the first entry for a total synthesis of any type A trans-hydrindane 
sesterterpenoid with this relative configuration. A second significant task concerning 
trans-hydrindane 191 is the selective installation of the alcohol functionality at the five-membered 
ring, formally going along with a 1,2-oxygen transposition. 
Having successfully established a practical synthesis of the two intermediates 190 and 191, we would 
aim in second place at launching a total synthesis program, allowing a collective preparation of several 
type A trans-hydrindane iso-propyl sesterterpenoids (Scheme 1.26). On the one hand, we became 
particularly fascinated by the unique pentacarbocyclic architecture found within astellatol (103),[93] 
comprising four-, five, six- and seven-membered rings and a total of ten stereogenic centers. Thereby, 
a total synthesis would allow for the elucidation of the absolute configuration and for a verification of 
the reported structure, which has been only assigned based on extensive NMR studies to date. In 
addition, the biological properties of this beautiful structure 103 have not been explored yet. Thus, a 
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viable route would pave the way for investigations concerning the function of astellatol (103) in 
Nature. 
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Scheme 1.26 Molecular structures of the sesterterpenoids astellatol (103) and YW 3548 (112), potentially accessible by total 
synthesis from the bisoxygenated trans-hydrindane building block 191. 
 
On the other hand, we were interested in the GPI anchor inhibitors YW 3548 (112) and 
YW 3699 (113) due to their fascinating biological profile (cf. Chapter 5.1) and their intriguing 
structural features.[101,102] Analogously to astellatol (101), the absolute configuration as well as the 
relative stereochemistry at the heptanoate side chain has not been determined and thus their structures 
remain unconfirmed. In addition, synthetic intermediates could provide a valuable starting point for 
testing their biological activities and further derivatization of the natural products could initiate SAR 
studies.  
 
 
Scheme 1.27 Molecular structures of the sesterterpenoids nitiol (110) and (+)-retigeranic acid B (102), potentially accessible 
by total synthesis from the monooxygenated trans-hydrindane building block 190. 
 
As we were aware of the fact that the installation of the correct oxygenation pattern at the five-
membered ring within bicycle 191 might be plagued by selectivity problems, preventing a practical 
preparation on large scale, we aimed additionally for synthetic studies toward nitiol (110, 
Scheme 1.27).[99] Even more, a successful route toward the monooxygenated bicycle 190 would also 
allow to revisit the retigeranic acids, particularly in order to develop a first route toward retigeranic 
acid B (102).[92] 
From a general synthetic perspective, efforts toward this class of natural products would stand as an 
excellent framework upon which to develop and apply state-of-the-art synthetic methods and examine 
their feasibility in a congested steric environment. Moreover, we envisaged implementing a 
bioinspired key step,[114] i.e. a cascade reaction[115] which rapidly builds up structural complexity in 
order to access the unique architectures presented above. Such a strategy has become a signature of the 
Trauner laboratories as evidenced by recently published reports,[116] and would allow to gain 
information on the potential biogenesis of the target molecules.  
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2 A UNIFIED APPROACH TOWARD TRANS-HYDRINDANE 
ISO-PROPYL SESTERTERPENOIDS 
 
2.1 Retrosynthetic Analysis 
 
As described in the previous chapter, the first major aim of this Ph.D. thesis consisted in the 
establishment of a robust route to two building blocks 190 and 191 which could be employed for the 
synthesis of type A trans-hydrindane iso-propyl sesterterpenoids. In our initial retrosynthetic proposal, 
we envisioned accessing building block 190 from alcohol 192 by a deoxygenation, e.g. following the 
Barton-McCombie protocol,[117] and subsequent liberation of the ketone functionality (Scheme 2.1). 
Alcohol 192 could also be seen as a retrosynthetic precursor for the bisoxgenated building block 191 
by a two-step protection/deprotection sequence. The order of these transformations could easily be 
inverted in case the envisaged TBS protecting group would not resist the acidic conditions required for 
an acetal cleavage. Thus, alcohol 192 would represent the branching point toward both building 
blocks 190 and 191. 
 
 
Scheme 2.1 Initial retrosynthetic analysis of the two trans-hydrindane iso-propyl building blocks 190 and 191. 
 
The key intermediate 192 could arise from an electronically controlled regioselective 
hydroboration/oxidation protocol leading to alkene 193 as a logical precursor In addition, we assumed 
that the angular methyl group in bicycle 193 would prevent the initial hydroboration to occur from the 
top face, thus efficiently setting two stereogenic centers in one single reaction. The latter 
compound 193 could be traced back to enone 194 by a Michael addition, Saegusa-Ito oxidation[118] and 
deoxygenation.[119] In analogy to the discussed hydroboration, the 1,4-addition was thought to proceed 
preferentially from the bottom face due to the shielding effect of the methyl group, thus providing the 
undesired stereochemistry and requiring a subsequent reoxidation to invert the stereochemistry (vide 
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infra). A direct trapping of the Cu enolate resulting from the Michael addition, with TMSCl was 
envisaged, which would directly provide the silyl enol ether necessary for a Saegusa-Ito oxidation.[120] 
Further retrosynthetic simplification would give ketone 195, which should be readily available from 
ESWHP ketone (116)[25] according to literature precedence.  
 
 
2.2 Preparation of the ESWHP-Ketone and Installation of the trans-Ring 
Junction† 
 
With the envisaged retrosynthesis in mind (cf. Chapter 2.1), we first set out to prepare ESWHP 
ketone (116) on large scale following the procedure described by Hajos and Parrish.[121] To this end, 
commercially available diketone 196 was submitted to acidic reaction conditions (catalytic amount of 
AcOH) in the presence of MVK (122) on a 100 g scale, triggering a Michael-addition to yield 
triketone 197, which was used in the next step without further purification (Scheme 2.2). 
Subsequently, an aldol cyclization catalyzed by L-proline (198) discriminated the two enantiotopic 
carbonyl functionalities on the six-membered ring within triketone 197 and provided bicycle 200 in 
approximately 90% ee.[121]  
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Scheme 2.2 Large scale preparation of diketone 116 utilizing an enantioselective organocatalytic protocol. 
 
As pointed out before (cf. Chapter 1.1), this reaction is an early example of enantioselective 
organocatalysis that involves the formation of an enamine. More precisely, the reaction presumably 
proceeds via the Houk-List transition state 199[122], in which an intramolecular activation by the 
carboxylic acid differentiates the two carbonyl functionalities. Having successfully introduced 
asymmetry, enantioenriched bicycle 200 was then dehydrated in the same reaction vessel by treatment 
with H2SO4 at elevated temperature to furnish the desired diketone 116. The obtained crude 
                                                 
†  Part of the experimental work on large scale was carried out in collaboration with Sebastian Rappenglück, Thomas M. 
Wildenhof, Martin Rossa and Florian Weinzierl as part of their Bachelor’s Theses (S. R., M. R.) and undergraduate 
research stays (T. M. W., F. W.) in the Trauner laboratories. 
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product 116 was purified by sequential extraction, flash column chromatography and finally 
recrystallization to increase the enantiomeric excess. The procedure allowed the preparation of 80 g of 
the desired diketone 116 in a single batch and provided hydrindenone 116 in 96% ee and with an 
overall yield of 55% over three steps. Moreover, the X-ray crystal structure of diketone 116 was 
elucidated for the first time.[123] It should be noted that both enantiomers of diketone 116 are readily 
available following this strategy, depending solely on the chiral information of the catalyst 198 
employed. Since the absolute configuration of the major targets astellatol (103), nitiol (110) and 
YW 3548 (112) has not been established, we used the less expensive L-proline (198) for our synthetic 
studies.  
Next, our attention was shifted to the installation of the trans-ring junction. As discussed 
previously (cf. Chapter 1.3), such a transformation presents a significant challenge and only a handful 
of protocols have been explored. This is especially true for enone precursors like diketone 116 lacking 
a substituent at the 4-position (IUPAC numbering) and bearing an angular substituent.[105] Initially, we 
envisioned to follow a report by Daniewski and co-workers,[124] who developed a direct installation of 
the trans-junction by exposure of diketone 116 to a bulky CuH species formed in situ from a mixture 
of CuI, t-BuMgCl and DIBAL-H. In addition, the use of HMPA as a highly polar solvent to break 
metal clusters is required to provide trans-hydrindane 118 in good yield and high 
diastereoselectivity (d.r. = 27:1). 
 
 
Scheme 2.3 Irreproducible diastereoselective reduction of diketone 116 following Daniewski’s protocol.  
 
Although this protocol has been utilized a few times in the literature on scaled up to 1 g,[125] the 
procedure was barely reproducible in our hands and led to the desired trans-hydrindane 118 in 40% 
yield and 10:1 d.r. despite several attempts (Scheme 2.3). In the other cases, the reaction furnished the 
cis-fused bicycle and alcohol side-products. Facing these selectivity issues and being aware that the 
opening steps of the envisioned total synthesis had to be applicable on large scale,[126] we focused on a 
five-step protocol to install the trans-ring junction. This procedure was originally reported on multi-
gram scale by an industry research group headed by Hajos and Parrish in 1975[127] and has been 
adapted by the groups of Danishefsky,[128] Nicolaou,[129] Sörensen[130] and recently by Myers[131] during 
their synthetic programs on the total syntheses of paclitaxel (5) and the cortistatin family, respectively.  
The protocol commenced with a chemoselective reduction of the less electron-rich carbonyl in 
diketone 116 via the slow addition of NaBH4 (0.30 eq.) to a solution of diketone 116 in EtOH at 
−18 °C (Scheme 2.4).[132] Noteworthy, the steric shielding of the angular methyl group induced a 
substrate controlled diastereoselectivity providing exclusively bicycle 201 in quantitative yield. The 
alcohol functionality in enone 201 was then protected as its t-Bu ether by exposure to 
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isobutylene (202) in the presence of H3PO4 and BF3·OEt2 to obtain indenone 203. In their seminal 
work,[133] Hajos and Parrish observed that the choice of a sterically demanding protecting group such 
as t-Bu is crucial to increase the trans-selectivity in the hydrogenation step (vide supra). Even more 
important is the installation of a substituent at the 4-position for the successful construction of the 
trans-ring junction, although the reasons for that observation are not completely understood. As no 
substituent at this position is required in our synthesis, the introduced residue has to be easily 
removable after the desired hydrogenation. Again, it was the industry research group headed by Hajos 
and Parrish, who found a solution for this problem.[126,133] More precisely, they developed an efficient 
protocol for the installation of an acid functionality. In these studies, they observed that the use of 
methoxymagnesium methyl carboxylate (MMC, 204), essentially a magnesium methoxide with a 
built-in source of CO2, resulted in a superior regioselectivity (C-4 vs. C-6) compared to other reagent 
combinations (e.g. NaH/CO2).[126] The authors attributed this finding to “the enhanced stability of the 
resultant magnesium chelates produced (relative to the analogous sodium chelates[…])”, which 
reduces the reversibility of the carboxylation process. 
 
 
Scheme 2.4 Large scale installation of the trans-hydrindane pattern in ketone 207 following a known five-step protocol and 
X-ray structure of acid 205. 
 
In practice, exposure of indenone 203 to MMC (204) in DMF at 130 °C provided the desired acid 205 
in 66% yield along with its C-6 regioisomer (not shown), which spontaneously decarboxylated during 
acidic work up (Scheme 2.4). After separation, the thus reisolated starting material 203 was again 
subjected to the carboxylation conditions furnishing acid 205 in an overall yield of 82% after a second 
cycle on a 57 g scale. In addition, the structure of acid 205 was determined by X-ray 
crystallography.[123] It exhibits an intramolecular hydrogen bonding of the acidic proton with the 
adjacent carbonyl functionality. More interestingly, no situation is visible, which might explain the 
higher selectivity for the installation of the trans-ring junction compared to diketone 116 based on a 
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preferred reaction face. With large amounts of acid 205 prepared, the crucial hydrogenation was 
carried out in the presence of catalytic amounts of Pd/BaSO4 under elevated pressure of 
H2 (3.5 bar),[134] affording β-keto acid 206. This intermediate 206 was immediately subjected to a heat- 
and vacuo-mediated decarboxylation[126] to furnish trans-hydrindane 207 in 59% yield over the two 
steps. On the largest scale, 27 g of building block 207 were prepared that was contaminated with 
approximately 6% of its cis-isomer. In addition to the investigations presented in this chapter, 
ketone 207 served as starting point for model studies toward a total synthesis of astellatol (103, 
cf. Chapter 3). Having successfully completed the installation of the trans-hydrindane backbone, the 
focus was now turned to the incorporation of the iso-propyl moiety. 
 
 
2.3 Diastereoselective Installation of the iso-Propyl Moiety 
 
Considering the retrosynthetic analysis, we opted to install the iso-propyl moiety at C-3 (IUPAC 
numbering) of the trans-hydrindane portion via a cuprate 1,4-addition. For this purpose, we had to 
adjust the oxidation states and manipulate protecting groups, commencing with the cleavage of the 
t-Bu ether by exposure of trans-hydrindane 207 to 6N aqueous HCl in refluxing EtOH (Scheme 
2.5).[135] Notably, these harsh reaction conditions cleanly led to the formation of alcohol 208 in almost 
quantitative yield and did not provoke any rearrangement by the formation of carbocationic 
intermediates.  
 
 
Scheme 2.5 Synthesis of trans-hydrindanone 195 via redox and protecting-group manipulations and verification of the 
trans-hydrindane pattern by X-ray crystal analysis of ketone 195. 
 
Subsequently, the free carbonyl within ketone 208 was protected as its 1,3-dioxalane by treatment with 
ethylene glycol (209) in the presence of catalytic amounts of pTsOH and utilizing a Dean-Stark 
apparatus. The obtained alcohol 210 was next oxidized to the corresponding ketone 195 using PCC 
under buffered reaction conditions. It turned out that the latter compound 195 was highly crystalline 
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and a final recrystallization from hexanes not only allowed for the removal of any traces of the 
undesired cis-isomer (vide supra), but also for a verification of the desired trans-hydrindane pattern by 
X-ray crystallography.[123] Overall, this reaction sequence was six steps longer compared to the direct 
reduction following Daniewski’s protocol (cf. Chapter 2.2) and an ensuing regioselective 
protection.[136] However, the developed route is very robust, scalable and provided on the largest batch 
19 g of ketone 195 in an overall yield of 29% for eight steps starting from diketone 116. 
 
 
Scheme 2.6 Preparation of enone 194 via Saegusa-Ito oxidation on 1 g scale. 
 
With a significant amounts of bicycle 195 prepared, the attention was now turned to the installation of 
a α,β-unsaturated ketone in order to prepare a substrate for the envisaged Michael addition. A 
literature survey revealed that a Saegusa-Ito oxidation[118] is the method of choice for such 
transformations in trans-hydrindane systems. We thus decided to investigate this reaction first. Hence, 
ketone 195 was converted to the corresponding TMS silyl enol ether 211 by sequential exposure to 
LDA and TMSCl/Et3N. This intermediate 211 was carefully isolated by aqueous work up and used 
without chromatographic purification for the next step. Thereby, treatment with 1.1 equivalents of 
Pd(OAc)2 at 40 °C resulted in the formation of metallic palladium, indicating the successful oxidation 
of ketone 195. Indeed, after careful flash column chromatography, the desired product 194 was 
obtained in 79% yield along with recovered starting material 195 on a 1 g scale (Scheme 2.6). 
 
 
Scheme 2.7 Mechanism of the (catalytic) Saegusa-Ito oxidation. 
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Mechanistically,[137] treatment of intermediate 211 with stoichiometric amounts of Pd(OAc)2 results in 
the cleavage of the Si−O bond and the formation of a PdII enolate, which can be either described as its 
η3-complex 212 or as η1-complex 213 (Scheme 2.7). The latter intermediate 213 then undergoes a 
β-hydride elimination to liberate the desired product 194 and an H−PdII species that collapses 
immediately to form Pd0, usually observed as a palladium mirror on the flask. Over the years, several 
methods have been developed in order to reoxidize Pd0 to PdII utilizing terminal oxidants as e.g. O2, 
benzoquinone or allyl methyl carbonate and thus rendering the process catalytic in PdII.[138] However, 
one has to state that these protocols still show room for improvement, as in most cases a stoichiometric 
use of Pd(OAc)2 is favored due to superior yields.[139] Since ‘classical’ Saegusa-Ito oxidation show 
high costs on large scale, we explored other procedures including catalytic protocols of the Saegusa-
Ito oxidation to install the requisite enone 194 prior to up-scale.  
These investigations‡ commenced with attempts to effect an α-bromination on ketone 195 giving rise 
to compound 214. This intermediate 214 could be later elaborated to the enone system in tricycle 194 
by exposure to basic conditions,[140] constituting a cheap alternative on large scale. In order to avoid 
cleavage of the dioxolane moiety by strongly acidic reaction conditions utilizing Br2, we employed 
PhMe3NBr3 (PTAB) as a substitute. 
 
Table 2.1 Studies toward the synthesis of α-bromo ketone 214: variation of reaction conditions.a 
 
 
Entry Source of Br+ Promoter Solvent T [°C] t [h] Observation 
1 PhNMe3Br3 HOAc THF 0 to rt 4 decomposition 
2 NBS NH4OAc Et2O rt 10 s.m. 
3 NBS Amberlyst-15 EtOAc rt 4 monobromination/ 
acetal cleavage 
4 NBS KMMDS THF −78 to rt 20 little conversion/ 
mainly s.m. 
(a) All reactions were carried out on 200 μmol scale of ketone 195. rt = room temperature, s.m. = starting material. 
 
However, reaction of ketone 195 with this source of Br+ in the presence of catalytic amounts HOAc[141] 
resulted in decomposition (Table 2.1, Entry 1). We next examined NBS as a potential other mild 
source of Br+. While subjecting ketone 195 to acidic conditions with NH4OAc as reported by 
Tanemura and co-workers[142] did not lead to conversion (TLC analysis, Entry 2), the use of 
Amberlyst-15[143] resulted in full conversion and the isolation of a new compound (Entry 3). 
Subsequent 1H NMR analysis showed a successful monobromination as indicated by the specific 
                                                 
‡  These investigations were carried out in collaboration with Florian Weinzierl as part of his undergraduate research stay in 
the Trauner laboratories. 
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signals around 4.7 ppm (two diastereomers). However, these reaction conditions also caused the 
cleavage of the dioxolane moiety in ketone 195. Therefore, the nature of the isolated diastereomeric 
mixture as well as the bromination site-selectivity was not further investigated and anionic conditions 
were tested. To this end, ketone 195 was converted to the corresponding potassium enolate by 
treatment with KHMDS at low temperature and then reacted with NBS while allowing the reaction 
mixture to warm to room temperature (Entry 4). Although this procedure has been described in 
literature on a related system by Rawal and co-workers,[144] no conversion was observed. 
 
 
Scheme 2.8 Unsuccessful attempts to synthesize enone 194 by the Nicolaou-Baran method utilizing IBX (215). 
 
Since attempts toward selective α-bromination proved unsuccessful, the attention was next turned to 
the Nicolaou-Baran method for unsaturation of ketones.[145] Thus, ketone 195 was treated with 
IBX (215) in DMSO, a highly polar solvent which is necessary due to the poor solubility of 
oxidant 215 in most common organic solvents. Unfortunately, neither reaction at 60 °C for three days 
nor with catalytic amounts of TFA[146] at 100 °C for 18 h resulted in any conversion (Scheme 2.8). It 
should be noted that in further efforts the IBX·MPO complex could be explored, which has been 
reported to show superior reactivity compared to IBX (215) in the oxidation of silyl enol ethers to the 
corresponding enones.[147] 
Another frequently used method to oxidize a cyclic ketone to the corresponding enone involves an 
α-selenylation followed by oxidation to the selenoxide, triggering an intramolecular syn-elimination to 
furnish the alkene moiety. To this end, ketone 195 was initially deprotonated with LiHMDS and the 
thus generated Li-enolate was reacted with PhSeBr to form ketone 216 as an undetermined mixture of 
diastereomers (Scheme 2.9). 
 
 
Scheme 2.9 Unexpected Baeyer-Villiger oxidation generating bicyclic lactone 217 during attempts to install a 
cyclopentenone pattern via a selenoxide elimination. 
 
Without further purification, the oxidation/elimination step was next examined. Whereas the use of 
NaIO4 as oxidant did not result in any conversion, utilizing excess H2O2 according to a procedure by 
Shair and co-workers[148] prompted the formation of a new UV-active product as indicated by TLC 
analysis. Following purification, examination of NMR spectroscopic and mass spectrometric data of 
the new compound 217 revealed that the desired unsaturated system was successfully installed in a 
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poor yield of 18%. Unfortunately, the reaction conditions concomitantly led to a Baeyer-Villiger 
oxidation forming bicyclic lactone 217, presumably due to the release of ring strain.[149] Further 
attempts to avoid this side reaction employing exactly one equivalent of H2O2 resulted in poor 
conversion and the detection of traces of the desired enone 194 as indicated by TLC analysis. 
 
 
Scheme 2.10 Toward unsaturation of ketone 195: exploration of a protocol developed by Corey and co-workers. 
 
The focus was then centered on Pd-mediated enone formations. Thereby, a publication by Corey and 
co-workers captured our attention. They reported the formation of cyclic enones from the 
corresponding TIPS enol ethers in the presence of Pearlman’s catalyst (Pd(OH)2/C) and Na2HPO4 and 
utilizing excess t-BuOOH under O2 atmosphere as terminal oxidants.[150] Thus, TIPS enol ether 218 
was prepared by treatment of ketone 195 with TIPSOTf and Et3N at 0 °C as indicated by 1H NMR 
spectroscopy (Scheme 2.10). Subsequently, the crude silyl enol ether 218 was submitted to the 
reaction conditions developed by Corey. Although the reaction was performed for a prolonged time of 
four days and with a excess of reagents, no formation of the desired product 194 could be detected.  
 
Table 2.2 Toward a catalytic Saegusa-Ito oxidation: variation of reaction conditions.a 
 
Entry R 
Pd(OAc)2 
[mol-%] 
Equivalents of 
allyl methyl carbonate 
t [h] Observation 
1 TIPS 40 9.45 144 13% 194 isolated 
2b TMS 10 1.35 1 195:194 = 2:1 
3b TMS 40 1.35 1 195:194 = 3:1 
(a) All reactions were carried out on 0.2 mmol scale in MeCN (2 mL), preparing the corresponding silyl enol ether immediately prior to use. 
(b) The ratio was determined by 1H NMR spectroscopy after filtering the reaction mixture over silica (eluting with hexanes:EtOAc = 1:1). 
 
Finally, we returned to Saegusa-Ito conditions and investigated catalytic protocols employing 
commercially available allyl methyl carbonate as a stoichiometric oxidant. As the reactivity and the 
stability of the employed silyl enol ether plays a crucial role, we first tested the TIPS enol ether 218 
due to its previously observed enhanced stability compared to TMS enol ether 211. However, a 
prolonged reaction time and a final total amount of 40 mol-% Pd(OAc)2 resulted in a low yield of 13% 
(Table 2.2, Entry 1). Changing the silyl group for a less sterically demanding TMS enol ether 211, and 
using 10 mol-% Pd(OAc)2 resulted in a 2:1 ratio of ketone 195 and 194 as indicated by 1H NMR 
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spectroscopy of baseline separated signals for the angular methyl groups (Entry 2). Unexpectedly, this 
first promising ratio dropped to 3:1 while employing 40 mol-% catalyst loading (Entry 3).  
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Scheme 2.11 Preparation of enone 194 via Saegusa-Ito oxidation on large scale and its X-ray structure. 
 
Due to the unsuccessful results, we abandoned these investigations at this stage in order to further 
explore the retrosynthetic proposal. In future experiments, however, additional protocols for the 
synthesis of enone 194 should be examined.[138,147,151] Thus, we finally returned to ‘classical’ Saegusa-
Ito conditions for the preparation of enone 194 on larger scale. While increasing the amount of 
employed substrate 195 to 6 g, the yield decreased form 79% to 69%. However, resubjection of the 
isolated starting material to the reaction conditions raised the overall conversion from ketone 195 to 
Michael acceptor 194, providing 15.2 g of enone 194 in 82% yield on the largest scale after the 
combination of different reaction batches (Scheme 2.11). In addition to the previously employed 
standard analytical methods such as NMR spectroscopy and mass spectrometry, the structure of 
bicycle 194 was now also resolved by X-ray diffraction of a single crystal.[123] 
The next task ahead was the investigation of a cuprate addition in order to install the desired 
iso-propyl substituent. Based on a literature precedent by Molander and co-workers[109] and due to the 
enhanced reactivity of vinyl cuprates, we decided to explore the Michael addition of an isopropenyl 
residue first. To this end, a higher order cyano cuprate was prepared by slow addition of 
4.5 equivalents of isopropenylmagnesium bromide (219) to 2.25 equivalents CuCN at 0 °C. After an 
additional 30 min, the mixture was cooled to −78 °C and enone 194 was added resulting in the 
formation of alkene 220 as a single diastereomer in a good yield of 81% (Scheme 2.12). 
 
 
Scheme 2.12 Diastereoselective installation of an isopropylene substituent via a cuprate addition. 
 
Surprisingly, 2D NOE NMR spectroscopy indicated that this addition occurred from the top face, i.e. 
syn to the angular methyl group, which was assumed to shield this side. This stereochemical outcome 
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was unexpected based on inspecting molecular models and the X-ray structure of enone 194 and was 
later on unambiguously confirmed by X-ray crystallography.[123] To our delight, this result matched the 
iso-propyl’s relative stereochemistry found in our major synthetic targets astellatol (103), nitiol (110) 
and YW 3548 (112). As experiments with an iso-propyl cuprate gave only unsatisfactory results in our 
hands (not shown), we scaled up the installation of the isopropylene unit. Due to the experienced 
sensitivity of this cuprate addition, the reaction was conducted on not more than 1.5 g of ketone 194 in 
a single reaction vessel. A combined flash column chromatography of several reaction batches 
provided around 11.5 g of ketone 220 on the largest scale. To the best of our knowledge, only two 
examples with similar diastereoselective outcome in trans-hydrindenones have been reported by the 
groups of Molander[109] and Bull[152] in their efforts toward (+)-variecolin (104, cf. Chapter 1.3) and on 
an estrone derivative (not shown), respectively. Since our results rendered a second unsaturation in 
order to install the desired stereochemistry of the iso-propyl substituent redundant (cf. Chapter 2.1), 
we revisited our retrosynthetic analysis and shifted the attention directly to the syntheses of building 
blocks 190 and 191.  
 
 
2.4 En Route to Building Blocks for trans-Hydrindane iso-Propyl 
Sesterterpenoids 
 
Given the successful and unexpected diastereoselective installation of an isopropylene residue, the 
retrosynthetic analysis was revised. We now envisioned accessing bisoxgenated building block 191 
via a three-step sequence featuring a diastereo- and regioselective hydroboration as a key element and 
thus tracing ketone 191 back to alkene 221 (Scheme 2.13). 
 
 
Scheme 2.13 Revised retrosynthetic analysis of the trans-hydrindane iso-propyl building blocks 190 and 191. 
 
Whereas the diastereoselective outcome of the crucial hydroboration was not considered a problem 
based on the steric bias induced by both the angular methyl and the iso-propyl moiety, the 
regioselectivity could be problematic since both alkene carbons atoms in compound 221 are 
monosubstituted. However, the different steric environment at C-1 (being neopentylic) and 
C-2 (possessing an adjacent trisubstituted carbon atom) could suffice to discriminate the rates of 
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hydroboration in favor of the desired regioisomeric outcome. In addition, a careful choice of the 
hydroboration agent might enhance the regioselectivity to provide a practical entry into this series of 
type A trans-hydrindane iso-propyl sesterterpenoids. On the other hand, monooxygenated building 
block 190 could as well arise from alkene 221 via a hydrogenation/deprotection protocol, thus 
rendering the latter compound 221 the new branching point. Dioxolane 221 could in turn be prepared 
from ketone 220 by sequential hydrogenation and alkene installation, e.g. via an E2 elimination of the 
corresponding mesylate or a Shapiro reaction.[153]  
 
 
Scheme 2.14 Reduction of alkene 220 under standard hydrogenation conditions.  
 
Following this retrosynthesic plan, the first step was readily accomplished by submitting alkene 220 to 
standard hydrogenation conditions (Pd/C, H2) furnishing ketone 222 in 91% yield after purification by 
recrystallization (Scheme 2.14). It should be noted that we verified the unexpected epimerization at 
C-3 observed in this reaction by X-ray crystallography later on (cf. Chapter 2.5). Within the 
experiments discussed in this section, no assignment of the relative stereochemistry at C-3 was 
possible based on 2D NOE NMR spectroscopy due to overlaying signals in the 1H NMR spectra. 
Moreover, we were not aware at this stage of any literature example describing an almost complete 
epimerization or racemization of an adjacent stereogenic center under hydrogenation conditions. It 
was thus assumed that the relative stereochemistry in ketone 222 matched the one established in 
alkene 220 (vide infra). It should be emphasized, however, that the transformations tested on this 
system provided helpful information for the further synthesis with the desired stereochemistry 
at C-3 (cf. Chapter 2.6). 
 
 
Scheme 2.15 Attempts to convert ketone 222 to tosylhydrazone 223. 
 
Having prepared substantial amount of ketone 222, the installation of an alkene moiety following 
different strategies was next explored. Initially, we aimed for a two-step Shapiro protocol and we thus 
subjected ketone 222 to hydrazone formation conditions with pTsNHNH2.[154] However, neither 
reaction in refluxing EtOH with a pTsOH/NaOAc buffer nor in boiling THF in the presence of pTsOH 
and MgSO4 effected the desired formation of hydrazone 223 (Scheme 2.15). These findings were 
attributed to the neopentylic nature and steric encumbrance of the carbonyl functionality. In addition, 
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the use of strong aqueous acids such as H2SO4 or HCl known to accelerate the desired reaction was 
avoided due to the acid sensitivity of the dioxolane moiety within ketone 220. 
In an alternative approach, ketone 222 was cleanly reduced to alcohol 224 by treatment with NaBH4 
and the relative configuration of the newly installed stereogenic center was established by NOESY 
experiments (Scheme 2.16). Subsequently, dehydration attempts utilizing either Martin’s sulfurane[155] 
or sequential mesylation and E2 elimination in the presence of DBU were explored. These protocols 
remained unfruitful since no formation of alkene 225 was observed.  
 
 
Scheme 2.16 En route to alkene 221: dehydration attempts and first successful synthesis via Chugaev elimination. 
 
Next, we resorted to a syn-elimination protocol involving a protocol pioneered by Chugaev.[156] For 
this purpose, reaction of alcohol 224 with chlorothionocarbonate 226 in the presence of pyridine[157] 
afforded tricycle 227 in 90% yield (Scheme 2.16). Initial experiments in a melting point 
apparatus (neat in a tubule, 230 °C) resulted in conversion of intermediate 227 to a new compound as 
indicated by TLC analysis. We thus explored this reaction on a larger scale heating neat 
compound 227 to 275 °C in a Kugelrohr apparatus according to a literature precedent by Trost and 
co-workers.[158] Fortunately, the desired product 225 was directly distilled out of the reaction mixture 
in poor yield and its structure was subsequently verified by NMR spectroscopy and mass analysis. A 
further optimization of the reaction conditions conducting the transformation in a high boiling point 
solvent such as Ph2O or in 1,2-dichlorobenzene under microwave-conditions[159] was not investigated 
since a more convenient synthesis of alkene 225 was accomplished via another 
strategy (Scheme 2.17).  
 
 
Scheme 2.17 Efficient two-step protocol for the synthesis of alkene 221. 
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Therein, exposure of ketone 220 to KHMDS at low temperature generated the corresponding 
potassium enolate, which in turn was trapped with PhNTf2 furnishing enol triflate 228. This latter 
compound 228 was directly subjected to reductive coupling conditions employing n-Bu3N, formic acid 
and catalytic amounts of Pd(PPh3)2Cl2.[160] This protocol led to the clean formation of alkene 225 in a 
high yield of 87% over the two steps. Notably, the use of volatile solvents such as Et2O and n-pentane 
was necessary during the work up and purification process presumably due to the apolar nature and the 
previously observed low boiling point of alkene 225.  
 
 
Scheme 2.18 Catalytic cycle of the Pd-catalyzed reductive detriflation. 
 
Mechanistically,[161] this reaction proceeds via a standard Pd-catalyzed cross-coupling mechanism. The 
catalytic cycle commences with an oxidative addition of the in situ formed Pd0 species into the alkenyl 
triflate bond of tricycle 228 forming PdII complex 230, which in turn undergoes a ligand exchange 
with the in situ formed ammonium formate (Scheme 2.18). This intermediate 231 presumably falls 
apart instantly under extrusion of CO2 generating H−PdII complex 229 by a process which formally 
constitutes a β-hydride elimination. The catalytic cycle is terminated by a reductive elimination, 
liberating the desired product 225 and regenerating the catalytically active Pd0 species.  
Having established an efficient access to alkene 225, the attention was next focused on the envisioned 
hydroboration.[162] To this end, alkene 225 was subjected to different hydroboration agents (Table 2.3), 
followed by oxidative work up and determination of the regioisomeric ratio between alcohols 232 
and 233 in the 1H NMR spectra of the crude reaction mixture. The ratio was determined by integration 
of the characteristic signals at the newly formed stereogenic center (d at δ = 3.69 ppm for alcohol 232, 
ddd at δ = 4.40 ppm for alcohol 233). These investigation commenced with the exposure of alkene 225 
to excess BH3·THF complex at 0 °C. Upon slowly warming the reaction temperature to room 
temperature and performing an oxidative work up, decomposition of the starting alkene 225 was 
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observed (Table 2.3, Entry 1). Next, the amount of BH3·THF complex was reduced to equimolar 
stoichiometry, which surprisingly cleaved the acetal moiety instead of performing the desired 
hydroboration as observed by 1H NMR spectroscopy (Entry 2). This observation was attributed to the 
Lewis acidity of the hydroboration agent and similar findings have been reported previously.[163]  
 
Table 2.3 Toward a regioselective hydroboration of alkene 225: variation of reaction conditions.a 
 
Entry Borane (equiv.) T [°C] t [h] 
Ratio 232:233b 
(yield) 
Observation 
1 BH3·THF (5.0) 0 to rt 0.5 - decomposition 
2 BH3·THF (1.0) 0 to rt 0.5 - acetal cleaved 
3 BH3·SMe2 (1.1) 0 to rt 1 2:1 (90%) - 
4 BH3·SMe2 (1.2) 0 4 1.7:1 incomplete 
conversion 
5 BACH-EI (234, 1.2) 0 5 1.7:1 incomplete 
conversion 
6 ThxBH2 (235, 2.0)c 0 to rt 2 1.7:1 - 
7 (sia)2BH (236, 2.0)c 0 to 66 16 - s.m. 
8 9-BBN (237, 2.0)d 66 16 - s.m. 
9e 9-BBN (237, 3.0)d 180 6 - decomposition 
10 
Rh(PPh)3Cl (0.05) 
catBH (238, 2.0) 
0 to 66 16 - s.m. 
11f BH3·SMe2 (1.25) 0 to rt  1:1 (76%) - 
(a) All reactions were carried out on 10 mg scale in THF (20mM), unless otherwise stated. (b) The ratio was determined by 1H NMR 
spectroscopy of the crude reaction mixture. (c) The hydroboration agent was prepared immediately prior to use from the corresponding 
alkene and BH3·SMe2 complex. (d) A solution of 9-BBN (237) in the appropriate solvent was freshly prepared from 9-BBN dimer. (e) The 
reaction was conducted in toluene in a pressure tube. (f) The reaction was carried out on 200 mg scale. s.m. = starting material. 
 
Thus, we resorted to the BH3·SMe2 complex, featuring enhanced stability and therefore less Lewis 
acidic properties. Indeed, the reaction proceeded smoothly and furnished a 2:1 mixture of 
regioisomeric alcohols 232 and 233 in a combined yield of 90% (Entry 3). Unexpectedly, this ratio 
was in favor of the undesired isomer 232. Upon separation by flash column chromatography, both 
isomers 232 and 233 were characterized. By comparison with its epimer 224 obtained by reduction 
with NaBH4, alcohol 232 revealed different physical properties (NMR data, Rf value). In addition a 
NOESY correlation between the proton at C-1 and the angular methyl group confirmed that the 
hydroboration occurred from the bottom face. Further variation of the reaction temperature and 
utilizing the BACH-EI complex (234, Figure 2.1) did not alter the regioisomeric ratio dramatically, 
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enhancing it slightly to 1.7:1 with incomplete conversion (Table 2.3, Entries 4, 5). Thus, more bulky 
hydroboration agents such as ThxBH2 (235), (sia)2BH (236) or 9-BBN (237) were examined. 
However, these reagents either did not influence the selectivity (Entry 6), resulted in no 
conversion (Entries 7, 8) or led to decomposition (Entry 9). Besides, a Rh-catalyzed hydroboration 
utilizing Wilkinson’s catalyst and catecholborane (238), which has been reported to invert the 
regioselectivity obtained under standard hydroboration conditions in some cases,[164,165] was explored. 
This protocol was unsuccessful since again only starting material was observed (Entry 10).  
 
 
Figure 2.1 Molecular structures of the employed hydroboration agents BACH-EITM (234), thexylborane (235), 
disiamylborane (236), 9-BBN (237) and catecholborane (238). 
 
Ultimately, the most convenient procedure with BH3·SMe2 complex was scaled to 200 mg of 
alkene 225 and, interestingly, both alcohols 232 and 233 were obtained in an approximate 1:1 mixture 
in a combined yield of 76% (Table 2.3, Entry 11). As pointed out previously, separation of the isomers 
by flash column chromatography was facile and would potentially allow to increase the overall 
efficiency of this process by recycling the undesired isomer 232 via an oxidation/alkene installation 
sequence. Nevertheless, a higher yielding and more straight-forward route to compound 233 would be 
beneficial to provide multi-gram quantities for our total synthesis program. We therefore examined 
alternative protocols in that regard. To this end, alkene 225 was initially reacted with mCPBA to yield 
epoxide 239 as a single diastereomer (Scheme 2.19). This intermediate 239 was subsequently 
subjected to different hydride reagents in order to effect a regioselective epoxide opening. 
Unfortunately, treatment with LiAlH4 (THF, reflux) or Super-Hydride® (THF, 0 °C to rt) resulted in a 
clean reaction generating selectively the undesired regioisomeric alcohol 232, the spectroscopic data 
of which matched the ones obtained previously via hydroboration. 
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Scheme 2.19 Further attempts to install the desired oxidation pattern at the cyclopentane moiety via hydride epoxide opening 
or a radical-mediated regioselective reduction. 
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In another attempt to install the desired oxidation pattern at the cyclopentene moiety, alkene 225 
smoothly underwent dihydroxylation in the presence of OsO4 and K3Fe(CN)6 as terminal oxidant 
yielding diol 240 (Scheme 2.18). This compound 240 was in turn exposed to 
thiocarbonyldiimidazole 241 at elevated temperature to yield thiocarbonate 242. When submitting the 
intermediate 242 to reductive radical conditions (Bu3SnH, AIBN) to initiate a regioselective 
reduction,[166] no reaction took place in our hands. 
Having all these results in mind, we decided to focus on the preparation of the deoxygenated bicyclic 
building block 190, applicable for studies toward nitiol (110) or retigeranic acid B (102). Hence, 
submission of alkene 225 to hydrogenation conditions (Pd/C, H2) eventually furnished saturated trans-
hydrindane 243 (Scheme 2.20). The use of n-pentane as a rather unusual solvent was owed to the 
observed volatility of substrate 225 and the thus assumed similar physical properties of bicycle 243. 
 
 
Scheme 2.20 Two protocols for the synthesis of the trans-hydrindane building block ent-141. 
 
Subsequently, the carbonyl functionality was unmasked by treatment with catalytic amounts of iodine 
in acetone[167] to furnish ketone ent-141. It should be noted that the overall reaction step count could be 
reduced by one step when converting ketone 220 to diene 245 via enol triflate 244 following the 
protocol established previously. Again, hydrogenation of diene 245 employing Pd/C as catalyst 
smoothly afforded the fully saturated bicycle 245, which in turn was elaborated to ketone ent-141 on a 
1.0 g scale, albeit in a lower yield compared to the first route. Having successfully established a robust 
route toward the monooxygenated trans-hydrindane building block ent-141, we were still confident at 
this time that the iso-propyl residue at C-3 was α-configured. Since the enantiomer of ketone ent-141 
had been previously prepared,[168] we were now interested in comparing our analytical data with the 
one reported in the literature. Particularly, we were curious to explore how the relative configuration at 
C-3 would change the spectroscopic properties of the two diastereomers. These investigations and the 
surprising outcome of an X-ray single crystal analysis will be described in the next subchapter. 
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2.5 Evolution of Hydrogenation Catalysts as a Diversification Tool 
 
As pointed out before, the successful enantioselective synthesis of ketone ent-141 enabled a 
comparison to the analytical data of trans-hydrindane 141. Surprisingly, a literature survey revealed 
that only the optical rotation of this compound 141 had been published.[168] This was in contrast to the 
fact that ketone 141 has been prepared several times and was an important intermediate in the 
synthesis of retigeranic acid A (101) by Hudlicky[86] and Corey.[88] The former research group reported 
the optical rotation of enantiopure ketone 141 prepared from menthene (139) (cf. Chapter 1.3) with a 
levorotary value of −10.0 (c 0.07, CDCl3, Figure 2.2).  
 
 
Figure 2.2 Comparison of specific optical rotation for enantiomeric ketones 141 and ent-141 and X-ray structure of ketone 
ent-141. 
 
Having this data in mind, we initially set out to measure the optical rotation of the prepared bicycle 
ent-141 that was still assumed to be its diastereomer 190 (Figure 2.2). Since our synthetic studies were 
conducted in the enantiomeric series relative to Hudlicky’s report,[88] we unsurprisingly determined a 
dextrorotary specific rotation with a value of +101.3 (c 1.00, CDCl3). Based on the discrepancy of the 
absolute values, we were confident to have prepared ketone 190. On the other hand, we realized that 
our value differed from the one reported by Hudlicky solely by a factor of 10, which could easily arise 
from mistyping or miscalculating. Due to this observation, we opted to prove our assumed 
structure 190 unambiguously by growing crystals suitable for X-ray diffraction. To our surprise, the 
X-ray analysis of our prepared compound revealed that the iso-propyl moiety within ketone ent-141 
resided in a trans-relationship to the angular methyl group,[123] thus matching the structure reported by 
Hudlicky.[88] It remained unclear however at which stage of the reaction sequence the observed 
epimerization occurred. 
In light of this unexpected stereochemistry, several previously observed results could now be 
rationalized based on steric arguments. With respect to the hydroboration of alkene 225, the relative 
configuration at C-3 created a sterically more demanding situation at C-2. Moreover, the steric setting 
induced a preference to locate the boron atom at the less crowded C-1 carbon (Figure 2.3), ultimately 
leading to alcohol 232 as the major regioisomer (cf. Table 2.3). 
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Figure 2.3 Retrospective rationalization of previously observed selectivity with reactions of alkene 225 and epoxide 239 
based on the now established steric environment.  
 
Despite the relative stereochemistry of the iso-propyl moiety, this addition as well as the epoxidation 
and the dihydroxylation (cf. Scheme 2.19) were notably still highly diastereoselective and only 
controlled by the angular methyl group shielding the top face. Additionally, the outcome of the 
regioselective opening of epoxide 239 could be explained as this reaction occurs via a SN2 mechanism, 
i.e. a back-side attack at C-2 that is more easily accessible from the top face than C-1. 
Overall, the surprising X-ray structure of ketone ent-141 prompted us to thoroughly check the 
proceeded route in order to discover the reaction conditions that led to this unexpected and undesired 
epimerization. Starting from the unambiguously assigned structure of ketone 220, we reexamined our 
synthetic procedures and meticulously analyzed the spectroscopic data.  
 
 
 
Scheme 2.21 (a) Hydrogenation of ketone 220 in the presence of Pd/C required a recrystallization to obtain pure ketone 222. 
(b) Observation of small amounts of a second diastereomer in the 13C NMR spectrum prior to purification. 
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Thereby, it was possible to identify the hydrogenation step as a potential origin for this isomerization 
since a second set of signals observed in the 13C NMR spectra captured our attention (Scheme 2.21). 
This impurity or, seen from the retrospect, potential diastereomer was conveniently removed in the 
original procedure by recrystallization yielding ketone 222 in 91% yield. A thorough literature survey 
revealed that transition metal catalyzed hydrogenations sometimes lead to double bond isomerization 
prior to reduction.[169] Although often unnoticed in substrates where the isomerized product is 
subsequently reduced without any consequences, this process holds the potential to result in 
epimerization or racemization. Consequently, the choice of the hydrogenation catalyst was revisited 
and Pd/C was replaced with Adam’s catalyst (PtO2), which has been used for the hydrogenation of 
isopropylene residues in complex environments.[170] Notably, conducting the reaction in MeOH 
resulted in partial reduction of the carbonyl functionality in ketone 220. This undesired side reaction 
was bypassed when submitting ketone 220 to Adam’s catalyst in EtOH under an atmosphere of 
hydrogen. Following this protocol, the reaction resulted in a clean conversion to a product identical to 
the one observed with Pd/C as catalyst by TLC analysis.  
 
Scheme 2.22 (a) Changing the catalyst from Pd/C to PtO2 resulted in the formation of a new compound. (b) Comparison of 
1H NMR spectra for the hydrogenation of ketone 220 in the presence of Pd/C (top) and PtO2 (bottom). 
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The compound was isolated in 93% yield and an ensuing NMR analysis revealed the formation of a 
diastereomer 246 comprising distinctly different NMR properties compared to ketone 222. This is 
exemplified with protons at C-2 and C-3a (IUPAC numbering). For ketone 222, a signal for 2-HA at 
δ = 2.40 ppm is visible and the diastereotopic proton 2-HB was part of a multiplet at 
δ = 1.98−1.87 ppm. In contrast, the corresponding protons for ketone 246 are centered at δ = 2.48 ppm 
for 2-HA and at δ = 2.37 ppm for 2-HB, respectively (Scheme 2.22). This significant downfield shift 
was also observed for the methine at C-3a. Its signal was determined as part of a multiplet at 
δ = 1.86−1.76 ppm for ketone 222, while a clean ddd at δ = 2.28 ppm was observed in the case of 
diastereomer 246. Moreover, the analysis of the 13C NMR spectra revealed the carbon signals for 
ketone 246 match those of the ‘impurity’ observed during the preparation of hydrogenation 
product 222. While these observations already indicated the successful synthesis of the desired 
ketone 246, an unambiguous proof of these assumptions was worth striving for.  
 
Scheme 2.23 (a) X-ray structures of hydrogenation products 222 and 246. (b) Proposed mechanism for the observed 
epimerization during hydrogenation of ketone 220 with Pd/C. 
 
To this end, attempts to crystallize both epimers 222 and 246 finally culminated in the elucidation of 
their structures by X-ray crystallography as depicted in Scheme 2.23.[123] Mechanistically, it is 
assumed that the use of Pd/C results in a double bond isomerization furnishing either tetrasubstituted 
alkene 247 or enone 248, which might both be instantly reduced with H2 (Scheme 2.23). It was shown 
that the presence of H2 played a crucial role since a blank experiment employing solely the catalyst 
Pd/C under N2 atmosphere did not result in any conversion. Interestingly, the hydrogenation of the 
isomerized alkene then occurred syn to the angular methyl group in analogy to the previously observed 
Michael reaction (cf. Chapter 2.3). One might argue that this reaction pathway is favorable as it 
provides the presumably more thermodynamically stable ketone 222, avoiding unfavored interactions 
between the angular methyl group and the iso-propyl substituent. Ultimately, it should be stated that 
this outcome can be exploited in a useful way for synthetic studies to both retigeranic acids A (102) 
and B (103, Scheme 2.24). While the preparation of ketone ent-141 was already accomplished (cf. 
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Chapter 2.4), a successful synthesis of its epimeric congener 190 would provide the basis to construct 
the pentacyclic architecture 103.  
 
 
Scheme 2.24 Hydrogenation catalysts as a diversification tool for synthetic programs toward retigeranic acids A (101) 
and B (102). 
 
Thus, these observations represent a handle for diversification in these total syntheses since simply 
changing the catalyst can provide both products 222 and 246 in high yield and selectivity. This is 
underlined by the fact that the hydrogenation with PtO2 was easily scalable, furnishing a total of 9.9 g 
of ketone 246 in 93% yield on the largest scale. With substantial amount of ketone 246 prepared, 
further transformations en route to the key building blocks 190 and 191 were then tackled. 
 
 
2.6 Synthesis of Two Versatile Building Blocks for Type A trans-
Hydrindane iso-Propyl Sesterterpenoids 
 
Having unambiguously assigned the point of epimerization, we embarked on the synthesis of building 
blocks 191 and 190. At first, ketone 246 was converted to the corresponding enol triflate 249 by 
sequential exposure to KHMDS and PhNTf2 (Scheme 2.25). This intermediate 249 then smoothly 
underwent the Pd-catalyzed reductive detriflation,[160] yielding alkene 221 in an excellent yield of 92% 
over the two steps. The reaction was conducted on up to 3 g of ketone 221 and on the largest scale, 
8.5 g of alkene 221 have been prepared. In analogy to the hydrogenation products 222 and 246, 
alkenes 225 and 221 showed remarkably different properties in NMR spectroscopy, indicating the 
successful preparation of alkene 221 without any unexpected epimerization at C-3 (IUPAC 
numbering). Alkene 221 was then treated with mCPBA to yield epoxide 250 with a fully substituted 
cyclopentane moiety. The structure of tetracycle 250 was established by X-ray crystallography,[123] 
confirming once more the correct relative stereochemistry at C-3. Interestingly, subjecting 
epoxide 250 to a hydride donor such as Super-Hydride® did not result in any conversion, even when 
conducting the reaction at 140 °C in boiling Bu2O. These observations clearly underlined that the 
trajectory for an SN2 displacement was now blocked at both C-1 and C-2 by geometric constraints. 
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Scheme 2.25 Successful large scale preparation of alkene 221 and verification of the C-3 relative stereochemistry by X-ray 
diffraction of epoxide 250. 
 
Next, a screening of alkene hydroboration conditions was carried out. Initially, a slight excess of 
BH3·SMe2 complex was employed and the reaction was allowed to warm from 0 °C to room 
temperature (Table 2.4 Entry 1).  
 
Table 2.4 Hydroboration of alkene 221: variation of reaction conditions.a 
 
 
Entry  
Borane 
(equiv.) 
T [°C] t [h] Ratio 192:251b 
Observation/ 
Remarks 
1 BH3·SMe2 (1.3) 0 to rt 0.5 2.7:1 - 
2 BH3·SMe2 (1.3) rt 0.5 2.6:1 - 
3 BH3·SMe2 (1.3) rt 2 2.0:1 
slow addition of 
BH3 in 2 h at 0 °C 
4 BH3·SMe2 (1.3) 0 to rt 0.5 2.7:1 
0.2M in alkene 
221 
5 BH3·SMe2 (1.6) 0 to rt 1 2.1:1 - 
6 BH3·SMe2 (0.7) 0 to rt 1 2.9:1 - 
7 9-BBN (237, 5.0) 0 to 66 15 - s.m. 
8 ThxBH2 (235, 1.6)c 0 to rt 1 - acetal cleavedd  
9 (sia)2BH (236, 2.5)c 0 to rt 1 - acetal cleavedd 
(a) All reactions were carried out on 10 mg scale in THF (c 0.03M) unless otherwise stated. (b) The ratio was determined by 1H NMR 
spectroscopy of the crude reaction mixture. (c) The hydroboration agent was prepared immediately prior to use. (d) Observed by 1H NMR 
spectroscopy of the crude reaction mixture. rt = room temperature, s.m. = starting material. 
 
After oxidative work up, this procedure delivered a 2.7:1 mixture of regioisomeric alcohols 192 
and 251 as assigned by 1H NMR spectroscopy (ddd at δ = 4.32 ppm for alcohol 192, d at δ = 3.74 ppm 
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for regioisomer 251, cf. Figure 2.4) in favor of the desired product 192. Thereafter, parameters such as 
temperature (Table 2.4, Entries 2, 3), addition rate (Entry 3), concentration (Entry 4) and equivalents 
of hydroboration agent (Entries 5, 6) were varied, but did not result in a significant improvement of 
the regioselectivity. Thus, the more bulky boron reagents ThxBH2 (235), (sia)2BH (236) and 
9-BBN (237) were tested. Unfortunately, they all remained unsuccessful and either led to acetal 
cleavage (Entries 8, 9) or no conversion of the starting material (Entry 7). It is worth noting that the 
amount of equivalents of hydroboration agent exceeds a profound effect on the regioselectivity of the 
reaction. Whereas the best result was obtained by quick addition of a substoichiometric amount (0.7 
equivalents) of BH3·SMe2, the ratio dropped to 2.1:1 by employing 1.6 equivalents. Potentially, this 
observation could be rationalized by the in situ formation of a chiral hydroboration agent RBH2.  
 
 
Scheme 2.26 Preparation of the chiral hydroboration agent IpcBH2 (253). 
 
Consequently, a pinene-derived chiral hydroboration agent developed by Brown and co-workers[171] 
was examined. Hence, commercially available (S)-Alpine-BoramineTM (252) was treated with 
BF3·OEt2 to liberate the free chiral compound 253 along with the precipitated BF3·TMEDA 
complex (254), which was conveniently removed by filtration (Scheme 2.26).[171] The resulting 
solution of enantiopure borane 253 was immediately used in the subsequent hydroboration with 
alkene 221. To our delight, 1H NMR spectroscopy of the crude reaction mixture after oxidative work 
up revealed an improved regiomeric ratio of 3.7:1 (Scheme 2.27).  
 
Scheme 2.27 1H NMR of the crude reaction mixture from the hydroboration of alkene 221 with IpcBH2 (253). 
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In contrast to the hydroboration of alkene 225, alcohols 192 and 251 were hardly separable, but careful 
flash column chromatography allowed for an enhancement of the ratio to 5.5:1 with a 84% yield on a 
550 mg scale (Table 2.5, Entry 1).  
 
Table 2.5 Hydroboration of alkene 221 with the chiral borane 253.a 
 
 
Entry Scale [g] Equiv. 253 
Yield after  
FCC [%] 
Ratio 192:251 
After FCCb 
1 0.55 1.5 84 5.5:1 
2 3.20 1.2 73 6.6:1 
3 3.80 1.2 67 12.4:1 
(a) The initial ratio of hydroboration remained unchanged. For further details on the reaction conditions see the experimental section. (b) The 
ratio was determined by 1H NMR spectroscopy. FCC = flash column chromatography. 
 
During scale-up with 16.1 and 13.6 mmol of alkene 221, this result was even further improved and 
delivered alcohol 192 in a ratio of 12.4:1 and 6.6:1, respectively (Table 2.5, Entries 2, 3) yielding a 
total amount of 5.20 g on the largest scale. Besides, the reaction with the enantiomeric borane ent-253, 
generated from (R)-Alpine BoramineTM, was tested and gave an approximately 1:1 mixture of 
regioisomers 192 and 251 (not shown). Therefore, the reaction of alkene 225 with borane 253 
constituted a matched case of double diastereoselection. 
 
Table 2.6 Conversion of dioxolanes 192 and 251 to ketones 255 and 256. 
 
 
Entry Scale [mg] Ratio 192:251 Yield after FCC [%] Ratio 255:256a 
1 495 5.5:1 75 12:1 
2 2660 12.4:1 82 ˃95:5 
(a) The ratio was determined by 1H NMR spectroscopy. For details on reaction conditions see the experimental section. FCC = flash column 
chromatography. 
 
Having synthesized substantial amounts of dioxolane 192, the next task was a deprotection/protection 
sequence. Hence, the diastereomeric mixture of alcohols 192 and 251 was subjected to acidic 
conditions employing PPTS in an acetone/water mixture[172] to liberate the carbonyl functionality 
within ketones 255 and 256. Gratifyingly, a slightly easier separation by flash column chromatography 
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was feasible at this stage, allowing for an improvement of the regioisomeric ratio from 5.5:1 to 12:1 
with a yield of 75% on a 495 mg scale (Table 2.6, Entry 1). On a 2.66 g scale, an initial 12.4:1 mixture 
was converted to pure alcohol 255 (˃95:5) in 82% yield (Entry 2). The major amount of material has 
not been employed for further studies and has been stored in case another protecting group would 
prove necessary. 
 
Scheme 2.28 Synthesis and X-ray structure of trans-hydrindane iso-propyl building block 191. 
 
With ketone 255 in hand, a suitable protecting group needed to be installed in order to further 
transform the cylcohexanone core. For this purpose, a TBS silyl ether was chosen and alcohol 255 was 
submitted to standard silylation conditions. This protocol furnished the pure ketone 191 in 91% yield 
(Scheme 2.28) and, overall, approximately 900 mg of this bicycle 191 have been prepared to date. The 
structure of this versatile trans-hydrindane building block 191 was unambiguously proven by X-ray 
diffraction.[123] It should be noted that an inverted order of the protecting group manipulations was 
inconvenient as the secondary TBS ether did not resist the acidic conditions required for the 
deprotection of the dioxolane moiety (not shown). 
 
 
Scheme 2.29 Successful preparation of building block 190 exploiting a diimide reduction of alkene 221. 
 
Having successfully accomplished the synthesis of the first envisaged building block 191, the attention 
was now focused on the deoxygenated analog 190. Thus, alkene 221 was subjected to hydrogenation 
conditions and, in analogy to the hydrogenation of ketone 220 (cf. Chapter 2.5), the use of Pd/C as a 
catalyst resulted in epimerization. The outcome was less pronounced in this case and gave rise to a 1:2 
ratio of the two diastereomers 243 and 257 as indicated by 1H NMR spectroscopy. More interestingly, 
the hydrogenation in the presence of PtO2 also occurred with partial epimerization in the same ratio as 
with Pd/C. This contrasts the previous experiences on the transformation of alkene 220 to ketone 246. 
We thus resorted to a non-metal mediated reduction protocol. Hence, alkene 221 was treated with 
pTsNHNH2 and NaOAc at 80 °C,[173] generating diimide in situ and resulting in a clean reaction to 
afford dioxolane 257 (Scheme 2.29). Ultimately, the carbonyl functionality was unmasked by 
treatment with PPTS to yield building block 190, which exhibited distinctly different properties in 
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comparison with its diastereomeric counterpart ent-141 regarding NMR spectroscopy and optical 
rotation. 
 
 
2.7 Conclusion 
 
In conclusion, this chapter detailed the evolution of the synthesis of three building 
blocks (ent-141, 190 and 191) starting from enantiomerically pure diketone 116. The developed route 
featured several highly diastereoselective transformations and showcased the diversification of two 
building blocks 220 and 221, thus constituting a unified approach. Moreover, the observed 
epimerization during hydrogenation of ketone 220 emphasized the importance of meticulous analysis 
of intermediates, even with seemingly straightforward reactions. Ultimately, it should be noted that the 
strategy was, as envisaged, robust and easily scalable to multigram quantities. These findings provided 
the basement for synthetic studies toward all type A trans-hydrindane iso-propyl sesterterpenoids, for 
which little progress has been reported previously. The details concerning our efforts toward the 
enantioselective syntheses of astellatol (103), nitiol (110) and YW3548 (112) will be presented in the 
next chapters of this Ph.D. thesis. 
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3 SYNTHETIC STUDIES TOWARD ASTELLATOL 
 
3.1 Astellatol: Isolation and Background 
 
The sesterterpenoid astellatol (103) was isolated in 1989 by Simpson and Sadler from aspergillus 
variecolor (syn A. stellatus).[93] Its unique architecture was elucidated by extensive applications of a 
variety of NMR techniques,[174] establishing astellatol (103) as a member of the rare class of 
pentacarbocyclic sesterterpenoids. More precisely, the carbon backbone comprises four-, five-, six- 
and seven-membered rings and features a total of ten stereogenic centers, three of which are all-carbon 
substituted. In addition to the previously introduced sterically encumbered trans-hydrindane portion, 
astellatol (103) possesses an exocyclic methylene moiety attached to a four-membered ring. 
Remarkably, only a single oxygenated site was established, thus rendering astellatol (103) a 
challenging target for total synthesis. Although astellatol (103) has been found by Simpson during the 
course of structural and biosynthetic studies on xanthone pigments, the authors did not examine the 
biological properties of this daunting natural product. Thus, a total synthesis of astellatol (103) would 
not only allow one to unambiguously confirm its relative and absolute configuration, but would also 
provide the basis to investigate its biological function in Nature. 
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Scheme 3.1 Proposed biosynthesis of astellatol (103) from pyrophosphate 34 put forward by Simpson.[175] 
 
Beside elucidating the structural features of astellatol (103), Simpson also put forth a biosynthetic 
proposal some years later.[175] Within this report, he supported his hypothesis by 13C labeled acetate 
feeding experiments, which indicates an origin along the lines of classical terpenoid biogenesis, thus 
commencing from an initial folding of geranylfarnesyl pyrophosphate (34, Scheme 3.1).[12] In the 
presence of the terpenecyclase, pentaene 34 undergoes the first C−C bond formation with generation 
of a carbocation to form bicycle 258, setting the cis-relationship between angular methyl group and the 
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iso-propyl residue. In the following, a 1,5-hydride shift is accompanied by the generation of the trans-
hydrindane portion, eventually leading to tertiary carbocation 259. This intermediate 259 is now prone 
to undergo a series of two stereospecific 1,2-hydride shifts, the result of which is the relative 
configuration of the two stereogenic centers at C-9 and C-10 (astellatol numbering). The thus 
constructed homoallylic carbocation 260 is further driven to the thermodynamic minimum by a 
homoallyl-cyclopropylcarbinyl-cyclobutyl rearrangement, generating the intriguing ring system in 
pentacarbocyclic intermediate 261 via a ring-expansion of cyclopropane 262. Ultimately, a site-
selective enzymatic oxidation furnishes the natural product 103.  
 
 
3.2 Retrosynthetic Analysis 
 
Retrosynthetically, we envisaged to access astellatol (103) via a bioinspired cationic cascade from 
allylic alcohol 263 according to the biosynthetic proposal of Simpson (Scheme 3.2).[175] In the forward 
sense, treatment of alcohol 263 with a Lewis or a Brønsted acid would form the stabilized tertiary 
carbocation 266, which could then trigger a ring closure to form tetracycle 265. In order to access the 
natural product by a stereospecific 1,2-hydride shift to form homoallylic cation 264, this cyclization 
should result in the diastereomer 265. Finally, carbocation 264 could next engage in the 
aforementioned homoallyl-cyclopropylcarbinyl-cyclobutyl rearrangement[176] to furnish the natural 
product 103 after subsequent deprotection.  
 
 
Scheme 3.2 Proposed retrosynthesis of astellatol (103) via a biomimetic cationic cascade. 
 
Domino transformations of this kind are highly challenging to realize in the laboratory without the 
help of an enzymatic environment, given the number of possible reaction pathways and side products. 
However, we assumed that the conformational bias associated with the already installed trans-
hydrindane portion might influence the outcome of the cascade in favor of the formation of 
astellatol (101). It should be stressed that this novel cationic cascade would explore the boundaries of 
biomimetic synthesis,[114] rapidly build up complexity and provide insight into the biogenesis of 
astellatol (103). 
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One major challenge concerning this envisaged route was the construction of the highly strained 
11-membered ring in tricycle 263 comprising two (E)-configured trisubstituted alkenes. Although 
these moieties have been found in natural products such as the dolabellane terpenoids, only a few 
successful routes toward their synthesis have been described in literature.[177,178] In this first 
retrosynthetic proposal, we aimed at closing the macrocycle by a ring-closing metathesis (RCM) from 
allylic alcohol 267, a moiety which is known to engage in RCM reactions (Scheme 3.3).[179,180] The 
latter intermediate 267 in turn could arise from alkene 268 by a sequential B-alkyl Suzuki 
coupling[181,182] and a vinyl lithium addition. 
 
 
Scheme 3.3 Retrosynthetic analysis of tricycle 263 by a RCM. 
 
Further retrosynthetic dissection via a lactol-Wittig reaction would give lactone 269, which already 
features the desired cis-relationship between the C-9 methine and the C-10 methyl group (astellatol 
numbering). The installation of this relative stereochemistry might be otherwise difficult to address at 
a later stage of the synthesis. We further envisaged installing the C-10 stereogenic center by the 
conformational bias (‘open-book effect’) of a tricyclic compound. To this end, tricycle 269 should be 
formed by a series of diastereo- and regioselective transformations, finally tracing astellatol (103) back 
to our previously synthesized building block 191. Although we had prepared larger amounts of trans-
hydrindane building block 191 and the associated route was practical, we decided to base our 
investigations on the more easily accessible model system 207. This ketone 207 differs from 
bicycle 191 only in the substitution pattern at the five-membered ring and we thus reasoned that both 
compounds would behave similarly in reactions at the cyclohexanone moiety. Moreover, reports on 
the mild and functional group tolerant cleavage of the t-butyl ether have been published,[183] which 
might allow for the installation of the required portion of astellatol (103) at a later stage of the 
synthesis following the chemistry established previously (cf. Chapter 2). 
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Scheme 3.4 Alternative strategies to construct tricycle 263, the precursor for the envisaged biomimetic cascade. 
 
In addition to this RCM strategy, we also envisioned closing the 11-membered rings by means of other 
methodologies. In particular, we thought that we could construct the macrocycle by an intramolecular 
B-alkyl Suzuki coupling from vinyl iodide 270 (Scheme 3.4). Alternatively, we aimed at examining an 
intramolecular allylation of allylic sulfone 271, the sulfur moiety of which could be later reductively 
cleaved. Notably, both cyclization precursors 270 and 271 should also be accessible from alkene 268, 
thus rendering this compound 268 a key intermediate in our efforts toward astellatol (103). A more 
detailed retrosynthetic analysis of these approaches will be given at the relevant sections (cf. Chapters 
3.5, 3.6). 
 
 
3.3 Installation of the Stereogenic Centers at C-9 and C-10 
 
In light of the retrosynthesis presented above, we embarked on a total synthesis program toward 
astellatol (103). Thereby, the installation of the two adjacent stereogenic centers at C-9 and C-10 was 
initially center stage. As pointed out before, these investigations were conducted utilizing 
enantiomerically pure ketone 207 as a model substrate.  
 
 
Scheme 3.5 Proof of site-selective reactivity of ketone 207: preparation of enone 273 and bicycle 276. 
 
In order to establish the desired regioselectivity in reactions involving the carbonyl functionality in 
ketone 207, we initially carried out two simple transformations (Scheme 3.5). On the one hand, 
ketone 207 was treated with phenyltrimethylammonium tribromide (PTAB) in the presence of 
catalytic amounts of HOAc[141] to generate a diastereomeric mixture of α-bromo carbonyl 
compound 272. This compound was further elaborated to enone 273 by exposure to LiBr and 
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Li2CO3[140] at 120 °C in 49% yield over the two steps as the sole product. Notably, 
trans-hydrindenone 273 might at some point serve as an intermediate for synthetic studies toward the 
structurally related sesquiterpenoid 8,10-dihydroseiricardine A (274).[184] On the other hand, we 
conducted a regioselective methoxy-carbonylation by sequential treatment with LDA and Mander’s 
reagent (275)[185] and the structure of the single product, β-keto ester 276, was elucidated by 2D NMR 
analysis. Furthermore, we investigated the conversion of compound 276 to vinyl allyl ether 277 
following a protocol reported by Jacobsen and co-workers.[186] However, a brief screen of reaction 
conditions employing 1,1’-(azodicarbonyl)dipiperidine (ADDP) did not result in any conversion. We 
were particularly interested in this transformation since the latter intermediate 277 could serve as a 
precursor for a Claisen rearrangement.[62] Potentially, such a process could install the C-9 and C-10 
stereogenic centers in intermediate 278 by a stereospecific reaction via a chair-like six-membered 
transition state.  
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Scheme 3.6 Attempts to functionalize hydrindanone 207 via alkylation or allylation: diastereo- and regioselective synthesis 
of ketone 280 by Pd-catalysis and two proposed catalytic cycles. 
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Since a proof for the desired regioselectivity in transformations of ketone 207 had been achieved, we 
next focused on alkylation/allylation protocols utilizing different electrophiles such as allyl iodide or 
α-halo acetic acid derivatives (Scheme 3.6). Unfortunately, ketone 207 was resistant to all the attempts 
to form product 279 resulting in no or very poor conversion. These observations were in accordance 
with previous reports by Collins[187] as well as by Covey and co-workers[134,188] in their efforts to 
construct rearranged steroid ring systems. Fortunately, Covey found in these investigations that 
indenone 207 can be “alkylated regio- and diastereoselectively at C-6 (IUPAC numbering) with allylic 
electrophiles via potassium enoxyborates in the presence of catalytic amounts of a palladium 
complex”.[187] This methodology had been developed earlier by Negishi and co-workers and was 
shown to be general for a broad range of ketones.[189] Encouraged by this report, we set out to 
reproduce these results in our hands. Eventually, generation of the potassium enolate of ketone 207 by 
exposure to KHMDS at room temperature was followed by sequential addition of Et3B and a mixture 
of allyl bromide and catalytic amounts of Pd(PPh3)4 at −78 °C. Upon warming to room temperature for 
3 h and subsequent aqueous work up, the desired product 280 was isolated in 75% yield on a 5 g scale. 
The relative configuration of the newly installed stereogenic center was verified by 2D NOESY 
experiments. Noteworthy, it turned out that the success of this reaction was highly dependent on the 
quality of the Et3B solution employed since reliable results were only obtained by preparing a solution 
of Et3B immediately prior to use from neat Et3B and thoroughly degassed THF. While the mechanism 
of this reaction has been not illuminated thus far, a plausible catalytic cycle commences by the 
formation of PdII π-allyl complex 282 from allyl bromide and the active Pd0 species. In the following, 
this intermediate 282 might undergo a transmetallation with potassium enoxyborate 285 generated 
previously. The resulting Pd-enolate could be described as η1,η3-complex 283 or the 
bis-η1-complex 284. The latter intermediate 284 was recently proposed by Morken and co-workers in 
a Pd-catalyzed allyl-allyl cross coupling of allylic boronates[190] and was proven in silico to be the 
active species for the enantioselective decarboxylative Tsuji allylation by Stoltz and Goodard.[191] 
Intermediate 284 could undergo a reductive 3,3’-elimination to furnish the desired product 280 and 
regenerate Pd0. Alternatively, one could formulate a direct SN2-type substitution of the enoxy 
boronate 285 on the η1-bound complex 281. Such a mechanism would presumably rather involve an 
outer-sphere nucleophilic attack as found for Pd-catalyzed allylations with stabilized enolates in the 
pioneering work of Helmchen.[192]  
Having prepared substantial amounts of allylated hydrindane 280, we examined a reduction of the 
ketone moiety. In the event, we found a reversal of diastereoselectivity depending on the reducing 
reagent employed (Scheme 3.7). Whereas exposure of ketone 280 to NaBH4 at 0 °C delivered 
alcohol 286 in 79% yield, treatment of intermediate 280 with the bulky hydride donor 
K-Selectride® (287)[193] exclusively led to an equatorial attack to furnish α-diastereomer 288 in high 
yield. The structure of alcohol 286 was elucidated based on 2D NOESY experiments and careful 
analysis of coupling constants. 
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Scheme 3.7 Reagent controlled reduction of ketone 280 and preparation of lactone 290. 
 
In order to install the envisioned γ-lactone moiety, we subsequently sought to covert alkene 288 to the 
corresponding aldehyde by ozonolysis in a CH2Cl2/ROH solvent mixture. Unfortunately, under these 
reaction conditions, the intermediately generated lactol 289 was quantitatively converted to the 
corresponding acetals by reaction with the protic co-solvents EtOH or MeOH (not shown). As 
carrying out an ozonolysis in CH2Cl2 resulted with multiple unidentified side products, we next 
submitted alkene 288 to a Lemieux-Johnson oxidation employing a catalytic amount of OsO4 in the 
presence of NaIO4 and 2,6-lutidine and using 1,4-dioxane and H2O as a solvent mixture.[194] These 
reaction conditions, essentially a dihydroxylation followed by diol cleavage in one pot, efficiently 
provided a diastereomeric mixture of lactol 289, which was oxidized to the corresponding lactone 290 
by treatment with PCC. Overall, this two-step protocol gave tricycle 290 in an excellent yield of 90% 
on a 3.6 g scale and the three-dimensional architecture was verified by key NOE correlations as shown 
in Scheme 3.7. 
 
 
Scheme 3.8 (a) Diastereoselective synthesis of lactone 291 benefiting from the conformational bias of substrate 290. 
(b) Structure elucidation of tricycle 291 by coupling constant analysis and X-ray diffraction. 
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Next, the installation of the C-10 methyl residue was explored. For this purpose, deprotonation of 
lactone 290 with LiHMDS generated the lithium enolate, which in turn was intercepted with excess 
MeI.[195] As expected from the cyclic conformational bias of the substrate 290, tricycle 291 was 
obtained as a single diastereomer in good yield. The desired stereochemical outcome of this reaction 
was initially elucidated by careful analysis of coupling constants. As shown in Scheme 3.8, the C-10 
methine proton was observed as a quartet, originating from coupling with the three protons of the 
newly installed methyl residue. This observation indicated a dihedral angle H10−C10−C9−H9 of around 
90°, resulting in a small coupling constant close to 0 Hz according to the Karplus curve.[196] DFT 
calculations performed by Dr. R. Webster in the Trauner Group revealed an dihedral angle of 87° for 
lactone 291, which was in agreement with the observed spectroscopic data. Later on, we additionally 
established the structure of tricycle 291 unambiguously by X-ray crystallography.  
 
 
Scheme 3.9 Attempts to effect a Wittig reaction on lactol 292: synthesis of unsaturated ester 295. 
 
As outlined in our retrosynthetic analysis (cf. Chapter 3.2), the focus was now turned to the installation 
of an alkene moiety. To this end, we initially reduced lactone 291 to the corresponding lactol 292 by 
treatment with DIBAL-H at low temperature (Scheme 3.9). Thereafter, we envisioned to transform 
this intermediate 292 into secondary alcohol 293 by exposure to standard Wittig methylenation 
conditions, a process well precedent in literature.[197] In our hands however, this reaction proceeded 
only at elevated temperatures and provided alcohol 293 in traces as a mixture of diastereomers as 
indicated by 1H NMR spectroscopy. In contrast, reaction with ylene 294 yielded a single 
diastereomer 295, albeit in moderate yield even at prolonged reaction times (40 h) and 110 °C. Its 
relative stereochemistry at C-10 could not be assigned unambiguously. 
With these results in mind, we decided to pursue another strategy and synthesized diol 296 by 
treatment with LiAlH4 in excellent yield (Scheme 3.10). In order to avoid an orthogonal protecting 
group strategy to distinguish the two free alcohol functionalities present in bicycle 296, we exploited 
the potential of Swern oxidation conditions to convert primary TES ethers directly to aldehydes.[198] To 
this end, we accessed intermediate 297 by double silylation of diol 296 with Et3SiOTf and investigated 
the subsequent Swern oxidation. 
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Scheme 3.10 Synthesis of building block 299 via deprotective Swern oxidation. 
 
We found that a careful control of the external temperature not exceeding −60 °C and prolonged 
reaction times (7−8 h) were crucial for a success of the reaction since otherwise lower yields and/or 
the bisoxidized carbonyl compound were observed (not shown). Under the optimized reaction 
conditions, aldehyde 298 was obtained in 88% yield on a 1.48 g scale as a single diastereomer, not 
indicating any epimerization at the α-stereogenic center by NMR spectroscopy. While scaling to 
5.31 g of bissilyl ether 297, the yield decreased (75%) and remaining starting material 297 was 
recovered (8%). Therefore, the reaction times should be further extended in future experiments on this 
or any larger scale. Ultimately, a Wittig methylenation converted aldehyde 298 to alkene 299 in a high 
yield of 93%. On the largest scale, 2.86 g of this valuable intermediate 299 have been prepared, which 
served as the branching point for several routes toward constructing the strained 11-membered 
ring (cf. Chapters 3.4−3.7).  
 
 
Scheme 3.11 Conversion of alkene 299 to tricyclic lactone 301. 
 
In order to provide additional proof for the relative stereochemistry at C-10, the alkene moiety present 
in trans-hydrindane 299 was subjected to hydroboration conditions with 9-BBN (237) and subsequent 
oxidative work up gave rise to primary alcohol 300 (Scheme 3.11). Upon CSA mediated silyl ether 
cleavage, the resulting diol (not shown) was further elaborated to lactone 301 by a TEMPO/BAIB 
oxidation.[199] Unfortunately, the proton signals at C-9 and C-10 (astellatol numbering) possess the 
same shifts in the 1H NMR spectrum in CDCl3, but a NOE correlation between the C-10 methyl group 
and the C-1 methine indicated that no epimerization took place during LiAlH4 reduction, Swern 
oxidation and Wittig olefination. 
Having established an efficient and scalable route to alkene 299, we set out to adapt the reaction 
conditions to trans-hydrindane building block 191 with the correct substitution pattern on the five-
membered ring in place. Thus, we submitted ketone 191 to the allylation conditions established 
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previously and isolated the desired product 302 in 82% yield as a single diastereomer (Scheme 3.12). 
Subsequently, exposure of ketone 302 to K-Selectride® (287) gave rise to secondary alcohol 303, 
which in turn set the stage for the Lemieux-Johnson oxidation. After some optimization, this reaction 
proceeded smoothly and we accomplished the synthesis of tricycle 304 after PCC oxidation in 
86% yield over the two steps. 
  
 
Scheme 3.12 Application of reaction conditions from the model studies: synthesis of building block 268. 
 
Compared to the model system, the subsequent diastereoselective methylation required a slightly 
higher reaction temperature of −40 °C in order to achieve full conversion, leading cleanly to the 
formation of lactone 269 in 83% yield (Scheme 3.12). In analogy to the preparation of alkene 299, this 
intermediate 269 was next reduced with LiAlH4 and the generated corresponding diol (not shown) was 
immediately used in the following reaction. This was due to the acid sensitivity of the diol that became 
apparent by partial cleavage of the secondary TBS ether e.g. in the NMR solvent CDCl3 despite 
previous neutralization by filtering over basic alumina. Nevertheless, subsequent silylation with 
Et3SiCl gave access to bicycle 305 in 88% yield over the two steps. At last, deprotective Swern 
oxidation and Wittig methylenation completed the preparation of alkene 268 on a largest scale of 
80 mg. In initial experiments, we already found that a selective cleavage of the TES ether in 
bicycle 268 under acidic conditions (e.g. CSA or PPTS in CH2Cl2/MeOH) will require careful control 
of the reaction times to avoid a concomitant cleavage of the sterically more demanding TBS ether (not 
shown). In future experiments, a thorough screening of reagents and reaction conditions should be 
investigated since both secondary alcohols need to be distinguished by orthogonal protecting groups in 
the further course of the synthetic studies toward astellatol (103). Alternatively, a more robust 
protecting group such as TBDPS, TIPS, SEM or MOM at the C-5 hydroxyl group (astellatol 
numbering) should be introduced before conducting the reaction sequence presented in this chapter. 
With the correct relative stereochemistry at C-9 and C-10 installed, the preparation of the strained 
11-membered ring for the envisioned biomimetic cationic cascade was now focused on.  
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3.4 Toward Constructing the Macrocycle: The Metathesis Approach 
 
As pointed out earlier, our studies toward the construction of the 11-membered macrocycle were 
carried out on a model system (cf. Chapter 3.2). Since we had prepared substantial quantities of 
alkene 299, our route toward the precursor for a RCM macrocyclization commenced with the 
synthesis of an appropriate vinyl iodide for a Pd-catalyzed B-alkyl Suzuki coupling.[181] To this end, 
commercially available alkyne 306 was subjected to Negishi carboalumination conditions following a 
protocol by Floreancig and co-workers (Scheme 3.12).[200] Thereby, alkyne 306 was reacted with 
AlMe3 in the presence of catalytic amounts of Cp2ZrCl2 and 1.0 equivalent of H2O, both being known 
to facilitate the desired transformation.[201,202] Following syn-selective carboalumination, the 
intermediate organoaluminum species (not shown) was next intercepted with I2 to yield vinyl 
iodide 307 under retention of the alkene geometry. Subsequently, silylation of the free alcohol under 
standard reaction conditions gave rise to coupling partner 308, the (E)-configuration of which was 
verified by NOE spectroscopy. 
 
 
Scheme 3.13 (a) Two-step synthesis of vinyl iodide 308 by a Negishi carbalumination strategy. (b) Fragment coupling of 
alkene 299 and vinyl iodide 308 via a B-alkyl Suzuki coupling and synthesis of aldehyde 312. 
 
With both reaction partners in hand, efforts toward the fragment coupling were 
undertaken (Scheme 3.13). As a guide we considered the previous studies on the hydroboration of 
alkene 299 with 9-BBN (237). It was established that this reaction occurs best while heating the 
unsaturated intermediate 299 with hydroboration agent 237 to 40 °C for 3 h (cf. Chapter 3.3). Using 
these conditions, we generated the corresponding alkyl-boron species 309, which was subsequently 
treated with aqueous Cs2CO3 solution to form the corresponding boronate 310. This intermediate was 
then combined with vinyl iodide 308 in the presence of catalytic amounts of Pd(dppf)Cl2 and AsPh3 as 
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an additional ligand in a THF/DMF/H2O mixture.[203] The desired coupling occurred smoothly and 
provided trisubstituted alkene 311, which could not be entirely purified at this stage. Nevertheless, 
bissilyl ether 311 was submitted to the previously established deprotective Swern oxidation 
conditions (cf. Chapter 3.3) furnishing aldehyde 312 in a good yield of 69% over the two steps. This 
sequence demonstrated the robustness and generality of B-alkyl Suzuki couplings, which has led to 
widespread applications in organic synthesis,[181] e.g. evidenced by the large scale synthesis of 
discodermolide performed at Novartis.[204] 
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Scheme 3.14 Catalytic cycle of for the Pd-catalyzed B-alkyl Suzuki coupling. 
 
Mechanistically,[181] this reaction proceeds via a standard catalytic cycle of a Pd-mediated cross 
coupling and commences with the oxidative addition of Pd0 into the C−I bond of alkene 308 to furnish 
PdII-complex 314 (Scheme 3.14). An ensuing transmetallation with the previously generated 
boronate 310 delivers intermediate 313 and sets the stage for a final reductive elimination to afford the 
coupled product 311 under regeneration of the catalytically active Pd0 species. The ligand dppf was 
employed in this process due to its large bite angle since this ligand scaffold has previously been 
shown to suppress β-hydride eliminations in cross coupling reactions.[205] Additionally, ligands with 
larger bite angles have proven to accelerate reductive eliminations. The choice of the ligand thus 
allows for the Pd-catalyzed coupling of aliphatic organometallic reagents, which is usually 
complicated by competing hydride elimination processes. This mechanistic route would first result in 
the formation of alkene 299 and H−PdII species 315 that in turn would instantly regenerate 
catalytically active Pd0 and the protodeiodinated coupling partner 316. Moreover, the use of AsPh3 as 
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an additive has been shown to provide cleaner reactions at higher turnover rates by Johnson[206] and is 
since then frequently used in B-alkyl Suzuki couplings. 
 
 
Scheme 3.15 Efficient preparation of RCM precursor 320. 
 
In order to complete the synthesis of the model RCM precursor 320, the aldehyde functionality in 
bicycle 312 was converted to an alkene via a Wittig reaction giving rise to diene 317 in high 
yield (Scheme 3.15). Next, the silyl ether within trans-hydrindane 317 was cleaved and the resulting 
secondary alcohol 318 was oxidized with Dess-Martin periodinane (DMP)[207,208] under buffered 
reaction conditions. By this two-step sequence, ketone 319 was efficiently accessed in 85% yield. All 
remaining was the installation of an isopropylene moiety that was realized by addition of a vinyl 
lithium species generated in situ from 2-bromopropene and t-BuLi at −78 °C. The desired 
transformation was surprisingly high yielding (92%) given the steric encumbrance at the carbonyl 
functionality, and furnished tertiary alcohol 320 as single diastereomer. The relative configuration at 
the newly formed stereogenic center could not be assigned unambiguously at this stage, but we 
assumed an equatorial attack due to the shielding effect of the adjacent substituent, blocking an axial 
attack from the si-face. It should be noted that the relative configuration was inconsequential for the 
further synthesis as the tertiary alcohol would serve as the precursor for the generation of a 
carbocation to trigger the envisaged cationic cascade (cf. Chapter 3.2).  
Next, we embarked on the investigation of the key RCM metathesis. Although, the power of this 
synthetic tool has been increasing over the years, there is only little precedence reported for the 
preparation of 11-membered rings.[209] This fact is especially true for the synthesis of trisubstituted 
alkenes, thus underlining the challenges associated with the envisaged ring closure. Following a report 
by Fujii and co-workers,[210] we initially tested the use of Grubbs 2nd generation catalyst (323) in 
refluxing CH2Cl2 (Table 3.1, Entry 1). This and the following reactions were performed at high 
dilution (0.004M) to disfavor intermolecular reactions. These conditions led to the formation of a new 
product, which was not the desired tricycle 321, but rather the homocoupled dimer 322 as an 
undetermined mixture of the (E)- and (Z)-isomers. 
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Table 3.1 Toward a RCM macrocyclization: variation of reaction conditions.a 
 
 
Entry 
Catalyst 
[mol-%] 
Solvent T [°C] t [h] Observation 
1 323 (20) CH2Cl2 40 6 Dimer 322 
2b 323 (30) benzene 81 16 Dimer 322 
3b 324 (10) DCE 83 19 Dimer 322 
4b,c 323 (20) PhMe 110 24 s.m. 
5b 323 (30) PhMe 110 72 Dimer 322 
6b 325 (40) benzene 81 40 Dimer 322 
(a) All reactions were carried out on 5 mg scale in degassed solvents (3 x freeze-pump-thaw). (b) The substrate was added to a refluxing 
solution of the employed catalyst (0.2 mM) within 2−4 h using a syringe-pump. (c) The reaction was carried out with para-benzoquinone 
(30 mol-%) as additive. s.m. = starting material. 
 
This product 322 was indentified by ESI mass spectrometry and 1H NMR and HSQC spectroscopy. 
The 1H NMR spectrum clearly showed the consumption of the terminal alkene by the disappearance of 
the respective 1H NMR signals (ddt at δ = 5.81 ppm and centrosymmetric multiplets at δ = 5.01 and 
4.94 ppm). At the same time, a new signal at δ = 5.39 and 5.34 ppm for the (E)- and (Z)-isomer 
appeared. In addition, the characteristic signals for the isopropylene moiety at δ = 5.09 and 4.88 ppm 
remained unchanged. (Figure 3.1). We assumed that this outcome might be attributed to a high 
activation barrier for the formation of the strained macrocycle and thus changed the solvent to the 
higher boiling benzene (Table 3.1, Entry 2). Furthermore, the dilution was increased by slowly adding 
a solution of substrate 320 to catalyst 323. However, this procedure did not provide any new reaction 
product as indicated by 1H NMR spectroscopy.  
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Figure 3.1 Comparison of 1H NMR spectra (both recorded at 600 MHz in CDCl3) of substrate 320 and obtained 
homocoupled dimer 322. 
 
We next examined the use of the Grubbs-Hoveyda 2nd generation catalyst (324) in refluxing 
1,2-dichloroethane (DCE), a solvent that has been shown to avoid decomposition of the catalyst at 
elevated temperatures (Table 3.1, Entry 3).[211] While following this protocol, we could again only 
observe the homocoupled dimer 322 and we therefore resorted to toluene as an ever higher boiling 
solvent. In this experiment, we used catalyst 323 and added p-benzoquinone to the reaction mixture, 
which has been shown to suppress Ru-catalyzed alkene isomerisation processes.[212] Interestingly, 
these reaction conditions resulted mainly in the reisolation of starting material 320, even when using 
20 mol-% catalyst loading and prolonged reaction times (Entry 4). Next, we repeated the experiment 
without the additive and after 72 h, only the formation of dimer 322 was observed (Entry 5). In an 
additional experiment, we examined the reactivity of the Stewart-Grubbs catalyst 325. This 
Ru-complex 325 was developed for sterically demanding substrates and has been efficiently utilized 
for the cross metathesis of hindered allylic alcohols[213] and the construction of tri- and even 
tetrasubstituted alkenes by RCM.[214] Unfortunately, exposure of substrate 320 to catalyst 325 again 
resulted in the formation of dimer 322 (Entry 6) and we thus focused on other strategies to assemble 
the strained 11-membered ring in the following.  
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Figure 3.2 Potential substrates for future RCM strategies. 
 
Ultimately, it should be stated that is worth revisiting the RCM strategy and examine other catalysts 
such as the Mo-based ones reported by Schrock and co-workers.[215] In addition, one reason for the so 
far unsuccessful attempts could be the encumbered reaction site at the isopropylene residue since 
metathesis reaction are often highly sensitive to the steric environment. Thus, one possibility for 
further investigations following this strategy could involve a relay metathesis, first introduced by 
Hoye[216] and recently applied several times for the construction of ring systems in natural product 
synthesis.[217] Such a process would involve the synthesis of tetraene 326 (Figure 3.2). Alternatively, 
one could envisage relocating the reaction sites for the RCM with triene 327, in which the terminal 
alkene and the isopropylene moiety are embedded in a sterically less demanding setting.  
 
 
3.5 Toward Constructing the Macrocycle: The B-Alkyl Suzuki Approach 
 
In addition to the RCM approach described in the previous chapter, three further strategies toward the 
total synthesis of astellatol (103) were investigated in the course of this Ph.D. thesis, all starting from 
the versatile building block 299. One of these routes involved an intramolecular B-alkyl Suzuki 
coupling of alkene 328 to close the 11-membered macrocycle in tricycle 321 for the envisioned 
bioinspired cationic cascade (Scheme 3.16). As discussed, the B-alkyl Suzuki reaction is frequently 
employed in organic synthesis[181] and it has been utilized by several research groups to access strained 
medium-sized rings.[218]  
 
Scheme 3.16 (a) Envisaged route toward tricycle 321 via a B-alkyl Suzuki macrocyclization. (b) Three-step synthesis of 
vinyl iodide 330. 
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From a retrosynthetic point of view, we envisaged to accomplish the synthesis of cyclization 
precursor 328 via addition of a vinyl lithium species to a ketone and a subsequent elaboration of a 
primary alcohol functionality to vinyl iodide 328 by a Negishi carboalumination. Thus, this strategy 
would allow for the stereospecific installation of the double bond geometries found in triene 328. In 
order to access the desired substrate 328, we initially prepared a C6-building block following a 
procedure by Zakarian and co-workers as outlined in Scheme 3.16.[219] The sequence commenced with 
the protection of the alcohol functionality in alkyne 306 as its PMB ether (not shown). Generation of 
the resulting alkynyl lithium species by exposure to n-BuLi was followed by reaction with excess MeI 
to afford alkyne 329. Notably, this reaction required the addition of HMPA to proceed in completion. 
Otherwise, a mixture of starting material and the desired product 329 was obtained, which was 
inseparable by flash column chromatography. Next, alkyne 329 was subjected to hydrozirconation 
conditions, which are known to result in good regioselectivity for methyl substituted internal alkynes. 
To this end, treatment of intermediate 329 with Schwartz’s reagent Cp2Zr(Cl)H[220] generated in situ 
from Cp2ZrCl2 and DIBAL-H and subsequent stereospecific iododezirconation afforded vinyl 
iodide 330 as an approximately 10:1 mixture of regioisomers as determined by 1H NMR spectroscopy. 
Careful flash column chromatography allowed for the isolation of pure fragment 330, albeit in a 
modest yield of 43%. 
 
 
Scheme 3.17 Synthesis of tertiary alcohol 333 and its preferred conformation based on NOE spectroscopy and coupling 
constant analysis. 
 
With vinyl iodide 330 in hand, we next deprotected the silylated secondary alcohol functionality in 
bicycle 299 under acidic conditions and the resulting alcohol 331 was oxidized by DMP[207] to provide 
ketone 332 in 90% yield over the two steps (Scheme 3.17). Thereafter, both fragments were coupled. 
To this end, a halogen-lithium exchange of vinyl iodide 330 with t-BuLi provided the corresponding 
organo lithium species, which cleanly reacted with ketone 332 at −78 °C to afford allylic alcohol 333 
as a single diastereomer. The outcome of this reaction was verified by key NOE correlations as shown 
in Scheme 3.17. Moreover, careful analysis of the spectroscopic data revealed the preferred 
conformation of the stereogenic center at C-10. Based on the lacking NOE signal between 10-H and 
9−H, both groups could potentially point into opposite directions. This assumption was further 
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supported by the scalar coupling of the C-9 methine (ddd at δ = 1.86 ppm with J = 12.7, 3.7 and 
2.3 Hz). While the first two values could be identified to an axial-axial coupling and an axial-
equatorial coupling within the six-membered ring (to 8-H), the remaining coupling constant of 
J = 2.3 Hz accounts for the coupling of 10-H. Thus, this value indicates a dihedral angle of around 67° 
according to the Karplus curve.[221] Consequently, this observation suggested that a rotation around the 
C9−C10 bond would be required for an efficient ring closure, thus constituting an important factor for 
the activation barrier. 
Having combined the two fragments, we next focused on the transformation of the PMB ether in 
trans-hydrindane 333 to an alkyne moiety, the precursor for the installation of the required vinyl 
iodide. For this purpose, the PMB ether was cleaved under oxidative reaction conditions using DDQ 
and the resulting diol 334 was smoothly oxidized under Swern conditions[222] to furnish 
aldehyde 335 (Scheme 3.18). In contrast to this protocol, the latter transformation occurred only at 
elevated temperature and in the presence of a large excess of oxidation agent when using DMP. 
 
 
Scheme 3.18 Three-step sequence from PMB ether 333 to alkyne 337 and attempted Negishi carbalumination. 
 
Next, the crude intermediate 335 was homologated using the Ohira-Bestmann reagent (336)[223] that 
generates the Gilbert-Seyferth reagent[224] in situ by a retro aldol reaction of β-keto phosphonate 335 
with KOMe. This three-step sequence efficiently provided access to alkyne 337, which in turn was 
subjected to Negishi carboalumination conditions. Unfortunately, consecutive exposure of alkyne 337 
to Cp2ZrCl2/AlMe3 and I2 led to decomposition of the starting material, although there has been 
literature precedence for the exploitation of this methodology in complex settings.[225] Due to this 
observation, we resorted to an alternative four-step protocol for the preparation of the requisite vinyl 
iodide 328, which involved a regioselective Pd-catalyzed silylstannylation of the terminal alkyne 
moiety present in tertiary alcohol 337. This methodology was first reported by Chenard at DuPont[226] 
and has been successfully applied in natural product synthesis.[227] In addition, the research group of 
RajanBabu has expanded the scope of this catalytic procedure,[228] thereby demonstrating that free 
alcohol functionalities poison the catalyst and thus lower the efficiency of the process. Therefore, we 
initially set out to silylate alcohol 337. As we were aware of the fact that the alkyne moiety is prone to 
78  THEORETICAL SECTION 
be deprotonated, we avoided the use of strong bases such as KHMDS, LDA or n-BuLi and examined 
other protocols as presented in Table 3.2. 
 
Table 3.2 Attempted silylation of alcohol 337: variation of reaction conditions.a 
 
 
Entry 
Silylation 
Agent 
Base/additive Solvent T [°C] t [h] Observation 
1 TMSOTf 2,6-lutidine CH2Cl2 0 to 40 5 s.m. 
2 Et3SiCl DMAP pyridine 90 20 s.m. 
3 339 - DMF rt 16 s.m. 
(a) All reactions were carried out on 5 mg scale with excess silylation agent (3−10 eq.). s.m. = starting material, rt = room temperature. 
 
However, neither using TMSOTf/2,6-lutidine in boiling CH2Cl2 (Table 3.2, Entry 1)[229] nor 
Et3SiCl/DMAP in pyridine[230] at 90 °C (Entry 2) effected the desired transformation to a silyl 
ether 338. As even subjection of alcohol 337 to the highly reactive silylation agent BSTFA (339) in 
DMF[231] resulted in reisolation of starting material (Entry 3), we reasoned that the alcohol 
functionality in alkyne 337 might be sterically so inaccessible that it would not thwart the Pd-catalysis.  
Thus, we exposed alkyne 337 to a catalytic amount of Pd(PPh3)4 and excess Me3SiSnBu3 in refluxing 
THF following a procedure by Williams (Scheme 3.19).[232] Gratifyingly, these conditions resulted in 
the formation of vinyl stannane 340 as a single regioisomer in 75% yield and we verified the 
diastereoselective outcome by HMBC and NOE spectroscopy. It should be mentioned that the reasons 
for this selectivity have not been clarified in the literature to date to the best of our knowledge. 
 
 
Scheme 3.19 Toward the installation of a vinyl iodide: synthesis of vinyl silane 343 via regioselective silylstannylation.  
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With the addition product 340 in hand, we embarked on the installation of the trisubstituted alkene 
moiety. To this end, intermediate 340 engaged in a chemoselective iododestannylation by treatment 
with 1.0 equivalent of I2 at −40 °C in the presence of the bulky pyridine derivative 341[232] to furnish 
vinyl iodide 342 in high yield. A subsequent cuprate coupling afforded vinyl silane 343, at which point 
we established the (E)-double bond geometry by NOESY experiments once more. Notably, triene 343 
contained all carbon atoms required for the construction of the pentacyclic backbone of 
astellatol (103), only missing the correct substitution pattern at the cyclopentane portion. The 
iododesilylation of vinyl silane 343 remained to be studied in order to access macrocyclization 
precursor 328. Hence, we treated vinyl silane 343 with excess NIS (≈ 2.5 equivalents) in MeCN[232] 
and observed the formation of a new product. Upon isolation, 1H NMR spectroscopy revealed that the 
iododesilylation took place as indicated by a downfield shift of the vinyl proton from δ = 5.20 ppm to 
δ = 5.89 ppm. Unfortunately, the reaction conditions presumably also caused an iodoetherification as 
proton signals at δ = 4.53 and 3.61 ppm were observed, which could belong to protons attached to a 
heteroatom. In addition, the characteristic protons signals for a terminal vinyl group disappeared and 
we thus tentatively assigned the structure of the new compound as tricycle 344. While the use of 
excess NIS in MeCN is usually required for the iododesilylation to secure retention of the double bond 
geometry,[233] Zakarian has shown that the use of 1,1,1,3,3,3-hexafluoro-2-pronanol (HFIP) as solvent 
allows to lower the amount of NIS to stoichiometric quantities.[234] Unfortunately, this protocol 
resulted in decomposition of vinyl silane 343 in our hands. In light of the observation of side 
product 344, we rationalized that a protection of the alcohol functionality might avoid the 
intramolecular cyclization, but the examined conditions (KHMDS, Et3SiCl or Ac2O, py, 90 °C) did not 
meet with success. Due to material constraints, no further investigations could be undertaken at this 
stage. Thus, this strategy should be reexamined with larger quantities of vinyl silane 343 in order to 
perform at thorough screening for the protection of the alcohol functionality and to test other 
iododesilylation conditions. 
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Scheme 3.20 Revised strategy to vinyl iodide 328 involving a late-stage alkene installation. 
 
An alternative solution for the above presented problem of the undesired etherification could be a late-
stage installation of the terminal alkene in cyclization precursor 328. This aim could be achieved by a 
Grieco elimination[235] from the corresponding primary alcohol 345 (Scheme 3.20) since protocols for 
this transformation in the presence of a sensitive vinyl iodide moiety are known.[236] Bicycle 345 in 
turn should be accessible from previously prepared alcohol 300 based on our earlier explorations (vide 
supra). 
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Scheme 3.21 Progress toward the preparation of vinyl iodide 351: a seven-step synthesis of alkyne 350. 
 
In order to examine this route, alcohol 300 (cf. Chapter 3.3) was converted to its TBDPS ether (not 
shown) and a chemoselective desilylation under acidic conditions provided secondary alcohol 346 in 
87% yield (Scheme 3.21). Following Swern oxidation[222] to afford ketone 347, the two fragments 347 
and 330 were coupled as previously established. Thus, exposure of trans-hydrindane 347 to an organo 
lithium species generated from vinyl iodide 330 furnished allylic alcohol 348 in a moderate yield of 
60%. Next, cleavage of the PMB ether with DDQ provided access to diol 349, which in turn was 
elaborated to alkyne 350 by sequential Swern oxidation[222] and Ohira-Bestmann homologation.[223] 
The following steps toward vinyl iodide 351 and cyclization precursor 328 have not yet been explored 
and should be addressed in future efforts.  
 
 
3.6 Toward Constructing the Macrocycle: The Allylation Approach 
 
In parallel to the two approaches detailed in the previous subchapters, we explored a third strategy to 
close the strained 11-membered macrocycle in alcohol 321. This route hinged on an intramolecular 
allylation of sulfone 352 and a subsequent desulfurization based on a report by Yamada,[237] who 
successfully accessed dolabellane marine diterpenoids[177] with this strategy (Scheme 3.22). Allyl 
sulfone 352 should again arise from alkene 299 by sequential B-alkyl Suzuki coupling, vinyl lithium 
addition to a cyclohexanone moiety and selective manipulation of functional groups. For this purpose, 
we first prepared an appropriate vinyl iodide fragment 357 suitable for the installation of a 
trisubstituted alkene by B-alkyl Suzuki coupling. The synthesis started from malonate 353, which was 
alkylated with iodoform to yield diester 354 on multigram scale according to a procedure by Menche 
and co-workers (Scheme 3.22).[238] 
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Scheme 3.22 (a) Envisaged strategy to close the strained 11-membered ring via an intramolecular allylation. (b) Synthesis of 
vinyl iodide 357 starting from malonate 353.  
 
This intermediate 354 underwent then saponification with concomitant decarboxylative elimination in 
the presence of KOH in a refluxing 3:1 mixture of EtOH and H2O. An ensuing reduction of the 
resulting carboxylic acid 355 with LiAlH4 gave rise to vinyl iodide 356 with (E)-alkene geometry, 
which was verified by NOE spectroscopy and matched the data reported by Menche.[238] Ultimately, a 
silylation provided a convenient access to silyl ether 357 in four steps.  
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Scheme 3.23 Fragment union of alkene 299 and vinyl iodide 357 and synthesis of ketone 361. 
 
Having prepared substantial quantities of vinyl iodide 357, the Pd-catalyzed coupling with the boron 
species derived from alkene 299 and 9-BBN (237) was explored. This reaction occurred smoothly and 
delivered trans-hydrindane 358 that in turn was globally desilylated to provide diol 359 in 63% overall 
yield (Scheme 3.23). A protection of the primary alcohol as its pivalate 360 differentiated between the 
two alcohol functionalities and the remaining secondary alcohol was next oxidized with DMP[207] 
accomplishing the synthesis of ketone 361.  
In the following investigations, the preparation of a second vinyl iodide building block was center 
stage. For this purpose, we took advantage of a protocol originally developed by Sato[239] and recently 
applied by Paterson and co-workers.[240] Therein, alkyne 362 was exposed to i-BuMgCl in the presence 
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of Cp2TiCl2 to trigger a hydrotitanation. After complete conversion, the resulting organometallic 
species was reacted with I2 to give the desired vinyl iodide 363, albeit in a poor yield of 15% 
(literature:[240] 49%, Scheme 3.24). 
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Scheme 3.24 Two-step synthesis of vinyl iodide 364. 
 
This disappointing outcome was attributed to the addition of solid I2, which was barely soluble in the 
reaction mixture. In future experiments, one should thus resort to the addition of I2 in solution and 
conceivably add HMPA as reported by Gibbs.[241] Nevertheless, we obtained sufficient amounts of 
alcohol 363 and a final silylation completed the synthesis of vinyl iodide 364, the structure of which 
was verified by 2D NOE experiments. 
Next, the two fragments 361 and 364 were combined in analogy to the previous approaches. Hence, 
treatment of vinyl iodide 364 with t-BuLi generated an organo lithium species in situ, which in turn 
was slowly added to ketone 361 to form tertiary alcohol 365 in high yield and as a single 
diastereomer (Scheme 3.25). The relative configuration of the new introduced stereogenic center was 
assigned based on the previous results (cf. Chapter 3.5). Noteworthy, the pivalate remained intact 
despite using excess of the vinyl lithium species. Furthermore, product 365 already contained all 
carbon atoms necessary for the model studies toward astellatol (103). Having successfully installed the 
second side chain, we cleaved the pivaloyl ester in alcohol 365 with excess DIBAL-H at −78 °C, 
which furnished diol 366 in good yield. While we pursued a step-wise procedure in these initial 
experiments, a direct cleavage of the protecting group could be accomplished by adding excess MeLi 
or EtMgBr to the reaction mixture after complete conversion. Such a protocol has been utilized 
recently by Carreira and co-workers[242] and would reduce the overall step count. 
 
 
Scheme 3.25 Progress toward the synthesis of cyclization precursor 352. 
 
The latest transformation examined to date was the conversion of allylic alcohol 366 to a 
toluenesulfone species. Thereby, treatment of intermediate 366 with I2 in the presence of PPh3 and 
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imidazole yielded an allylic iodide (not shown) which was substituted with NaSO2p-tol in DMF.[232] 
The desired compound 367 was obtained in 46% yield and characterized by NMR spectroscopy and 
mass spectrometry. However, the reaction was accompanied by the formation of an inseparable 
unidentified side product (d.r. ≈ 4:1). We reasoned that this observation might be attributed to the 
ability of I2 to isomerize double bonds. Thus, further protocols for the installation should be 
investigated in future, including a consecutive tosylation/iodination/substitution procedure. 
Alternatively, the use of PBu3/PhSSPh in pyridine should be examined since this reagent combination 
has been shown to convert allylic alcohols into the corresponding sulfides,[237] the oxidation state of 
which could then be adjusted by selective oxidation to the sulfone. If this transformation is 
successfully optimized, the desilylation and conversion to an allylic chloride 352 are yet to be 
investigated in order to set the stage for the investigation of the envisaged ring closure.  
 
 
3.7 An Alternative Approach: Toward a Ketene-Alkene Cycloaddition 
 
While the strategies discussed in the earlier chapters toward a total synthesis of astellatol (103) 
focused on assembling the pentacarbocyclic architecture by a bioinspired cationic cascade, we also 
developed an additional route hinging on an intramolecular [2+2]-cycloaddition to construct the 
cyclobutane moiety (Scheme 3.26).[243,244] 
 
 
Scheme 3.26 Retrosynthetic strategy toward construction of the pentacyclic architecture 368 via an intramolecular 
cycloaddition and potential isomer 372 arising from this approach. 
 
From a retrosynthetic point of view, the pentacyclic structure 368 was traced back to 
cyclobutanone 369 by the sequential interconversion of two carbonyl functionalities including a 
substrate controlled diastereoselective hydrogenation. This intermediate 369 in turn should arise from 
ketene 370 via the aforementioned cycloaddition strategy. We were aware of the fact that this reaction 
might be accompanied by the formation of another pentacyclic backbone 372, which also is a highly 
strained ring system. Independently of which isomer might arise, this transformation would build up 
structural complexity, set two all-carbon stereogenic centers in one single operation and was thus 
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worth being examined in our eyes. Beside the potential exploitation of Lewis acid catalysis,[245] we 
were interested how the relative confirmation of the allylic stereogenic center at C-14 (astellatol 
numbering) and a variation of the associated alcohol protecting group could influence the selectivity of 
this reaction. As starting point, we envisioned utilizing the α-epimer at C-14 to direct an approach of 
the ketene moiety from the top. The precursor 370 should be generated in situ from the corresponding 
acid chloride (not shown) that should arise from carboxylic acid 371. Following a one carbon 
homologation, further retrosynthetic simplification would dissect intermediate 371 to alkene 299 and 
an appropriate vinyl iodide via a B-alkyl Suzuki coupling.[181] 
In practice, we commenced with the synthesis of a suitable coupling partner by transferring 
cyclopentenone 373 to the corresponding α-iodo enone 374 under standard reaction conditions (I2, 
K2CO3, DMAP, Scheme 3.27),[246] setting the stage for an enantioselective Corey-Itsuno 
reduction.[247,248] For this purpose, ketone 374 was exposed to the oxazaborolidine catalyst 375 and 
BH3·THF complex following a procedure developed by Uskokovic[249] to furnish allylic alcohol 377 in 
82% yield and 96% ee on multigram scale.[250] 
 
 
Scheme 3.27 Enantioselective synthesis of vinyl iodide 377 via a Corey-Itsuno reduction. 
 
Mechanistically, this reaction proceeds via the boat like transition state 376, in which the larger 
substituent of the prochiral ketone, i.e. the iodoalkene fragment, adopts a position to minimize the 
disfavored steric interactions with the catalyst as depicted. Such a conformation results in a 
preferential intramolecular delivery of the hydride form the re-face and forms the desired product 377. 
Moreover, it has been shown that the catalyst 375 differentiates the two substituents with 
extraordinary selectivity in cyclic α-halo enones.[248]  
In subsequent experiments, the alcohol functionality of vinyl iodide 377 was protected as its PMB 
ether under basic conditions (NaH, PMBCl, Scheme 3.28). Interestingly, the obtained optical rotation 
of alkene 378 (+2.2, c 1.00, CHCl3) differed dramatically from the one reported by Paquette and 
co-workers for ent-378 (+37.0, c 1.08 CHCl3),[251] but an alternative preparation under acidic 
conditions (PMBTCA, CSA) gave the exact same value. Thus, we were confident that no 
epimerization occurred and submitted cyclopentenol 378 to the B-alkyl Suzuki reaction conditions 
employed previously. To our delight, a sole product 379 was obtained in 88% yield, indicating that 
enantiomerically pure vinyl iodide 378 had been employed. Next, the silyl ether in trans-
hydrindane 379 was cleaved under acidic conditions (CSA, CH2Cl2/MeOH) that we had frequently 
used before (vide supra). These conditions were chosen since the ‘real’ system would necessitate a 
differentiation between a secondary TES ether and a secondary TBS ether (cf. Chapter 3.3). 
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Scheme 3.28 Synthesis of ketone 382 via B-alkyl Suzuki coupling and observation of a transetherification. 
 
While this reaction occurred smoothly on a 20 mg scale, we observed two products 380 and 381 in an 
approximately 1:1 ratio when utilizing 710 mg of substrate 379 (Scheme 3.28). Thereby, the more 
polar product 381 was identified as the desired secondary alcohol. Interestingly, the reaction 
conditions also effected a concomitant conversion of the PMB protecting group to a methyl ether 380 
as established by NMR spectroscopy and mass spectrometry. The latter product 380 was obtained as a 
single diastereomer, but its relative configuration at C-14 (astellatol numbering) was not assignable 
based on 2D NMR experiments. Therefore, no hints on the mechanistic nature of this unexpected 
transetherification, presumably involving a SN2-substitution, were gained. In the future, one should 
examine other desilylation agents such as TBAF or HF·pyridine. Due to these not unexpected 
difficulties, ketone 382 was isolated after oxidation of alcohol 381 with DMP[207] in a disappointingly 
low yield of 34% over the two steps.  
In addition, we converted side product 380 to cyclohexanone 385 under Swern conditions[222] and 
utilized this intermediate for initial experiments toward a homologation (Scheme 3.29). For this 
purpose, two reaction conditions have been examined so far. Whereas exposure of ketone 385 to the 
Kluge-Wittig ylide derived from phosphonium chloride 383 did not result in any conversion to enol 
ether 384,[252] the more nucleophilic lithium salt of phosphine oxide 386[253] reacted with ketone 385 to 
some extent. Due to incomplete conversion, the temperature was raised to 66 °C triggering an 
elimination of the addition product 387 to enol ether 384 in the same reaction pot. Usually, this 
transformation is accomplished in a separate reaction by exposure to a strong base such as NaH.[254] 
However, no complete conversion of ketone 385 was observed. The intermediate approximate 1:1 
mixture of enol isomers 384 could not be characterized properly to date due to the fact that the sample 
decomposed during the recording of NMR spectra. Presumably, aldehyde 388 was formed by traces of 
acid present in CDCl3 as indicated by characteristic signals observed in the 1H and the 13C NMR 
spectra at δ = 9.48 (d, 3J = 4.6 Hz) ppm and δ = 205.7 ppm, respectively. 
 
86  THEORETICAL SECTION 
 
Scheme 3.29 Efforts toward a homologation: reaction of ketone 385 with the lithium salt of phosphine oxide 386. 
 
With these observations in mind, we are optimistic that the desired homologation of ketone 385 to 
aldehyde 388 can be optimized in near future. Moreover, the developed protocols could be adopted for 
ketone 380 to provide sufficient quantities of the corresponding homologated aldehyde (not shown). If 
this reaction sequence proves successful, a subsequent Pinnick oxidation[255] should then give rise to 
acid 371 and provide the basis to investigate the key intramolecular [2+2]-cycloaddition. Due to the 
observed acid sensitivity of the PMB ether however, it might be necessary to install a more robust 
protecting group such as MOM, SEM, TIPS or TBDPS. 
 
 
3.8 Conclusion and Future Directions 
 
In summary, this chapter detailed our current progress toward a total synthesis of the pentacarbocyclic 
sesterterpenoid astellatol (103). Therein, we succeeded in the synthesis of the bicyclic building 
block 268, which comprises the correct relative configuration of astellatol (103) at six stereogenic 
centers. The preparation of alkene 268 was accomplished by a series of diastereoselective operations, 
mainly originating from substrate control. In the course of these ventures, we established the 
installation of the C-9 and C-10 stereogenic centers in model studies and accessed 
trans-hydrindane 299 on multigram scale. This intermediate 299 in turn provided the basis for the 
examination of four different strategies to assemble the carbon backbone assigned for the natural 
product 103. Whereas the major portion of experiments was dedicated to the installation of a strained 
11-membered macrocycle in order to pursue a bioinspired route via a cationic cascade (cf. Chapter 
3.4−3.6), the last strategy focused on a more ‘traditional’ route, namely a [2+2]-cycloaddition to 
construct the cyclobutane moiety within astellatol (103, cf. Chapter 3.7). Despite enormous efforts 
however, these approaches did not yet meet with success or the precursors for the key cyclizations 
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have not been accessed to date. Therefore, these strategies will be further investigated in our on-going 
synthetic program en route to the total synthesis of type A trans-hydrindane iso-propyl 
sesterterpenoids.  
 
 
Scheme 3.30 Alternative strategy to access the precursor for a biomimetic cationic cascade under Barbier conditions. 
 
In our studies toward the macrocycle, we encountered problems concerning the tertiary allylic alcohol 
at C-1. Thus, an alternative route toward the 11-membered ring in tricycle 321 could involve the late-
stage installation of this moiety. To this end, one could prepare vinyl iodide 389 along the lines of the 
previously explorations, involving a B-alkyl Suzuki coupling of alkene 299 (Scheme 3.30). This 
intermediate 389 could then be transformed the macrocycle in tricycle 321 under Barbier conditions 
employing e.g. Zn.[256] Moreover, one could think of a plethora of methodologies, e.g. a Nozaki-
Hiyama-Kishi coupling,[257] to construct this strained ring by other retrosynthetic disconnections, thus 
proving an array of opportunities for future experiments.  
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4 SYNTHETIC STUDIES TOWARD NITIOL 
 
4.1 Nitiol: Isolation and Background 
 
In 1999, the group of Kawahara reported the novel structure of a sesterterpenoid named nitiol (110, 
Figure 4.1). This natural product 110 was extracted from ‘Hercampuri’ (Gentianella nitida),[99] which 
is used in Peruvian folk medicine as a remedy for hepatitis and in the treatment of obesity. Based on 
extensive NMR spectroscopic investigations, the authors assigned the tricarbocyclic architecture 
comprising two five-membered rings and a central 12-membered macrocycle. Moreover, careful 
analysis of NOE spectra allowed for the elucidation of the relative configuration of all fives 
stereogenic centers and the double bond geometry of the three alkenes present in nitiol (110). In 
analogy to astellatol (103) and the retigeranic acids, nitiol (110) only contains one oxygenated site, 
thus requiring careful retrosynthetic planning of functional group interconversions. 
 
 
Figure 4.1 Molecular structures of the sesterterpenoids nitiol (110) and nitidasin (111), both isolated from ‘Hercampuri’, a 
Peruvian folk medicine 
 
Nitiol (110) was found during efforts to identify new low-molecular lipophilic probes in order to study 
intracellular signal transduction mechanisms in human cells. Thus, Kawahara et al. determined the 
effect of nitiol (110) on the gene expression of interleukin-2 (IL-2).[258] This polypeptide regulates the 
activity of white blood cells and is necessary for the growth and proliferation of T-cells, which are 
produced during an immune response. Additionally, the application of synthetic IL-2 has been 
approved as an immunotherapy for the treatment of renal cell cancer and malignant melanoma. Within 
their tests, Kawahara and co-workers found that nitiol (110) enhanced the IL-2 mRNA level in Jurkat 
cells by a factor of three, whereas its structural analog nitidasin (111),[100] isolated as well from 
Gentianella nitida, remained ineffective. In conclusion, the authors stated that the structure of 
nitiol (112), distinctly differing from other known IL-2 gene expression modulators, might serve as a 
new tool to gain further insights into signal transduction pathways, ultimately leading to the 
transcriptional control of the IL-2 gene.  
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4.2 Retrosynthetic Analysis 
 
From a retrosynthetic perspective, we envisioned to access nitiol (110) via a dienyne metathesis and a 
subsequent reduction from precursor 390 (Scheme 4.1). On the one hand, this strategy would avoid the 
difficulty to carry out a late-stage deoxygenation of a carbonyl or an alcohol functionality, which 
might be very problematic as experienced by Dake and co-workers (cf. Chapter 1.3).[110b] On the other 
hand, this route would also elegantly construct two rings in one single operation and constitute a rare 
example of macrocycle formation via dienyne metathesis.[259,260] Dienyne 390 could arise from 
aldehyde 391 by sequential standard functional group manipulation. This intermediate 391 could in 
turn stem from homoallylic iodide 393 and ephedrine derivative 392 via a Myers alkylation followed 
by reductive removal of the auxiliary.[261] Myers’ protocol is widely used in organic synthesis and 
allows for the diastereoselective installation of various alkyl substituents, even on sterically hindered 
substrates. Within the proposed synthesis, this transformation would thus generate the desired 
cis-relationship between the two substituents at C-6 and C-7 (nitiol numbering). 
  
 
Scheme 4.1 Retrosynthetic analysis of nitiol (110) featuring a dienyne metathesis as key step. 
 
Whereas the western fragment 392 should be accessible from the corresponding acid, the eastern 
portion 393 could be prepared starting from dicarbonyl compound 394. This pathway could be 
realized by a multistep sequence involving a vinyl Grignard addition and a subsequent 
[3,3]-sigmatropic rearrangement according to the Johnson-Claisen protocol to selectively install the 
trisubstituted alkene present in cyclopentane 393. It should be noted that such an approach would 
require the dissection of one carbon atom. Alternatively, other classical olefination strategies such as a 
Horner-Wadsworth-Emmons reaction might also be considered. Further retrosynthetic simplification, 
in particular ozonolysis of a silyl enol ether, should ultimately trace nitiol (110) back to building 
block 190, the synthesis of which has already been accomplished previously (cf. Chapter 2). 
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4.3 Synthesis of the Western Fragment§  
 
Our studies toward nitiol (110) commenced with the synthesis of the western fragment 392. The first 
task at hand was to install the requisite absolute configuration of the stereogenic center at C-3 (IUPAC 
numbering) in a selective fashion. A literature survey revealed that the corresponding acid has been 
synthesized in its enantiomeric form via a ketene-aldehyde cycloaddition approach (not shown).[262] 
Since this strategy required the multistep synthesis of a chiral ligand, we resorted to a classical route 
employing a diastereoselective cuprate addition to crotyl amide derivative 399 as described by 
Williams and co-workers.[263] Therein, the chiral auxiliary (readily prepared from cheap commercially 
available starting materials) induces a high degree of diastereoselectivity in order to install the desired 
absolute configuration at C-3. 
 
 
Scheme 4.2 Diastereoselective installation of the stereogenic center at C-3. 
 
Along these lines, we prepared oxazolidinone 397 from amino acid 395 in a two-step 
protocol (Scheme 4.2).[264] Subsequently, treatment of auxiliary 397 with n-BuLi followed by addition 
of crotyl chloride (398) furnished α,β-unsaturated compound 399, the substrate for the aforementioned 
1,4-addition.[265] Eventually, exposure of the intermediate 399 to a Yamamoto organocopper(I) species 
generated in situ from equimolar amounts of allylmagnesium bromide, BF3·Et2O and CuBr·SMe2 
yielded the addition product 400 in 79% yield on a 100 mg scale. Moreover, the chiral auxiliary 
induced a high diastereoselectivity of >95:5 as determined by 1H NMR spectroscopy. Unfortunately, 
the yield of this reaction dropped dramatically upon scale up (400 mg – 3.0 g). Apart from recovered 
starting material, one side product 401, arising from two consecutive Michael additions, was isolated. 
This product was characterized by mass spectrometry and NMR spectroscopy albeit without 
establishing the relative configuration of the newly installed stereogenic centers. Mechanistically, the 
                                                 
§  The experimental part of this subchapter was conducted in collaboration with Thomas M. Wildenhof as part of his 
undergraduate research stay in the Trauner laboratories. 
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diastereoselective outcome of the initial allyl cuprate addition is not completely understood and 
Williams and co-workers concluded: “stereocontrol […] is complicated by the availability of several 
activated conformers, by the nature of the Lewis acid, and by the structure and mechanism associated 
with the organocopper species itself”.[263] Unfortunately, we were not able to obtain crystals suitable 
for X-ray diffraction and we thus converted 400 (obtained from the cuprate addition) to the 
corresponding Weinreb amide 402 (>95% ee). This compound 402 was literature known (90% ee, 
obtained via Sakurai reaction conditions, vide infra) and our analytical data including optical rotation 
agreed in all respects to the ones previously reported.[266]  
 
 
Scheme 4.3 (a) Preparation of the western fragment 392 via Sakurai allylation. (b) 1H NMR spectra (both in CDCl3 at 
400 MHz) of the diasterotopic protons at C-2: proof of inverse outcome by changing cuprate for Sakurai conditions.[267]  
 
Since the cuprate route was impractical on larger scale, we resorted to a different approach. This was 
based on the fact that Williams and co-workers had discovered a counterintuitive reversal in selectivity 
of the 1,4-addition by simply changing from an organocopper addition to a Sakurai allylation.[267] 
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Eventually, treatment of the optical antipode ent-399 (obtained in analogy to the previously described 
protocol) with TiCl4 and allyltrimethylsilane smoothly delivered adduct 403 in 91% yield on a 700 mg 
scale following a modified procedure from Takayama (Scheme 4.3).[266] The reversed 
diastereoselectivity could be easily observed by comparison of the chemical shifts of the diasterotopic 
protons at C-2 as depicted in Scheme 4.3b. Whereas the signals of diastereotopic protons at C-2 for the 
(3R,9R)-diastereomer 400 were centered at δ = 2.98 ppm and δ = 2.69 ppm, the corresponding signals 
for (3R,9S)-diastereomer 403 were observed at δ = 2.89 ppm and δ = 2.82 ppm, respectively. One 
small drawback of this more convenient procedure was the lower diastereoselectivity, which provided 
alkene 403 in a d.r. of 8.3:1. Nevertheless, the Evans auxiliary in amide 403 was readily cleaved upon 
exposure to LiOOH generated in situ[268] to furnish acid (404). The determined optical rotation of 
acid 404 (+1.6, c 0.53, CHCl3),matched the absolute values of −0.71 (c 1.13, CHCl3) and −2.8 (c 1.00, 
CHCl3) for its antipode ent-404 reported by Chang[269] and Nevado,[262] respectively. Once more, this 
finding confirmed the desired (R)-configuration at C-3. In order to finish the synthesis of western 
fragment 392, the incorporation of the pseudoephedrine auxiliary 405 was then attempted. This task 
was readily accomplished by treatment of acid 404 with EDCI and DMAP in the presence of Et3N 
affording amide 392 in 89% yield.[270] With the first substrate 392 for the fragment coupling in hand, 
we next focused on the synthesis of alkyl iodide 393.  
 
 
4.4 Progress toward the Eastern Fragment 
 
According to our retrosynthetic analysis, (cf. Chapter 4.2), we opted to access alkyl iodide 393 starting 
from ketone 190. Since we had prepared larger quantities of its diastereomeric counterpart ent-141, we 
carried out our preliminary investigations with the α-series, which would ultimately provide access to 
the C-18 epimer of nitiol (110). Based on our previous experiences with the regioselective 
deprotonation of ketone 207 (cf. Chapter 3.3), trans-hydrindane building block ent-141 was exposed to 
KHMDS at −78 °C and the resulting potassium enolate was intercepted with Et3SiCl to furnish silyl 
enol ether 406 (Scheme 4.4). Following aqueous work up, this intermediate 406 was instantly 
subjected to ozonolysis reaction conditions.[271] Upon treatment with Me2S, labile keto acid 407 was 
obtained and was used immediately for the next transformation. Thus, aldehyde 407 was reacted with 
excess isopropenylmagnesium bromide (219)[272] to provide allylic alcohol 409 as an inconsequential 
1:1 mixture of diastereomers in 42% yield over three steps. The isolation of the desired product 409 
was accompanied by the formation of ε-lactone 408, presumably generated upon acidic work up with 
2N HCl. Notably, bicycle 408 was obtained as a single diastereomer in 12% yield, but its relative 
configuration could not be assigned. In future experiments, the formation of side product 408 could be 
bypassed by carrying out the work up under less acidic conditions using aqueous NH4Cl. As seco 
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acid 409 proved to be somewhat unstable, it was instantly reduced to the corresponding diol (not 
shown) by treatment with LiAlH4. 
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Scheme 4.4 Toward the synthesis of an appropriate eastern fragment.  
 
Next, a monosilylation of the primary alcohol was accomplished with TBDPSCl to furnish allylic 
alcohol 410,[273] setting the stage for the Johnson variant of the Claisen rearrangement (Scheme 4.4).[62] 
To this end, alcohol 410 was dissolved in orthoester 411 and the mixture was heated to 130 °C in the 
presence of catalytic amounts of propionic acid.[274] This procedure resulted in the formation of 
ester 412 in an excellent yield of 86% over three steps. Moreover, a single alken isomer was obtained, 
the desired (E)-configuration of which was verified by 2D NOE NMR experiments. With ester 412 in 
hand, the next task was to shorten the chain by one carbon atom that we initially envisaged to prepare 
the alcohol 414 via a diol cleavage and NaBH4 reduction. For this purpose, we aimed at preparing 
alcohol 413 by an α-oxygenation of the ester functionality, which would provide the requisite diol 
upon LiAlH4 reduction. Unfortunately, variation of bases (LDA, KHMDS), oxygenation agents 
(MoOPh,[275] chiral and achiral Davis’ oxaziridine[276]) and reaction temperatures resulted in poor 
conversion and isolation of only small quantities of the desired product 413 as indicated by mass 
spectrometry and 1H NMR spectroscopy.  
With this in mind, we decided to alter our retrosynthesis and install the oxygenation pattern necessary 
for a diol cleavage at the stage of the [3,3]-sigmatropic rearrangement. To this end, we opted for a 
variant of the Claisen rearrangement introduced by Kallmerten and Burke[277] and thus treated 
lactone 408 with LiAlH4 to obtain diol 415, now as a single diastereomer (Scheme 4.5). 
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Scheme 4.5 Potential access to alcohol 419 via a Kallmerten-Burke rearrangement. 
 
Since we had encountered difficulties in purifying the regioselective silylation product when using 
TBDPSCl due to hardly separable silanol byproducts, diol 415 was monosilylated with TBSCl.[278] 
Next, the resulting allylic alcohol 416 was acetylated with acetic acid derivative 417[279] to access 
ester 418, the precursor for the aforementioned rearrangement, in a yield of 51% over the three steps. 
In an initial experiment on small scale, the corresponding TMS silyl enol ether generated by sequential 
treatment with LiHMDS and TMSCl triggered the desired [3,3]-sigmatropic rearrangement upon 
warming to room temperature.[280] A subsequent LiAlH4 reduction formed alcohol 419 as indicated by 
1H NMR analysis. 
 
 
4.5 Conclusion and Future Directions 
 
In summary, first attempts toward the envisaged total synthesis of nitiol (110) have been investigated. 
Thereby, we accomplished the synthesis of western fragment 392 based on literature precedence 
starting from oxazolidinones 397 and ent-397 (cf. Chapter 4.3). It turned out that an approach 
involving a cuprate addition resulted in almost complete diastereoselective control, whereas Sakurai 
conditions utilizing the enantiomeric chiral auxiliary were more convenient for a preparation on larger 
scale. We also explored the synthesis of eastern fragment 422 commencing with ketone ent-141 (cf. 
Chapter 4.4). This route featured a regioselective cleavage of the cyclohexanone moiety by sequential 
enol ether formation and ozonolysis. Despite the unstable nature of some intermediates, we installed 
the trisubstituted alkene in 412 via a Johnson-Claisen rearrangement. As our attempts to shorten the 
side chain in ester 412 were met with little success so far, we embarked on another strategy starting 
from lactone 408 (a side product from the previous investigations) that involved a Kallmerten-Burke 
rearrangement. A first promising result indicating the formation of primary alcohol 419 was obtained 
on small scale. In the future, this experiment should be repeated on a larger scale and the subsequent 
transformations toward the alkyl iodide 422 should be examined. Alternatively, one could examine a 
Hunsdiecker reaction[281] to convert the corresponding acid of ester 418 directly to alkyl iodide 393. 
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Scheme 4.6 Proposed alternative strategy to generate alkyl iodide 421 involving a Wittig olefination. 
 
Additionally, a second strategy toward alternative fragment 421 could be tested as outlined in 
Scheme 4.6. Thereby, an initial esterification of acid 407 would be followed by a Wittig olefination to 
access keto ester 420, which in turn could be elaborated to the corresponding allyl iodide (not shown) 
by a chemoselective reduction and an Appel reaction. Finally, a one carbon extension developed by 
Knochel and co-workers[282] would furnish iodide 421. 
 
 
Scheme 4.7 Proposed fragment combination and the key dienyne metathesis toward 18-epi-nitiol (424). 
 
With both portions 392 and 422 (or 421) in hand, a Myers alkyation combining these two fragments 
should be feasible. Additional reactions, including the key dienyne metathesis of intermediate 423, 
along the lines of the presented retrosynthetic analysis (cf. Chapter 4.2) could furnish 
18-epi-nitiol (424, Scheme 4.7). If this protocol proves to be efficient, it should be readily 
transferrable to building block 190 and allow for a synthesis of the naturally occurring nitiol (110). 
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5 SYNTHETIC STUDIES TOWARD YW 3548 
 
5.1 YW 3548: Isolation and Background 
 
The sesterterpenoid YW 3548 (112) was isolated from the fungal strain Paecilomyces inflatus by 
Wang et al. in 1998 and its relative configuration was established by thorough analysis of NMR 
spectroscopic data, including 1H, 13C, DQ-COSY, ROESY, HSQC and HMBC experiments (Figure 
5.1a).[101] Structurally, YW 3548 (112) exhibits a unique tricarbocyclic sesterterpenoid δ-lactone 
architecture featuring a total of ten stereogenic centers, one of which is all-carbon substituted. 
Moreover, this type A trans-hydrindane iso-propyl sesterterpenoid 112 comprises the sterically 
enbumbered trans-hydrindane portion fused to an eight-membered ring bearing both an exomethylene 
group and an embedded trisubstituted alkene moiety. Furthermore, this intriguing carbon backbone, 
YW 3548 (112) is regioselectively acylated by a heptanoate side chain with two further stereogenic 
centers. The relative configuration at this site as well as the absolute configuration of YW 3548 (112) 
was not evaluated and its structure remains thus unconfirmed. 
 
 
Figure 5.1 (a) Molecular structures of the GPI anchor inhibitors YW 3548 (112) and YW 3699 (113). (b) Conserved GPI 
core structure and possible modifications, adapted from reference [288]. 
 
The research team at Novartis Pharma Inc. discovered YW 3548 (112) while seeking for novel 
inhibitors of gycosylphosphatidylinositiol (GPI) anchoring, a biological process which has been 
discovered almost three decades ago.[283,284] From a biological point of view, the authors determined 
YW 3548 (112) and its analog YW 3699 (113)[102] to selectively inhibit GPI-anchor synthesis in vitro 
by yeast mircosomes with a minimal inhibiton concentration (MIC) of 3.4 nM and 3.5 mM, 
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respectively.[285] Among eukaryotes, GPI-anchoring covalently binds proteins to the extracellular 
space of the cell membrane.[286] More specifically, the C-terminus of the protein is connected via 
ethanolamine to a glycan, which in turn is linked to the 6-position of the myo-inositol ring of 
phosphatidylinositol (PI, Figure 5.1b). Ultimately, two fatty acid units on the PI moiety anchor the 
protein to the cell membrane. Once the protein is attached to the extracellular surface of the 
membrane, it often plays a crucial role as receptor or co-receptor for ligands that modulate signal 
transduction.[286] Although the process of GPI anchoring is common to mammals and protozoa, 
sharing an identical glycan core, different biosynthetic pathways have been reported over the years.[286] 
In addition, it was established that protozoa tend to express a significantly higher density of GPI-
anchored protein than eukaryotes, playing an important role in determining survival and infectiveness 
of the parasite. This is exemplified on Trypanosoma Brunei, the parasite causing the African sleeping 
sickness: it expresses a cell-surface coat of a GPI-anchored glycoprotein, which acts on the one hand 
as a barrier against macromolecules from the host immune system and on the other hand enables the 
evasion of specific immune attacks through antigenetic variation.[287] Thus, selective inhibitors of GPI-
anchoring in protozoa could act as potential drugs against these parasites.  
 
 
Figure 5.2 Artificial analogues of YW 3548 (112) exhibiting less activity in inhibition of GPI anchor biosynthesis. 
 
Based on initial SAR studies, Wang and co-workers revealed that the δ-lactone moiety and the double 
bonds within YW 3548 (112) were necessary for its activity. Indeed, chemically prepared 
analogues 425, 426 and 427 (Figure 5.2) caused a loss of activity, represented by MIC of 3.2, 1.7 and 
17 μM, respectively.[101,285] The authors further speculated on the mode of inhibition and finally stated 
that YW 3548 (112) blocks the addition of the third mannose unit to the GPI backbone. Additionally, 
it eventually prevents the incorporation of [3H]myo-inositol into proteins and thus the transport of GPI-
anchored proteins to the Golgi, resulting in toxicity. These effects have been proven for mammalian 
cells as well as for yeast, whereas YW 3548 (112) remained ineffective for protozoa. Nevertheless, the 
novel structure of YW 3548 (112), synthetic precursors and related analogues could provide a basis to 
gain further insights into the mechanism of inhibition and might provide hints toward lead structures 
for selective inhibition of the protozoa pathway. In addition, the synthetic efforts could contribute to 
expand the knowledge about the function of the GPIs, which is, as opposed to the biological 
significance, still hardly explored and a current topic of interest in chemical biology.[288] These 
interesting biological activity and the unique tetracyclic backbone of YW 3548 (112) prompted us to 
develop a convergent retrosynthetic analysis. 
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5.2 Retrosynthetic Analysis 
 
From a retrosynthetic point of view, we envisioned installing the heptanoate side chain of 
YW 3548 (112) by means of a late-stage acylation (Scheme 5.1). The diol moiety in the lactone 
portion could arise from a Lewis or Brønsted acid-mediated epoxide opening,[289] providing 
tetracycle 428 as a synthetic precursor that in turn could be prepared from ketone 429 by sequential 
nucleophilic epoxidation and a chemoselective Lombardo olefination.[290] Further dissection by an 
acyl-Stille coupling[291] and a challenging RCM[180] to close the central eight-membered ring with a 
trisubstituted double bond would lead back to western fragment 430 and eastern portion 431 as key 
building blocks. Notably, such a RCM strategy has been explored by the group of Tori in their model 
studies toward YW 3699 (113) (cf. Chapter 1.3).[111]  
 
 
Scheme 5.1 Convergent retrosynthetic analysis for YW 3548 (112) via an acyl-Stille coupling and a RCM to close the central 
eight-membered ring. 
 
Further retrosynthetic simplification would trace western fragment 430 back to three simple building 
blocks: acetaldehyde (432), acetic anhydride (433) and a 5-pentenoic acid derivative 434 containing an 
Evans-auxiliary. The envisaged route would proceed via a Heathcock anti-aldol reaction[292] followed 
by acetylation and Dieckmann condensation.[293] A final Pd-catalyzed stannylation would then furnish 
vinyl stannane 430. On the other hand, eastern fragment 431 should be accessible starting from the 
previously synthesized building block 191 via a Pd-catalyzed carbonylation[294] or a Shapiro 
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reaction[153] and an ensuing diastereoselective cuprate addition. Alternatively, the installation of the 
isopropylene moiety might be achieved following Koga’s protocol utilizing a tert-leucine derived 
directing group (not shown), which allows for the selective 1,4-addition of Grignard reagents.[295] 
Concerning the configuration of the aldehyde functionality, we assumed that this residue would adapt 
the desired thermodynamically more favored feasible by a base-promoted epimerization. A final 
Pinnick oxidation[255]/acid chloride formation protocol would then provide access to the envisaged key 
fragment 431. Along these lines, we embarked on the total synthesis of YW 3548 (112), thereby 
mainly focusing on developing a convenient access to western fragment 430. 
 
 
5.3 Progress toward the Western Fragment** 
 
Based on the retrosynthetic analysis, our synthesis commenced with the large scale preparation of 
L-valine (435) derived Evans-auxiliary 436 by sequential LiAlH4 reduction and carbamate formation 
with diethyl carbonate (396) following literature procedures (Scheme 5.2).[296]  
 
 
Scheme 5.2 (a) Synthesis of alcohol 439 via the Heathcock modification of the Evans-aldol reaction proceeding through an 
open transition state 438. (b) The logic of the syn-Evans aldol chemistry, which would lead to alcohol 441. 
 
                                                 
** The experimental work of this subchapter was performed together with Sebastian Rappenglück as part of his Bachelor’s 
Thesis in the Trauner laboratories. 
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The lithium species generated by treatment of carbamate 436 with n-BuLi was then reacted with 
commercially available acid chloride 437 to furnish oxazolidinone 434,[297] the precursor for a 
Heathcock anti-aldol reaction.[292] To this end, compound 434 was treated with two equivalents of 
Bu2BOTf[298] in the presence of DIPEA to give rise to the corresponding (Z)-enolate (not shown). This 
intermediate was in turn further reacted with acetaldehyde (432) at −78 °C and careful work 
up (quenching with tartaric acid at −78 °C) afforded the desired anti-aldol product 439 in good 
yield (85%) and high diastereoselectivity (d.r. = 94:6) on a reasonable 1.5 g scale. However, the 
resulting alcohols 439 and 441 were inseparable by flash column chromatography at this stage. 
Mechanistically, this reaction proceeds via an open transition state 438. Therein, the stereoselectivity 
solely originates from the minimization of the steric interactions between the alkyl residue of the 
aldehyde (i.e. a methyl group) and the auxiliary (Scheme 5.2a).[292] Thus, a reaction with 
acetaldehyde (432) is extremely challenging as the transition state 438 has to discriminate between a 
proton and a methyl group, which itself is not highly sterically demanding. Furthermore, the absolute 
configuration of the chiral auxiliary enforces an exclusive si-face attack, thus conferring a high level 
of induced diastereoselectivity. In contrast, a standard Evans-aldol reaction employing one equivalent 
of Bu2BOTf involves a closed Zimmermann-Traxler transition state 440 that results in the selective 
formation of the syn-isomer 441 (Scheme 5.2b). This is due to four factors: (a) selective formation of 
the (Z)-enolate, (b) the aldehyde residue R adopts a pseudo-equatorial position, (c) the iso-propyl 
moiety induces diastereoselectivity by residing in a position which minimizes steric interactions with 
the chair transition state, (d) the overall dipole moment of the transition state is minimized.[299] 
Considering these arguments, it is remarkable that the simple use of one additional equivalent 
Bu2BOTf allows for a reversal of the diastereoselectivity in Heathcock’s modification. 
 
 
Scheme 5.3 Synthesis of vinyl triflate 446 via a Dieckmann-type cyclization and verification of the desired outcome of the 
anti-aldol reaction by X-ray crystallography of carbamate 443. 
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Since a verification of the outcome of the Heathcock anti-aldol reaction was worth striving for, a 
sample of the mixture was reacted with p-bromophenyl isocyanate 442 using Steglich’s catalyst 
DMAP (Scheme 5.3).[300] Gratifyingly, the resulting carbamates could be separated by flash column 
chromatography and the major isomer 443 was isolated in 86% yield (minor isomer was not 
characterized). Moreover, the structure and the absolute configuration of the desired anti-aldol 
derivative 443 were unambiguously verified by X-ray crystallography. With this result in mind, we 
turned our attention to the envisaged acetylation, which occurred smoothly by treatment of 
alcohols 439 and 441 with acetic anhydride (433) in the presence of DMAP. Fortunately, the 
generated acetates 444 and 445 were also easily separated by flash column chromatography, 
furnishing the desired isomer 445 in 85% yield. Next, acetate 445 was exposed to excess KHMDS at 
−78 °C to trigger an Dieckmann condensation while liberating the free auxiliary 436 (not shown).[293b] 
As the purification of this intermediate was surprisingly difficult, the crude reaction mixture was 
subsequently reacted with triflic anhydride in the presence of Et3N[301] to furnish enol triflate 446 in a 
good yield of 75% over the two steps. With enol triflate 446 in hand, the stage was set for the 
investigation of a Pd-catalyzed triflate-Sn exchange. To this end, different reaction conditions were 
examined (Table 5.1), among which was a catalytic system that was recently successfully applied in 
the Trauner laboratories.[302] 
 
Table 5.1 Toward a triflate-Sn exchange: variation of the reaction conditions.a 
 
O
OTf
O
Me
446
condit ions
O
SnMe3
O
Me
430
O
Me
O
O
O
Me
447  
Entry Catalyst (eq.) 
eq. of 
Me6Sn2  
Additive 
(eq.) 
Solvent T [°C] t [h] Observation 
1 Pd(PPh3)4 (0.1) 1.5 LiCl (6.0) THF 60 16 decomp. 
2 Pd(PPh3)4 (0.2) 2.0 CuI (0.4) DMF rt 1.2 decomp. 
3 Pd(PPh3)4 (0.2) 1.5 - DMF rt 2.5 decomp. 
4 Pd(PPh3)4 (0.1) 1.5 - benzene 80  decomp. 
5 Pd2dba3 (0.17) 1.5 CuI (0.3) DMF rt 1 447 (72%) 
(a) All reactions were carried out on 10−30 mg scale. eq. = equivalents, decomp. = decomposition, rt = room temperature. 
 
Unfortunately, submitting enol triflate 446 to coupling conditions with Me6Sn2 in the presence of 
catalytic amounts of Pd(PPh3)4 and excess LiCl resulted only in decomposition, and no desired product 
formation was observed by 1H NMR spectroscopy (Table 5.1, Entry 1). Similarly, when exchanging 
LiCl with CuI (Entry 2) or using no additive (Entry 3) and switching to DMF as a solvent, only 
decomposition was detected. The same observation was made when utilizing benzene as a solvent at 
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elevated temperature (Entry 4). As these results were not fruitful, we opted for an alternative source of 
Pd0. Therefore, we exchanged Pd(PPh3)4 with Pd2dba3. When reacting enol triflate 446 with Me6Sn2 in 
the presence of this catalyst and CuI at room temperature,[302] a new product was detected, the 
structure of which was subsequently elucidated by NMR spectroscopy and mass 
spectrometry (Entry 5). Interestingly, these investigations revealed the new compound to be the 
homocoupled dimer 447 instead of the desired stannane 430. It is assumed that the initially formed 
vinyl stannane 430 instantly reacts with remaining triflate 430 to form the observed product 447.  
 
 
Scheme 5.4 Proof for the capability of triflate 446 to undergo Pd-catalyzed couplings: synthesis of lactone 448. 
 
In light of this finding, we decided to explore a direct coupling of enol triflate 446 with organometallic 
reagents rather than converting triflate 446 to stannane 430. In order to provide a proof of principle, 
we conducted an initial Suzuki-coupling with phenylboronic acid in the presence of Pd(PPh3)4 and CuI 
in benzene/EtOH.[303] The expected reaction occurred smoothly and furnished the coupled product 448 
in a high yield of 88% (Scheme 5.4).  
 
Table 5.2 Toward a Pd-catalyzed cross coupling: variation of the reaction conditions 
 
O
OTf
O
Me
446
condit ions
O
O
Me
449
452
Cy
M
MeH
HH
OTBS
CypinB
CyMe3Sn
451
450
 
Entry 
Coupling 
Partner 
Pdb Additive Basec Solvent 
T 
[°C] 
t [h] Observation 
1 450 Pd(PPh3)4 TBABd Na2CO3 benzene 80 16 decomp. 
2 450 Pd(dppf)Cl2 TBABd K3PO4 MeCN 81 1.2 decomp. 
3 450 Pd(PPh3)4 TBABe K3PO4 Dioxane/H2O reflux 2.5 decomp. 
4 451 Pd(PPh3)4 CuI, CsFf - DMF 50 1.3 decomp. 
5 451 Pd2dba3 CuIf - DMF 50 3.3 decomp. 
(a) All reactions were carried out on 10−25 mg scale. (b) 0.1 eq. for entries 1−3, 0.15 eq. for entries 4, 5. (c) 6.9 eq. for entry 1, 3.0 eq. for 
entries 2, 3. (d) 0.14 eq. (e) 0.28 eq. (f) 0.25 eq. CuI, 2.0 eq. CsF. eq. = equivalents, decomp. = decomposition, rt = room temperature. 
 
Encouraged by the capability of enol triflate 346 to engage in Pd-catalyzed cross coupling reactions, 
we prepared literature known boron-pinacol ester 450[304] and vinyl stannane 451[305] (syntheses not 
shown), both representing an alternative eastern fragment 452. Next, their reactivity in a Suzuki or a 
Stille coupling with enol triflate 446 was explored to obtain intermediate 449. For this purpose, we 
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initially altered the solvents as well as the source of Pd0 using boron species 450 as coupling 
partner (Table 5.2, Entries 1−3).[306] However, solely decomposition of the starting material was 
observed. Unfortunately, submission of enol triflate 446 to reaction conditions for a Stille coupling 
with stannane 451 also resulted in decomposition of the substrate (Entries 4, 5).[307] 
 
 
5.4 Conclusion and Future Directions 
 
This chapter detailed our preliminary studies directed toward the synthesis of the potent GPI anchor 
inhibitor YW 3548 (112), focusing on the preparation of a suitable western fragment. Within these 
endeavors, we enantioselectively constructed enol triflate 446 in a concise five-step sequence starting 
from Evans auxiliary 436 (cf. Chapter 5.3). In addition, we conducted initial experiments on the ability 
of enol triflate 446 to undergo Pd-catalyzed coupling reactions. Although the preparation of the 
corresponding vinyl stannane 430 has not been accomplished yet, we were pleased to find that enol 
triflate 446 engaged smoothly in a Suzuki coupling with phenylboronic acid.  
Since initial investigations to install an exomethylene moiety with organometallic reagents via Suzuki 
or Stille coupling remained unsuccessful,[308] a thorough screening with variation of temperature, 
solvent, base, Pd-sources and ligands should be performed in future to accomplish a synthesis of 
intermediate 453 (Scheme 5.5). In addition, other reaction partners such as boronic acids,[309] BF3K[310] 
salts or organozinc species[311] should be explored. It should be noted that side reactions such as an 
intramolecular Heck reaction might occur when using ‘real’ coupling partner 452. In this case, an 
alternative strategy could be investigated that involves a direct addition of a cuprate species[312] or an 
organotitanium reagent[313] to enol triflate 446. However, such a protocol could be accompanied by a 
C−C bond fragmentation/ring opening of cyclic vinylogous acyl triflate 446 as described by Dudley 
for the addition of Grignard and organolithium nucleophiles.[301,314] 
 
Scheme 5.5 Potential strategies for the combination of fragments en route to the tetracyclic backbone 457 of YW 3548 (112).  
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Alternatively, one could explore a NHK coupling[257] of vinyl triflate 446 with aldehyde 455 to form 
secondary alcohol 456. However, the synthesis of this or the related eastern fragment 452 has not been 
examined to date. Along the lines of the NHK reaction, it might be worth to investigate the 
transformation of vinyl triflate 446 into the corresponding vinyl bromide 454 following a recently 
published procedure.[315,316] Such strategy would not only represent the preparation of another coupling 
partner for Pd-catalysis, but would also pave the way for a strategy hinging on a nucleophilic attack of 
the corresponding lithium species on aldehyde 455. Overall, enol triflate 446 seems to be a valuable 
and readily accessible intermediate offering multiple possibilities for further investigations. If the task 
of fragment combination can be solved, the next challenge would be the closure of the central eight-
membered ring by RCM. Ultimately, the endgame proposed in the retrosynthetic analysis should 
culminate in the first preparation of the tetracyclic backbone 457 of YW 3548 (112). 
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6 SUMMARY 
 
In summary, this Ph.D. thesis detailed our progress toward the total synthesis of the type A 
trans-hydrindane iso-propyl sesterterpenoids astellatol (103), nitiol (110) and YW 3548 (112). Our 
program commenced with the evolution of an enantioselective route to three versatile building blocks 
suitable for synthetic studies toward these and structurally related natural products. Starting form 
enantiomerically pure diketone 116, we prepared enone 194 in a multistep sequence on decagram 
scale, which in turn underwent a counterintuitive, but diastereoselective cuprate addition to furnish 
alkene 220 as the sole diastereomer (Scheme 6.1). Interestingly, the relative configuration at the newly 
introduced stereogenic center matched the one found in our target molecules. This result constituted a 
major achievement since it allowed for the selective installation of a cis-relationship between the 
angular methyl group and the isopropylene residue on a trans-hydrindane portion, a configuration 
which is otherwise difficult to address. 
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Scheme 6.1 Divergent asymmetric synthesis of versatile building blocks ent-141, 190 and 191 suitable for type A trans-
hydrindane iso-propyl sesterterpenoids, and X-ray structures of important intermediates. 
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In the following investigations, we serendipitously discovered a highly selective diversification of 
ketone 220 utilizing hydrogenation conditions (Scheme 6.1). Whereas the use of Pd/C as a catalyst 
resulted in an almost complete inversion of the stereochemistry at the former allylic stereogenic center 
furnishing bicycle 222 in 91% yield, subjection of alkene 220 to PtO2 under an atmosphere of 
hydrogen exclusively afforded the desired β-isomer 246 in 93% yield. Notably, we exploited this rare 
observation of an alkene isomerization under hydrogenation conditions in useful ways. On the one 
hand, we prepared ketone ent-141 in a four-step reaction sequence starting from a-epimer 222. On the 
other hand, ketone 246 was converted to alkene 221 via a highly efficient Pd-catalyzed 
hydrodetriflation. A subsequent straight-forward two-step protocol then provided building block 190. 
Whereas ketone ent-141 has been an intermediate in Corey’s and Hudlicky’s total syntheses of the 
pentacarbocyclic architecture of retigeranic acid A (101), its diastereomeric counterpart 190 could 
serve as the starting point for the first preparation of retigeranic acid B (102). Efforts toward this 
synthesis are currently under investigation by Florian M. E. Huber, a graduate student in the Trauner 
laboratories. Furthermore, these studies enabled us to access a third trans-hydrindane building 
block 191, which contains an oxidized site in the cyclopentane moiety by diversification of 
alkene 221. An extensive screening of hydroboration conditions revealed that the use of the chiral 
borane 253 gave the best results in respect to the regioselectivity. With this protocol, alcohols 192 
and 251 were obtained in a synthetically useful ratio of 3.7:1 in favor of the desired product 192. The 
reaction as well constituted a matched case of double diastereoselection. Upon careful flash column 
chromatography in the subsequent steps, we succeeded in the isolation of pure ketone 191. Overall, 
this developed first-generation route was as envisaged robust and scalable and allowed for the 
preparation of multigram quantities of versatile intermediates 190 and 191 albeit requiring a total of 19 
and 20 steps, respectively. Since 1H and 2D NMR analysis was often thwarted by overlaying signals, 
our studies heavily relied on X-ray crystal structure analysis for unambiguous structure elucidation. 
Moreover, the observed stereochemical surprises emphasize a meticulous analysis of products, even 
with seemingly straight-forward reactions. 
 
 
Scheme 6.2 Progress toward astellatol (103): installation of the stereogenic centers at C-9 and C-10 in alkene 268 by a series 
of diastereoselective operations starting from building block 191. 
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After the successful preparation of building blocks ent-141, 190 and 191, we launched further studies 
toward type A trans-hydrindane iso-propyl sesterterpenoids. The major portion of these investigations 
was focused on intermediates en route to the unique pentacarbocyclic structure of astellatol (103). To 
this end, we initially opted to secure a reliable route for the installation of two adjacent stereogenic 
centers at C-9 and C-10 (astellatol numbering) and decided to take advantage of the conformational 
bias of a tricyclic system. As ketone 191 proved to be complicated to alkylate at C-9 under standard 
conditions, we resorted to a Pd-catalyzed allylation of the corresponding boron enolate to yield 
ketone 302 (Scheme 6.2). Further reactions including two highly diastereoselective transformations, a 
reagent-controlled reduction and a substrate controlled methylation, gave lactone 269 as single 
diastereomer that in turn was elaborated to alkene 268 in several steps. The key feature of this protocol 
was a chemoselective deprotective Swern oxidation, requiring a careful optimization of reaction 
conditions regarding temperature and time. Notably, at this stage the final fragment 268 incorporated 
the correct relative configuration at six out of ten stereogenic centers found in astellatol (103).  
 
 
Scheme 6.3 First generation approach en route to tricycle 328: attempted RCM of triene 320. 
 
As this reaction sequence had been previously established on a more easily accessible model 
system 207, we performed further studies toward the synthesis of astellatol (103) utilizing alkene 299 
as the branching point. This intermediate 299 was synthesized on multigram scale and four strategies 
to assemble the pentacyclic carbon skeleton of astellatol (103) were examined in the course of this 
Ph.D. thesis. Three of these routes hinged on the preparation of a strained 11-membered 
macrocycle 321, the precursor for an envisaged biomimetic cationic cascade to prepare 
pentacycle 368 (Scheme 6.3). In our first approach, we elaborated alkene 299 in several synthetic 
operations to triene 320 featuring a B-alkyl Suzuki coupling and a second deprotective Swern 
oxidation as key elements. Unfortunately, the investigated RCM reaction conditions have not yet 
effected a ring closure to macrocycle 321 but rather furnished the homodimer, arising from cross 
metathesis at the more easily accessible terminal vinyl moiety (cf. Chapter 3.4). 
In a second route, alkene 299 was converted to vinyl silane 342 in a multistep sequence involving a 
regioselective Pd-catalyzed silylstannylation and a diastereoselective vinyl lithium addition as key 
transformations (Scheme 6.4). While investigating the required iododesilylation to prepare vinyl 
iodide 328, the precursor for a B-alkyl Suzuki macrocyclization, an undesired iodoetherification took 
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place (cf. Chapter 3.5). Initial experiments to circumvent this side reaction have failed so far, and this 
strategy thus will be studied more thoroughly in future experiments. In addition, we designed an 
approach involving a late-stage alkene installation and already prepared alkyne 350, which needs to be 
elaborated to vinyl iodide 328. 
 
 
Scheme 6.4 Progress toward constructing the macrocycle in key substrate 321: successful synthesis of advanced 
intermediates and future milestones for the B-alkyl Suzuki and the allylation approach, respectively. 
 
In contrast to the two earlier routes which rely on modern transition metal catalysis to close the 
11-membered ring, a third strategy was based on an intramolecular allylation of sulfone 352. To this 
end, alkene 299 was elaborated to alcohol 367 by sequential B-alkyl Suzuki coupling, vinyl lithium 
addition and selective functional group manipulations (Scheme 6.4). The remaining two steps for the 
synthesis of allyl chloride 352 have not been examined in the course of this Ph.D. thesis and will be 
explored in near future. Notably, the prepared intermediates 320, 342 and 352 and contain all 
22 carbon atoms necessary for the construction of tricycle 321. 
 
 
Scheme 6.5 Progress toward the assembly of pentacycle 369 via a thermal [2+2]-cycloaddition: synthesis of ketone 382. 
 
As an alternative to the highly challenging preparation of astellatol (103) via a bioinspired cationic 
cascade starting from tricycle 321, we embarked on efforts toward the installation of the carbon 
backbone by an intramolecular [2+2]-cycloadditon. In these studies, alkene 299 served again as the 
starting point and was elaborated to ketone 382 utilizing a B-alkyl Suzuki coupling (Scheme 6.5). In 
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initial experiments on an analog bearing a methyl instead of the PMB ether, we partially succeeded in 
homologating the ketone functionality to an aldehyde (cf. Chapter 3.7). Thus, we are optimistic that 
the reaction conditions can be optimized soon. If this task is realized, the developed protocols need to 
be tested on ketone 382 in order to prepare the substrate for the envisaged key ketene-alkene 
cycloaddition to construct pentacycle 369.  
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Scheme 6.6 En route to 18-epi-nitiol (424): successful synthesis of western fragment 392 and progress toward the 
preparation of alkyl iodides 393 and 422. 
 
Beside these extensive studies toward astellatol (103), we investigated the total synthesis of the 
tricyclic sesterterpenoid nitiol (110). Since the surprising stereochemical outcome of the 
hydrogenation of ketone 220 in the presence of Pd/C was only established at a later stage, substantial 
amounts of ketone ent-141 were still left. This material was employed for model studies toward the 
C-18 epimer 424 of nitiol (110). In our initial approach toward a suitable eastern fragment 393 or 422, 
we accomplished the synthesis of ester 412 starting from ketone ent-141 in several steps that included 
an ozonolysis of a regioselectively generated silyl enol ether and a Claisen-Johnson rearrangement to 
install the trisubstituted alkene (Scheme 6.6). As attempts to shorten the side chain by one carbon atom 
met with little success, we prepared ester 418 in a second-generation route. This compound 418 
constitutes a precursor for a Kallmerten-Burke rearrangement and has the additional oxygen 
functionality already in place to later conduct a diol cleavage. In preliminary studies, we already 
observed the desired product originating from the desired sigmatropic rearrangement. Thus future 
explorations should address experiments along the lines of this promising result. In addition, we 
succeeded in the synthesis of the western fragment 392, comprising a pseudoephedrine auxiliary for 
the envisaged fragment union by a Myers alkylation. The preparation of amide 392 commenced with 
diastereoselective 1,4-additions under cuprate or Sakurai conditions, which interestingly required the 
use of enantiomeric Evans-auxiliaries 397 (cf. Chapter 4.3). In the course of these studies, the Sakurai 
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reaction turned out to be more convenient on larger scale albeit less diastereoselective. Ultimately, 
simple saponification of the chiral auxiliary and an EDCI mediated coupling with pseudoephedrine 
gave the desired fragment 392. 
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Scheme 6.7 En route to YW 3548 (112): enantioselective five-step synthesis of enol triflate 446, obtained coupling 
product 448 and key disconnections for the construction of the central eight-membered ring. 
 
The last part of this Ph.D. thesis discussed the studies toward a δ-lactone 446, which might serve as a 
valuable intermediate for the total synthesis of the structurally intriguing GPI anchor inhibitor 
YW 3548 (112). We exploited the Heathcock anti-aldol protocol to establish two adjacent 
stereocenters with high diastereoselectivity. In this reaction, the syn-selectivity of a standard Evans 
aldol reaction is inverted by adding a second equivalent of Bu2BOTf. Further synthetic operations 
including a Dieckmann condensation to close the six-membered ring with concomitant cleavage of the 
amide auxiliary 436 furnished enol triflate 446 (Scheme 6.7). While attempts to convert this 
compound 446 to the corresponding vinyl stannane have not been successful yet, we demonstrated the 
ability of enol triflate 446 to engage in Pd-catalyzed cross coupling reactions by preparing alkene 448. 
In future directions, a thorough screening of reaction conditions such as ligands, solvents, 
temperatures and the careful choice of a suitable coupling partner will be required in order to construct 
the tetracyclic architecture of YW 3548 (112). 
Overall, the pursued strategies presented in this Ph.D. thesis constituted significant progress toward 
the first total synthesis of any type A trans-hydrindane iso-propyl sesterterpenoid, exhibiting a 
sterically encumbered trans-hydrindane portion with an iso-propyl moiety residing in a cis-
relationship with the angular methyl group. The developed robust and scalable route to various 
versatile building blocks provided a basis for further efforts toward these structurally intriguing natural 
products that are currently under investigation in the Trauner laboratories. Thus, these challenging 
architectures will certainly continue to inspire and train a new generation of synthetic chemists, which 
will hopefully access one of these sesterterpenoids in the near future. 
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1 GENERAL WORKING METHODS 
 
All reactions were magnetically stirred and carried out under a positive pressure of inert-gas (N2 or 
argon) utilizing standard Schlenk-techniques. Glassware was dried in an oven at 120 °C and 
repeatedly at 650 °C in vacuo prior to use. Liquid reagents and solvents were added by syringes or 
oven-dried stainless steel cannulas through rubber septa. Solids were added under inert gas counter 
flow or were dissolved in appropriate solvents. Low temperature reactions were carried out in a Dewar 
vessel using a cryo cooler or filled with a cooling agent: acetone/dry ice (−78 °C), acetonitrile/liquid 
N2 (−40 °C), NaCl/ice (−20 °C) or ice/water (0 °C). Reaction temperatures above room temperature 
were conducted in a heated oil bath. High pressure reactions were conducted in a miniclave steel 
apparatus from BÜCHI AG. Drying of organic extracts over MgSO4 or Na2SO4 implicates a 
subsequent removal of the drying agent by filtration and rinsing of the filter cake with an appropriate 
solvent. Yields refer to isolated homogeneous and spectroscopically pure materials. 
 
Solvents and reagents 
 
Tetrahydrofurane (THF) and diethyl ether (Et2O) were distilled under N2 atmosphere from 
Na/benzophenone as drying agent prior to use. Triethylamine (Et3N), diisopropylamine (DIPA) and 
Hünig’s base (DIPEA) were distilled under N2 atmosphere from CaH2 as drying agent prior to use. 
Further dry solvents such as dichloromethane (CH2Cl2), N,N-dimethylformamide (DMF), 
acetonitrile (MeCN), acetone, methanol (MeOH), benzene and toluene were purchased as ‘Extra Dry 
over Molecular Sieves’ from Acros Organics and were used as received. 
Hexamethylphosphoramide (HMPA) was distilled from CaH2 in vacuo and stored over molecular 
sieves under an atmosphere of N2. Solvents for extraction, crystallization and flash column 
chromatography were purchased in technical grade and distilled under reduced pressure prior to use. 
(S)-Alpine-BoramineTM, (R)-Alpine-BoramineTM, 9-BBN dimmer and CBS catalyst 375 were 
purchased from Sigma-Aldrich and stored in a UNIlab glove-box from MBRAUN. Methyl vinyl 
ketone (MVK, 122) was purchased in technical grade (90%) and distilled immediately prior to use. 
Allyl bromide was distilled prior to use and stored under an atmosphere of N2. Et3B was purchased 
neat and appropriate solutions in degassed THF (freeze-pump-thaw method) were freshly prepared 
immediately prior to use. The following reagents were prepared according to literature procedures: 
Evans auxiliaries 397,[264] ent-397[264] and 436,[296] oxazolidinone 403,[266] vinyl iodide 307,[200] 
PMB ether 329,[219] Ohira-Bestmann reagent (336),[317] vinyl iodide 356,[238] vinyl iodide 363,[240] 
vinyl iodide 377,[249] pinacol borate 450,[304] vinyl stannane 451,[305] DMP,[208] Bu2BOTf,[298] 
MoOPH.[275] All other reagents and solvents were purchased from chemical suppliers (Sigma-Aldrich, 
Acros Organics, Alfa Aesar, Merck, Strem, ABCR, TCI Europe) and were used as received. 
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Chromatography 
 
Reactions and chromatography fractions were monitored by qualitative thin-layer chromatography 
(TLC) on silica gel F254 TLC plates from Merck KGaA. Analytes on the glass plates were visualized by 
irradiation with UV-light and/or by immersion of the TLC plate in an appropriate staining solution 
followed by heating with a hot-air gun (350 °C). The following staining solutions were applied: 
• p-anisaldehyde staining solution (3.7 mL p-anisaldehyde, 5.0 mL concentrated aqueous 
H2SO4, 1.5 mL glacial AcOH, 135 mL EtOH). 
• CAM staining solution (5.0 g, Ce(SO4)2, 25 g (NH4)6Mo7O24·4H2O, 50 mL concentrated 
aqueous H2SO4, 450 mL H2O). 
• KMnO4 staining solution (3.0 g KMnO4, 20 g K2CO3, 5.0 mL aqueous 5% NaOH, 300 mL 
H2O). 
• DNP staining solution (12 g 2,4-dinitrophenylhydrazine, 60 mL concentrated aqueous H2SO4, 
200 mL EtOH, 80 mL H2O). 
Flash column chromatography was performed on Geduran® Si60 (40−63 μm) silica gel from Merck 
KGaA. All fractions containing a desired substrate were combined and solvents were removed under 
reduced pressure followed by drying in high vacuo (10−2 mbar). 
 
NMR spectroscopy 
 
NMR spectra were recorded by the analytic section of the Department of Chemistry of the Ludwig-
Maximilians-Universität München using Bruker AXR300, Varian VXR400 S and Bruker AMX600 
spectrometers operating at 300 MHz, 400 MHz and 600 MHz for proton nuclei (75 MHz, 100 MHz, 
150 MHz for carbon nuclei). CDCl3, CD2Cl2 and C6D6 were purchased from Sigma-Aldrich and 
Euriso-top. The 1H NMR shifts are reported in ppm related to the chemical shift of TMS. 1H NMR 
shifts were calibrated to residual solvent resonances: CDCl3 (7.26 ppm), CD2Cl2 (5.32 ppm) 
C6D6 (7.16 ppm). 13C NMR shifts were calibrated to the center of the multiplet signal of the residual 
solvent resonance: CDCl3 (77.16 ppm), CD2Cl2 (54.00 ppm), C6D6 (128.37 ppm). 
1H NMR spectroscopic data are reported as follows: Chemical shift in ppm (multiplicity, coupling 
constants J, integration intensity). The multiplicities are abbreviated with s (singlet), br s (broad 
singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and mC (centrosymmetric multiplet). In case 
of combined multiplicities, the multiplicity with the larger coupling constant is stated first. Except for 
multiplets, the chemical shift of all signals, as well for centrosymmetric multiplets, is reported as the 
center of the resonance range. Additionally to recording 1H and 13C NMR spectra, 2D NMR 
techniques such as homonuclear correlation spectroscopy (COSY), heteronuclear single quantum 
coherence (HSQC), heteronuclear multiple bond coherence (HMBC), nuclear Overhauser 
enhancement correlation spectroscopy (NOESY) were used to assign signals. Thereby, the numbering 
of the carbon skeleton does not correspond to the IUPAC nomenclature. If two signals could not be 
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assigned unambiguously by these methods, the assigned carbon atoms are marked as ‘*’, ‘**’, etc. and 
the assignment is interchangeable. Coupling constants nJA/B between protons A and B across n bonds 
are reported in Hz, if an assignment of the two coupling partners was possible. Otherwise, coupling 
constants are given as J in Hz. Diastereotopic protons were named as HA and HB with HA 
corresponding to the more downfield-shifted signal. All NMR spectra were analyzed using the 
program MestRe NOVA 5.2.0 from Mestrelab Research S. L. 
 
Mass spectrometry 
 
All mass spectra were measured by the analytic section of the Department of Chemistry of the 
Ludwig-Maximilians-Universität München. Mass spectra were recorded on the following 
spectrometers (ionization mode in brackets): MAT 95 (EI) and MAT 90 (ESI) from Thermo Finnigan 
GmbH or JMS-700 (FAB) from Jeol Ltd. Mass spectra were recorded in high-resolution and the only 
characteristic molecule fragments or molecule ion peaks are indicated for each analyte. The method 
used is reported at the relevant section of the experimental part. 
 
IR spectroscopy 
 
IR spectra were recorded on a PerkinElmer Spectrum BX II FT-IR system. All substances were 
dissolved in CH2Cl2 and directly applied on the ATR unit. The measured wave numbers are reported 
in cm−1 and the band intensities are described with br (broad), s (strong), m (medium) and w (weak). 
 
Melting points 
 
Melting points were measured on a B-540 melting point apparatus from BÜCHI Labortechnik AG and 
are uncorrected. 
 
Optical rotation 
 
Optical rotation values were recorded on a polarimeter P8000-T from A. Krüss Optronic GmbH or on 
a PerkinElmer 241 polarimeter. The specific rotation is calculated as follows: 
 
[ ] [ ]
dc ⋅
⋅
=
100αα ϑλ  
 
The wave length λ is reported in nm and the measuring temperature ϑ in °C. α resembles the recorded 
optical rotation at the apparatus, c the concentration of the analyte in 10 mg/mL and d the length of the 
cuvette in dm. Thus, the specific rotation is given in 10−1·deg·cm2·g−1. Usage of the sodium D 
line (λ = 589 nm) is indicated by D instead of the wavelength in nm. The respective concentration as 
well as the solvent is denoted in the analytical part of the experimental description. 
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2 EXPERIMENTAL PROCEDURES 
 
2.1 Experimental Procedures for Chapter 2: ‘A Unified Approach 
toward trans-Hydrindane iso-Propyl Sesterterpenoids’ 
 
Synthesis of the ESWHP Ketone (116) 
 
 
To a suspension of diketone 196 (100 g, 890 mmol, 1.0 eq.) in H2O (220 mL) was added 
methylvinylketone (122, 130 mL, 1.59 mol, 1.8 eq.) followed by AcOH (2.70 mL, 47.0 mmol, 
5.3 mol-%). The reaction apparatus was shielded from light and the mixture was heated to 75 °C for 
4 h. The reaction was allowed to cool to room temperature and the product was extracted with 
CH2Cl2 (1 x 500 mL, 2 x 100 mL). The combined organic layers were washed with saturated aqueous 
NaCl (1 x 300 mL, 1 x 200 mL) and the combined aqueous layers were re-extracted with CH2Cl2 (2 x 
150 mL). The combined organic layers were dried over MgSO4 and the solvent was removed under 
reduced pressure to afford crude triketone 197 (147 g, 808 mmol, 91%) as a light-orange oil, which 
was used without further purification. 
A light-protected suspension of (S)-proline (198, 2.80 g, 24.3 mmol, 3.0 mol-%) in DMF (607 mL) 
was degassed four times (evacuated and backfilled with N2) and stirred at 16 °C for 1 h. Then, a 
solution of crude triketone 197 (147 g, 808 mmol, 1.0 eq.) in DMF (200 mL + 2 x 25 mL rinse) was 
added and the mixture was degassed four times. After slowly warming to room temperature and 
stirring for an additional four days at ambient temperature, the reaction was judged to be complete by 
TLC and the mixture, containing crude bicycle 200, was used in the next step without further 
purification. 
Initially, a solution of H2SO4 in DMF was prepared by dropwise addition of concentrated 
H2SO4 (6.36 mL) to DMF (116 mL) at −21 °C. 
The above prepared mixture of crude bicycle 200 in DMF was heated to 95 °C. When the external 
temperature reached 75 to 80 °C, an aliquot of the H2SO4 solution (58 mL) was added. After stirring 
for 1 h at 95 °C, another aliquot of the H2SO4 solution (23 mL) was added and the mixture was stirred 
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for an additional 3.5 h at this temperature, before being allowed to cool to room temperature. The 
solvent was removed under reduced pressure and the resulting residual dark brown oil was dissolved 
in CH2Cl2 (1.1 L). The organic layer was washed with NaCl-saturated H2SO4 (1M, 2 x 500 mL), NaCl-
saturated aqueous saturated NaHCO3 (2 x 500 mL) and with saturated aqueous NaCl (500 mL). Each 
aqueous layer was extracted with the same fraction of CH2Cl2 (2 x 500 mL). The combined organic 
layers were dried over MgSO4 and the solvent was removed under reduced pressure. The residual 
brown oil was dissolved in EtOAc and the solution was filtered over dry silica. The product containing 
fractions were combined and the solvent was removed under reduced pressure to obtain a brownish 
solid. Such material was subjected to bulb-to-bulb distillation (210 °C, 0.4 mbar) giving a pale yellow 
solid. Finally, recrystallization (Et2O/hexanes) afforded diketone 116 (80 g, 488 mmol, 55% over three 
steps, 96% ee) as colorless crystals, which were suitable for X-ray analysis. 
 
Rf = 0.30 (hexanes:EtOAc = 1:1). 
 
Melting point = 63.0−64.0 °C (Et2O/hexanes). 
 
1H NMR (300 MHz, CDCl3): δ = 5.93 (mC, 1H, 5-H), 2.93 (mC, 1H, 3-HA), 2.82−2.67 (m, 2H, 2-HA, 
3-HB), 2.56−2.33 (m, 3H, 2-HB, 7-H), 2.07 (ddd, 2J8A/8B = 13.5 Hz, 3J8A/7 = 5.1, 2.2 Hz, 1H, 8-HA), 
1.82 (ddd, 2J8B/8A = 3J8B/7 = 13.7 Hz, 3J8B/7 = 5.6 Hz, 1H, 8-HB), 1.29 (s, 3H, 10-H) ppm. 
 
13C NMR (75 MHz, CDCl3): δ = 216.6 (C-1), 198.2 (C-6), 169.8 (C-4), 123.9 (C-5), 48.8 (C-9), 
36.0 (C-2), 33.0 (C-7), 29.3 (C-8), 26.9 (C-3), 20.7 (C-10) ppm.  
 
EI-MS for C10H12O2+ [M+]: calcd. 164.0832 
 found 164.0831. 
 
IR (ATR): ῦ/cm−1 = 2932 (w), 2871 (w), 1745 (s), 1667 (s), 1448 (w), 1348 (w), 1232 (w), 1148 (w), 
1060 (w), 866 (w). 
 
[ ]20Dα  = +332.0 (c 1.00, toluene). 
 
The analytical data matched those reported previously.[121] 
 
118  EXPERIMENTAL SECTION 
Synthesis of Alcohol 201 
 
 
Due to the limited capacities of Dewar vessels, two experiments were set up in parallel: To a solution 
of diketone 116 (25.4 g, 155 mmol, 1.0 eq.) in EtOH (400 mL) at −18 °C was added dropwise a 
solution of NaBH4 (1.76 g, 46.6 mmol, 0.30 eq.) in EtOH (275 mL) within 3.5 h (dropping funnel) and 
the mixture was stirred for an additional 1 h at this temperature. Then, the reaction was quenched by 
slow addition of aqueous HCl (2M) until the pH was adjusted to approximately 6. Both 
experiments (50.5 g of diketone 116 in total) were combined and the solvent was evaporated under 
reduced pressure. The resulting residue was partitioned between EtOAc (500 mL) and saturated 
aqueous NaCl (125 mL) and the aqueous layer was extracted with EtOAc (3 x 125 mL). The combined 
organic layers were dried over MgSO4 and the solvents were evaporated under reduced pressure. The 
thus obtained crude product was purified by flash column chromatography (silica, CH2Cl2:MeOH = 
93:7) to yield title compound 201 (51.2 g, 308 mmol, quant.) as a pale yellow wax. 
 
Rf = 0.23 (CH2Cl2:MeOH = 93:7). 
 
1H NMR (300 MHz, CDCl3): δ = 5.76 (mC, 1H, 5-H), 3.83 (dd, 3J1/2 = 10.3, 7.6 Hz, 1H, 1-H), 
2.69 (mC, 1H, 3-HA), 2.57−2.31 (m, 4H, 3-HB, 7-H, OH), 2.18−2.05 (m, 2H, 2-HA, 8-HA), 
1.88−1.70 (m, 2H, 2-HB, 8-HB), 1.13 (s, 3H, 10-H) ppm. 
 
13C NMR (75 MHz, CDCl3): δ = 199.5 (C-6), 175.5 (C-4), 123.5 (C-5), 80.7 (C-1), 45.3 (C-9), 
34.2 (C-8), 33.4 (C-7), 29.2 (C-2), 26.6 (C-3), 15.2 (C-10) ppm.  
 
EI-MS for C10H14O2+ [M+]: calcd. 166.0988 
 found 166.0980. 
 
IR (ATR): ῦ/cm−1 = 3400 (br s), 2967 (m), 2867 (w), 1643 (s), 1417 (w), 1349 (m), 1322 (w), 
1201 (m), 1086 (m), 1074 (m), 1034 (w), 956 (w). 
 
[ ]20Dα  = +78.6 (c 1.00, CH2Cl2). 
 
The analytical data matched those reported previously.[127,132] 
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Synthesis of Enone 203 
 
 
To a solution of alcohol 201 (40.7 g, 245 mmol, 1.0 eq.) in CH2Cl2 (400 mL) at −78 °C was added 
isobutylene (202, approximately 200 mL, 2.23 mol, 9.0 eq.) and H3PO4 (100%, 4.50 mL, 0.34 eq.) 
followed by BF3·OEt2 (10.3 mL, 83.5 mmol, 0.34 eq.). The reaction was stirred for 2 h at −78 °C and 
was then allowed to warm to room temperature. After stirring for an additional 18 h at room 
temperature, the reaction was quenched by addition of aqueous NH4OH (2M, 400 mL). The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 x 350 mL). The combined organic 
layers were dried over MgSO4 and the solvents were evaporated under reduced pressure. The crude 
product was purified by flash column chromatography (silica, hexanes:EtOAc = 3:1 to 2:1) to yield 
enone 203 (47.8 g, 215 mmol, 88%) as a colorless solid.  
 
Rf = 0.51 (hexanes:EtOAc = 3:1). 
 
1H NMR (300 MHz, CDCl3): δ = 5.74 (mC, 1H, 5-H), 3.55 (dd, 3J1/2 = 9.8, 7.3 Hz, 1H, 1-H), 2.67 (mC, 
1H, 3-HA), 2.49 (ddd, J = 17.7, 14.3, 5.2 Hz, 1H, 7-HA), 2.41−2.28 (m, 2H, 3-HB, 7-HB), 2.05−1.90 (m, 
2H, 2-HA, 8-HA), 1.85−1.64 (m, 2H, 2-HB, 8-HB), 1.16 (s, 9H, 12-H), 1.09 (s, 3H, 10-H) ppm. 
 
13C NMR (75 MHz, CDCl3): δ = 199.5 (C-6), 175.6 (C-4), 123.0 (C-5), 79.8 (C-1), 73.2 (C-11), 
44.9 (C-9), 34.5 (C-8), 33.6 (C-7), 29.7 (C-2), 28.8 (C-12), 27.0 (C-3), 15.8 (C-10) ppm.  
 
EI-MS for C14H23O2+ [(M+H)+]: calcd. 223.1685 
 found 223.1693. 
 
IR (ATR): ῦ/cm−1 = 2973 (m), 2936 (w), 1671 (s), 1464 (w), 1419 (w), 1390 (w), 1364 (w), 1218 (m), 
1199 (m), 1092 (m), 1028 (w), 1005 (w), 956 (w), 891 (w). 
 
[ ]20Dα  = +49.9 (c 1.00, CHCl3). 
 
The analytical data matched those reported previously.[127] 
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Synthesis of Carboxylic Acid 205 
 
 
To a solution of indenone 203 (56.9 g, 256 mmol, 1.0 eq.) in DMF (560 mL) was added MMC (204, 
450 mL of a 2M solution in DMF, 900 mmol, 3.5 eq.) and the mixture was degassed (N2 bubbling) for 
30 min. Then, the reaction vessel was placed in an oil bath (pre-heated to 130 °C) and the mixture was 
stirred for 4 h at 130 °C (Caution: initially vigorous gas evolution). The mixture was allowed to cool 
to room temperature and then further cooled to 0 °C before slowly adding aqueous HCl (2N) until the 
solution solidified. Thereafter, Et2O (500 mL) was added followed by concentrated aqueous HCl until 
the pH was adjusted to 2−3 and two homogenous layers were formed (Caution: slow addition of HCl 
is necessary due to gas evolution). The phases were separated and the aqueous layer was extracted 
with Et2O (4 x 600 mL, 1 x 400 mL). The combined organic layers were splitted into two 
equivolumetric parts and each aliquot was washed with 10% aqueous NaCl (300 mL acidified with 
HCl to pH = 2−3). The aqueous layers were re-extracted with Et2O (2 x 300 mL) and the combined 
organic layers were dried over MgSO4. Having evaporated the solvents under reduced pressure, the 
crude product was recrystallized from hexanes at −78 °C to yield acid 205 (35.4 g, 133 mmol, 52%). 
The mother liquor was concentrated and subjected to flash column chromatography (silica, 
hexanes:EtOAC:HOAc = 8:1:0.045 to 8:1:0.09 to 4:1:0.09 to yield additional acid 205 (9.27 g, 
34.8 mmol, 14%) along with recovered starting material 203 (16.6 g, 74.8 mmol, 29%), which was 
subjected to another cycle as described above.  
Overall, indenone 203 (56.9 g, 256 mmol) was converted to acid 205 (55.7 g, 209 mmol) in 82% yield.  
 
Crystals suitable for X-ray analysis were obtained by slow evaporation of a solution of acid 205 in 
hexanes. 
 
Rf = 0.18 (hexanes:EtOAc = 4:1, 1% HOAc). 
 
1H NMR (300 MHz, CDCl3): δ = 3.65 (dd, 3J1/2 = 10.3, 7.1 Hz, 1H, 1-H), 3.34−3.08 (m, 2H, 3-H), 
2.77 (ddd, 2J7A/7B = 18.8 Hz, 3J7A/8 = 14.1, 5.7 Hz, 1H, 7-HA), 2.62 (ddd, 2J7B/7A = 18.9 Hz, 3J7B/8 = 5.6, 
2.0 Hz, 1H, 7-HB), 2.11−1.98 (m, 2H, 2-HA, 8-HA), 1.93−1.73 (m, 2H, 2-HB, 8-HB), 1.17 (s, 12H, 
10-H, 12-H) ppm. 
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13C NMR (75 MHz, CDCl3): δ = 202.9 (C-6), 196.3 (C-13), 164.3 (C-4), 120.5 (C-5), 78.9 (C-1), 
73.6 (C-11), 48.4 (C-9), 33.6 (C-7), 32.0 (C-8), 31.5 (C-3), 30.1 (C-2), 28.7 (C-12), 16.4 (C-10) ppm.  
 
ESI-MS for C15H21O4− [(M−H)−]: calcd. 265.1445 
 found 265.1441. 
 
IR (ATR): ῦ/cm−1 = 2979 (m), 2943 (w), 1737 (s), 1630 (s), 1390 (m), 1352 (m), 1284 (w), 1264 (w), 
1193 (m), 1103 (m), 1031 (w), 1020 (w), 941 (w). 
 
[ ]20Dα  = +30.2 (c 1.00, CH2Cl2). 
 
The analytical data matched those reported previously.[127,134] 
 
 
Synthesis of Ketone 207 
 
 
To a solution of carboxylic acid 205 (25.3 g, 94.8 mmol, 1.0 eq.) in MeOH (200 mL) was added 
Pd/BaSO4 (5% Pd, 5.10 g, 2.41 mmol, 2.5 mol-%) and the mixture was purged with H2 (50 psi) for 3 h 
in a pressure reactor. The H2 pressure was released and the mixture was filtered over a pad of Celite® 
(washings with MeOH). The solvent was removed under reduced pressure to yield β-keto acid 206 as 
colorless foam which was used without further purification. 
The flask containing crude β-keto acid 206 was evacuated under high pressure and was subsequently 
heated to 90 °C (pre-heated oil bath) with stirring, resulting in gas evolution. The mixture was stirred 
for 1 h and was then cooled to room temperature. The crude product was purified by flash column 
chromatography (silica, hexanes:EtOAc = 16:1) to give trans-hydrindane 207 as a colorless solid, 
which was contaminated by ca. 6% of the cis-product. 
Purification by flash column chromatography was carried out on the crude product of several reaction 
batches. Overall, keto-acid 205 (54.1 g, 203 mmol) was converted to trans-hydrindane 207 (26.8 g, 
120 mmol) in 59% yield. 
 
Rf = 0.21 (hexanes:EtOAc = 16:1). 
 
Melting point = 37.3−38.3 °C (hexanes/EtOAc). 
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1H NMR (400 MHz, CDCl3): δ = 3.45 (dd, 3J1/2 = 9.1, 7.7 Hz, 1H, 1-H), 2.40 (ddd, J = 16.3, 12.8. 
7.0 Hz, 1H, 7-HA), 2.34−2.25 (m, 3H, 5-H, 7-HB), 2.04−1.90 (m, 2H, 2-HA, 8-HA), 1.77−1.66 (m, 1H, 
4-H),1.64−1.53 (m, 2H, 2-HB, 3-HA), 1.46−1.34 (m, 2H, 3-HB, 8-HB), 1.13 (s, 9H, 12-H), 0.96 (s, 3H, 
10-H) ppm. 
 
13C NMR (100 MHz, CDCl3): δ  = 212.3 (C-6), 79.5 (C-1), 72.7 (C-11), 44.8 (C-4), 43.1 (C-5), 
42.2 (C-9), 37.5 (C-7), 35.4 (C-8), 31.9 (C-2), 28.8 (C-12), 25.9 (C-3), 10.3 (C-10) ppm.  
 
EI-MS for C14H25O2+ [(M+H)+]: calcd. 225.1850 
 found 225.1845. 
 
IR (ATR): ῦ/cm−1 = 2971 (s), 2874 (m), 1711 (s), 1464 (w), 1418 (w), 1362 (m), 1252 (w), 1193 (s), 
1123 (m), 1104 (w), 1060 (s), 901 (w). 
 
[ ]20Dα  = +79.0 (c 1.00, CH2Cl2). 
 
The analytical data matched those reported previously.[127,134] 
 
 
Synthesis of Alcohol 208 
 
 
To a solution of trans-hydrindane 207 (30.4 g, 136 mmol, 1.0 eq.) in EtOH (310 mL) was added 
aqueous HCl (6N, 44 mL) and the reaction mixture was heated to reflux for 4 h. After cooling to 0 °C, 
the pH was adjusted to 7 by adding solid Na2CO3 and the solvent was evaporated under reduced 
pressure. The residue was diluted with CH2Cl2 (800 mL) and H2O (200 mL) was added. The organic 
layer was separated, washed with saturated aqueous NaCl (200 mL) and dried over Na2SO4. The 
solvents were removed under reduced pressure and the crude product was purified by flash column 
chromatography (silica, hexanes:EtOAc = 1:1) to yield the title compound 208 (22.6 g, 134 mmol, 
99%) as a colorless oil. 
 
Rf = 0.16 (hexanes:EtOAc = 2:1). 
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1H NMR (CDCl3, 300 MHz): δ = 3.74 (dd, 3J1/2 = 9.1, 8.2 Hz, 1H, 1-H), 2.74−2.19 (m, 4H, 5-H, 7-H), 
2.19−2.09 (m, 1H, 2-HA), 2.00 (mC, 1H, 8-HA), 1.86 (br s, 1H, OH), 1.76 (mC, 1H, 4-H), 1.69−1.34 (m, 
4H, 2-HB, 3-H, 8-HB), 0.98 (s, 3H, 10-H) ppm. 
 
13C NMR (CDCl3, 75 MHz): δ = 211.7 (C-6), 80.4 (C-1), 44.8 (C-4), 43.0 (C-5), 42.5 (C-9), 
37.3 (C-7), 34.8 (C-8), 31.2 (C-2), 25.4 (C-3), 9.9 (C-10) ppm. 
 
EI-MS for C10H16O2+ [M+]: calcd. 168.1150 
 found 168.1147. 
 
IR (ATR): ῦ/cm−1 = 3420 (br m), 2951 (m), 2872 (m), 1702 (s), 1466 (w), 1417 (w), 1317 (m), 
1200 (w), 1124 (m), 1044 (s), 998 (w). 
 
[ ]20Dα  = +75.6 (c 1.00, CH2Cl2). 
 
 
Synthesis of Dioxolane 210 
 
 
To a solution of alcohol 208 (22.6 g, 135 mmol, 1.0 eq.) and ethylene glycol (209, 63.0 mL, 1.13 mol, 
8.4 eq.) in benzene (500 mL) was added p-toluenesulfonic acid (2.50 g, 14.5 mmol, 11 mol-%) and the 
suspension was heated to reflux for 2 h using a Dean-Stark trap to remove the liberated water. The 
mixture was allowed to cool to room temperature and the reaction was quenched by adding saturated 
aqueous NaHCO3 (400 mL). After phase separation, the aqueous layer was extracted with EtOAc (3 x 
400 mL) and the combined organic layers were washed with saturated aqueous NaCl (300 mL), dried 
over Na2SO4 and the solvents were removed under reduced pressure. The obtained crude product was 
purified by flash column chromatography (silica, hexanes:EtOAc = 3:2) to yield alcohol 210 (27.5 g, 
130 mmol, 96%) as a pale yellow oil. 
 
Rf = 0.45 (hexanes:EtOAc = 1:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 4.00−3.84 (m, 4H, 11-H, 12-H), 3.71 (dd, 3J1/2 = 8.8, 7.9 Hz, 1H, 
1-H), 2.18−2.06 (m, 1H, 2-HA), 1.79−1.42 (m, 9H, 2-HB, 3-HA, 4-H, 5-H, 7-H, 8-HA, OH), 
1.39−1.22 (m, 2H, 3-HB, 8-HB), 0.81 (s, 3H, 10-H) ppm. 
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13C NMR (CDCl3, 100 MHz): δ = 110.1 (C-6), 81.1 (C-1), 64.4 (C-11)*, 64.3 (C-12)*, 42.6 (C-9), 
42.5 (C-4), 35.8 (C-5)**, 33.7 (C-8), 31.2 (C-7)**, 31.1 (C-2), 25.1 (C-3), 9.7 (C-10) ppm. 
 
EI-MS for C12H20O3+ [M+]: calcd. 212.1412 
 found 212.1405. 
 
IR (ATR): ῦ/cm−1 = 3420 (br m), 2949 (s), 2874 (s), 1469 (w), 1446 (w), 1349 (m), 1192 (m), 
1117 (s), 1074 (s), 1043 (s), 944 (s), 894 (s), 858 (s). 
 
[ ]20Dα  = +18.8 (c 1.00, CH2Cl2). 
 
 
Synthesis of Ketone 195 
  
 
To a suspension of pyridinium chlorochromate (68.0 g, 320 mmol, 2.5 eq.) and NaOAc (52.0 g, 
640 mmol, 5.0 eq.) in CH2Cl2 (700 mL) at 0 °C was added dropwise a solution of alcohol 210 (27.2 g, 
128 mmol, 1.0 eq.) in CH2Cl2 (150 mL). The mixture was allowed to warm to room temperature and 
stirred for an additional 4 h. After filtering over a plug of silica (eluted with hexanes:EtOAc = 1:2) and 
evaporation of the solvents under reduced pressure, the crude product was purified by flash column 
chromatography (silica, hexanes:EtOAc = 5:1) to yield ketone 195 (22.1 g, 106 mmol, 80%) as a 
colorless solid, being contaminated by the cis-isomer from the previous reactions. Further purification 
by recrystallization from hexanes yielded pure trans-hydrindane 195 (19.0 g, 90.4 mmol, 71%) as a 
colorless crystalline solid.  
 
Crystals suitable for X-ray analysis were obtained by recrystallization from n-pentane. 
 
Rf = 0.61 (hexanes:EtOAc = 1:1). 
 
Melting point = 76.0−77.0 °C (hexanes). 
 
1H NMR (CDCl3, 600 MHz): δ = 3.94 (mC, 4H, 11-H, 12-H), 2.45 (ddd, 2J2A/2B = 19.3 Hz, 3J2A/3B = 
8.8 Hz, 3J2A/3A = 1.1 Hz, 1H, 2-HA), 2.14 (ddd, 2J2B/2A = 19.2 Hz, 3J2B/3A = 3J2B/3B = 9.2 Hz, 1H, 2-HB), 
2.01 (dddd, 3J4/5 = 18.9 Hz, 3J4/3B = 13.0 Hz, 3J4/3A = 5.8 Hz, 3J4/5 = 3.8 Hz, 1H, 4-H), 1.86 (dddd, 
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2J3A/3B = 12.4 Hz, 3J3A/2B = 8.9 Hz, 3J3A/4 = 5.8 Hz, 3J3A/2A = 1.1 Hz, 1H, 3-HA), 1.79−1.69 (m, 5H, 5-H, 
7-H, 8-HA), 1.62 (dddd, 2J3B/3A = 3J3B/4 = 12.7 Hz, 3J3B/2A = 3J3/2B = 9.0 Hz, 1H, 3-HB), 1.49 (mC, 1H, 
8-HB), 0.93 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 219.7 (C-1), 109.6 (C-6), 64.6 (C-11)*, 64.4 (C-12)*, 47.1 (C-9), 
42.8 (C-4), 36.2 (C-2), 35.6 (C-5), 30.9 (C-7), 28.7 (C-8), 23.7 (C-3), 12.3 (C-10) ppm. 
 
EI-MS for C12H18O3+ [M+]: calcd. 210.1256 
 found 212.1249. 
 
IR (ATR): ῦ/cm−1 = 2924 (w), 1730 (s), 1412 (w), 1350 (w), 1118 (s), 1066 (s), 1036 (s), 938 (s). 
 
[ ]20Dα  = +83.6 (c 1.00, CH2Cl2). 
 
This compound has been prepared by an alternative route, having identical physical properties.[125c,d] 
 
 
Synthesis of Enone 194 
 
 
To a solution of diisopropylamine (12.0 mL, 86.0 mmol, 3.0 eq.) in THF (120 mL) at −78 °C was 
added n-BuLi (34.0 mL of a 2.5M solution in hexanes, 86.0 mmol, 3.0 eq.). The yellowish solution 
was stirred for 10 min at −78 °C and an additional 15 min at 0 °C before being cooled to −78 °C. 
Then, a solution of ketone 195 (6.00 g, 28.6 mmol, 1.0 eq.) in THF (30 mL) was added within 15 min. 
After stirring for 45 min at −78 °C, Et3N (18.0 mL, 129 mmol, 4.5 eq.) was added followed by TMSCl 
(14.6 mL, 114 mmol, 4.0 eq.). The solution was stirred for 30 min at −78 °C and was then allowed to 
warm to 0 °C. The reaction was quenched by addition of saturated aqueous NaHCO3 (50 mL) and the 
mixture was diluted with n-pentane (100 mL). The phases were separated and the aqueous layer was 
extracted with n-pentane (3 x 50 mL). The combined organic layers were washed with saturated 
aqueous NaCl (50 mL) and dried over Na2SO4. Evaporation of the solvent under reduced pressure 
(water bath temperature: 35 °C) yielded crude silyl enol ether 211 which was used without further 
purification. 
To a solution of crude silyl enol ether 211 in CH2Cl2 (100 mL) and MeCN (34 mL) was added 
Pd(OAc)2 (7.67 g, 31.5 mmol, 1.1 eq.) in one portion and the solution was stirred at 37 °C for 4 h. The 
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mixture was filtered over a plug of silica (eluted with hexanes:EtOAc = 1:1) and the solvents were 
evaporated under reduced pressure. The crude product was purified by flash column 
chromatography (silica, hexanes:EtOAc = 7:1 to 5:1 to 4:1 to 2:1) to yield α,β-unsaturated 
ketone 194 (4.10 g, 19.7 mmol, 69%) as a colorless crystalline solid along with recovered starting 
material 195 (1.30 g, 6.20 mmol, 22%). 
A second cycle of the above described reaction and additional reaction batches resulted in an overall 
transformation from ketone 195 (18.8 g, 89.5 mmol) to enone 194 (15.2 g, 73.1 mmol) in 82% yield.  
 
Crystals suitable for X-ray analysis were obtained by recrystallization from hexanes. 
 
Rf = 0.50 (hexanes:EtOAc = 1:1). 
 
Melting point = 127.5−129.5 °C (hexanes/EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.38 (dd, 3J3/2 = 5.9 Hz, 3J3/4 = 1.8 Hz, 1H, 3-H), 6.03 (dd, 3J2/3 = 
5.9 Hz, 4J2/4 = 3.2 Hz, 1H, 2-H), 4.00−3.92 (m, 4H, 11-H, 12-H), 3.04 (mC, 1H, 4-H), 1.96−1.86 (m, 
3H, 5-H, 7-HA), 1.82−1.74 (m, 2H, 7-HB, 8-HA), 1.69 (ddd, 2J8B/8A = 13.2 Hz, 3J8B/7A = 3J8B/7B = 4.8 Hz, 
1H, 8-HB), 1.13 (s, 3H, 10-H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 211.7 (C-1), 160.6 (C-3), 132.0 (C-2), 109.7 (C-6), 64.8 (C-11)*, 
64.3 (C-12)*, 50.7 (C-9), 48.1 (C-4), 33.6 (C-5), 31.7 (C-7), 26.8 (C-8), 19.4 (C-10) ppm. 
 
EI-MS for C12H16O3+ [M+]: calcd. 208.1099 
 found 208.1097. 
 
IR (ATR): ῦ/cm−1 = 2963 (w), 2934 (w), 1699 (s), 1466 (w), 1237 (w), 1180 (w), 1134 (w), 1092 (s), 
1066 (w), 949 (w). 
 
[ ]20Dα  = −67.2 (c 1.00, CH2Cl2). 
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Synthesis of Lactone 217 
 
 
To a solution of ketone 195 (43.0 mg, 200 μmol, 1.0 eq.) in THF (2 mL) at −78 °C was slowly added 
LiHMDS (300 μL of a 1.0M solution in THF, 300 μmol, 1.5 eq.) and the mixture was stirred for 1 h at 
this temperature. Then, a solution of PhSeBr (80.0 mg, 340 μmol, 1.7 eq.) in THF (1 mL) was added 
dropwise and the mixture was stirred for an additional 1 h at −78 °C prior to be quenched by addition 
of saturated aqueous NH4Cl (4 mL). The layers were separated and the aqueous layer was extracted 
with CH2Cl2 (3 x 10 mL). The combined organic layers were washed with saturated aqueous NaCl (10 
mL) and dried over MgSO4. Evaporation of the solvents under reduced pressure yielded ketone 216 as 
a mixture of diastereomers, which was used without further purification. 
To a solution of ketone 216 (assumed 200 μmol) in THF/CH2Cl2 (1:1, 2 mL) at 0 °C was slowly added 
H2O2 (900 μL of a 30 wt% solution in H2O, 800 μmol, 4.0 eq.) and the mixture was stirred at this 
temperature for 30 min. The reaction was quenched by addition of saturated aqueous Na2S2O3 (2 mL) 
and the biphasic mixture was extracted with EtOAc (3 x 5 mL). The combined organic layers were 
dried over MgSO4 and the solvents were evaporated under reduced pressure. The crude product was 
purified by flash column chromatography (silica, hexanes:EtOAc = 2:1 to 1:1) to yield 
lactone 217 (8.0 mg, 36 μmol, 18%) as a colorless solid.  
 
Rf = 0.16 (hexanes:EtOAc = 2:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 6.51 (dd, 3J3/2 = 9.7 Hz, 3J3/4 = 2.1 Hz, 1H, 3-H), 6.02 (dd, 3J2/3 = 
9.6 Hz, 4J2/4 = 3.2 Hz, 1H, 2-H), 4.02−3.93 (m, 4H, 11-H, 12-H), 3.04 (mC, 1H, 4-H), 2.05 (mC, 1H, 
8-HA), 1.93−1.86 (m, 2H, 5-HA, 7-HA), 1.83 (mC, 1H, 7-HB), 1.70 (ddd, J = 14.2, 14.2, 4.8 Hz, 1H, 
8-HB), 1.64 (dd, J = 14.0, 13.4 Hz, 1H, 5-HB), 1.39 (s, 3H, 10-H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 164.1 (C-1), 148.1 (C-3), 121.7 (C-2), 108.0 (C-6), 82.6 (C-9), 
64.9 (C-11)*, 64.6 (C-12)*, 39.9 (C-4), 36.4 (C-5), 35.7 (C-8), 32.1 (C-7), 17.0 (C-10) ppm. 
 
EI-MS for C12H16O4+ [M+]: calcd. 224.1043 
 found 224.1051. 
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IR (ATR): ῦ/cm−1 = 2954 (br w), 1718 (s), 1381 (w), 1259 (w), 1159 (w), 1117 (s), 1090 (m), 
1057 (m), 1004 (w), 982 (w), 817 (w). 
 
[ ]20Dα  = +15.0 (c 0.17, CH2Cl2). 
 
 
Synthesis of Ketone 220 
 
 
To a suspension of CuCN (1.45 g, 16.2 mmol, 2.25 eq.) in Et2O (48 mL) at 0 °C was added 
isopropylenemagnesium bromide (219, 65.0 mL of a 0.5M solution in THF, 32.4 mmol, 4.5 eq.) within 
15 min. The resulting mixture was stirred for 30 min at this temperature and subsequently cooled to 
−78 °C. Then, a solution of enone 194 (1.50 g, 7.20 mmol, 1.0 eq.) in THF (15 mL) was added slowly 
and, after stirring for an additional 2 h at −78 °C, the reaction was quenched by addition of saturated 
aqueous NH4Cl (40 mL). The mixture was allowed to warm to room temperature, diluted with Et2O 
(100 mL) and filtered over a pad of Celite® (washings with Et2O). The phases were separated and the 
aqueous layer was extracted with Et2O (3 x 40 mL). The combined organic layers were washed with 
saturated aqueous NaCl (50 mL), dried over MgSO4 and the solvents were evaporated under reduced 
pressure. The crude product was purified by flash column chromatography (silica, hexanes:EtOAc = 
7:1 to 5:1) to yield alkene 220 as a colorless solid. 
Flash column chromatography was carried out to purify the combined crude products of several 
reactions which were carried out as described above. In overall, use of substrate 194 (11.9 g, 
57.2 mmol) resulted in the formation of the desired product 220 (11.5 g, 46.0 mmol) in 81% yield. 
 
Crystals suitable for X-ray analysis were grown by slow evaporation of a solution of ketone 220 in 
n-pentane at −25 °C. 
 
Rf = 0.43 (hexanes:EtOAc = 3:1). 
 
Melting point = 69.0−70.5 °C (hexanes/EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.97 (s, 1H, 14-HA), 4.83 (s, 1H, 14-HB), 4.03−3.89 (m, 4H, 11-H, 
12-H), 2.86 (mC, 1H, 3-H), 2.77 (dd, 2J2A/2B = 19.7 Hz, 3J2A/3 = 1.8 Hz, 1H, 2-HA), 2.49 (dd, 2J2B/2A = 
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19.5 Hz, 3J2B/3 = 9.2 Hz, 1H, 2-HB), 2.41−2.34 (m, 1H, 4-H), 1.99−1.91 (m, 2H, 5-H), 1.81 (s, 3H, 
15-H), 1.75 (ddd, 2J7A/7B = 3J7A/8B = 13.8 Hz, 3J7A/8A = 4.8 Hz, 1H, 7-HA), 1.68 (mC, 1H, 7-HB), 
1.63 (ddd, 2J8A/8B = 13.1 Hz, 3J8A/7A = 4.6 Hz, 3J8A/7B = 2.6 Hz, 1H, 8-HA), 1.43 (ddd, 2J8B/8A = 3J8B/7A = 
13.5 Hz, 3J8B/7B = 3.9 Hz, 1H, 8-HB), 1.04 (s, 3H, 10-H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 220.6 (C-1), 146.1 (C-13), 112.3 (C-14), 109.8 (C-6), 64.7 (C-11),* 
64.4 (C-12)*, 47.1 (C-9), 45.8 (C-4), 42.2 (C-2), 41.9 (C-3), 35.7 (C-5), 30.9 (2C, C-7, C-8), 
24.9 (C-15), 15.3 (C-10) ppm. 
 
EI-MS for C15H22O3+ [M+]: calcd. 250.1569 
 found 250.1565. 
 
IR (ATR): ῦ/cm−1 = 2954 (m), 2879 (m), 1737 (s), 1440 (w), 1350 (w), 1291 (w), 1135 (m), 1095 (s), 
1053 (s), 942 (w), 894 (w). 
 
[ ]20Dα  = +30.6 (c 1.00, CH2Cl2). 
 
 
Synthesis of Ketone 222 
 
 
To a solution of alkene 220 (250 mg, 1.00 mmol, 1.0 eq.) in MeOH (10 mL) was added Pd/C (10% Pd, 
20 mg, 19 μmol, 1.9 mol-%) and the solution was stirred under an atmosphere of H2 (double layer 
balloon, 1 atm) for 16 h. The reaction mixture was filtered over a pad of Celite® (washings with 
EtOAc) and the solvents were evaporated under reduced pressure. The resulting crude product was 
purified by flash column chromatography (silica, hexanes:EtOAc = 4:1) to yield the title 
compound 222 (240 mg, 952 μmol) as a colorless solid, which was contaminated by a small 
impurity (<5% by NMR). Recrystallization from n-pentane provided pure ketone 222 (230 mg, 
913 μmol, 91%). 
 
Crystals suitable for X-ray analysis were grown by slow evaporation of a solution of ketone 222 in 
Et2O/n-pentane. 
 
Rf = 0.54 (hexanes:EtOAc = 3:1). 
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Melting point = 88−90 °C (hexanes/EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 3.94 (mC, 4H, 11-H, 12-H), 2.40 (mC, 1H, 2-HA), 1.98−1.87 (m, 2H, 
2-HB, 3-H), 1.86−1.76 (m, 3H, 4-H, 5-HA, 13-H), 1.75−1.66 (m, 3H, 7-H, 8-HA), 1.62 (mC, 1H, 5-HB), 
1.54−1.45 (m, 1H, 8-HB), 0.97 (s, 3H, 10-H), 0.94 (d, 3J15/13 = 6.8 Hz, 3H, 15-H)*, 0.84 (d, 3J14/13 = 
6.9 Hz, 3H, 14-H)* ppm.  
  
13C NMR (CDCl3, 150 MHz): δ = 219.0 (C-1), 109.6 (C-6), 64.6 (C-11)*, 64.4 (C-12)*, 48.8 (C-9), 
45.4 (C-4), 42.0 (C-3), 38.1 (C-2), 33.9 (C-5), 30.8 (C-7), 29.0 (C-8), 28.0 (C-13), 22.0 (C-14)**, 
17.4 (C-15)**, 13.5 (C-10) ppm. 
 
FAB-MS for C15H25O3+ [(M+H)+]: calcd. 253.1798 
 found 253.1793. 
 
IR (ATR): ῦ/cm−1 = 2960 (m), 2875 (m), 1737 (s), 1466 (w), 1389 (w), 1351 (w), 1231 (w), 1141 (m), 
1122 (m), 1046 (m), 975 (w), 938 (m), 902 (w), 858 (w). 
 
[ ]20Dα  = +65.0 (c 1.00, CH2Cl2). 
 
 
Synthesis of Alcohol 224 
 
 
To a solution of ketone 222 (100 mg, 398 μmol, 1.0 eq.) in EtOH (10 mL) at −20 °C was added a 
solution of NaBH4 (30 mg, 0.80 mmol, 2.0 eq.) in EtOH (3 mL) within 1 h. The solution was stirred 
for an additional 2 h at this temperature and was then allowed to warm to room temperature. The 
reaction was quenched by addition of saturated aqueous NH4Cl (5 mL) and the solvent was evaporated 
under reduced pressure. The residue was dissolved in EtOAc (30 mL) and the organic layer was 
sequentially washed with H2O (5 mL) and saturated aqueous NaCl (5 mL). The organic layer was 
dried over Na2SO4 and the solvent was removed under reduced pressure. The crude product was 
purified by flash column chromatography (silica, hexanes:EtOAc = 4:1 to 2:1) to yield 
alcohol 224 (93 mg, 0.37 mmol, 93%) as a colorless solid. 
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The stereochemistry at C-1 was established by 2D NOESY spectroscopy, indicating no correlation 
between the signals at C-1 (δ = 3.66−3.59 ppm) and at C-10 (δ = 0.85 ppm). This is in contrast to the 
observation for its C-1 diastereomeric counterpart (vide infra). 
 
Rf = 0.20 (hexanes:EtOAc = 3:1). 
  
Melting point = 117.0−118.5 °C (hexanes/EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 3.96−3.89 (m, 4H), 3.66−3.59 (m, 1H), 1.89−1.81 (m, 1H), 
1.76−1.66 (m, 3H), 1.66−1.57 (m, 3H), 1.55−1.46 (m, 3H), 1.40 (br s, 1H, OH), 1.35−1.28 (m, 1H), 
0.87 (d, J = 6.7 Hz, 3H), 0.85 (s, 3H), 0.81 (d, J = 6.8 Hz, 3H) ppm.  
  
13C NMR (CDCl3, 150 MHz): δ = 110.1 (Cq), 80.2 (CH), 64.4 (CH2), 64.3 (CH2), 45.1 (CH), 
43.9 (CH), 43.8 (Cq), 34.8 (CH2), 34.2 (CH2), 34.0 (CH2), 31.2 (CH2), 29.4 (CH), 22.0 (CH3), 
18.2 (CH3), 10.9 (CH3) ppm. 
 
FAB-MS for C15H27O3+ [(M+H)+]: calcd. 255.1955 
 found 255.1954. 
 
IR (ATR): ῦ/cm−1 = 3260 (br m), 2950 (s), 2872 (m), 1466 (w), 1387 (w), 1301 (w), 1196 (w), 
1122 (m), 1091 (m), 1076 (m), 1050 (m), 942 (m).  
 
 
Synthesis of Thionocarbonate 227 
 
 
To a solution of alcohol 224 (25 mg, 0.10 mmol, 1.0 eq.) in CH2Cl2 (2 mL) at 0 °C was sequentially 
added pyridine (20 μL, 0.11 mmol, 1.1 eq.) and phenyl chlorothionocarbonate (226, 21 μL, 
0.27 mmol, 2.7 eq.). The resulting yellow solution was allowed to warm up to room temperature and 
was stirred for 3 h. The reaction was quenched by addition of saturated aqueous NH4Cl (5 mL) and the 
aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed 
with H2O (5 mL), saturated aqueous NaHCO3 (5 mL) and saturated aqueous NaCl (5 mL), and were 
dried over Na2SO4. After removal of the solvents under reduced pressure, the crude product was 
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purified by flash column chromatography (silica, hexanes:EtOAc = 19:1) to yield 
thionocarbonate 227 (35 mg, 90 μmol, 90%) as a pale yellow solid.  
 
Rf = 0.13 (hexanes:EtOAc = 16:1). 
 
Melting point = 116.0−118.0 °C (hexanes/EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.40 (mC, 2H), 7.28 (mC, 1H), 7.10 (mC, 2H), 5.09 (dd, J = 9.3, 
7.0 Hz, 1H), 4.00−3.87 (m, 4H), 2.27−2.17 (m, 1H) 1.79−1.60 (m, 8H), 1.56−1.51 (m, 2H), 0.97 (s, 
3H), 0.90 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.7 Hz, 3H) ppm.  
  
13C NMR (CDCl3, 150 MHz): δ = 195.1 (Cq), 153.6 (Cq), 129.6 (CH), 126.6 (CH), 122.1 (CH), 
109.7 (Cq), 91.0 (CH), 64.5 (CH2), 64.3 (CH2), 44.6 (CH), 44.0 (CH), 43.9 (Cq), 34.4 (CH2), 
34.2 (CH2), 31.0 (CH2), 30.4 (CH2), 29.2 (CH), 21.9 (CH3), 18.0 (CH3), 12.3 (CH3) ppm. 
 
FAB-MS for C22H31O4S+ [(M+H)+]: calcd. 391.1938 
 found 391.1935. 
 
IR (ATR): ῦ/cm−1 = 2955 (m), 2927 (m), 1491 (w), 1308 (m), 1296 (m), 1276 (m), 1201 (s), 1093 (w), 
1018 (w), 945 (w), 884 (w), 770 (w), 689 (w).  
 
[ ]20Dα  = +42.2 (c 0.50, CH2Cl2). 
 
 
Synthesis of Alkene 225 
 
 
To a solution of ketone 222 (380 mg, 1.51 mmol 1.0 eq.) in THF (25 mL) at −78 °C was added 
dropwise KHMDS (4.83 mL of a 0.5M solution in toluene, 2.41 mmol, 1.6 eq.) and the resulting 
slightly yellow solution was stirred for 15 min. After adding PhNTf2 (755 mg, 2.11 mmol, 1.4 eq.) in 
one portion, the reaction mixture was stirred for an additional 30 min at this temperature. The reaction 
was quenched by addition of saturated aqueous NH4Cl (10 mL) and the mixture was allowed to warm 
to room temperature. The layers were separated and the aqueous phase was extracted with 
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Et2O (3 x 10 mL). The combined organic layers were dried over Na2SO4 and the solvents were 
removed under reduced pressure to yield crude enol triflate 228.  
The obtained crude enol triflate 228 (assumed 1.51 mmol) was dissolved in DMF (10 mL) and 
n-Bu3N (1.07 mL, 838 mg, 4.53 mmol, 3.0 eq.), HCOOH (140 μL, 173 mg, 3.78 mmol, 2.5 eq.) and 
Pd(PPh3)2Cl2 (53 mg, 80 μmol, 5.0 mol-%) were sequentially added. The yellow suspension was 
placed in an oil-bath (pre-heated to 75 °C) forming a clear solution which turned dark red. After 
stirring for an additional 2 h at 75 °C, the mixture was allowed to cool to room temperature and the 
reaction was quenched by adding H2O (10 mL). Following extraction with Et2O (5 x 15 mL), the 
combined organic layers were washed with 10% aqueous NaCl (3 x 15 mL) and dried over Na2SO4. 
The solvents were evaporated under reduced pressure (600 mbar) and the crude product was purified 
by flash column chromatography (silica, n-pentane:Et2O = 49:1 to 19:1) to yield alkene 225 (310 mg, 
1.31 mmol, 87%) as a colorless oil. 
 
Rf = 0.52 (hexanes:EtOAc = 7:1). 
 
1H NMR (CD2Cl2, 400 MHz): δ = 5.85 (dd, 3J1/2 = 5.8 Hz, 4J1/3 = 2.5 Hz, 1H, 1-H), 5.66 (dd, 3J2/1 = 
5.8 Hz, 3J2/3 = 1.5 Hz, 1H, 2-H), 3.96−3.86 (m, 4H, 11-H, 12-H), 2.20 (mC, 1H, 3-H), 1.83−1.59 (m, 
7H, 4-H, 5-H, 7-H, 8-HA, 13-H), 1.56−1.47 (m, 1H, 8-HB), 0.98 (d, 3J14/13 = 6.9 Hz, 3H, 14-H)*, 
0.86 (d, J = 0.5 Hz, 3H, 10-H), 0.84 (d, 3J15/13 = 6.8 Hz, 3H, 15-H)* ppm.  
  
13C NMR (CD2Cl2, 100 MHz): δ = 142.7 (C-1), 132.9 (C-2), 110.7 (C-6), 64.8 (C-11)*, 64.6 (C-12)*, 
52.2 (C-3), 49.4 (C-4), 46.5 (C-9), 34.1 (2C, C-5, C-8), 32.2 (C-7), 28.8 (C-13), 22.3 (C-14)**, 
19.4 (C-15)**, 16.8 (C-10) ppm. 
 
EI-MS for C15H24O2+ [M+]: calcd. 236.1771 
 found 236.1778. 
 
IR (ATR): ῦ/cm−1 = 3043 (w), 2945 (s), 2872 (s), 1465 (w), 1432 (w), 1350 (w), 1294 (w), 1255 (w), 
1167 (w), 1119 (m), 1082 (s), 1054 (m), 954 (m), 883 (w), 730 (w).  
 
[ ]20Dα  = +85.8 (c 1.00, CH2Cl2). 
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Synthesis of Alcohols 232 and 233 
 
 
To a solution of alkene 225 (200 mg, 850 μmol, 1.0 eq.) in THF (20 mL) at 0 °C was added dropwise 
BH3·SMe2 complex (530 μL of a 2.0M solution in THF, 1.06 mmol, 1.25 eq.) and the mixture was 
stirred for an additional 30 min at room temperature before being cooled to 0 °C. Subsequently, 
aqueous NaOH (3N, 7.5 mL) and H2O2 (30 wt%, 7.5 mL) were added and the biphasic mixture was 
heated to 45 °C for 30 min. The mixture was cooled to room temperature and the reaction was 
quenched by addition of saturated aqueous NH4Cl (15 mL). The aqueous phase was extracted with 
EtOAc (3 x 30 mL) and the combined organic layers were dried over Na2SO4. After evaporation of the 
solvents under reduced pressure, the crude product was purified by flash column 
chromatography (silica, hexanes:EtOAc = 7:1 to 4:1) to yield alcohol 232 (85 mg, 0.33 mmol, 39%) as 
a colorless solid along with its regioisomer 233 (80 mg, 0.31 mmol, 37%) as a colorless oil.  
 
Analytical data for regioisomer 233: 
 
Rf = 0.50 (hexanes:EtOAc = 2:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.40 (ddd, 3J2/1A = 3J2/3 = 7.4 Hz, 3J2/1B = 5.5 Hz, 1H, 2-H), 
3.99−3.88 (m, 4H, 11-H, 12-H), 2.11 (dd, 2J1A/1B = 12.9 Hz, 3J1A/2 = 7.3 Hz, 1H, 1-HA), 1.90 (mC, 1H, 
13-H), 1.86−1.80 (m, 2H, 4-H, 7-HA) 1.76−1.69 (m, 1H, 5-HA), 1.64−1.59 (m, 2H, 5-HB, 8-HA) 
1.51−1.43 (m, 3H, 3-H, 7-HB, 8-HB), 1.32 (br s, 1H, OH), 1.14 (dd, 2J1B/1A = 13.0 Hz, 3J1B/2 = 5.6 Hz, 
1H, 1-HB), 1.04−0.93 (m, 6H, 14-H, 15-H), 0.81 (s, 3H, 10-H) ppm.  
 
13C NMR (CDCl3, 150 MHz): δ = 110.1 (C-6), 74.1 (C-2), 64.4 (C-11)*, 64.3 (C-12)*, 51.0 (C-1), 
50.6 (C-3), 46.0 (C-4), 38.8 (C-9), 36.4 (C-8), 35.8 (C-7), 31.3 (C-5), 27.0 (C-13), 23.0 (C-14)**, 
21.5 (C-15)**, 18.7 (C-10) ppm. 
 
FAB-MS for C15H27O3+ [(M+H)+]: calcd. 255.1960 
 found 255.1969. 
 
IR (ATR): ῦ/cm−1 = 3484 (m), 2954 (s), 2974 (s), 1465 (w), 1441 (w), 1386 (w), 1367 (w), 1354 (w), 
1306 (w), 1267 (w), 1244 (w), 1136 (w), 1082 (m), 1040 (w), 893 (w), 819 (w). 
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[ ]20Dα  = +42.6 (c 0.65, CH2Cl2). 
 
Analytical data for regioisomer 232: 
 
Rf = 0.40 (hexanes:EtOAc = 2:1). 
 
Melting point = 76.4−77.4 °C (hexanes/EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.01−3.86 (m, 4H, 11-H, 12-H), 3.69 (mC, 1H, 1-H), 2.23 (ddd, 
3J2A/2B = 15.1 Hz, 3J2A/3 = 10.1 Hz, 3J2A/1 = 5.9 Hz, 1H, 2-HA), 1.86 (ddd, J = 13.3, 11.6 Hz, 3.5 Hz, 1H, 
4-H), 1.83−1.73 (m, 3H, 5-HA, 7-HA, 8-HA), 1.72−1.64 (m, 2H, 5-HB, 13-H), 1.53 (dddd, 3J3/13 = 
16.8 Hz, 3J3/2A = 10.1 Hz, 3J3/2B = 6.7 Hz, 3J3/4 = 5.2 Hz, 1H, 3-H), 1.47 (dd, 2J7B/7A = 3J7B/6A = 13.0 Hz, 
1H, 7-HB), 1.38−1.34 (m, 1H, 8-HB), 1.27 (dd, 2J2B/2A = 15.3 Hz, 3J2B/3 = 6.8 Hz, 1H, 2-HB), 1.23 (br s, 
1H, OH), 0.90 (d, 3J14/13 = 6.9 Hz, 3H, 14-H)*, 0.85 (d, 3J15/13 = 6.7 Hz, 3H, 15-H)*, 0.77 (s, 3H, 10-H) 
ppm.  
 
13C NMR (CDCl3, 150 MHz): δ = 110.0 (C-6), 78.0 (C-1), 64.4 (C-11)*, 64.3 (C-12)*, 45.8 (C-9), 
45.5 (C-3), 42.6 (C-4), 36.2 (C-2), 34.9 (C-7), 30.9 (C-5), 29.5 (C-13), 28.7 (C-8), 22.1 (C-14)**, 
18.4 (C-15)**, 17.0 (C-10) ppm. 
 
FAB-MS for C15H27O3+ [(M+H)+]: calcd. 255.1960 
 found 255.1963. 
 
IR (ATR): ῦ/cm−1 = 3490 (br m), 2952 (s), 2871 (s), 1464 (w), 1440 (w), 1387 (w), 1353 (w), 
1301 (w), 1265 (w), 1189 (w), 1129 (m), 1136 (m) 1081 (s), 1039 (m), 1018 (w), 973 (m), 894 (w), 
820 (w). 
 
[ ]20Dα  = +17.4 (c 0.65, CH2Cl2). 
 
 
Synthesis of Epoxide 239 
 
 
136  EXPERIMENTAL SECTION 
To a solution of alkene 225 (18 mg, 76 μmol, 1.0 eq.) in CH2Cl2 (2 mL) at 0 °C was added 
mCPBA (20 mg, 0.11 mmol, 1.5 eq.) in one portion and the resulting colorless solution was stirred in 
the melting ice bath for 16 h. After diluting with CH2Cl2 (5 mL), washing with saturated aqueous 
K2CO3 (3 mL) and phase separation, the aqueous phase was extracted with CH2Cl2 (3 x 5 mL). The 
combined organic layers were dried over Na2SO4 and the solvents were evaporated under reduced 
pressure. The thus obtained crude product was purified by flash column chromatography (silica, 
n-pentane:Et2O = 16:1 to 9:1) to yield epoxide 239 (15 mg, 59 μmol, 78%) as a colorless solid. 
 
Rf = 0.25 (hexanes:EtOAc = 7:1). 
 
Melting point = 60.0−61.0 °C (pentane/Et2O). 
 
1H NMR (CD2Cl2, 400 MHz): δ = 3.97−3.80 (m, 4H, 11-H, 12-H), 3.29 (dd, 3J2/1 = 3.0 Hz, 3J2/3 = 
1.1 Hz, 1H, 2-H), 3.00 (dd, 3J1/2 = 3.1 Hz, 4J = 0.8 Hz, 1H, 1-H), 1.81−1.70 (m, 2H, 7-HA, 13-H), 
1.68−1.58 (m, 3H, 5-HA, 7-HB, 8-HA), 1.53−1.41 (m, 3H, 4-H, 5-HB, 8-HB), 1.36 (mC, 1H, 3-H), 
1.05 (d, 3J14/13 = 7.0 Hz, 3H, 14-H)*, 0.98 (d, 3J15/13 = 6.9 Hz, 3H, 15-H)*, 0.82 (s, 3H, 10-H) ppm.  
 
13C NMR (CD2Cl2, 100 MHz): δ = 110.2 (C-6), 64.9 (C-11)*, 64.7 (C-12)*, 59.8 (C-1), 55.6 (C-2), 
47.0 (C-3), 41.6 (C-9), 38.4 (C-4), 33.6 (C-5), 31.8 (C-7), 30.6 (C-8), 27.9 (C-13), 22.8 (C-14)**, 
20.1 (C-15)**, 15.4 (C-10) ppm. 
 
FAB-MS for C15H25O3+ [(M+H)+]: calcd. 253.1804 
 found 253.1824. 
 
IR (ATR): ῦ/cm−1 = 2953 (s), 2932 (m), 2879 (m), 1464 (m), 1385 (m), 1342 (w), 1299 (w), 1255 (w), 
1172 (m), 1125 (m), 1087 (s), 1075 (s), 1034 (w), 994 (w), 943 (m), 869 (s), 805 (w), 676 (w). 
 
 
Synthesis of Alcohol 232 by Reductive Epoxide Opening 
 
 
To a solution of epoxide 239 (5.0 mg, 20 μmol, 1.0 eq.) in THF (2 mL) at 0 °C was added 
LiHBEt3 (200 μL of a 1.0M solution in THF, 200 μmol, 10 eq.). The resulting colorless solution was 
allowed to warm to room temperature and stirred for 4 h before the reaction was quenched by slow 
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addition of saturated aqueous NH4Cl (2 mL) at 0 °C. After phase separation the aqueous layer was 
extracted with EtOAc (3 x 3 mL) and the combined organic layers were washed with brine (2 mL) and 
dried over MgSO4. Having evaporated the solvent under reduced pressure, the crude product was 
purified by flash column chromatography (silica, hexanes:EtOAc = 3:1) to yield the title 
compound 232 (4.0 mg, 16 μmol, 79%) as a colorless solid. 
 
The analytical data matched those obtained previously. 
 
 
Synthesis of Diol 240 
 
 
To a stirred biphasic mixture of alkene 225 (10 mg, 42 μmol, 1.0 eq.) in t-BuOH/H2O (1:1, 2.5 mL) 
was sequentially added K3Fe(CN)6 (138 mg, 420 μmol, 10 eq.), K2CO3 (58 mg, 420 μmol, 10.0 eq.), 
DABCO (5.2 mg, 42 μmol, 1.0 eq.) and OsO4 (30 μL of a 2.5 wt% solution in t-BuOH, 2.1 μmol, 
5.0 mol-%). The resulting yellow reaction mixture was stirred for 2 h before being quenched by 
addition of solid Na2SO3 (40 mg). The mixture was stirred for an additional 45 min, filtered over a 
plug of Celite® and diluted with H2O (3 mL). After extraction with EtOAc (3 x 5 mL), the combined 
organic layers were dried over Na2SO4 and the solvent was removed under reduced pressure. The 
crude product was purified by flash column chromatography (silica, hexanes:EtOAc = 2:1) to yield 
diol 240 (10 mg, 37 μmol, 88%) as a colorless solid. 
 
Rf = 0.26 (hexanes:EtOAc = 2:1). 
 
Melting point = 91.0−92.5 °C (hexanes/EtOAc). 
 
1H NMR (CDCl3, 400 MHz): δ = 4.42 (ddd, 3J2/3 = 8.6 Hz, 3J2/OH = 8.0 Hz, 3J2/1 = 5.3 Hz, 1H, 2-H), 
3.99−3.89 (m, 4H, 11-H, 12-H), 3.64 (dd, 3J1/2 = 5.4 Hz, 3J1/OH = 4.0 Hz, 1H, 1-H), 2.51 (d, 3JOH/2 = 
7.9 Hz, 1H, OH), 2.46 (d, 3JOH/1 = 4.0 Hz, 1H, OH), 2.04 (ddd, 3J4/3 = 3J4/5B = 12.8 Hz, 3J4/5A = 3.3 Hz, 
1H, 4-H), 1.92−1.84 (m, 3H, 5-HA, 8-HA, 13-H), 1.76 (ddd, J = 13.4, 13.4, 4.4 Hz, 1H, 7-HA), 
1.68 (mC, 1H, 7-HB), 1.52 (ddd, 3J3/4 = 12.3 Hz, 3J3/2 = 8.6 Hz, 3J3/13 = 6.4 Hz, 1H, 3-H), 1.48 (dd, 
2J5B/5A = 3J5B/4 = 13.1 Hz, 1H, 5-HB), 1.41 (mC, 1H, 8-HB), 1.00 (d, 3J14/13 = 6.9 Hz, 3H, 14-H)*, 
0.98 (d, 3J15/13 = 6.9 Hz, 3H, 15-H)*, 0.79 (s, 3H, 10-H) ppm.  
138  EXPERIMENTAL SECTION 
13C NMR (CDCl3, 100 MHz): δ = 109.8 (C-6), 77.8 (C-1), 73.5 (C-2), 64.4 (C-11)*, 64.3 (C-12)*, 
49.2 (C-3), 42.9 (C-9), 41.9 (C-4), 35.8 (C-5), 30.6 (C-7), 29.3 (C-8), 27.3 (C-13), 23.3 (C-14)**, 
21.4 (C-15)**, 16.9 (C-10) ppm. 
 
ESI-MS for C15H25O4− [(M−H)−]: calcd. 269.1758 
 found 269.1758. 
 
IR (ATR): ῦ/cm−1 = 3412 (br s), 2951 (s), 2872 (s), 1464 (w), 1434 (w), 1382 (w), 1356 (w), 1306 (w), 
1269 (w), 1184 (w), 1118 (m), 1081 (s), 1045 (m), 970 (w). 
 
[ ]20Dα  = +24.4 (c 0.50, CH2Cl2). 
 
 
Synthesis of Thionocarbonate 242 
 
 
To a solution of diol 240 (14 mg, 56 μmol, 1.0 eq.) in toluene (5 mL) was added 
1,1’-thiocarbonyldiimidazole (241, 98 mg, 0.54 mmol, 10 eq.) and the resulting yellow solution was 
heated to reflux for 20 h. After cooling to room temperature, the solvent was evaporated under reduced 
pressure and the crude product was purified by flash column chromatography (silica, hexanes:EtOAc 
= 4:1) to yield thiocarbonate 242 (16 mg, 51 μmol, 92%) as an off-white solid. 
 
Rf = 0.42 (hexanes:EtOAc = 2:1). 
 
Melting point = 174.0−175.5 °C (hexanes/EtOAc). 
 
1H NMR (C6D6, 400 MHz): δ = 4.35 (dd, 3J2/1 = 3J2/3 = 6.1 Hz, 1H, 2-H), 3.81 (d, 3J1/2 = 6.2 Hz, 1H, 
1-H), 3.57−3.35 (m, 4H, 11-H, 12-H), 2.07−1.93 (m, 2H, 4-H, 8-HA), 1.79 (dd, 2J5A/5B = 13.1 Hz, 
3J5A/4 = 3.2 Hz, 1H, 5-HA), 1.70 (mC, 1H, 13-H), 1.62−1.52 (m, 2H, 7-H), 1.37 (dd, 2J5B/5A = 3J5B/4 = 
13.0 Hz, 1H, 5-HB) 1.19 (mC, 1H, 8-HB), 1.03 (ddd, 3J = 13.1, 7.1, 6.0 Hz, 1H, 3-H), 0.94 (d, 3J14/13 = 
6.9 Hz, 3H, 14-H)*, 0.89 (d, 3J15/13 = 7.0 Hz, 3H, 15-H)*, 0.19 (s, 3H, 10-H) ppm.  
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13C NMR (C6D6, 100 MHz): δ = 191.7 (C-16), 108.7 (C-6), 90.2 (C-1), 87.8 (C-2), 64.5 (C-11)*, 
64.3 (C-12)*, 50.7 (C-3), 33.0 (C-9), 41.9 (C-4), 35.1 (C-5), 30.5 (C-7), 29.3 (C-8), 27.1 (C-13), 
21.2 (C-14)**, 21.1 (C-15)**, 15.9 (C-10) ppm. 
 
ESI-MS for C15H24O4ClS− [(M+Cl)−]: calcd. 347.1089 
 found 347.1088. 
 
IR (ATR): ῦ/cm−1 = 2959 (w), 2876 (w), 1465 (w), 1435 (w), 1349 (m), 1280 (s), 1173 (m), 1137 (w), 
1117 (w), 1085 (m), 1009 (m), 976 (m), 913 (w), 889 (w), 829 (w). 
 
[ ]20Dα  = +63.4 (c 0.50, CH2Cl2). 
 
 
Synthesis of Ketone ent-141 
 
 
To a solution of alkene 225 (300 mg, 1.27 mmol, 1.0 eq.) in n-pentane (15 mL) was added Pd/C (10% 
Pd, 33 mg, 25 μmol, 2.0 mol-%) and the resulting suspension was stirred under an atmosphere of 
H2 (balloon, 1 atm) for 16 h. The reaction mixture was filtered over a pad of Celite® (washings with 
Et2O) and the solvents were carefully removed under reduced pressure. The thus obtained colorless 
oil, ketal 243, was used without further purification. 
To a solution of crude ketal 243 (assumed 1.27 mmol) in acetone (15 mL) was added I2 (86 mg, 
0.34 mmol, 26 mol-%) in one portion. The solution was stirred for 10 min at room temperature and the 
reaction was quenched by addition of aqueous Na2S2O3 (5 wt%, 10 mL). The mixture was extracted 
with CH2Cl2 (3 x 20 mL) and the combined organic layers were dried over MgSO4. After evaporation 
of the solvents under reduced pressure, the crude product was purified by flash column 
chromatography (silica, n-pentane:Et2O = 24:1 to 19:1) to yield ketone ent-141 (234 mg, 1.21 mmol, 
95%) as a colorless solid. 
 
Crystals suitable for X-ray analysis were grown from a solution of ketone 141 in n-pentane at −25 °C. 
 
Rf = 0.55 (hexanes:EtOAc = 7:1). 
 
Melting point = 64.5−66.0 °C (CH2Cl2). 
140  EXPERIMENTAL SECTION 
1H NMR (CDCl3, 600 MHz): δ = 2.44−2.36 (m, 2H, 5-HA, 7-HA), 2.31 (dddd, J = 16.5, 5.7, 1.8, 
1.8 Hz, 1H, 7-HB), 2.15 (mC, 1H, 5-HB), 1.90−1.79 (m, 2H, 2-HA, 8-HA), 1.67−1.58 (m, 2H, 3-H, 
11-H), 1.57−1.44 (m, 4H, 1-HA, 2-HB, 4-H, 8-HB), 1.21−1.14 (m, 1H, 1-HB), 0.99 (s, 3H, 10-H), 
0.87 (d, 3J12/11 = 6.6 Hz, 3H, 12-H)*, 0.79 (d, 3J13/11 = 6.7 Hz, 3H, 13-H)* ppm.  
 
13C NMR (CDCl3, 150 MHz): δ = 212.2 (C-6), 50.2 (C-4), 47.2 (C-3), 42.8 (C-5), 41.3 (C-9), 
38.3 (C-1), 37.9 (C-7), 37.2 (C-8), 29.4 (C-11), 25.1 (C-2), 21.9 (C-12)*, 18.1 (C-13)*, 
17.3 (C-10) ppm. 
 
EI-MS for C13H22O+ [M+]: calcd. 199.1665 
 found 199.1661. 
 
IR (ATR): ῦ/cm−1 = 2950 (s), 2870 (s), 1703 (s), 1465 (w), 1412 (w), 1387 (w), 1278 (w), 1240 (w), 
1228 (w), 1214 (w), 1140 (w), 1079 (w), 738 (w). 
 
[ ]20Dα  = +92.8 (c 0.50, CH2Cl2), [ ]20Dα  = +101.3 (c 1.00, CDCl3). 
 
 
Synthesis of Diene 245 
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To a solution of ketone 220 (1.36 g, 5.44 mmol, 1.0 eq.) in THF (75 mL) at −78 °C was added 
dropwise KHMDS (17.4 mL of a 0.5M solution in toluene, 8.70 mmol, 1.6 eq.). After 10 min 
PhNTf2 (2.72 g, 7.62 mmol, 1.4 eq.) was added in one portion and the mixture was stirred for 30 min 
at −78 °C. The reaction was quenched by addition of saturated aqueous NH4Cl (20 mL) and the 
organic layer was separated. The aqueous layer was extracted with Et2O (3 x 30 mL) and the 
combined organic layers were dried over Na2SO4. The solvents were removed under reduced 
pressure (water bath temperature: 35 °C) to give enol triflate 244 as a yellowish oil which was used 
without further purification. 
To a solution of crude enol triflate 244 (assumed 5.44 mmol) in DMF (30 mL) was added 
n-Bu3N (3.87 mL, 16.3 mmol, 3.0 eq.), HCOOH (513 μL, 13.6 mmol, 2.5 eq.) and 
Pd(PPh3)2Cl2 (190 mg, 270 μmol, 5.0 mol-%) and the reaction mixture was heated to 75 °C for 9 h. 
The reaction was quenched by addition of H2O (20 mL) and the mixture was extracted with 
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Et2O (4 x 50 mL). The combined organic layers were washed with 10% aqueous NaCl (3 x 40 mL), 
dried over Na2SO4 and the solvents were removed under reduced pressure. The crude product was 
purified by flash column chromatography (silica, n-pentane:Et2O = 99:1 to 19:1) to yield 
diene 245 (980 mg, 4.15 mmol, 76% over two steps) as a colorless liquid. 
 
Rf = 0.66 (hexanes:EtOAc = 7:1). 
 
1H NMR (CD2Cl2, 400 MHz): δ  = 5.95 (mC, 1H, 1-H), 5.77 (dd, 3J2/1 = 5.8 Hz, 3J2/3 = 2.8 Hz, 1H, 
2-H), 4.81−4.78 (m, 1H, 15-HA), 4.70−4.65 (m, 1H, 15-HB), 3.99−3.85 (m, 4H, 11-H, 12-H), 3.01 (mC, 
1H, 3-H), 2.23 (ddd, 3J = 14.4, 8.5, 2.8 Hz, 1H, 4-H), 1.92 (mC, 1H, 5-HA), 1.81 (ddd, 2J7A/7B = 3J7A/8B 
= 13.8 Hz, 3J7A/8A = 5.3 Hz, 1H, 7-HA), 1.80−1.73 (m, 4H, 5-HB, 14-H), 1.64 (mC, 1H, 7-HB), 
1.56 (ddd, 2J8A/8B = 12.6 Hz, 3J8A/7A = 5.3 Hz, 3J8A/7B = 2.3 Hz, 1H, 8-HA), 1.44 (mC 1H, 8-HB), 0.93 (d, 
4J = 0.6 Hz, 3H, 10-H) ppm.  
 
13C NMR (CD2Cl2, 100 MHz): δ  =147.5 (C-13), 142.8 (C-1), 132.9 (C-2), 112.3 (C-15), 110.7 (C-6), 
65.0 (C-11)*, 64.7 (C-12)*, 53.1 (C-3), 48.8 (C-4), 46.8 (C-9), 34.5 (C-5), 35.1 (C-8), 32.5 (C-7), 
24.4 (C-14), 18.9 (C-10) ppm. 
 
FAB-MS for C15H23O2+ [(M+H)+]: calcd. 235.1693 
 found 235.1692. 
 
IR (ATR): ῦ/cm−1 = 3041 (w), 2951 (s), 2877 (s), 1440 (w), 1348 (m), 1287 (w), 1247 (w), 1184 (m), 
1102 (m), 1054 (m), 974 (w), 946 (w), 892 (w), 749 (w). 
 
 
Synthesis of Ketone 246 
 
 
To a solution of ketone 220 (3.98 g, 15.9 mmol, 1.0 eq.) in EtOH (300 mL) was added PtO2 (181 mg, 
800 μmol, 5.0 mol-%) and the resulting suspension was purged with H2 (balloon, 1 atm) for 60 min. 
The mixture was filtered over a pad of Celite® (washings with Et2O) and the solvent was evaporated 
under reduced pressure. The crude product was purified by flash column chromatography (silica, 
hexanes:EtOAc = 5:1) to yield ketone 246 as colorless solid. 
142  EXPERIMENTAL SECTION 
Flash column chromatography was carried out to purify the combined crude of several reactions which 
were carried out as described above. Thus, use of substrate (10.7 g, 42.3 mmol) resulted in the 
formation of the desired product 246 (9.90 g, 39.3 mmol) in 93% yield. 
 
Crystals suitable for X-ray analysis were grown by slow evaporation of a solution of ketone 246 in 
Et2O/n-pentane. 
 
Rf = 0.46 (hexanes:EtOAc = 3:1). 
 
Melting point = 65.5−67.0 °C (CH2Cl2). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.00−3.87 (m, 4H, 11-H, 12-H), 2.48 (dd, 2J2A/2B = 19.7 Hz, 3J2A/3 = 
2.4 Hz, 1H, 2-HA), 2.37 (dd, 2J2B/2A = 19.7 Hz, 3J2B/3 = 8.9 Hz, 1H, 2-HB), 2.28 (ddd, 3J4/5A = 13.8 Hz, 
3J4/3 = 7.2 Hz, 3J4/5B = 3.2 Hz, 1H, 4-H), 2.00 (dd, 3J5A/4 = 13.7 Hz, 2J5A/5B = 12.8 Hz, 1H, 5-HA), 
1.91 (ddd, 2J5B/5A = 12.7 Hz, 3J5B/4 = 3.2 Hz, 4J5B/7 = 2.2 Hz, 1H, 5-HB), 1.89−1.79 (m, 2H, 3-H, 13-H), 
1.74−1.62 (m, 3H, 7-H, 8-HA), 1.44 (ddd, J = 13.3, 13.3, 4.8 Hz, 1H, 8-HB), 1.04 (s, 3H, 10-H), 
0.96 (d, 3J14/13 = 6.0 Hz, 3H, 14-H)*, 0.87 (d, 3J15/13 = 6.1 Hz, 3H, 15-H)* ppm. 
   
13C NMR (CDCl3, 150 MHz): δ = 220.7 (C-1), 109.9 (C-6), 64.6 (C-11)*, 64.4 (C-12)*, 46.5 (C-9), 
45.5 (C-4), 43.5 (C-3), 41.9 (C-2), 35.8 (C-5), 30.7 (C-7), 30.6 (C-8), 29.9 (C-13), 23.7 (C-14)*, 
23.2 (C-15)*, 15.9 (C-10) ppm. 
 
EI-MS for C15H24O3+ [M+]: calcd. 252.1720 
 found 252.1722. 
 
IR (ATR): ῦ/cm−1 = 2954 (s), 2879 (s), 1740 (s), 1472 (w), 1406 (w), 1382 (w), 1346 (w), 1306 (w), 
1290 (w), 1263 (w), 1231 (w), 1172 (w), 1139 (m), 1113 (m), 1102 (m), 1086 (s), 1045 (s), 1010 (w), 
970 (w), 942 (m), 921 (w), 885 (w), 861 (w).  
 
[ ]20Dα  = +56.6 (c 1.00, CH2Cl2). 
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Synthesis of Alkene 221 
 
 
To a solution of ketone 246 (3.00 g, 11.9 mmol 1.0 eq.) in THF (120 mL) at −78 °C was added 
dropwise KHMDS (33.4 mL of a 0.5M solution in toluene, 16.7 mmol, 1.4 eq.) and the resulting 
slightly yellow solution was stirred for 15 min. After adding PhNTf2 (6.37 g, 17.9 mmol, 1.5 eq.) in 
one portion the reaction mixture was stirred an additional 10 min at −78 °C. The reaction was allowed 
to warm to 0 °C and stirred for an additional 30 min at this temperature before being quenched by 
addition of saturated aqueous NH4Cl (40 mL). The aqueous phase was extracted with Et2O (3 x 
40 mL) and the combined organic layers were washed with saturated aqueous NaCl (30 mL). The 
organic layer was dried over MgSO4 and the solvents were removed under reduced pressure to obtain 
crude enol triflate 249.  
The crude enol triflate 249 (assumed 11.9 mmol) was dissolved in DMF (30 mL) and n-
Bu3N (8.47 mL, 6.60 g, 35.7 mmol, 3.0 eq.), HCOOH (1.12 mL, 1.37 g, 29.8 mmol, 2.5 eq.) and 
Pd(PPh3)2Cl2 (334 mg, 476 μmol, 4.0 mol-%) were sequentially added. The yellow suspension was 
placed in a pre-heated oil bath at 75 °C and stirred for 1 h forming a clear solution which turned dark 
red. After cooling to room temperature, the reaction was quenched by adding H2O (30 mL). The 
mixture was filtered over a plug of Celite® (washings with Et2O) and the aqueous layer was extracted 
with Et2O (5 x 40 mL). The combined organic layers were washed with 10% aqueous NaCl (3 x 
75 mL) and dried over MgSO4. Having evaporated the volatiles under reduced pressure (600 mbar) the 
crude product was purified by flash column chromatography (silica, n-pentane:Et2O = 49:1 to 19:1) to 
yield alkene 221 (2.57 g, 10.9 mmol, 92% over two steps) as a colorless oil. Due to volatility of title 
compound 221, evaporation of the solvents was carried out at min. 600 mbar. 
 
Rf = 0.68 (hexanes:EtOAc = 7:1). 
 
1H NMR (CD2Cl2, 400 MHz): δ = 5.86 (mC, 1H, 1-H), 5.81 (dd, 3J2/1 = 5.9 Hz, 3J2/3 = 2.8 Hz, 1H, 
2-H), 3.94−3.88 (m, 4H, 11-H, 12-H), 2.15 (ddd, 3J = 12.6, 7.6, 4.4 Hz, 1H, 4-H), 2.06 (dddd, 3J3/13 = 
9.9 Hz, 3J3/4 = 7.6 Hz, 3J3/2 = 2.8 Hz, 4J3/1 = 1.4 Hz, 1H, 3-H), 1.90−1.84 (m, 2H, 5-HA, 5-HB), 
1.79 (dd, 2J7A/7B = 13.8 Hz, 3J7A/8A = 5.1 Hz, 1H, 7-HA), 1.72 (dtt, 3J13/3 = 9.8 Hz, 3J13/14 = 3J13/15 = 
6.6 Hz, 1H, 13-H), 1.64 (mC, 1H, 7-HB), 1.56 (ddd, 2J8A/8B = 12.5 Hz, 3J8A/7A = 5.2 Hz, 3J8A/7B = 2.4 Hz, 
1H, 8-HA), 1.45 (mC, 1H, 8-HB), 1.00 (d, J = 0.6 Hz, 3H, 10-H), 0.91 (d, 3J14/13 = 6.5 Hz, 3H, 14-H)*, 
0.85 (d, 3J15/13 = 6.7 Hz, 3H, 15-H)* ppm. 
144  EXPERIMENTAL SECTION 
13C NMR (CD2Cl2, 100 MHz): δ = 142.2 (C-1), 134.5 (C-2), 110.8 (C-6), 64.9 (C-11)*, 64.7 (C-12)*, 
54.8 (C-3), 48.8 (C-4), 46.2 (C-9), 35.4 (2C, C-5, C-8), 32.6 (C-7), 30.3 (C-13), 23.9 (C-14)**, 
22.6 (C-15)**, 21.5 (C-10) ppm. 
 
EI-MS for C15H24O2+ [M+]: calcd. 236.1771 
 found 236.1758. 
 
IR (ATR): ῦ/cm−1 = 3045 (w), 2952 (s), 2932 (s), 2868 (s), 1465 (w), 1348 (w), 1291 (w), 1249 (w), 
1185 (w), 1108 (w), 1085 (m), 1052 (w), 973 (w), 942 (w), 879 (w), 818 (w), 741 (w).  
 
[ ]20Dα  = −75.8 (c 1.00, CH2Cl2). 
 
 
Synthesis of Epoxide 250 
 
 
To solution of alkene 221 (30 mg, 0.13 mmol, 1.0 eq.) in CH2Cl2 (4 mL) at 0 °C was added 
mCPBA (33 mg, 0.19 mmol, 1.5 eq.) in one portion and the solution was stirred in the melting ice bath 
for 16 h. The reaction was quenched by addition of saturated aqueous K2CO3 (3 mL) and the mixture 
was extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were dried over MgSO4 and the 
solvents were removed under reduced pressure. The crude product was purified by flash column 
chromatography (silica, n-pentane:Et2O = 19:1 to 7:1) to yield epoxide 250 (29 mg, 0.12 mmol, 91%) 
as a colorless solid. 
 
Crystals suitable for X-ray analysis were obtained by slow evaporation of a solution of 250 in Et2O/n-
pentane. 
 
Rf = 0.35 (hexanes:EtOAc = 7:1). 
 
Melting point = 69.0−71.0 °C (CH2Cl2). 
 
1H NMR (CDCl3, 600 MHz): δ = 3.97−3.88 (m, 4H, 11-H, 12-H), 3.40 (mC, 1H, 2-H), 3.16 (mC, 1H, 
1-H), 1.94 (ddd, J = 14.2, 7.3, 3.4 Hz, 1H, 4-H), 1.81 (mC, 1H, 5-HA), 1.80−1.71 (m, 3H, 3-H, 5-HB, 
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7-HA), 1.71−1.61 (m, 3H, 7-HB, 8-HA, 13-H), 1.49 (ddd, 2J8B/8A = 11.9 Hz, 3J8B/7 = 4.5, 2.0 Hz, 1H, 
8-HB), 0.98 (d, 3J15/13 = 6.6 Hz, 3H, 15-H)*, 0.97 (s, 3H, 10-H), 0.90 (d, 3J14/13 = 6.4 Hz, 3H, 
14-H)* ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 110.1 (C-1), 64.6 (C-11)*, 64.3 (C-12)*, 62.7 (C-1), 57.7 (C-2), 
47.6 (C-3), 40-7 (C-9), 40.1 (C-4), 33.9 (C-5), 31.7 (C-8), 31.5 (C-7), 27.2 (C-13), 24.2 (C-14)**, 
21.8 (C-15)**, 17.4 (C-10) ppm. 
 
EI-MS for C15H25O3+ [(M+H)+]: calcd. 253.1798 
 found 253.1787. 
 
IR (ATR): ῦ/ cm−1 = 2956 (s), 2873 (s), 1468 (w), 1388 (w), 1354 (w), 1293 (w), 1252 (w), 1179 (w), 
1115 (w), 1087 (m), 1060 (w), 949 (w), 848 (w). 
 
[ ]20Dα  = −33.5 (c 0.20, CH2Cl2). 
 
 
Synthesis of Alcohols 192 and 251 
 
 
To a solution of (S)-Alpine-BoramineTM (252, 1.26 g, 3.02 mmol, 1.3 eq.) in THF (4.8 mL) was added 
BF3·OEt2 (744 μL, 6.04 mmol, 2.6 eq.) and the mixture was stirred at room temperature for 2 h 
forming a white precipitate. The mixture was filtered using a syringe filter and the resulting solution of 
enantiopure IpcBH2 (253) was used directly. The concentration was considered to be ca. 1M.[171] 
To a solution of alkene 221 (550 mg, 2.33 mmol, 1.0 eq.) in THF (60 mL) at 0 °C was added dropwise 
(+)-IpcBH2 (253, 3.5 mL of a ca. 1M solution in THF, 3.5 mmol, 1.5 eq.). The mixture was allowed to 
warm to room temperature and stirred an additional 30 min, at which time thin layer chromatography 
indicated complete consumption of the starting material. The mixture was cooled to 0 °C and 
MeOH (500 μL) was added followed by aqueous NaOH (3N, 10 mL) and aqueous H2O2 (30%, 
10 mL). After heating the biphasic mixture to 55 °C for 40 min, the mixture was allowed to cool to 
room temperature and saturated aqueous NH4Cl (20 mL) was added. The phases were separated and 
the aqueous layer was extracted with Et2O (3 x 30 mL). The combined organic layers were washed 
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with saturated aqueous NaCl (2 x 40 mL), which in turn were re-extracted with Et2O (2 x 20 mL). The 
combined organic layers were dried over MgSO4 and the solvents were evaporated under reduced 
pressure. The crude product was purified by flash column chromatography (silica, hexanes:EtOAc = 
2:1) to yield the regioisomers 192 and 251 (3.7:1, 549 mg, 2.16 mmol, 92%) as a colorless oil. Further 
purification by flash column chromatography (silica, hexanes:EtOAc = 4:1) yielded alcohols 17 
and 18 (502 mg, 1.98 mmol, 84%) in an enhanced ratio of 5.5:1. 
On larger scale, 3.8 g (16.1 mmol) and 3.2 g (13.6 mmol) of alkene 221, respectively, the initial ratio 
of hydroboration remained unchanged. Careful flash column chromatography, however, gave 
alcohols 192 and 251 (2.70 g, 10.6 mmol, 67% and 2.50 g, 9.84 mmol, 73%) in lower yield but in 
enhanced ratios of 12.4:1 and 6.6:1, respectively. 
 
An analytical sample of regioisomer 192 was obtained by repeated flash column chromatography. The 
analytical data of alcohol 251 was obtained from a sample which was contaminated by ca. 14% of 
alcohol 192 as assigned by 1H NMR spectroscopy. 
 
Analytical data for alcohol 192: 
 
Rf = 0.34 (hexanes:EtOAc = 2:1, stains green with anisaldehyde). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.32 (ddd, 3J2/1B = 8.6 Hz, 3J2/1A = 7.2 Hz, 3J2/3 = 4.4 Hz, 1H, 2-H), 
3.98−3.90 (m, 4H, 11-H, 12-H), 2.25 (ddd, 3J = 14.1, 10.5, 3.3 Hz, 1H, 4-H), 2.01 (dd, 2J1A/1B = 
11.6 Hz, 3J1A/2 = 7.1 Hz, 1H, 1-HA), 1.85 (mC, 1H, 5-HA), 1.73−1.62 (m, 3H, 5-HB, 7-HA, 13-H), 
1.58 (mC, 1H, 7-HB), 1.54 (ddd, J = 12.8, 4.7, 2.5 Hz, 1H, 8-HA), 1.48 (ddd, 3J3/4 = 3J3/13 = 10.4 Hz, 
3J3/2 = 4.3 Hz, 1H, 3-H), 1.42 (mC, 1H, 8-HB), 1.37 (br s, 1H, OH), 1.22 (mC, 1H, 1-HB), 1.00 (d, 3J14/13 
= 6.6 Hz, 3H, 14-H)*, 0.94 (d, 3J15/13 = 6.6 Hz, 3H, 15-H)*, 0.87 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 110.4 (C-6), 77.9 (C-2), 64.5 (C-11)*, 64.4 (C-12)*, 57.2 (C-3), 
50.1 (C-1), 46.9 (C-4), 41.2 (C-9), 36.9 (C-8), 34.8 (C-5), 30.8 (C-7), 29.9 (C-13), 24.1 (C-15)**, 
22.0 (C-14)**, 19.1 (C-10) ppm. 
 
EI-MS for C15H26O3+ [M+]: calcd. 254.1876 
 found 254.1879. 
 
IR (ATR): ῦ/cm−1 = 3418 (br s), 2950 (s), 2876 (s), 1457 (w), 1388 (w), 1354 (w), 1289 (w), 1255 (w), 
1193 (w), 1111 (m), 1095 (m), 1035 (m), 994 (w), 946 (w), 874 (w).  
 
[ ]20Dα  = −1.3 (c 1.00, CH2Cl2). 
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Analytical data for alcohol 251: 
 
Rf = 0.31 (hexanes:EtOAc = 2:1, stains violet with anisaldehyde). 
 
1H NMR (CDCl3, 600 MHz): δ  = 3.99−3.92 (m, 4H, 11-H, 12-H), 3.74 (d, 3J1/2A = 5.1 Hz, 1H, 1-H), 
2.37 (ddd, 3J = 14.3, 9.8, 3.5 Hz, 1H, 4-H), 2.00 (mC, 1H, 2-HA), 1.93 (mC, 1H, 5-HA), 1.85 (mC, 1H, 
3-H), 1.82−1.71 (m, 4H, 2-HB, 5-HB, 7-HA, 8-HA), 1.69−1.64 (m, 1H, 7-HB), 1.63−1.58 (m, 1H, 13-H), 
1.36−1.27 (m, 2H, 8-HA, OH), 0.90 (d, 3J14/13 = 6.4 Hz, 3H, 14-H)*, 0.84 (s, 3H, 10-H), 0.82 (d, 
3J15/13 = 6.6 Hz, 3H, 15-H)* ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 110.4 (C-6), 79.0 (C-1), 64.5 (C-11)*, 64.4 (C-12)*, 45.6 (C-9), 
44.9 (C-3), 42.4 (C-4), 38.5 (C-2), 34.9 (C-5), 30.8 (C-7), 30.7 (C-13), 29.6 (C-8), 24.1 (C-14)**, 
22.3 (C-15)**, 18.3 (C-10) ppm. 
 
EI-MS for C15H26O3+ [M+]: calcd. 236.1876 
 found 236.1869. 
 
IR (ATR): ῦ/cm−1 = 3446 (br s), 2954 (s), 2872 (s), 1461 (w), 1386 (w), 1353 (w), 1291 (w), 1257 (w), 
1190 (w), 1112 (w), 1086 (m), 1057 (w), 1036 (w), 976 (w), 948 (w), 884 (w).  
 
[ ]20Dα  = −46.0 (c 0.50, CH2Cl2). 
 
 
Synthesis of Ketones 255 and 256 
 
 
To a solution of alcohols 192 and 251 (5.5:1, 495 mg, 1.95 mmol, 1.0 eq.) in acetone/H2O (10:1, 
44 mL) was added PPTS (635 mg, 2.53 mmol, 1.3 eq.) and the mixture was heated to reflux for 3 h. 
The reaction was allowed to cool to room temperature and the pH was adjusted to 7−8 by adding solid 
NaHCO3. The mixture was subsequently freed of acetone and the residue was diluted with 
Et2O (80 mL). The organic layer was consecutively washed with saturated aqueous NaHCO3 (2 x 
20 mL), aqueous HCl (1N, 2 x 20 mL) and saturated aqueous NaHCO3 (20 mL). The combined 
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NaHCO3 layers and the combined HCl layers were separately re-extracted with Et2O (2 x 20 mL) and 
the combined organic layers were dried over MgSO4. The solvents were removed under reduced 
pressure and the crude product was purified by flash column chromatography (silica, hexanes:EtOAc 
= 4:1 to 2:1) to yield ketones 255 and 256 (12:1, 307 mg, 1.46 mmol, 75%) as a colorless solid.  
On a larger scale, reaction of a 12.4:1 mixture of alcohols 192 and 251 (2.66 g, 10.5 mmol) provided 
pure ketone 255 (1.81 g, 8.62 mmol) in 82% yield. 
 
Analytical samples of both regioisomers 255 and 256 were obtained by repeated flash column 
chromatography. Ketone 256 was obtained as viscous colorless oil. 
 
Analytical data for ketone 255: 
 
Rf = 0.22 (hexanes:EtOAc = 2:1, stains yellow-green with anisaldehyde). 
 
Melting point = 52.5−54.5 °C (hexanes/EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.42 (ddd, 3J2/1A = 9.4 Hz, 3J2/1B = 7.0 Hz, 3J2/3 = 4.9 Hz, 1H, 2-H), 
2.58 (ddd, J = 14.3, 3.4, 1.7 Hz, 1H, 5-HA), 2.44−2.30 (m, 4H, 4-H, 5-HB, 7-H), 2.10 (dd, 2J1A/1B = 
11.7 Hz, 3J1A/2 = 7.0 Hz, 1H, 1-HA), 1.84 (ddd, J = 13.0, 7.1, 2.1 Hz, 1H, 8-HA), 1.73−1.67 (m, 1H, 
11-H), 1.62−1.55 (m, 3H, 3-H, 8-HB, OH), 1.31 (dd, 2J1B/1A = 11.7 Hz, 3J = 9.3 Hz, 1H, 1-HB), 1.04 (d, 
3J13/11 = 6.6 Hz, 3H, 13-H)*, 1.04 (s, 3H, 10-H), 0.94 (d, 3J12/11 = 6.4 Hz, 3H, 12-H)* ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 212.0 (C-6), 77.7 (C-2), 56.6 (C-3), 49.4 (C-1), 48.6 (C-4), 
41.6 (C-5), 40.9 (C-9), 37.7 (C-8), 37.2 (C-7), 29.2 (C-11), 24.2 (C-12)*, 21.7 (C-13)*, 
19.1 (C-10) ppm. 
 
EI-MS for C13H22O2+ [M+]: calcd. 210.1614 
 found 210.1613. 
 
IR (ATR): ῦ/cm−1 = 3406 (br s), 2955 (s), 2932 (s), 2871 (m), 1703 (s), 1462 (w), 1420 (w), 1388 (w), 
1228 (w), 1170 (w), 1149 (w), 1129 (w), 1101 (w), 1034 (m), 999 (w), 973 (w), 818 (w), 741 (w).  
 
[ ]20Dα  = +72.0 (c 0.125, CH2Cl2). 
 
2 Experimental Procedures  149 
Analytical data for ketone 256:  
 
Rf = 0.28 (hexanes:EtOAc = 2:1, stains violet with anisaldehyde). 
 
1H NMR (CDCl3, 600 MHz): δ = 3.84 (d, 3J1/2A = 4.8 Hz, 1H, 1-H), 2.63 (mC, 1H, 5-HA), 
2.54−2.36 (m, 4H, 4-H, 5-HB, 7-H), 2.06 (ddd, 2J2A/2B = 14.7 Hz, 3J2A/3 = 7.3 Hz, 3J2A/1 = 4.7 Hz, 1H, 
2-HA), 2.04−1.98 (m, 1H, 8-HA), 1.98−1.92 (m, 1H, 3-H), 1.83 (dd, 2J2B/2A = 14.8 Hz, 3J2B/3 = 8.9 Hz, 
1H, 2-HB), 1.64 (mC, 1H, 11-H), 1.59 (ddd, J = 12.7, 7.1, 2.4 Hz, 1H, 8-HB), 1.41 (br s, 1H, OH), 
1.00 (d, J = 0.6 Hz, 3H, 10-H), 0.90 (d, 3J = 6.6 Hz, 3H, 12-H)*, 0.86 (d, 3J = 6.6 Hz, 3H, 
13-H)* ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 212.6 (C-6), 78.4 (C-1), 45.5 (C-9), 44.6 (C-3), 44.2 (C-4), 
41.5 (C-5), 38.8 (C-2), 37.1 (C-7), 30.1 (C-11), 30.0 (C-8), 24.1 (C-12)*, 22.0 (C-13)*, 
18.4 (C-10) ppm. 
 
EI-MS for C13H22O2+ [M+]: calcd. 210.1614 
 found 210.1614. 
 
IR (ATR): ῦ/cm−1 = 3434 (br s), 2957 (s), 2894 (s), 2874 (s), 1698 (s), 1466 (w), 1424 (w), 1386 (w), 
1368 (w), 1343 (w), 1309 (w), 1266 (w), 1234 (w), 1171 (w), 1144 (w), 1127 (w), 1031 (m), 954 (w). 
 
[ ]20Dα  = −9.2 (c 0.50, CH2Cl2). 
 
 
Synthesis of trans-Hydrindane Building Block 191 
 
 
To a solution of alcohols 255 and 256 (12:1, 100 mg, 480 μmol, 1.0 eq.) in DMF (6 mL) at 0 °C was 
sequentially added imidazole (122 mg, 1.80 mmol, 3.8 eq.), DMAP (23 mg, 0.19 mmol, 40 mol-%) 
and TBSCl (181 mg, 1.20 mmol, 2.5 eq.). The mixture was allowed to warm to room temperature and 
stirred for 16 h. The reaction was quenched by addition of H2O (15 mL) and the biphasic mixture was 
extracted with Et2O (3 x 25 mL). The combined organic layers were washed with 10% aqueous 
NaCl (3 x 15 mL) and the combined aqueous layers were re-extracted with Et2O (2 x 15 mL). The 
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combined organic layers were dried over MgSO4 and the solvents were evaporated under reduced 
pressure. The crude product was purified by flash column chromatography (silica, hexanes: EtOAc = 
70:1 to 50:1 to 30:1) to yield ketone 191 (141 mg, 434 μmol, 91%) as a colorless solid and as single 
isomer. 
 
Crystals suitable for X-ray analysis were obtained by recrystallization from MeOH. 
 
Rf = 0.15 (hexanes:EtOAc = 30:1). 
 
Melting point = 49.5−51.0 °C (hexanes/EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.36 (ddd, 3J2/1B = 8.8 Hz, 3J2/1A = 6.9 Hz, 3J2/3 = 4.2 Hz, 1H, 2-H), 
2.56 (ddd, 2J5A/5B = 14.7 Hz, J = 3.6, 1.7 Hz, 1H, 5-HA), 2.43−2.36 (m, 2H, 5-HB, 7-HA), 2.35−2.28 (m, 
2H, 4-H, 7-HB), 1.98 (dd, 2J1A/1B = 11.8 Hz, 3J1A/2 = 6.9 Hz, 1H, 1-HA), 1.81 (ddd, 2J8A/8B = 12.9 Hz, 
3J8A/7B = 7.1 Hz, 3J8A/7A = 2.0 Hz, 1H, 8-HA), 1.71−1.63 (m, 2H, 3-H, 11-H), 1.58 (mC, 1H, 8-HB), 
1.27 (dd, 2J1B/1A = 11.7 Hz, 3J1B/2 = 8.8 Hz, 1H, 1-HB), 1.03 (s, 3H, 10-H), 0.98 (d, 3J13/11 = 6.2 Hz, 3H, 
13-H)*, 0.91 (d, 3J12/11 = 6.0 Hz, 3H, 12-H)*, 0.87 (s, 9H, 15-H), 0.06 (s, 3H, 16-H)**, 0.04 (s, 3H, 
17-H)** ppm. 
  
13C NMR (CDCl3, 150 MHz): δ  = 212.3 (C-6), 77.8 (C-2), 56.5 (C-3), 50.2 (C-1), 48.1 (C-4), 
41.6 (C-5), 40.9 (C-9), 38.0 (C-8), 37.3 (C-7), 29.2 (C-11), 26.0 (C-15), 24.4 (C-12)*, 21.9 (C-13)*, 
19.2 (C-10), 18.0 (C-14), −3.5 (C-16)**, −4.7 (C-17)** ppm. 
 
EI-MS for C18H33O2Si+ [(M−Me)+]: calcd. 309.2244 
 found 309.2226. 
 
IR (ATR): ῦ/cm−1 = 2956 (s), 2929 (s), 2899 (s), 2857 (s), 1711 (s), 1472 (w), 1462 (w), 1420 (w), 
1388 (w), 1254 (m), 1106 (m), 1073 (m), 1006 (w), 941 (w), 887 (w), 851 (w), 836 (m), 774 (m).  
 
[ ]20Dα  = +59.7 (c 0.33, CH2Cl2). 
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Synthesis of Dioxolane 257 
 
 
To a solution of alkene 221 (140 mg, 590 μmol, 1.0 eq.) and NaOAc (556 mg, 6.80 mmol, 11.5 eq.) in 
THF/H2O (1:1, 18 mL) was added p-toluenesulfonyl hydrazide (631 mg, 3.39 mmol, 5.8 eq.) in one 
portion. The mixture was heated to 80 °C for 4 h and was then allowed to cool to room temperature. 
The reaction was quenched by addition of saturated aqueous K2CO3 (2 mL), the organic layer was 
separated and the aqueous layer was extracted with Et2O (3 x 15 mL). The combined organic layers 
were dried over MgSO4 and the solvents were evaporated under reduced pressure. The resulting 
residue was suspended in n-pentane/Et2O (1:1, 5 mL) and purified by flash column 
chromatography (silica, n-pentane:Et2O = 19:1 to 9:1) to yield saturated compound 257 (130 mg, 
546 μmol, 93%) as a colorless oil. 
 
Rf = 0.37 (hexanes:EtOAc = 16:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.02−3.88 (m, 4H), 1.91−1.78 (m, 3H), 1.77−1.67 (m, 3H), 
1.64−1.53 (m, 4H), 1.47 (dd, J = 11.8, 7.6 Hz, 1H), 1.32 (mC, 1H), 1.13 (mC, 1H), 0.89 (d, J = 6.3 Hz, 
3H), 0.86 (br s, 3H), 0.82 (d, J = 6.6 Hz, 3H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 110.9, 64.4, 64.3, 48.4, 46.7, 41.0, 40.3, 37.2, 35.4, 31.3 (2C), 28.7, 
24.1, 22.4, 17.9 ppm. 
 
EI-MS for C15H26O2+ [M+]: calcd. 238.1927 
 found 238.1927. 
 
IR (ATR): ῦ/cm−1 = 2950 (s), 2873 (s), 1464 (w), 1386 (w), 1356 (w), 1289 (w), 1256 (w), 1190 (m), 
1115 (m), 1096 (s), 1057 (w), 947 (m), 882 (w), 718 (w), 668 (w).  
 
[ ]20Dα  = −24.8 (c 0.25, CH2Cl2). 
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Synthesis of Building Block 190 
 
 
To a solution of dioxolane 257 (100 mg, 0.420 mmol, 1.0 eq.) in acetone/H2O (9:1, 10 mL) was added 
PPTS (137 mg, 0.546 mmol, 1.3 eq.) and the reaction mixture was heated to reflux for 3 h. The 
mixture was allowed to cool to room temperature and the pH value was adjusted to 7−8 by the 
addition of solid NaHCO3. Having freed the mixture of acetone, the residue was diluted with 
Et2O (10 mL). The organic layer was separated and sequentially washed with saturated aqueous 
NaHCO3 (3 mL), HCl (2N, 2 x 3 mL) and saturated aqueous NaHCO3 (2 x 3 mL). The organic layer 
was dried over MgSO4 and the solvents were removed under reduced pressure. The crude product was 
purified by flash column chromatography (silica, n-pentane:Et2O = 20:1 to 9:1) to yield 
ketone 190 (80 mg, 0.41 mmol, 99%) as a colorless oil. 
 
Rf = 0.29 (hexanes:EtOAc = 16:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 2.58 (ddd, 2J5A/5B = 15.0 Hz, 3J5A/4 = 4.1 Hz, 4J5A/7B = 1.8 Hz, 1H, 
5-HA), 2.47−2.40 (m, 2H, 5-HB, 7-HA), 2.31 (dddd, 2J7B/7A = 16.3 Hz, 3J7B/8B = 5.7 Hz, 3J7B/8A = 
4J7B/5A = 1.8 Hz, 1H, 7-HB), 1.97−1.88 (m, 2H, 2-HA, 4-H), 1.86 (ddd, 2J8A/8B = 12.9 Hz, 3J8A/7A = 
7.3 Hz, 3J8A/7B = 1.9 Hz, 1H, 8-HA), 1.81−1.68 (m, 2H, 2-HB, 3-H) 1.65−1.57 (m, 2H, 1-HA, 11-H), 
1.49 (ddd, 2J8B/8A = 3J8B/7A = 13.0 Hz, 3J8B/7B = 5.8 Hz, 1H, 8-HB), 1.19 (ddd, 2J1B/1A = 3J1B/2 = 11.8 Hz, 
3J1B/2 = 8.4 Hz, 1H, 1-HB), 1.04 (s, 3H, 10-H), 0.88 (d, 3J12/11 = 6.4 Hz, 3H, 12-H)*, 0.86 (d, 3J13/11 = 
6.4 Hz, 3H, 13-H)* ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 213.2 (C-6), 50.2 (C-4), 46.5 (C-3), 42.3 (C-5), 41.1 (C-9), 
39.9 (C-1), 37.8 (C-8), 37.6 (C-7), 30.6 (C-11), 29.3 (C-2), 24.1 (C-12)*, 22.1 (C-13)*, 
17.8 (C-10) ppm. 
 
EI-MS for C13H22O+ [M+]: calcd. 194.1665 
 found 194.1674. 
 
IR (ATR): ῦ/cm−1 = 2954 (s), 2868 (s), 1711 (s), 1464 (w), 1420 (w), 1386 (w), 1289 (w), 1214 (w), 
1146 (w), 1045 (w), 921 (w), 816 (w).  
 
2 Experimental Procedures  153 
[ ]20Dα  = +11.2 (c 0.25, CH2Cl2). 
 
 
2.2 Experimental Procedures for Chapter 3: ‘Synthetic Studies 
toward Astellatol’ 
 
Synthesis of Enone 273 
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O
H
Li2CO3 (2.5 eq.)
LiBr (2.0 eq.)
DMF, 120 °C, 5 h
(49% over two
steps)207 272 273
C14H22O2
M = 222.32 g/mol
PTAB (1.3 eq.)
HOAc (0.1 mol-%)
THF, 0 °C, 15 min
 
To a solution of ketone 207 (200 mg, 893 μmol, 1.0 eq.) in THF (44 mL) at 0 °C was added 
PTAB (441 mg, 1.16 mmol, 1.3 eq.) in one portion followed by HOAc (0.66 mL of a 1 vol-% solution 
in THF, 0.12 nmol, 0.13 mol-%) and the mixture was stirred for 15 min at this temperature. The 
reaction was quenched by addition of saturated aqueous Na2S2O3 (15 mL), the phases were separated 
and the aqueous layer was extracted with Et2O (3 x 15 mL). The combined organic layers were 
washed with saturated aqueous NaCl (20 mL) and were dried over MgSO4. Having evaporated the 
solvents under reduced pressure, the crude product was purified by flash column 
chromatography (silica, hexanes:EtOAc = 16:1 to 14:1 to 9:1) to yield brominated 
compound 272 (223 mg, 738 μmol, 78%, Rf = 0.67, hexanes:EtOAc = 3:1) as a mixture of 
diastereomers. 
To a solution of α-bromo ketone 272 (150 mg, 500 μmol, 1.0 eq.) in DMF (6 mL) was added LiBr (87 
mg, 1.0 mmol, 2.0 eq.) and Li2CO3 (109 mg, 1.50 mmol, 2.5 eq.) and the resulting suspension was 
heated to 120 °C for 5 h. The mixture was allowed to cool to room temperature and the reaction was 
quenched by addition of saturated aqueous NH4Cl (10 mL). The mixture was extracted with Et2O (4 x 
10 mL) and the combined organic layers were washed with 10% aqueous NaCl (3 x 10 mL). Having 
dried the combined organic layers over MgSO4, the solvent was evaporated under reduced pressure 
and the crude product was purified by flash column chromatography (silica, hexanes:EtOAc = 20:1 to 
16:1) to yield enone 273 (70 mg, 315 μmol, 63%, 49% over two steps) as a colorless oil. 
 
Rf = 0.15 (hexanes:EtOAc = 16:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 7.12 (dd, 3J8/7 = 9.8 Hz, J = 0.7 Hz, 1H, 8-H), 5.84 (dd, 3J7/8 = 
9.7 Hz, 4J7/5A = 0.6 Hz, 1H, 7-H), 3.70−3.64 (m, 1H, 1-H), 2.44 (ddd, 2J5A/5B = 17.4 Hz, 3J5A/4 = 5.2 Hz, 
4J5A/7 = 0.7 Hz, 1H, 5-HA), 2.36 (dd, 2J5B/5A = 17.4 Hz, 3J5B/4 = 13.4 Hz, 1H, 5-HB), 2.07−1.93 (m, 2H, 
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2-HA, 4-H), 1.70−1.61 (m, 1H, 3-HA), 1.60−1.46 (m, 2H, 2-HB, 3-HB), 1.17 (s, 9H, 12-H), 0.93 (s, 3H, 
10-H). 
  
13C NMR (CDCl3, 100 MHz): δ = 200.9 (C-6), 157.3 (C-8), 128.6 (C-7), 75.6 (C-1), 72.9 (C-11), 
45.4 (C-9), 41.8 (C-4), 39.4 (C-5), 30.9 (C-2), 28.8 (C-12), 25.5 (C-3), 12.7 (C-10) ppm. 
 
EI-MS for C10H14O2+ [(M−C3H8)+]: calcd. 166.0988 
 found 166.0984. 
 
IR (ATR): ῦ/cm−1 = 2973 (s), 2906 (m), 2878 (m), 1676 (s), 1474 (w), 1364 (w), 1239 (w), 1194 (m), 
1122 (w), 1105 (w), 1070 (m), 902 (w), 780 (w). 
 
[ ]20Dα  = +30.4 (c 0.50, CH2Cl2). 
 
 
Synthesis of β-Keto Ester 276 
 
 
To a solution of ketone 207 (100 mg, 450 μmol, 1.0 eq.) in THF (4.5 mL) at −78 °C was added 
dropwise LiHMDS (0.54 mL of a 1.0M solution in THF, 0.54 mmol, 1.2 eq.). The mixture was 
allowed to warm to room temperature and was stirred for an additional 45 min before being cooled to 
−78 °C. Then, Mander’s reagent (275, 43 μL, 0.43 mmol, 1.2 eq.) was added dropwise and the mixture 
was stirred an additional 1 h at −78 °C. The reaction was diluted with Et2O (5 mL) and poured onto 
H2O (5 mL). The organic layer was separated and the aqueous layer was extracted with Et2O (2 x 
10 mL). The combined organic layers were washed with saturated aqueous NaCl (5 mL), dried over 
Na2SO4 and the solvents were evaporated under reduced pressure. The crude product was purified by 
flash column chromatography (silica, hexanes:EtOAc = 40:1) to yield β-keto ester 276 (88 mg, 
0.31 mmol, 69%) as a colorless oil. 
 
Rf = 0.55 (hexanes:EtOAc = 16:1). 
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1H NMR (CDCl3, 600 MHz): δ = 12.30 (s, 1H, OH), 3.75 (s, 3H, 14-H), 3.53 (mC, 1H, 1-H), 
2.35−2.29 (m, 2H, 5-HA, 8-HA), 2.11 (mC, 1H, 5-HB), 1.94 (mC, 1H, 2-HA), 1.88 (mC, 1H, 8-HB), 
1.69−1.48 (m, 3H, 2-HB, 3-HA, 4-H), 1.36 (mC, 1H, 3-HB), 1.17 (s, 9H, 12-H), 0.72 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 173.8 (C-13), 172.3 (C-6), 97.0 (C-7), 80.2 (C-1), 72.6 (C-11), 
51.6 (C-14), 41.7 (C-9), 40.0 (C-4), 35.1 (C-8), 32.3 (C-5), 31.6 (C-2), 28.9 (C-12), 25.8 (C-2), 
10.7 (C-10) ppm. 
 
EI-MS for C16H26O4+ [M+]: calcd. 282.1826 
 found 282.1836. 
 
IR (ATR): ῦ/cm−1 = 2972 (s), 1654 (s), 1608 (m), 1442 (m), 1383 (w), 1362 (m), 1269 (s), 1232 (w), 
1210 (s), 1117 (w), 1092 (w), 1062 (w).  
 
[ ]20Dα  = +103.6 (c 0.50, CH2Cl2). 
 
This compound has been prepared by an alternative procedure having identical physical properties.[134] 
 
 
Synthesis of Ketone 280 
 
 
To a solution of ketone 207 (5.00 g, 22.3 mmol, 1.0 eq.) in THF (200 mL) at room temperature was 
added dropwise KHMDS (50 mL of a 0.5M solution in toluene, 25.0 mmol, 1.1 eq.) and the resulting 
solution was stirred for 30 min. Then, the mixture was cooled to −78 °C and Et3B (25.0 mL of a 
freshly prepared 1.0M solution in THF, 25.0 mmol, 1.1 eq.) was added dropwise. After stirring an 
additional 10 min, a solution of Pd(PPh3)4 (1.28 g, 1.15 mmol, 5.0 mol-%) and allyl 
bromide (2.20 mL, 25.0 mmol, 1.1 eq.) in THF (20 mL) was slowly added. The cold bath was 
removed and the mixture was allowed to warm to room temperature, and was stirred for 3 h. The 
reaction was quenched by careful addition of 2N HCl (30 mL) and the layers were separated. The 
aqueous layer was extracted with Et2O (3 x 30 mL) and the combined organic layers were washed with 
saturated aqueous NaHCO3 (50 mL) and dried over NaSO4. The solvents were removed under reduced 
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pressure and the crude product was purified by flash column chromatography (silica, hexanes:EtOAc 
= 40:1 to 30:1) to yield ketone 280 (4.40 g, 16.7 mmol, 75%) as a colorless oil. 
 
Rf = 0.73 (hexanes:EtOAc = 7:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.76 (mC, 1H, 14-H), 5.04−4.96 (m, 2H, 15-H), 3.44 (dd, 3J1/2 = 8.9, 
7.6 Hz, 1H, 1-H), 2.56 (mC, 1H, 13-HA), 2.41 (mC, 1H, 7-H), 2.37−2.28 (m, 2H, 5-H), 2.06 (dd, 2J8A/8B 
= 12.8 Hz, 3J8A/7 = 6.3 Hz, 1H, 8-HA), 2.02−1.94 (m, 2H, 2-HA, 13-HB), 1.69−1.62 (m, 1H, 4-H), 
1.62−1.53 (m, 2H, 2-HB, 3-HA), 1.46−1.38 (m, 1H, 3-HB), 1.13 (s, 9H, 12-H), 1.08 (dd, 2J8B/8A = 3J8B/7 
= 12.8 Hz, 1H, 8-HB), 1.01 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 212.1 (C-6), 136.8 (C-14), 116.3 (C-15), 79.5 (C-1), 72.7 (C-11), 
45.8 (C-4), 45.3 (C-7), 43.1 (C-5), 42.8 (C-9), 42.3 (C-8), 34.1 (C-13), 32.0 (C-2), 28.8 (C-12), 
25.9 (C-3), 11.3 (C-10) ppm. 
 
EI-MS for C17H28O2+ [M+]: calcd. 264.2084 
 found 264.2082. 
 
IR (ATR): ῦ/cm−1 = 3076 (w), 2973 (s), 2876 (m), 1708 (s), 1463 (w), 1390 (w), 1361 (m), 1252 (w), 
1192 (m), 1114 (m), 1061 (m), 1027 (w), 999 (w), 903 (w).  
 
[ ]20Dα  = +56.3 (c 1.00, CH2Cl2). 
 
The analytical data matched those reported previously.[188] 
 
 
Synthesis of Alcohol 286 
 
 
To a solution of ketone 280 (26 mg, 0.10 mmol, 1.0 eq.) in EtOH (2 mL) at 0 °C was added 
NaBH4 (7.7 mg, 0.20 mmol, 2.0 eq.) in one portion and the mixture was stirred for an additional 2 h. 
The reaction was quenched by careful addition of HCl (2N, few drops) and the pH was adjusted to 7−8 
by addition of solid NaHCO3. The solvent was evaporated under reduced pressure and the residue was 
dissolved in EtOAc (10 mL). The organic layer was washed with saturated aqueous NH4Cl (5 mL) and 
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the aqueous layer was re-extracted with EtOAc (2 x 10 mL). The combined organic layers were 
washed with saturated aqueous NaCl (2 x 5 mL), dried over MgSO4 and the solvents were evaporated 
under reduced pressure. The residue was purified by flash column chromatography (silica, 
hexanes:EtOAc = 20:1 to 10:1) to yield alcohol 286 (21 mg, 79 μmol, 79%) as a colorless wax. 
  
The stereochemistry of the newly formed stereogenic center was assigned by 
2D NOESY experiments showing the proximity of protons as depicted beside. 
 
Rf = 0.43 (hexanes:EtOAc = 4:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.86 (dddd, 3J14/15A =17.3 Hz, 3J14/15B = 10.2 Hz, 3J14/13A = 3J14/13B = 
7.2 Hz, 1H, 14-H), 5.06 (mC, 1H, 15-HA), 5.01 (mC, 1H, 15-HB), 3.35 (dd, 3J1/2 = 8.9, 7.4 Hz, 1H, 1-H), 
3.27 (ddd, 3J6/7 = 3J6/5B = 10.3 Hz, 3J6/5A = 5.0 Hz, 1H, 6-H), 2.41 (mC, 1H, 13-HA), 2.01−1.95 (m, 1H, 
13-HB), 1.94−1.86 (m, 1H, 2-HA), 1.80 (ddd, J = 12.0, 5.0, 3.0 Hz, 1H, 5-HA), 1.75 (dd, 2J8A/8B = 
13.0 Hz, 3J8A/7 = 4.3 Hz, 1H, 8-HA), 1.72−1.59 (m, 2H, 7-H, OH), 1.59−1.41 (m, 2H, 2-HB, 3-HA), 
1.40−1.29 (m, 2H, 3-HB, 5-HB), 1.29−1.22 (m, 1H, 4-H), 1.12 (s, 9H, 12-H), 0.77 (s, 3H, 10-H), 
0.73 (dd, 2J8B/8A = 3J8B/7 = 12.9 Hz, 1H, 8-HB) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 137.8 (C-14), 116.3 (C-15), 80.5 (C-1), 76.2 (C-6), 72.5 (C-11), 
43.4 (C-4), 43.0 (C-9), 41.5 (C-8), 40.4 (C-7), 38.5 (C-13), 35.0 (C-5), 31.8 (C-2), 29.0 (C-12), 
25.5 (C-3), 11.9 (C-10) ppm. 
 
EI-MS for C17H30O2+ [M+]: calcd. 266.2240 
 found 266.2237. 
 
IR (ATR): ῦ/cm−1 = 3218 (br m), 3078 (w), 2973 (s), 2927 (s), 2910 (s), 2874 (m), 1465 (w), 1393 (w), 
1361 (w), 1256 (w), 1198 (w), 1126 (w), 1070 (w), 1038 (w), 907 (w).  
 
[ ]20Dα  = +0.4 (c 0.50, CH2Cl2). 
  
 
H
MeH
H
HO
O
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Synthesis of Alcohol 288 
 
 
To a solution of ketone 280 (2.70 g, 10.2 mmol, 1.0 eq.) in THF (100 mL) at −78 °C was added 
dropwise K-Selectride® (287, 15.4 mL of a 1.0M solution in THF, 15.4 mmol, 1.5 eq.). Upon complete 
addition, the cold bath was removed and the solution was stirred an additional 1.5 h at room 
temperature. The mixture was cooled to 0 °C, and MeOH (18 mL) was carefully added to quench 
excess hydride source. Subsequently, aqueous NaOH (3N, 36 mL) and H2O2 (30% in H2O, 27 mL) 
were added and the biphasic mixture was stirred an additional 3 h at room temperature. The mixture 
was diluted with saturated aqueous NH4Cl (30 mL) and the aqueous layer was extracted with Et2O (3 x 
50 mL). The combined organic layers were washed with saturated aqueous NaCl (2 x 50 mL), dried 
over MgSO4 and the solvents were removed under reduced pressure. The crude product was purified 
by flash column chromatography (silica, hexanes:EtOAc = 20:1 to 15:1) to yield alcohol 288 (2.61 g, 
9.81 mmol, 95%) as a colorless oil. 
 
The stereochemistry was assigned as depicted above since this compound was the minor product in the 
reduction with NaBH4. In addition, the small coupling constants (ca. 2.5 Hz) for the newly formed 
methine proton indicated no axial-axial coupling.  
 
Rf = 0.18 (hexanes:EtOAc = 10:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.84 (mC, 1H, 14-H), 5.06 (mC, 1H, 15-HA), 5.01 (mC, 1H, 15-HB), 
3.92 (mC, 1H, 6-H), 3.45 (dd, 3J1/2 = 8.8, 7.5 Hz, 1H, 1-H), 2.20−2.13 (m, 1H, 13-HA), 2.06−2.00 (m, 
1H, 13-HB), 1.95−1.87 (m, 1H, 2-HA), 1.74−1.63 (m, 3H, 4-H, 5-HA, 7-H), 1.56−1.40 (m, 4H, 2-HB, 
3-HA, 5-HB, 8-HA), 1.34−1.22 (m, 2H, 3-HB, OH), 1.13 (s, 9H, 12-H), 1.09 (dd, 2J8B/8A = 3J8B/7 = 
12.6 Hz, 1H, 8-HB), 0.73 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 137.7 (C-14), 115.9 (C-15), 80.6 (C-1), 72.4 (C-11), 69.0 (C-6), 
43.0 (C-9), 38.6 (C-8), 37.7 (C-13)*, 37.5 (C-7)*, 37.4 (C-4)*, 33.6 (C-5), 31.4 (C-2), 28.9 (C-12), 
25.6 (C-3), 10.9 (C-10) ppm. 
 
EI-MS for C17H30O2+ [M+]: calcd. 266.2240 
 found 266.2234. 
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IR (ATR): ῦ/cm−1 = 3408 (br m), 2973 (s), 2929 (s), 1462 (w), 1389 (w), 1361 (m), 1256 (m), 
1196 (s), 1128 (m), 1066 (s), 1029 (m), 1006 (m), 908 (m), 864 (w), 803 (w).  
 
[ ]20Dα  = +46.4 (c 0.25, CH2Cl2). 
 
 
Synthesis of Lactone 290 
 
 
To a solution of alkene 288 (3.59 g, 13.5 mmol, 1.0 eq.) in 1,4-dioxane/H2O (3:1, 200 mL) at 0 °C was 
sequentially added 2,6-lutidine (3.14 mL, 27.0 mmol, 2.0 eq.) and OsO4 (838 μL of a 4 wt% solution 
in H2O, 135 μmol, 1.0 mol-%). Then, NaIO4 (11.6 g, 54.0 mmol, 4.0 eq.) was added in portions and 
the mixture was allowed to warm to room temperature. After stirring for an additional 17 h, the 
reaction was diluted with H2O (150 mL) and the mixture was extracted with CH2Cl2 (4 x 200 mL). 
The combined organic layers were washed with saturated aqueous NaCl (100 mL) and dried over 
Na2SO4. The solvents were removed under reduced pressure to yield crude intermediate lactol 289 as a 
mixture of epimers (Rf = 0.2, hexanes:EtOAc = 4:1), which was used without further purification. 
To a suspension of PCC (7.30 g, 33.8 mmol, 2.5 eq.) in CH2Cl2 (200 mL) at 0 °C was added dropwise 
a solution of crude lactol 289 (assumed 13.5 mmol, 1.0 eq.) in CH2Cl2 (40 mL + 5 mL rinse). The 
resulting mixture was allowed to warm to room temperature and was stirred for an additional 1 h 
before being directly applied to flash column chromatography (silica, hexanes:EtOAc = 3:1). The 
solvent of the product containing fractions was evaporated under reduced pressure and the residue was 
purified by flash column chromatography (silica, hexanes:EtOAc = 8:1) to yield lactone 290 (3.23 g, 
12.1 mmol, 90% over two steps) as a colorless solid.  
 
The stereochemistry of the tricyclic system was assigned according to the key 
NOESY correlations as indicated beside. 
 
Rf = 0.38 (hexanes:EtOAc = 4:1). 
 
Melting point = 118.5−121.0 °C (CH2Cl2). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.56 (mC, 1H, 6-H), 3.39 (dd, 3J1/2 = 8.8, 8.0 Hz, 1H, 1-H), 2.73 (dd, 
2J13A/13B = 16.8 Hz, 3J13A/7 = 7.0 Hz, 1H, 13-HA), 2.51 (mC, 1H, 7-H), 2.20 (d, 2J13B/13A = 16.9 Hz, 1H, 
H Me
H
O
OO
H
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13-HB), 2.12 (mC, 1H, 5-HA), 1.92 (mC, 1H, 2-HA), 1.81 (dd, 2J8A/8B = 13.1 Hz, 3J8A/7 = 6.4 Hz, 1H, 
8-HA), 1.63−1.43 (m, 4H, 2-HB, 3-HA, 4-H, 5-HB), 1.31 (mC, 1H, 3-HB), 1.12 (s, 9H, 12-H), 0.91 (mC, 
1H, 8-HB), 0.73 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 177.4 (C-14), 80.2 (C-6), 80.1 (C-1), 72.6 (C-11), 41.1 (C-9), 
39.6 (C-8), 38.4 (C-13), 37.0 (C-4), 33.1 (C-7), 30.8 (C-2), 28.9 (C-12), 28.5 (C-5), 25.3 (C-3), 
10.4 (C-10) ppm. 
 
EI-MS for C16H26O3+ [M+]: calcd. 266.1876 
 found 266.1881. 
 
IR (ATR): ῦ/cm−1 = 2971 (s), 2932 (m), 2874 (m), 1779 (s), 1462 (w), 1389 (w), 1361 (w), 1215 (w), 
1196 (m), 1179 (m), 1155 (m), 1124 (w), 1062 (m), 1043 (w), 1028 (w), 1000 (w), 968 (w), 911 (w). 
 
[ ]20Dα  = +12.4 (c 1.00, CH2Cl2). 
 
 
Synthesis of Lactone 291 
 
 
To a solution of lactone 290 (3.23 g, 12.1 mmol, 1.0 eq.) in THF (180 mL) at −78 °C was added 
dropwise LiHMDS (18.2 mL of a 1.0M solution in THF, 18.2 mmol, 1.5 eq.) and the resulting mixture 
was stirred for 45 min at this temperature before adding MeI (3.80 mL, 60.5 mmol, 5.0 eq.) dropwise. 
After stirring the mixture for an additional 90 min, the reaction was quenched by addition of HCl (2N, 
40 mL). The mixture was allowed to warm to room temperature and was diluted with half-saturated 
aqueous NH4Cl (100 mL). The phases were separated and the aqueous layer was extracted with 
Et2O (3 x 100 mL). The combined organic layers were sequentially washed with saturated aqueous 
NaHCO3 (70 mL) and saturated aqueous NaCl (70 mL), and dried over Na2SO4. The solvents were 
evaporated under reduced pressure and the crude product was purified by flash column 
chromatography (short plug of silica, hexanes:EtOAc = 8:1). Further purification by flash column 
chromatography (silica, hexanes:EtOAc = 14:1 to 10:1 to 7:1) yielded lactone 291 (3.06 g, 10.9 mmol, 
90%) as a colorless solid and as single diastereomer. 
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Crystals suitable for X-ray analysis were obtained by cooling a saturated solution of lactone 291 in 
hexanes/EtOAc to −25 °C. 
 
Rf = 0.62 (hexanes:EtOAc = 4:1). 
 
Melting point = 152.0−154.0 °C (CH2Cl2). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.72−4.69 (m, 1H, 6-H), 3.37 (dd, 3J1/2 = 8.7, 8.0 Hz, 1H, 1-H), 
2.34 (q, 3J13/15 = 7.6 Hz, 1H, 13-H), 2.17−2.09 (m, 2H, 5-HA, 7-H), 1.91 (mC, 1H, 2-HA), 1.84 (dd, 
2J8A/8B = 13.1 Hz, 2J8A/7 = 6.5 Hz, 1H, 8-HA), 1.61−1.41 (m, 4H, 2-HB, 3-HA, 4-H, 5-HB), 1.33−1.25 (m, 
1H, 3-HB), 1.30 (d, 3J15/13 = 7.7 Hz, 3H, 15-H), 1.11 (s, 9H, 12-H), 0.88 (mC, 1H, 8-HB), 0.70 (s, 3H, 
10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 180.5 (C-14), 80.1 (C-1), 77.9 (C-6), 72.5 (C-11), 45.0 (C-13), 
42.0 (C-9), 40.0 (C-7)*, 39.9 (C-8)*, 37.1 (C-4), 30.8 (C-2), 28.9 (C-12), 28.5 (C-5), 25.3 (C-3), 
15.0 (C-15), 10.3 (C-10) ppm.  
 
EI-MS for C13H20O3+ [(M−C3H8)+]: calcd. 224.1407 
 found 224.1413. 
 
IR (ATR): ῦ/cm−1 = 2973 (s), 2938 (s), 2904 (m), 2874 (m), 1757 (s), 1464 (w), 1362 (w), 1213 (m), 
1200 (m), 1183 (m), 1132 (w), 1111 (w), 1083 (w), 1064 (w), 1023 (w), 974 (w), 941 (w). 
 
[ ]20Dα  = −2.6 (c 1.00, CH2Cl2). 
 
 
Synthesis of Alcohol 295 
 
 
To a solution of lactone 291 (82 mg, 0.29 mmol, 1.0 eq.) in CH2Cl2 (6 mL) at −78 °C was added 
dropwise DIBAL-H (0.58 mL of a 1.0M solution in CH2Cl2, 0.58 mmol, 2.0 eq.) and the mixture was 
stirred for 30 min at this temperature. Then, EtOAc (1 mL) was added to quench excess hydride 
source followed by half-saturated aqueous Rochelle salt (10 mL). The mixture was allowed to warm to 
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room temperature and was stirred vigorously for an additional 1 h. The organic layer was separated 
and the aqueous layer was extracted with CH2Cl2 (4 x 10 mL). The combined organic layers were 
dried over MgSO4 and the solvent was removed under reduced pressure. The crude product was 
filtered over a pad of silica (hexanes:EtOAc = 6:1) to yield lactol 292 as a mixture of epimers, which 
was used without further purification. 
To a solution of lactol 292 (20 mg, 71 μmol, 1.0 eq.) in benzene (6 mL) was added ylid 294 (148 mg, 
0.43 mmol, 6.0 eq.) and the mixture was heated to reflux for 24 h. As TLC indicated remaining 
starting material, more reagent 294 (49 mg, 0.14 mmol, 2.0 eq.) was added and the mixture was heated 
to reflux for an additional 16 h. The mixture was allowed to cool to room temperature and the reaction 
was quenched by addition of saturated aqueous NH4Cl (5 mL). After phase separation, the aqueous 
layer was extracted with EtOAc (3 x 5 mL) and the combined organic layers were dried over MgSO4. 
The solvents were removed under reduced pressure and the crude product was purified by flash 
column chromatography (silica, hexanes:EtOAc = 10:1 to 7:1) to yield ester 295 (14 mg, 37 μmol, 
52% over two steps) as a highly viscous colorless oil. 
 
Rf = 0.47 (hexanes:EtOAc = 4:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 6.94 (dd, 3J14/15 = 15.6 Hz, 3J14/13 = 9.5 Hz, 1H, 14-H), 5.87 (dd, 
3J15/14 = 15.6 Hz, 4J15/13 = 0.8 Hz, 1H, 15-H), 4.19 (q, 3J18/19 = 7.2 Hz, 2H, 18-H), 3.90 (mC, 1H, 6-H), 
3.46 (dd, 3J1/2 = 8.9, 7.7 Hz, 1H, 1-H), 2.39 (mC, 1H, 13-H), 1.95−1.88 (m, 1H, 2-HA), 1.74−1.65 (m, 
2H, 4-H, 8-HA), 1.60 (mC, 1H, 5-HA), 1.53−1.40 (m, 4H, 2-HB, 3-HA, 5-HB, 7-H), 1.34−1.23 (m, 1H, 
3-HB), 1.29 (t, 3J19/18 = 7.1 Hz, 3H, 19-H), 1.14 (s, 9H, 12-H), 1.10−1.02 (m, 1H, 8-HB), 1.05 (d, 
3J17/13 = 6.8 Hz, 3H, 17-H), 0.71 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 167.0 (C-16), 154.2 (C-14), 120.4 (C-15), 80.7 (C-1), 72.4 (C-11), 
68.1 (C-6), 60.4 (C-18), 42.8 (C-9), 42.7 (C-7), 38.7 (C-13), 37.4 (C-4), 35.9 (C-8), 34.0 (C-5), 
31.3 (C-2), 28.9 (C-12), 25.6 (C-3), 18.2 (C-17), 14.4 (C-19), 11.0 (C-11) ppm. 
 
EI-MS for C21H36O4+ [M+]: calcd. 352.2608 
 found 352.2624. 
 
IR (ATR): ῦ/cm−1 = 3480 (br w), 2973 (s), 2935 (s), 2874 (m), 1718 (m), 1463 (w), 1362 (w), 
1262 (w), 1225 (w), 1195 (w), 1125 (w), 1063 (w). 
 
[ ]20Dα  = +51.2 (c 0.25, CH2Cl2). 
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Synthesis of Diol 296 
 
 
To a suspension of LiAlH4 (806 mg, 21.2 mmol, 2.0 eq.) in THF (60 mL) at 0 °C was added a solution 
of lactone 291 (3.06 g, 10.9 mmol, 1.0 eq.) in THF (30 mL + 10 mL rinse) via cannula within 20 min 
and the mixture was stirred for an additional 15 min at this temperature. Then, half-saturated aqueous 
Rochelle salt (100 mL) was added and the biphasic mixture was vigorously stirred for 1 h at room 
temperature. The layers were separated and the aqueous layer was extracted with Et2O (3 x 100 mL). 
The combined organic layers were washed with saturated aqueous NaCl (80 mL) and dried over 
MgSO4. The crude product was purified by flash column chromatography (silica, CH2Cl2:MeOH = 
100:2.5) to yield diol 296 (2.99 g, 10.6 mmol, 97%) as a colorless solid. 
 
Rf = 0.24 (CH2Cl2:MeOH = 100:5). 
 
Melting point = 128.5−130.0 °C (CH2Cl2). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.11 (mC, 1H, 6-H), 3.68 (dd, 2J14A/14B = 10.7 Hz, 3J14A/13 = 2.8 Hz, 
1H, 14-HA), 3.58 (dd, 2J14B/14A = 10.8 Hz, 3J14B/13 = 6.1 Hz, 1H, 14-HB), 3.47 (dd, 3J1/2 = 8.8, 7.4 Hz, 
1H, 1-H), 3.08 (br s, 2H, OH), 1.94−1.87 (m, 1H, 2-HA), 1.76−1.63 (m, 3H, 4-H, 5-HA, 13-H), 
1.56−1.39 (m, 5H, 2-HB, 3-HA, 5-HB, 7-H, 8-HA), 1.32−1.22 (m, 2H, 3-HB, 8-HB), 1.13 (s, 9H, 12-H), 
1.00 (d, 3J15/13 = 7.2 Hz, 3H, 15-H), 0.72 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 80.8 (C-1), 72.4 (C-11), 66.9 (C-6), 65.8 (C-14), 43.1 (C-9), 
42.2 (C-7), 38.2 (C-13), 37.6 (C-4), 37.5 (C-8), 33.6 (C-5), 31.4 (C-2), 28.9 (C-12), 25.6 (C-3), 
16.3 (C-15), 11.0 (C-10) ppm.  
 
EI-MS for C17H32O3+ [M+]: calcd. 284.2346 
 found 284.2342. 
 
IR (ATR): ῦ/cm−1 = 3298 (br s), 2971 (s), 2929 (s), 2874 (s), 1462 (w), 1387 (w), 1360 (m), 1253 (w), 
1196 (m), 1114 (w), 1062 (m), 1009 (m), 972 (w), 937 (w), 902 (w). 
 
[ ]20Dα  = +38.0 (c 0.50, CH2Cl2). 
 
164  EXPERIMENTAL SECTION 
Synthesis of trans-Hydrindane 297 
 
 
To a solution of diol 296 (2.97 g, 10.5 mmol, 1.0 eq.) and 2,6-lutidine (4.90 mL, 42.1 mmol, 4.0 eq.) 
in CH2Cl2 (100 mL) at 0 °C was added dropwise Et3SiOTf (6.20 mL, 27.4 mmol, 2.6 eq.) and the 
mixture was stirred for 1 h at this temperature. The reaction was quenched by addition of saturated 
aqueous NaHCO3 (60 mL), the phases were separated and the aqueous layer was extracted with 
CH2Cl2 (3 x 50 mL). The combined organic layers were washed with saturated aqueous NaCl (50 mL) 
and dried over MgSO4. The crude product was purified by flash column chromatography (silica, 
hexanes:EtOAc = 100:1 to 60:1 to 40:1) to yield the title compound 297 (5.34 g, 10.4 mmol, 99%) as a 
colorless oil. 
 
Rf = 0.23 (hexanes:EtOAc = 30:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.00 (mC, 1H, 6-H), 3.52 (dd, 2J14A/14B = 9.5 Hz, 3J14A/13 = 5.0 Hz, 1H, 
14-HA), 3.45 (dd, 2J14B/14A = 9.6 Hz, 3J14B/13 = 6.1 Hz, 1H, 14-HB), 3.42 (dd, 3J1/2 = 8.9, 7.4 Hz, 1H, 
1-H), 1.95−1.84 (m, 1H, 2-HA), 1.77−1.65 (m, 2H, 4-H, 13-H), 1.56−1.51 (m, 2H, 5-HA, 7-H), 
1.50−1.32 (m, 4H, 2-HB, 3-HA, 5-HB, 8-HA), 1.25 (mC, 1H, 3-HB), 1.14 (s, 9H, 12-H), 1.12 (mC, 1H, 
8-HB), 0.99−0.94 (m, 18H, 17-H, 19-H), 0.89 (d, 3J15/13 = 6.9 Hz, 3H, 15-H), 0.70 (s, 3H, 10-H), 
0.63−0.54 (m, 12H, 16-H, 18-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 81.0 (C-1), 72.3 (C-11), 70.5 (C-6), 66.5 (C-14), 42.7 (C-9), 
38.7 (C-7), 37.4 (2C, C-4, C-13), 35.0 (C-8), 34.7 (C-5), 31.5 (C-2), 29.0 (C-12), 25.6 (C-3), 
15.1 (C-15), 11.1 (C-10), 7.2 (C-17)*, 7.0 (C-19)*, 5.5 (C-16)**, 4.6 (C-18)** ppm.  
 
EI-MS for C29H60O3Si2+ [M+]: calcd. 512.4076 
 found 512.4076. 
 
IR (ATR): ῦ/cm−1 = 2954 (s), 2911 (s), 2987 (s), 1459 (w), 1414 (w), 1387 (w), 1361 (w), 1238 (w), 
1196 (w), 1062 (m), 1015 (m), 976 (w), 725 (m). 
 
[ ]20Dα  = +24.2 (c 1.00, CH2Cl2). 
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Synthesis of Aldehyde 298 
 
 
To a solution of DMSO (1.02 mL, 14.5 mmol, 5.0 eq.) in CH2Cl2 (30 mL) at −78 °C was slowly added 
(COCl)2 (3.61 mL of a 2.0M solution in CH2Cl2, 7.22 mmol, 2.5 eq.) and the mixture was stirred for 
15 min at this temperature. Then, a solution of bissilyl ether 297 (1.48 g, 2.89 mmol, 1.0 eq.) in 
CH2Cl2 (7 mL) was added within 30 min using a syringe pump. The reaction was allowed to warm to 
−60 °C and was stirred for 7 h at −65 to −60 °C (cryocooler). The mixture was cooled to −78 °C and 
Et3N (3.95 mL, 28.4 mmol, 9.8 eq.) was added dropwise. The mixture was stirred for an additional 
10 min at this temperature and was allowed to warm slowly to 0 °C forming a white precipitate. After 
stirring an additional 15 min at 0 °C, the reaction was quenched by adding H2O (20 mL) and the 
biphasic mixture was extracted with CH2Cl2 (3 x 40 mL). The combined organic layers were washed 
with saturated aqueous NaCl (30 mL), dried over MgSO4 and the solvents were removed under 
reduced pressure. Purification by flash column chromatography (silica, hexanes:EtOAc = 60:1 to 30:1) 
yielded aldehyde 298 (992 mg, 2.53 mmol, 88%) as a colorless oil. 
On a larger scale (5.31 g, 10.4 mmol of bissilyl ether 297), aldehyde 298 (3.10 g, 7.82 mmol) was 
isolated in 75% yield along with recovered starting material 297 (430 mg, 840 μmol, 8%). 
 
Rf = 0.31 (hexanes:EtOAc = 30:1). 
 
1H NMR (CDCl3, 600 MHz): δ  = 9.74 (d, 3J14/13 = 1.7 Hz, 1H, 14-H), 4.04 (mC, 1H, 6-H), 3.44 (dd, 
3J1/2 = 9.0, 7.4 Hz, 1H, 1-H), 2.40 (qdd, 3J13/7 = 3J13/15 = 7.2 Hz, 3J13/14 = 1.7 Hz, 1H, 13-H), 
1.96−1.86 (m, 2H, 2-HA, 7-H), 1.73 (dddd, 3J = 13.0, 13.0, 7.0, 3.3 Hz, 1H, 4-H), 1.60 (ddd, 2J5A/5B = 
13.7 Hz, 3J5A/4 = 3J5A/6 = 3.2 Hz, 1H, 5-HA), 1.53−1.40 (m, 4H, 2-HA, 3-HA, 5-HB, 8-HA), 1.35 (dd, 
2J8B/8A = 3J8B/7 = 12.6 Hz, 1H, 8-HB), 1.31−1.23 (m, 1H, 3-HB), 1.14 (s, 9H, 12-H), 1.07 (d, 3J15/13 = 
7.1 Hz, 3H, 15-H), 0.94 (t, 3J17/16 = 8.0 Hz, 9H, 17-H), 0.74 (s, 3H, 10-H), 0.58 (q, 3J16/17 = 8.0 Hz, 6H, 
16-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 205.2 (C-14), 80.8 (C-1), 72.4 (C-11), 68.7 (C-6), 48.3 (C-13), 
42.9 (C-9), 40.3 (C-7), 37.2 (C-4), 36.2 (C-8), 33.9 (C-5), 31.4 (C-2), 29.0 (C-12), 25.5 (C-3), 
12.2 (C-15), 10.9 (C-10), 7.1 (C-17), 5.3 (C-16) ppm.  
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EI-MS for C23H44O3Si+ [M+]: calcd. 396.3054 
 found 396.3065. 
 
IR (ATR): ῦ/cm−1 = 2955 (s), 2876 (s), 1722 (s), 1461 (w), 1414 (w), 1389 (w), 1362 (w), 1238 (w), 
1195 (m), 1126 (w), 1086 (s), 1045 (s), 1005 (m), 973 (w), 945 (w), 919 (w), 726 (m). 
 
[ ]20Dα  = +63.6 (c 0.50, CH2Cl2). 
  
 
Synthesis of Alkene 299 
 
 
To a suspension of methyltriphenylphosphonium bromide (8.33 g, 23.3 mmol, 3.0 eq.) in 
THF (120 mL) at 0 °C was slowly added n-BuLi (6.20 mL of a 2.5M solution in hexanes, 15.6 mmol, 
2.0 eq.). The mixture was allowed to warm to room temperature, stirred for an additional 1 h and was 
subsequently cooled to −78 °C. Then, a solution of aldehyde 298 (3.08 g, 7.78 mmol, 1.0 eq.) in 
THF (12 mL + 5 mL rinse) was added within 15 min (syringe pump). The cold bath was removed and 
replaced by an ice/water bath. The mixture was stirred for 60 min at 0 °C and the reaction was 
quenched by addition of saturated aqueous NH4Cl (50 mL). The layers were separated and the aqueous 
layer was extracted with Et2O (3 x 70 mL). The combined organic layers were washed with saturated 
aqueous NaCl (50 mL) and dried over MgSO4. Having evaporated the solvents under reduced 
pressure, the crude product was purified by flash column chromatography (silica, hexanes:EtOAc = 
100:1 to 60:1) to afford alkene 299 (2.86 g, 7.26 mmol, 93%) as a colorless oil. 
 
Rf = 0.21 (hexanes:EtOAc = 60:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.77 (ddd, 3J14/15A = 17.3 Hz, 3J14/15B = 10.3 Hz, 3J14/13 = 8.2 Hz, 1H, 
14-H), 4.97 (ddd, 3J15A/14 = 17.3 Hz, 2J15A/15B = 2.1 Hz, 4J15A/13 = 1.0 Hz, 1H, 15-HA), 4.93 (ddd, 3J15B/14 
= 10.4 Hz, 2J15B/14A = 2.1 Hz, 4J15B/13 = 0.5 Hz, 1H, 15-HB), 4.00 (mC, 1H, 6-H), 3.43 (dd, 3J1/2 = 8.9, 
7.4 Hz, 1H, 1-H), 2.22 (mC, 1H, 13-H), 1.91 (mC, 1H, 2-HA), 1.74 (dddd, J = 12.9, 12.9, 7.0, 3.4 Hz, 
1H, 4-H), 1.58−1.52 (m, 2H, 5-HA, 8-HA), 1.48−1.34 (m, 3H, 2-HB, 3-HA, 5-HB), 1.29−1.21 (m, 2H, 
3-HB, 7-H), 1.15 (s, 9H, 12-H), 1.07 (dd, 2J8B/8A = 3J8B/7 = 12.4 Hz, 1H, 8-HB), 0.96 (t, 3J18/17 = 7.9 Hz, 
9H, 18-H), 0.95 (d, 3J16/13 = 6.9 Hz, 3H, 16-H), 0.70 (s, 3H, 10-H), 0.62−0.54 (m, 6H, 17-H) ppm. 
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13C NMR (CDCl3, 150 MHz): δ = 145.1 (C-14), 113.0 (C-13), 80.9 (C-1), 72.3 (C-11), 69.4 (C-6), 
43.6 (C-7), 42.8 (C-9), 39.0 (C-13), 37.3 (C-4), 35.6 (C-8), 34.4 (C-5), 31.6 (C-2), 29.0 (C-12), 
25.5 (C-3), 18.7 (C-16), 11.2 (C-10), 7.3 (C-18), 5.6 (C-17) ppm.  
 
EI-MS for C24H46O2Si+ [M+]: calcd. 394.3262 
 found 394.3262. 
 
IR (ATR): ῦ/cm−1 = 3087 (w), 2972 (s), 2955 (s), 2911 (s), 2876 (s), 1460 (m), 1415 (w), 1361 (w), 
1237 (w), 1196 (m), 1128 (w), 1060 (m), 1045 (m), 1106 (m), 974 (w), 909 (m), 796 (w), 724 (m). 
 
[ ]20Dα  = +37.6 (c 0.50, CH2Cl2). 
 
 
Synthesis of Alcohol 300 
 
 
To a solution of alkene 299 (394 mg, 1.00 mol, 1.0 eq.) in THF (12 mL) was added 9-BBN (237, 
4.00 mL of a 0.5M solution in THF, 2.00 mmol, 2.0 eq.) and the mixture was heated to 40 °C for 3.5 h. 
The mixture was cooled to 0 °C and MeOH (2 mL), aqueous NaOH (3N, 4 mL) and aqueous 
H2O2 (30 wt%, 4 mL) were consecutively added. The mixture was stirred at 40 °C for 1 h and for an 
additional 1 h at room temperature, and H2O (10 mL) was added. The mixture was extracted with 
Et2O (3 x 25 mL) and the combined organic layers were washed with saturated aqueous NaCl (2 x 
20 mL). The NaCl layers were re-extracted with Et2O (2 x 10 mL) and the combined organic layers 
were dried over MgSO4. The solvents were evaporated under reduced pressure and the crude product 
was purified by flash column chromatography (silica, hexanes:EtOAc = 9:1) to yield 
alcohol 300 (357 mg, 867 μmol, 87%) as a colorless oil.  
 
Rf = 0.17 (hexanes:EtOAc = 7:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.07 (mC, 1H, 6-H), 3.71 (ddd, 2J15A/15B = 10.4 Hz, 3J15A/14 = 8.5, 
5.5 Hz, 1H, 15-HA), 3.64 (ddd, 2J15B/15A = 10.3 Hz, 3J15B/14 = 8.2, 6.8 Hz, 1H, 15-HB), 3.42 (dd, 3J1/2 = 
8.8, 7.5 Hz, 1H, 1-H), 1.94−1.87 (m, 1H, 2-HA), 1.80−1.70 (m, 2H, 4-H, 14-HA), 1.67−1.61 (m, 1H, 
13-H), 1.59−1.54 (m, 1H, 5-HA), 1.49 (dd, 2J8A/8B = 12.3 Hz, 3J8A/7 = 3.5 Hz, 1H, 8-HA), 1.47−1.35 (m, 
4H, 2-HB, 3-HA, 5-HB, 13-H), 1.30−1.23 (m, 2H, 3-HB, 7-H), 1.16−1.08 (m, 1H, 8-HB), 1.14 (s, 9H, 
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12-H), 0.96 (t, 3J18/17 = 8.0 Hz, 9H, 18-H), 0.88 (d, 3J16/15 = 6.8 Hz, 3H, 16-H), 0.69 (s, 3H, 10-H), 
0.64−0.55 (m, 6H, 17-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 81.0 (C-1). 72.3 (C-11), 70.0 (C-6), 61.7 (C-15), 42.7 (2C, C-7, 
C-9), 38.3 (C-14), 37.4 (C-4), 35.2 (C-8), 34.6 (C-5), 31.6 (C-2), 31.4 (C-13), 29.0 (C-12), 25.5 (C-3), 
17.4 (C-16), 11.1 (C-10), 7.2 (C-18), 5.5 (C-17) ppm.  
 
EI-MS for C24H48O3Si+ [M+]: calcd. 412.3367 
 found 412.3359. 
 
IR (ATR): ῦ/cm−1 = 3355 (br m), 2955 (s), 2876 (s), 1461 (w), 1379 (w), 1362 (w), 1196 (w), 
1130 (w), 1062 (m), 1009 (w), 977 (w), 797 (w), 741 (w). 
 
[ ]20Dα  = +20.0 (c 0.33, CH2Cl2). 
 
 
Synthesis of Diol 458 
 
 
To a solution of silyl ether 300 (14 mg, 39 μmol, 1.0 eq.) in CH2Cl2/MeOH (7:1, 1.6 mL) at 0 °C was 
added (1R)-(−)-camphorsulfonic acid (spatula tip). The mixture was allowed to warm to room 
temperature and was stirred for 1 h before being diluted with CH2Cl2 (5 mL) and quenched by addition 
of saturated aqueous NaHCO3 (5 mL). The aqueous layer was separated and extracted with 
CH2Cl2 (3 x 5 mL). The combined organic layers were dried over MgSO4 and the solvents were 
evaporated under reduced pressure. The obtained crude product was purified by flash column 
chromatography (silica, CH2Cl2:MeOH = 100:2.5) to yield diol 458 (9 mg, 32 μmol, 83%) as a viscous 
colorless oil.  
 
Rf = 0.24 (CH2Cl2:MeOH = 100:5). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.15 (mC, 1H, 6-H), 3.76 (ddd, 2J15A/15B = 10.2 Hz, 3J15A/14 = 6.4, 
4.3 Hz, 1H, 15-HA), 3.64 (ddd, 2J15B/15A = 10.1 Hz, 3J15B/14 = 9.2, 5.4 Hz, 1H, 15-HB), 3.44 (dd, 3J1/2 = 
8.8, 7.5 Hz, 1H, 1-H), 2.06−1.82 (m, 4H, 2-HA, 14-HA, OH), 1.70−1.57 (m, 4H, 4-H, 5-HA, 8-HA, 
13-H), 1.55−1.41 (m, 3H, 2-HB, 3-HA, 5-HB), 1.34−1.23 (m, 3H, 3-HB, 7-H, 14-HB), 1.13 (s, 9H, 
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12-H), 1.02 (dd, 2J8B/8A = 3J8B/7 = 12.9 Hz, 1H, 8-HB), 0.94 (d, 3J16/13 = 6.8 Hz, 3H, 16-H), 0.70 (s, 3H, 
10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 80.8 (C-1), 72.4 (C-11), 67.6 (C-6), 61.6 (C-15), 42.8 (C-9), 
42.5 (C-7), 37.5 (C-4), 37.1 (C-14), 36.4 (C-8), 33.8 (C-5), 31.4 (C-2), 31.2 (C-13), 28.9 (C-12), 
25.6 (C-3), 18.6 (C-16), 11.0 (C-10) ppm.  
 
EI-MS for C18H34O3+ [M+]: calcd. 298.2502 
 found 298.2509. 
 
IR (ATR): ῦ/cm−1 = 3350 (br s), 2972 (s), 2931 (s), 2873 (s), 1462 (w), 1388 (w), 1361 (m), 1197 (m), 
1130 (w), 1062 (m), 1028 (w), 1008 (w), 976 (w), 903 (w). 
 
[ ]20Dα  = +40.8 (c 0.33, CH2Cl2). 
 
 
Synthesis of Lactone 301 
 
OMe
H
O
H
MeOt-BuMe
H
HO
H
Me TEMPO (2.0 eq.)
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0 °C to rt, 16 h
(85%)
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O
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M = 294.43 g/mol
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2
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To a solution of diol 458 (6.0 mg, 20 μmol, 1.0 eq.) and BAIB (32 mg, 0.10 mmol, 5.0 eq.) in 
CH2Cl2 (1.5 mL) at 0 °C was added TEMPO (1 mg, 4 μmol, 0.2 eq.). The mixture was allowed to 
warm to room temperature and stirred for 2 h. Then, additional TEMPO (9.0 mg, 36 μmol, 1.8 eq.) 
was added and the mixture was stirred for 14 h. The reaction was diluted with CH2Cl2 (10 mL) and 
was quenched by addition of saturated aqueous Na2SO3 (3 mL). After phase separation, the aqueous 
layer was extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were washed with saturated 
aqueous NaHCO3 (5 mL) and saturated aqueous NaCl (5 mL), and were dried over MgSO4. The 
solvent was removed under reduced pressure and the crude product was purified by flash column 
chromatography (silica, hexanes:EtOAc = 7:1) to yield lactone 301 (5.0 mg, 17 μmol, 85%) as a 
colorless solid. 
 
Rf = 0.18 (Hexanes:EtOAc = 7:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.50 (ddd, 3J6/5A = 3J6/5B = 3J6/7 = 3.0 Hz, 1H, 6-H), 3.42 (dd, 3J1/2A = 
8.8 Hz, 3J1/2B = 7.7 Hz, 1H, 1-H), 2.53 (dd, 2J14A/14B = 15.8 Hz, 3J14A/13 = 6.2 Hz, 1H, 14-HA) 2.18 (dd, 
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2J14B/14A = 15.8 Hz, 3J14B/13 = 9.6 Hz, 1H, 14-HB), 1.95 (ddd, 2J5A/5B = 14.1 Hz, 3J5A/4 = 3J5A/6 = 3.0 Hz, 
1H, 5-HA), 1.91 (dddd, J = 13.5, 9.2, 9.2, 6.3 Hz, 1H, 2-HA), 1.72−1.63 (m, 3H, 4-H, 7-H, 13-H), 
1.62 (dd, 2J8A/8B = 12.8 Hz, 3J8A/7 = 4.8 Hz, 1H, 8-HA), 1.58 (mC, 1H, 5-HB), 1.55−1.49 (m, 1H, 3-HA), 
1.47−1.40 (m, 1H, 2-HB), 1.28 (mC, 1H, 3-HB) 1.14 (d, 3J16/13 = 6.9 Hz, 3H, 16-H), 1.12 (s, 9H, 12-H), 
1.08 (dd, 2J8B/8A = 3J8B/7 = 12.8 Hz, 1H, 8-HB), 0.75 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 173.7 (C-15), 80.3 (C-1), 75.4 (C-6), 72.5 (C-11), 42.7 (C-9), 
40.2 (C-8), 37.7 (C-7)*, 37.5 (C-4), 35.8 (C-14), 32.0 (C-13)*, 31.1 (C-2), 30.3 (C-5), 28.9 (C-12), 
25.3 (C-3), 22.1 (C-16), 10.7 (C-10) ppm.  
 
EI-MS for C18H30O3+ [M+]: calcd. 294.2189 
 found 294.2177. 
 
IR (ATR): ῦ/cm−1 = 2971 (s), 2931 (s), 2873 (m), 1745 (s), 1461 (w), 1362 (w), 1308 (w), 1280 (w), 
1251 (m), 1196 (m), 1165 (w), 1123 (w), 1064 (m), 1004 (w), 902 (w). 
 
[ ]20Dα  = −7.2 (c 0.25, CH2Cl2). 
 
 
Synthesis of Ketone 302 
 
 
To a solution of ketone 191 (380 mg, 1.17 mmol, 1.0 eq.) in degassed THF (12 mL) at room 
temperature was added KHMDS (3.5 mL of a 0.5M solution in toluene, 1.75 mmol, 1.5 eq.) and the 
resulting yellow solution was stirred for 30 min before being cooled to −78 °C. Then, Et3B (3.50 mL 
of a freshly prepared 0.5M solution in THF, 1.75 mmol, 1.5 eq.) was added dropwise and the mixture 
was stirred for 5 min. After slowly adding a solution of Pd(PPh3)4 (135 mg, 117 μmol, 10 mol-%) and 
allyl bromide (151 μL, 1.75 mmol, 1.5 eq.) in degassed THF (4 mL), the cold bath was removed and 
the mixture was stirred for 2.5 h at room temperature. The reaction was quenched by addition of 
saturated aqueous NH4Cl (20 mL) and diluted with Et2O (20 mL). The phases were separated and the 
aqueous layer was extracted with Et2O (3 x 20 mL). The combined organic layers were washed with 
saturated aqueous NaCl (30 mL) and dried over MgSO4. The solvents were evaporated under reduced 
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pressure and the crude product was purified by flash column chromatography (silica, hexanes:EtOAc 
= 60:1) to yield ketone 302 (350 mg, 961 μmol, 82%) as a colorless oil.  
 
Rf = 0.38 (hexanes:EtOAc = 16:1) 
 
1H NMR (CDCl3, 600 MHz): δ = 5.73 (mC, 1H, 15-H), 5.03−4.97 (m, 2H, 16-H), 4.36 (ddd, 3J2/1B = 
8.6 Hz, 3J2/1A = 7.0 Hz, 3J2/3 = 4.2 Hz, 1H, 2-H), 2.58 (dd, 2J5A/5B = 13.8 Hz, 3J5A/4 = 3.8 Hz, 1H, 5-HA), 
2.57−2.53 (m, 1H, 14-HA), 2.45−2.36 (m, 2H, 5-HB, 7-H), 2.23 (ddd, 3J4/5B = 15.2 Hz, 3J4/3 = 9.9 Hz, 
3J4/5A = 3.8 Hz, 1H, 4-H), 2.04−1.96 (m, 1H, 14-HB), 1.97 (dd, 2J1A/1B = 11.5 Hz, 3J1A/2 = 7.0 Hz, 1H, 
1-HA), 1.93 (dd, 2J8A/8B = 12.8 Hz, 3J8A/7 = 6.3 Hz, 1H, 8-HA), 1.71−1.64 (m, 1H, 13-H), 1.62 (ddd, 
3J3/4 = 3J3/11 = 9.9 Hz, 3J3/2 = 4.2 Hz, 1H, 3-H), 1.28−1.21 (m, 2H, 1-HB, 8-HB), 1.07 (s, 3H, 10-H), 
0.97 (d, 3J13/11 = 6.4 Hz, 3H, 13-H)*, 0.90 (d, 3J12/11 = 6.2 Hz, 3H, 12-H)*, 0.86 (s, 9H, 18-H), 0.05 (s, 
3H, 20-H)**, 0.03 (s, 3H, 19-H)** ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 212.1 (C-6), 136.7 (C-15), 116.5 (C-16), 77.9 (C-2), 56.9 (C-3), 
50.3 (C-1), 49.3 (C-4), 45.2 (C-7), 45.0 (C-8), 42.0 (C-5)*, 41.7 (C-9)*, 34.0 (C-14), 29.3 (C-11), 
26.0 (C-18), 24.3 (C-12)**, 22.0 (C-13)**, 20.1 (C-10), 17.9 (C-17), −3.5 (C-19)***, 
−4.7 (C-20)*** ppm.  
 
EI-MS for C22H40O2Si+ [M+]: calcd. 364.2792 
 found 364.2808. 
 
IR (ATR): ῦ/cm−1 = 3077 (w), 2956 (s), 2928 (s), 2856 (s), 1708 (s), 1471 (w), 1462 (w), 1388 (w), 
1255 (w), 1108 (w), 1072 (m), 836 (m), 774 (w). 
 
[ ]20Dα  = +30.4 (c 0.50, CH2Cl2). 
 
 
Synthesis of Alcohol 303 
 
 
To a solution of ketone 302 (326 mg, 896 μmol, 1.0 eq.) in THF (12 mL) at −78 °C was added 
dropwise K-Selectride® (287, 1.35 mL of a 1.0M solution in THF, 1.35 mmol, 1.5 eq.). The mixture 
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was stirred for 10 min at this temperature and an additional 30 min at room temperature. The mixture 
was cooled to 0 °C and MeOH (1.6 mL) was added followed by NaOH (3N, 3.2 mL) and H2O2 (30% 
in H2O, 2.4 mL). The mixture was stirred at room temperature for 1 h and the reaction was diluted 
with saturated aqueous NH4Cl (10 mL). The phases were separated and the aqueous layer was 
extracted with Et2O (3 x 20 mL). The combined organic layers were washed with saturated aqueous 
NaCl (2 x 15 mL) and dried over MgSO4. The solvents were evaporated under reduced pressure and 
the crude product was purified by flash column chromatography (silica, n-pentane:Et2O = 12:1 to 9:1) 
to yield alcohol 303 (323 mg, 883 μmol, 98%) as a highly viscous colorless oil. 
 
Rf = 0.13 (hexanes:EtOAc = 16:1) 
 
1H NMR (CDCl3, 600 MHz): δ = 5.81 (ddt, 3J15/16A = 17.1 Hz, 3J15/16B = 10.3 Hz, 3J15/14 = 7.3 Hz, 1H, 
15-H), 5.05 (mC, 1H, 16-HA), 5.00 (mC, 1H, 16-HB), 4.26 (ddd, 3J2/1B = 8.3 Hz, 3J2/1A = 7.1 Hz, 3J2/3 = 
3.9 Hz, 1H, 2-H), 3.96 (ddd, 3J6/5A = 3J6/5B = 3J6/7 = 2.9 Hz, 1H, 6-H), 2.30 (ddd, 3J4/5B = 14.0 Hz, 3J4/3 = 
10.0 Hz, 3J4/5A = 3.1 Hz, 1H, 4-H), 2.16 (mC, 1H, 14-HA), 1.99 (mC, 1H, 1-HB), 1.92 (ddd, 2J5A/5B = 
13.5 Hz, 3J5A/4 = 3J5A/6 = 3.2 Hz, 1H, 5-HA), 1.87 (dd, 2J1A/1B = 11.5 Hz, 3J1A/2 = 7.0 Hz, 1H, 1-HA), 
1.69−1.58 (m, 3H, 5-HB, 7-H, 11-H), 1.56 (ddd, 3J3/4 = 3J3/11 = 10.1 Hz, 3J3/2 = 3.8 Hz, 1H, 3-H), 
1.42 (br s, 1H, OH), 1.36 (dd, 2J8A/8B = 12.8 Hz, 3J8A/7 = 3.9 Hz, 1H, 8-HA) 1.28 (dd, 2J8B/8A = 3J8B/7 = 
12.8 Hz, 1H, 8-HB), 1.22 (dd, 2J1B/1A = 11.6 Hz, 3J1B/2 = 8.4 Hz, 1H, 1-HB), 0.94 (d, 3J13/11 = 6.5 Hz, 
3H, 13-H)*, 0.92 (d, 3J12/11 = 6.2 Hz, 3H, 12-H)*, 0.86 (s, 9H, 18-H), 0.81 (s, 3H, 10-H), 0.04 (s, 3H, 
19-H)**, 0.02 (s, 3H, 20-H)** ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 137.6 (C-15), 116.0 (C-16), 77.5 (C-2), 69.4 (C-6), 56.9 (C-3), 
51.6 (C-1), 42.2 (C-9), 41.8 (C-4), 41.5 (C-8), 37.4 (C-14), 36.7 (C-7), 32.5 (C-5), 30.0 (C-11), 
26.0 (C-18), 24.4 (C-12)*, 22.2 (C-13)*, 20.0 (C-10), 18.0 (C-17), −3.5 (C-20)**, −4.7 (C-19)** ppm. 
 
EI-MS for C22H42O2Si+ [M+]: calcd. 366.2949 
 found 366.2947. 
 
IR (ATR): ῦ/cm−1 = 3387 (br w), 3076 (w), 2955 (s), 2928 (s), 2856 (s), 1471 (w), 1462 (w), 1387 (w), 
1367 (w), 1254 (m), 1108 (w), 1070 (m), 1016 (w), 911 (w), 889 (w), 859 (w), 835 (m), 773 (w). 
 
[ ]20Dα  = +34.5 (c 0.33, CH2Cl2). 
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Synthesis of Lactone 304 
 
 
To a solution of alkene 303 (155 mg, 420 μmol, 1.0 eq.) and 2,6-lutidine (100 μL, 0.85 mmol, 2.0 eq.) 
in 1,4-dioxane/H2O (3:1, 12 mL) at 0 °C was sequentially added OsO4 (27 μL of a 4 wt% solution in 
H2O, 4.2 μmol, 1.0 mol-%) and NaIO4 (364 mg, 1.70 mmol, 4.0 eq.). The mixture was allowed to 
warm to room temperature and was stirred for 16 h forming a white suspension. The mixture was 
partitioned between H2O (15 mL) and CH2Cl2 (30 mL) and the phases were separated. The aqueous 
layer was extracted with CH2Cl2 (3 x 20 mL) and the combined organic layers were washed with 
saturated aqueous NaCl (20 mL), and dried over MgSO4. The solvents were evaporated under reduced 
pressure to yield crude lactol 459 which was used in the next step without further purification. 
To a suspension of PCC (316 mg, 1.47 mmol, 3.5 eq.) and NaOAc (244 mg, 2.94 mmol, 7.0 eq.) in 
CH2Cl2 (10 mL) at 0 °C was added a solution of crude lactol 459 (assumed 0.42 mmol, 1.0 eq.) in 
CH2Cl2 (3 mL). The mixture was allowed to warm to room temperature and stirred for 3 h before 
being directly applied to flash column chromatography (silica, hexanes:EtOAc = 3:1). The title 
compound 304 (133 mg, 363 μmol, 86% over two steps) was obtained as a highly viscous colorless 
oil. 
Note: intermediate lactol 459 and lactone 304 are co-polar on TLC. 
 
Rf = 0.30 (hexanes:EtOAc = 4:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.60 (mC, 1H, 6-H), 4.24 (ddd, 3J2/1B = 8.8 Hz, 3J2/1A = 7.0 Hz, 3J2/3 = 
4.2 Hz, 1H, 2-H), 2.70 (dd, 2J14A/14B = 16.8 Hz, 3J14A/7 = 7.1 Hz, 1H, 14-HA), 2.47 (mC, 1H, 7-H), 
2.32 (m, 1H, 5-HA), 2.16 (d, 2J14B/14A = 16.9 Hz, 1H, 14-HB), 2.15−2.10 (m, 1H, 4-H), 1.85 (dd, 2J1A/1B 
= 11.6 Hz, 3J1A/2 = 7.0 Hz, 1H, 1-HA), 1.74 (ddd, 2J5B/5A = 3J5B/4 = 14.5 Hz, 3J5B/6 = 3.8 Hz, 1H, 5-HB), 
1.67 (dd, 2J8A/8B =13.2 Hz, 3J8A/7 = 6.4 Hz, 1H, 8-HA), 1.65−1.59 (m, 2H, 3-H, 13-H), 1.21 (dd, 
2J1B/1A = 11.6 Hz, 3J1B/2 = 8.8 Hz, 1H, 1-HB), 1.11 (dd, 2J8B/8A = 3J8B/7 = 12.6 Hz, 1H, 8-HB), 0.96 (d, 
3J12/11 = 6.4 Hz, 3H, 12-H)*, 0.95 (d, 3J13/11 = 6.0 Hz, 3H, 13-H)*, 0.86 (s, 9H, 17-H), 0.81 (s, 3H, 
10-H), 0.04 (s, 3H, 18-H)**, 0.02 (s, 3H, 19-H)** ppm. 
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13C NMR (CDCl3, 150 MHz): δ = 177.1 (C-15), 80.1 (C-6), 76.7 (C-2), 55.8 (C-3), 50.6 (C-1), 
42.4 (C-8), 41.1 (C-4), 40.5 (C-9), 38.3 (C-14), 32.3 (C-7), 29.4 (C-11), 26.5 (C-5), 26.0 (C-17), 
24.5 (C-13)*, 22.0 (C-12)*. 19.3 (C-10), 17.9 (C-16), −3.5 (C-19)**, −4.7 (C-18)** ppm.  
 
EI-MS for C21H37O3Si+ [(M−H)+]: calcd. 365.2506 
 found 365.2502. 
 
IR (ATR): ῦ/cm−1 = 2954 (s), 2938 (s), 2898 (s), 2855 (s), 1775 (s), 1389 (w), 1285 (w), 1253 (w), 
1191 (m), 1154 (m), 1096 (m), 1070 (m), 976 (w), 940 (m), 905 (w), 882 (w), 835 (m), 773 (m).  
 
[ ]20Dα  = −8.8 (c 0.50, CH2Cl2). 
 
 
Synthesis of Lactone 269 
 
 
To a solution of lactone 304 (100 mg, 273 μmol, 1.0 eq.) in THF (11 mL) at −78 °C was added 
dropwise LiHMDS (600 μL of a 1.0M solution in THF, 600 mmol, 2.2 eq.) and the resulting mixture 
was stirred for 30 min. Then, MeI (84 mL, 1.35 mmol, 5.0 eq.) was added and the mixture was 
allowed to warm to −40 °C (MeCN/liquid N2 bath). After stirring an additional 30 min at this 
temperature, the reaction was quenched by addition of half-saturated aqueous NH4Cl (10 mL). The 
biphasic mixture was allowed to warm to room temperature, the phases were separated and the 
aqueous layer was extracted with Et2O (3 x 15 mL). The combined organic layers were washed with 
saturated aqueous NaCl (10 mL) and dried over MgSO4. The solvents were evaporated under reduced 
pressure and the crude product was purified by flash column chromatography (silica, hexanes:EtOAc 
= 12:1) to yield lactone 269 (86 mg, 0.23 mmol, 83%) as a highly viscous colorless oil.  
 
Rf = 0.20 (hexanes:EtOAc = 10:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.73 (mC, 1H, 6-H), 4.22 (ddd, 3J2/1B = 8.9 Hz, 3J2/1A = 7.0 Hz, 3J2/3 = 
4.2 Hz, 1H, 2-H), 2.32 (mC, 1H, 5-HA), 2.29 (q, 3J14/16 = 7.6 Hz, 1H, 14-H), 2.14−2.06 (m, 2H, 4-H, 
7-H), 1.83 (dd, 2J1A/1B = 11.6 Hz, 3J1A/2 = 6.9 Hz, 1H, 1-HA), 1.74−1.67 (m, 2H, 5-HB, 8-HA), 
1.65−1.58 (m, 2H, 3-H, 11-H), 1.28 (d, 3J16/14 = 7.7 Hz, 3H, 16-H), 1.19 (dd, 2J1B/1A = 11.6 Hz, 3J1B/2 = 
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9.0 Hz, 1H, 1-HB), 1.08 (dd, 2J8B/8A = 3J8B/7 = 12.9 Hz, 1H, 8-HB), 0.94 (mC, 6H, 12-H, 13-H), 0.84 (s, 
9H, 18-H), 0.78 (s, 3H, 10-H), 0.03 (s, 3H, 20-H)*, 0.01 (s, 3H, 19-H)* ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 180.2 (C-15), 77.9 (C-6), 76.7 (C-2), 55.8 (C-3), 50.6 (C-1), 
44.9 (C-14), 42.8 (C-8), 41.1 (C-4), 40.5 (C-9), 39.2 (C-7), 29.4 (C-11), 26.4 (C-5), 26.0 (C-18), 
24.5 (C-12)*, 22.0 (C-13)*, 19.2 (C-10), 17.9 (C-17), 14.9 (C-16), −3.4 (C-19)**, −4.7 (C-20)** ppm.  
 
EI-MS for C22H39O3Si+ [(M−H)+]: calcd. 379.2663 
 found 379.2673. 
 
IR (ATR): ῦ/cm−1 = 2955 (s), 2931 (s), 2900 (s), 2855 (s), 1772 (s), 1389 (w), 1255 (w), 1190 (m), 
1109 (w), 1076 (m), 1008 (w), 941 (w), 836 (m), 773 (m). 
 
[ ]20Dα  = −13.8 (c 0.33, CH2Cl2). 
 
 
Synthesis of trans-Hydrindane 305 
 
 
To a suspension of LiAlH4 (15 mg, 0.40 mmol, 2.5 eq.) in THF (5 mL) at 0 °C was added dropwise a 
solution of lactone 269 (60 mg, 0.16 mmol, 1.0 eq.) in THF (3 mL) and the mixture was stirred for 
20 min. The reaction was quenched by careful addition of half-saturated aqueous Rochelle 
salt (10 mL) and the biphasic mixture was stirred vigorously at room temperature for 30 min. The 
mixture was diluted with Et2O (10 mL) and the phases were separated. The aqueous layer was 
extracted with Et2O (3 x 10 mL) and the combined organic layers were washed with saturated aqueous 
NaCl (10 mL), and dried over Na2SO4. Having evaporated the solvents under reduced pressure, the 
crude product was purified by short flash column chromatography (silica, CH2Cl2:MeOH = 100:2.5) to 
yield diol 460 (Rf = 0.17, CH2Cl2:MeOH = 95:5), which was immediately used in the next reaction. 
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To a solution of diol 460 (assumed 0.16 mmol, 1.0 eq.) in CH2Cl2 (8 mL) at 0 °C was sequentially 
added imidazole (64.5 mg, 0.95 mmol, 6.0 eq.), DMAP (7 mg, 63 μmol, 20 mol-%) and 
Et3SiCl (106 μL, 632 μmol, 4.0 eq.). The mixture was allowed to warm to room temperature and 
stirred for 4 h at which point the reaction was quenched by addition of saturated aqueous 
NaHCO3 (7 mL). The mixture was diluted with CH2Cl2 (10 mL) and the phases were separated. The 
aqueous layer was extracted with CH2Cl2 (3 x 7 mL) and the combined organic layers were washed 
with saturated aqueous NaCl (10 mL), and dried over Na2SO4. Having evaporated the solvent under 
reduced pressure, the crude product was purified by flash column chromatography (silica, 
hexanes:EtOAc = 100:1) to yield the title compound 305 (85 mg, 0.14 mmol, 88% over two steps) as a 
colorless oil. 
 
Rf = 0.31 (hexanes:EtOAc = 60:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 4.25 (ddd, 3J2/1B = 8.6 Hz, 3J2/1A = 7.0 Hz, 3J2/3 = 4.3 Hz, 1H, 2-H), 
4.06 (mC, 1H, 6-H), 3.48 (dd, 2J15A/15B = 9.7 Hz, 3J15A/14 = 5.2 Hz, 1H, 15-HA), 3.44 (dd, 2J15B/15A = 
9.7 Hz, 3J15/14 = 6.0 Hz, 1H, 15-HB), 2.38 (ddd, 3J4/5B = 13.6 Hz, 3J4/3 = 10.6 Hz, 3J4/5A = 3.0 Hz, 1H, 
4-H), 1.84 (dd, 2J1A/1B = 11.4 Hz, 3J1A/2 = 7.0 Hz, 1H, 1-HA), 1.81 (ddd, 2J5A/5B = 13.5 Hz, 3J5A/4 = 3J5A/6 
= 3.2 Hz, 1H, 5-HA), 1.67 (mC, 1H, 14-H), 1.63−1.56 (m, 1H, 11-H), 1.56−1.50 (m, 2H, 5-HB, 7-H), 
1.48 (ddd, 3J3/4 = 3J3/11 = 10.3 Hz, 3J3/2 = 4.2 Hz, 1H, 3-H), 1.34 (dd, 2J8A/8B = 3J8A/7 = 12.5 Hz, 1H, 
8-HA), 1.27 (dd, 2J8B/8A= 12.3 Hz, 3J8B/7 = 4.0 Hz, 1H, 8-HB), 1.23 (dd, 2J1B/1A = 11.4 Hz, 3J1B/2 = 
8.7 Hz, 1H, 1-HB), 0.99−0.92 (m, 18H, 22-H, 24-H), 0.93 (d, 3J12/11 = 6.8 Hz, 3H, 12-H)*, 0.91 (d, 
3J13/11 = 6.4 Hz, 3H, 13-H)*, 0.87 (s, 9H, 18-H), 0.86 (d, 3J16/14 = 6.9 Hz, 3H, 16-H), 0.78 (s, 3H, 
10-H), 0.64−0.54 (m, 12H, 21-H, 23-H), 0.05 (s, 3H, 19-H)**, 0.04 (s, 3H, 20-H)** ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 77.8 (C-2), 70.8 (C-6), 66.3 (C15), 56.8 (C-3), 51.8 (C-1), 
41.9 (C-9), 41.4 (C-4), 38.0 (C-8), 37.9 (C-7), 37.3 (C-14), 33.4 (C-5), 30.1 (C-11), 26.1 (C-18), 
24.3 (C-13)*, 22.3 (C-12)*, 20.2 (C-10), 18.0 (C-17), 15.0 (C-16), 7.2 (C-22)**, 7.0 (C-24)**, 
5.5 (C-21)***, 4.6 (C-23)***, −3.4 (C-20)****,  −4.6 (C-19)**** ppm.  
 
EI-MS for C34H72O3Si3+ [M+]: calcd. 612.4784 
 found 612.4770. 
 
IR (ATR): ῦ/cm−1 = 2954 (s), 2935 (s), 2909 (s), 2875 (s), 1461 (w), 1414 (w), 1386 (w), 1367 (w), 
1255 (w), 1070 (m), 1046 (w), 1006 (w), 887 (w), 836 (w), 741 (w).  
 
[ ]20Dα  = +22.4 (c 0.33, CH2Cl2). 
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Synthesis of Alkene 268 
 
 
To a solution of DMSO (73 μL, 1.0 mmol, 8.0 eq.) in CH2Cl2 (5 mL) at −78 °C was added dropwise 
(COCl)2 (260 μL of a 2.0M solution in CH2Cl2, 520 μmol, 4.0 eq.) and the mixture was stirred for 
15 min at this temperature. Then, a solution of silyl ether 305 (80 mg, 0.13 mmol, 1.0 eq.) in 
CH2Cl2 (1.5 mL) was added over 30 min (syringe pump). The mixture was allowed to warm to −60 °C 
and was stirred for 7 h at −65 to −60 °C (cryo cooler). The reaction was then cooled to −78 °C and 
Et3N (0.29 mL, 2.1 mmol, 16.0 eq.) was added dropwise. The cold bath was replaced by an ice/water 
bath and the mixture was stirred for 30 min at 0 °C before the reaction was quenched by addition of 
H2O (5 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). 
The combined organic layers were washed with saturated aqueous NaCl (10 mL) and dried over 
MgSO4. Having evaporated the solvents under reduced pressure, the crude product was purified by 
flash column chromatography (silica, hexanes:EtOAc = 80:1 to 60:1) to yield aldehyde 461 (57 mg, 
Rf = 0.16, hexanes:EtOAc = 30:1) as a pale yellow oil, which was immediately used in the next step. 
To a suspension of Ph3PMeBr (184 mg, 517 μmol, 4.0 eq.) in THF (5 mL) at 0 °C was added dropwise 
n-BuLi (138 μL of a 2.5M solution in hexanes, 345 μmol, 3.0 eq.) and the mixture was allowed to 
warm to room temperature. The mixture was stirred for 1 h and was subsequently cooled to −78 °C. 
Then, a solution of aldehyde 461 (57 mg, 0.15 mmol, 1.0 eq.) in THF (1.5 mL) was added slowly. The 
cold bath was replaced by an ice/water bath and the mixture was stirred for 1 h at 0 °C. The reaction 
was quenched by addition of saturated aqueous NH4Cl/H2O (1:1, 5 mL) and the biphasic mixture was 
extracted with Et2O (3 x 8 mL). The combined organic layers were washed with saturated aqueous 
NaCl (5 mL) and were dried over MgSO4. Having evaporated the solvents under reduced pressure, the 
crude product was purified by flash column chromatography (silica, hexanes:EtOAc = 1:0 to 100:1) to 
yield alkene 268 (45 mg, 91 μmol, 71% over two steps) as a colorless oil. 
 
Rf = 0.63 (hexanes:EtOAc = 60:1). 
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1H NMR (CDCl3, 600 MHz): δ = 5.75 (ddd, 3J15/16A = 17.1 Hz, 3J15/16B = 10.3 Hz, 3J15/14 = 8.2 Hz, 1H, 
15-H), 4.97 (ddd, 3J16A/15 = 17.2 Hz, 2J16A/16B = 2.1 Hz, 4J16A/14 = 1.0 Hz, 1H, 16-HA), 4.92 (ddd, 3J16B/15 
= 10.3 Hz, 2J16B/16A = 2.0 Hz, 4J16B/14 = 0.6 Hz, 1H, 16-HB), 4.24 (ddd, 3J2/1B = 8.4 Hz, 3J2/1A = 7.0 Hz, 
3J2/3 = 4.1 Hz, 1H, 2-H), 4.06 (mC, 1H, 6-H), 2.39 (ddd, 3J4/5B = 13.6 Hz, 3J4/3 = 10.6 Hz, 3J4/5A = 
3.0 Hz, 1H, 4-H), 2.20 (mC, 1H, 14-H), 1.85 (dd, 2J1A/1B = 11.1 Hz, 3J1A/2 = 7.0 Hz, 1H, 1-HA), 
1.83 (mC, 1H, 5-HA), 1.62−1.55 (m, 1H, 11-H), 1.53−1.44 (m, 2H, 3-H, 5-HB), 1.37 (dd, 2J8A/8B = 
11.9 Hz, 3J8A/7 = 3.5 Hz, 1H, 8-HA), 1.30 (dd, 2J8B/8A = 2J8B/7 = 12.1 Hz, 1H, 8-HB), 1.27−1.20 (m, 2H, 
1-HB, 7-H), 0.97 (t, 3J23/22 = 7.9 Hz, 9H, 23-H), 0.94 (d, 3J12/11 = 6.6 Hz, 3H, 12-H)*, 0.91 (d, 3J17/14 = 
6.8 Hz, 3H, 17-H), 0.90 (d, 3J13/11 = 6.3 Hz, 3H, 13-H)*, 0.87 (s, 9H, 19-H), 0.78 (s, 3H, 10-H), 
0.65−0.55 (m, 6H, 22-H), 0.05 (s, 3H, 20-H)**, 0.04 (s, 3H, 21-H)* ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 144.9 (C-15), 113.0 (C-14), 77.8 (C-2), 69.9 (C-6), 56.8 (C-3), 
51.7 (C-1), 42.9 (C-7), 42.0 (C-9), 41.3 (C-4), 38.9 (C-14), 38.7 (C-8), 33.2 (C-5), 30.1 (C-11), 
26.1 (C-19), 24.3 (C-13)*, 22.3 (C-12)*, 20.3 (C-10), 18.5 (C-17), 18.0 (C-18), 7.3 (C-23), 5.6 (C-22), 
−3.4 (C-21)**, −4.6 (C-20)** ppm.  
 
EI-MS for C25H49O2Si2+ [(M−t-Bu)+]: calcd. 437.3266 
 found 437.3277. 
 
IR (ATR): ῦ/cm−1 = 3077 (w), 2955 (s), 2932 (s), 2875 (s), 1461 (w), 1414 (w), 1387 (w), 1368 (w), 
1255 (w), 1070 (m), 1044 (m), 1005 (w), 911 (w), 835 (m), 773 (w).  
 
[ ]20Dα  = +27.3 (c 0.33, CH2Cl2). 
 
 
Synthesis of Vinyl Iodide 308 
 
 
To a solution of alcohol 307[200] (910 mg, 4.02 mmol, 1.0 eq.) in DMF (9 mL) at 0 °C was sequentially 
added imidazole (765 mg, 11.2 mmol, 2.8 eq.) and Et3SiCl (944 μL, 5.64 mmol, 1.4 eq.). The mixture 
was allowed to warm to room temperature and was stirred for 3 h. The reaction was diluted with n-
pentane (25 mL) and was then quenched by addition of H2O (10 mL). The organic layer was separated 
and the aqueous layer was extracted with n-pentane (3 x 15 mL). The combined organic layers were 
washed with 10% aqueous NaCl (2 x 10 mL) and dried over MgSO4. The solvents were evaporated 
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under reduced pressure and the crude product was purified by flash column chromatography (silica, 
hexanes:Et2O = 50:1) to yield vinyl iodide 308 (1.27 g, 3.74 mmol, 93%) as a colorless liquid. 
 
Rf = 0.33 (hexanes:Et2O = 50:1). 
 
1H NMR (CDCl3, 300 MHz): δ = 5.86 (dq, 4J1/3 = 4J1/6 = 1.1 Hz, 1H, 1-H), 3.59 (t, 3J5/4 = 6.4 Hz, 2H, 
5-H), 2.27 (mC, 2H, 3-H), 1.84 (d, 4J6/1 = 1.1 Hz, 3H, 6-H), 1.71−1.62 (m, 2H, 4-H), 1.00−0.92 (m, 9H, 
8-H), 0.65−0.54 (m, 6H, 7-H) ppm. 
  
13C NMR (CDCl3, 75 MHz): δ = 147.9 (C-2), 74.8 (C-1), 62.1 (C-5), 36.0 (C-3), 31.0 (C-4), 
24.1 (C-6), 6.9 (C-8), 4.6 (C-7) ppm.  
 
EI-MS for C12H25OISi+ [M+]: calcd. 340.0714 
 found 340.0716. 
 
IR (ATR): ῦ/cm−1 = 2953 (s), 2912 (s), 2876 (s), 1458 (w), 1414 (w), 1378 (w), 1268 (w), 1239 (w), 
1142 (w), 1103 (s), 1007 (m), 959 (w), 770 (w), 743 (m). 
 
 
Synthesis of Aldehyde 312 
 
 
To a solution of alkene 299 (394 mg, 1.00 mmol, 1.0 eq.) in THF (6 mL) was added 9-BBN (237, 
4.00 mL of a 0.5M solution in THF, 2.00 mmol, 2.0 eq.) and the reaction was heated to 40 °C for 3 h. 
The reaction was allowed to cool to room temperature and degassed aqueous Cs2CO3 (3N, 1.16 mL, 
3.48 mmol, 3.5 eq.) was added. The mixture was vigorously stirred for 40 min and then degassed (N2 
bubbling for 5 min). Next, a solution of vinyl iodide 308 (510 mg, 1.50 mmol, 1.5 eq.) and AsPh3 (122 
mg, 400 μmol, 40 mol-%) in degassed DMF (10 mL) was added followed by addition of 
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Pd(dppf)Cl2 (complex with CH2Cl2, 81 mg, 0.10 mmol, 10 mol-%). The mixture was stirred for 16 h at 
room temperature, diluted with Et2O (20 mL), and was subsequently quenched by addition of 
H2O (10 mL). The phases were separated and the aqueous layer was extracted with Et2O (4 x 20 mL). 
The combined organic layers were washed with 10% aqueous NaCl (3 x 15 mL), which in turn were 
re-extracted with Et2O (2 x 20 mL). The combined organic layers were dried over MgSO4 and the 
solvents were evaporated under reduced pressure. The obtained crude product was purified by flash 
column chromatography (silica, hexanes:EtOAc = 1:0 to 100:1) to yield the desired coupling 
product 311 (564 mg, 930 μmol, 93%), which was immediately used in the next step. 
To a solution of DMSO (390 μL, 5.54 mmol, 6.0 eq.) in CH2Cl2 (10 mL) at −78 °C was added 
dropwise (COCl)2 (1.39 mL of a 2.0M solution in CH2Cl2, 2.77 mmol, 3.0 eq.) and the mixture was 
stirred for 15 min at this temperature. Then, a solution of bissilyl ether 311 (564 mg, ~930 μmol, 
1.0 eq.) in CH2Cl2 (3 mL + 1 mL rinse) was added within 30 min (syringe pump). The mixture was 
allowed to warm to −65 °C and was stirred between −65 and −60 °C (cryo cooler) for 6 h. The 
reaction was cooled to −78 °C and Et3N (1.50 mL, 11.1 mmol, 12 eq.) was added. The mixture was 
stirred for an additional 10 min at this temperature, was allowed to warm to 0 °C and stirred for an 
additional 15 min. The reaction was quenched by addition of H2O (10 mL) and the biphasic mixture 
was diluted with CH2Cl2 (20 mL). After phase separation, the aqueous layer was extracted with 
CH2Cl2 (3 x 20 mL) and the combined organic layers were washed with saturated aqueous NaCl 
(20 mL). The organic layer was dried over MgSO4 and the solvents were removed under reduced 
pressure. The crude product was purified by flash column chromatography (silica, hexanes:EtOAc = 
40:1 to 30:1) to yield aldehyde 312 (340 mg, 691 μmol, 69% over two steps) as a colorless oil. 
 
Analytical data for bissilyl ether 311: 
 
Rf = 0.23 (hexanes:EtOAc = 30:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.13 (br t, 3J16/15 = 7.1 Hz, 1H, 16-H), 4.05 (mC, 1H, 6-H), 3.58 (t, 
3J20/19 = 6.9 Hz, 2H, 20-H), 3.42 (dd, 3J1/2 = 8.6, 7.7 Hz, 1H, 1-H), 2.08−1.95 (mC, 1H, 15-HA), 
2.00 (mC, 2H, 18-H), 1.94−1.84 (m, 2H, 2-HA, 15-HB), 1.77−1.70 (m, 1H, 4-H), 1.66−1.61 (m, 2H, 
19-H), 1.60 (s, 3H, 22-H), 1.56−1.36 (m, 7H, 2-HB, 3-HA, 5-H, 8-HA, 13-H, 14-HA), 1.28−1.21 (m, 2H, 
3-HB, 7-H), 1.16−1.05 (m, 1H, 14-HB), 1.14 (s, 9H, 12-H), 1.08 (dd, 2J8B/8A = 3J8B/7 = 12.3 Hz, 1H, 
8-HB), 1.00−0.91 (m, 18H, 24-H, 26-H), 0.86 (d, 3J21/13 = 6.8 Hz, 3H, 21-H), 0.69 (s, 3H, 10-H), 
0.64−0.54 (m, 12H, 23-H, 25-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 134.2 (C-17), 125.2 (C-16), 81.0 (C-1), 72.3 (C-11), 70.0 (C-6), 
62.8 (C-20), 42.7 (C-9), 42.6 (C-7), 37.4 (C-4), 36.0 (C-18), 35.4 (C-8), 35.3 (C-14), 34.7 (C-5), 
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34.0 (C-13), 31.6 (C-2), 31.4 (C-19), 29.0 (C-12), 25.6 (C-3)*, 25.5 (C-15)*, 17.2 (C-21), 16.1 (C-22), 
11.1 (C-10), 7.2 (C-24)**, 7.0 (C-26)**, 5.5 (C-23)***, 4.6 (C-25)*** ppm.  
 
EI-MS for C36H72O3Si2+ [M+]: calcd. 608.5015 
 found 608.5014. 
 
Analytical data for aldehyde 312: 
 
Rf = 0.10 (hexanes:EtOAc = 30:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 9.76 (t, 3J20/19 = 2.0 Hz, 1H, 20-H), 5.16 (mC, 1H, 16-H), 4.04 (mC, 
1H, 6-H), 3.42 (dd, 3J1/2 = 8.8, 7.5 Hz, 1H, 1-H), 2.53−2.49 (m, 2H, 19-H), 2.31 (mC, 2H, 18-H), 
2.07−1.99 (m, 1H, 15-HA), 1.94−1.83 (m, 2H, 2-HA, 15-HB), 1.73 (dddd, J = 13.0, 13.0, 7.0, 3.3 Hz, 
1H, 4-H), 1.62 (s, 3H, 22-H), 1.57−1.34 (m, 7H, 2-HB, 3-HA, 5-H, 8-HA, 13-H, 14-HA), 1.29−1.21 (m, 
2H, 3-HB, 7-H), 1.18−1.03 (m, 2H, 8-HB, 14-HB), 1.14 (s, 9H, 12-H), 0.99−0.91 (m, 9H, 24-H), 
0.85 (d, 3J21/13 = 6.7 Hz, 3H, 21-H), 0.69 (s, 3H, 10-H), 0.62−0.55 (m, 6H, 23-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 202.8 (C-20), 132.5 (C-17), 126.4 (C-16), 81.0 (C-1), 72.3 (C-11), 
69.9 (C-6), 42.7 (C-9), 42.6 (C-7), 42.4 (C-14), 37.4 (C-4), 35.4 (C-8), 35.2 (C-14), 34.7 (C-5), 
34.0 (C-13), 32.1 (C-18), 31.6 (C-2), 29.0 (C-12), 25.6 (C-15), 25.5 (C-3), 17.2 (C-21), 16.2 (C-22), 
11.1 (C-10), 7.2 (C-24), 5.5 (C-23) ppm.  
 
EI-MS for C30H56O3Si+ [M+]: calcd. 492.3993 
 found 492.3992. 
 
IR (ATR): ῦ/cm−1 = 2954 (s), 2912 (s), 2987 (s), 2712 (w), 1729 (m), 1460 (w), 1288 (w), 1362 (w), 
1237 (w), 1196 (w), 1129 (w), 1063 (m), 1009 (w), 797 (w), 741 (w). 
 
[ ]20Dα  = +42.8 (c 0.25, CH2Cl2). 
 
 
Synthesis of Diene 317 
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To a suspension of Ph3PMeBr (717 mg, 2.01 mmol, 3.0 eq.) in THF (12 mL) at 0 °C was added 
n-BuLi (540 μL of a 2.5M solution in hexanes, 1.34 mmol, 2.0 eq.). The resulting mixture was allowed 
to warm to room temperature and was stirred for 1 h at this temperature before being cooled to −78 °C. 
Then, a solution of aldehyde 312 (330 mg, 670 μmol, 1.0 eq.) in THF (2 mL) was added dropwise. 
The cold bath was replaced by an ice/water bath and the mixture was stirred for 30 min at 0 °C. The 
reaction mixture was diluted with Et2O (10 mL) and quenched by addition of saturated aqueous 
NH4Cl (10 mL). The phases were separated and the aqueous layer was extracted with Et2O (3 x 
15 mL). The combined organic layers were washed with saturated aqueous NaCl (20 mL), dried over 
MgSO4 and the solvents were removed under reduced pressure. Purification of the crude product by 
flash column chromatography (silica, hexanes:EtOAc = 100:1 to 60:1) yielded diene 317 (313 mg, 
639 μmol, 95%) as a colorless oil.  
 
Rf = 0.48 (Hexanes:EtOAc = 30:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.81 (ddt, 3J20/21A = 17.1 Hz, 3J20/21B = 10.2 Hz, 3J20/19 = 6.5 Hz, 1H, 
20-H), 5.14 (mC, 1H, 16-H), 5.01 (mC, 1H, 21-HA), 4.93 (mC, 1H, 21-HB), 4.05 (mC, 1H, 6-H), 
3.42 (mC, 1H, 1-H), 2.18−2.12 (m, 2H, 19-H), 2.09−1.99 (m, 3H, 15-HA, 18-H), 1.94−1.85 (m, 2H, 
2-HA, 15-HB), 1.73 (dddd, J = 13.0, 13.0, 7.1, 3.3 Hz, 1H, 4-H), 1.61 (s, 3H, 23-H), 1.57−1.36 (m, 7H, 
2-HB, 3-HA, 5-H, 8-HA, 13-H, 14-HA), 1.29−1.21 (m, 2H, 3-HB, 7-H), 1.17−1.05 (m, 2H, 8-HB, 14-HB), 
1.15 (s, 9H, 12-H), 0.99−0.93 (m, 9H, 25-H), 0.86 (d, 3J22/13 = 6.8 Hz, 3H, 22-H), 0.69 (s, 3H, 10-H), 
0.63−0.53 (m, 6H, 24-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 139.0 (C-20), 134.0 (C-17), 125.5 (C-16), 114.3 (C-21), 81.0 (C-1), 
72.3 (C-11), 69.9 (C-6), 42.7 (C-9), 42.5 (C-7), 39.3 (C-18), 37.4 (C-4), 35.4 (2C, C-8, C-14), 
34.7 (C-5), 34.0 (C-13), 32.6 (C-19), 31.6 (C-2), 29.0 (C-12), 25.5 (2C, C-3, C-15), 17.2 (C-22), 
16.1 (C-23), 11.1 (C-10), 7.2 (C-25), 5.5 (C-24) ppm.  
 
EI-MS for C31H58O2Si+ [M+]: calcd. 490.4201 
 found 490.4199. 
 
IR (ATR): ῦ/cm−1 = 3078 (w), 2954 (s), 2932 (s), 2913 (s), 2876 (s), 1460 (w), 1414 (w), 1379 (w), 
1361 (w), 1237 (w), 1063 (m), 1046 (m), 1007 (w), 977 (w), 910 (w), 797 (w), 741 (w). 
 
[ ]20Dα  = +32.4 (c 0.50, CH2Cl2). 
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Synthesis of Ketone 319 
 
 
To a solution of silyl ether 317 (313 mg, 638 μmol, 1.0 eq.) in CH2Cl2/MeOH (7:1, 4.8 mL) was added 
(1R)-(−)-camphorsulfonic acid (30 mg, 0.13 mmol, 20 mol-%) and the mixture was stirred for 5 h at 
room temperature. The reaction was quenched by addition of saturated aqueous NaHCO3 (10 mL) and 
the biphasic mixture was extracted with CH2Cl2 (3 x 15 mL). The combined organic layers were 
washed with saturated aqueous NaCl (10 mL) and dried over MgSO4. The solvents were removed 
under reduced pressure to yield crude alcohol 318 as pale yellow oil which was used without further 
purification in the next step. 
To a suspension of crude alcohol 318 (assumed 638 μmol, 1.0 eq.) and NaHCO3 (161 mg, 1.92 mmol, 
3.0 eq.) in CH2Cl2 (6 mL) was added DMP (407 mg, 960 μmol, 1.5 eq.) and the mixture was stirred 
for 1.5 h at room temperature. The reaction was quenched by addition of saturated aqueous 
NaHCO3/saturated aqueous Na2S2O3/H2O (1:1:1, 10 mL) and the aqueous layer was extracted with 
CH2Cl2 (3 x 15 mL). The combined organic layers were washed with saturated aqueous NaCl (10 mL) 
and dried over MgSO4. After evaporation of the solvents under reduced pressure, the crude product 
was purified by flash column chromatography (silica, hexanes:EtOAc = 40:1 to 30:1) to yield 
ketone 319 (202 mg, 540 μmol, 85% over two steps) as a colorless oil. 
 
Rf = 0.39 (Hexanes:EtOAc = 10:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.80 (ddt, 3J20/21A = 17.1 Hz, 3J20/21B = 10.2 Hz, 3J20/19 = 6.6 Hz, 1H, 
20-H), 5.14 (mC, 1H, 16-H), 5.00 (mC, 1H, 21-HA), 4.93 (mC, 1H, 21-HB), 3.47 (dd, 3J1/2 = 8.9, 7.7 Hz, 
1H, 1-H), 2.36−2.29 (m, 2H, 5-HA, 7-H), 2.29−2.21 (m, 2H, 5-HB, 13-H), 2.18−2.10 (m, 2H, 19-H), 
2.07−2.03 (m, 2H, 18-H), 2.02−1.91 (m, 3H, 2-HA, 15-H), 1.87 (dd, 2J8A/8B = 12.6 Hz, 3J8A/7 = 6.4 Hz, 
1H, 8-HA), 1.68−1.54 (m, 3H, 2-HB, 3-HA, 4-H), 1.59 (s, 3H, 23-H), 1.43−1.35 (m, 1H, 3-HB), 
1.27−1.13 (m, 3H, 8-HB, 14-H), 1.15 (s, 9H, 12-H), 0.97 (s, 3H, 10-H), 0.76 (d, 3J22/13 = 6.7 Hz, 3H, 
22-H) ppm. 
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13C NMR (CDCl3, 150 MHz): δ = 212.5 (C-6), 138.9 (C-20), 134.7 (C-17), 124.8 (C-16), 
114.4 (C-21), 80.0 (C-1), 72.7 (C-11), 49.3 (C-7), 44.6 (C-4), 43.3 (C-5), 42.2 (C-9), 39.2 (C-18), 
35.5 (C-8), 34.9 (C-14), 32.5 (C-19), 31.9 (C-2), 30.7 (C-13), 28.9 (C-12), 26.1 (C-15), 25.9 (C-3), 
16.1 (C-22)*, 16.0 (C-23)*, 11.2 (C-10) ppm.  
 
EI-MS for C25H42O2+ [M+]: calcd. 374.3179 
 found 374.3178. 
 
IR (ATR): ῦ/cm−1 = 3076 (w), 2972 (s), 2931 (s), 2876 (s), 1706 (s), 1461 (w), 1388 (w), 1362 (w), 
1252 (w), 1192 (m), 1120 (w), 1062 (m), 903 (w). 
 
[ ]20Dα  = +7.8 (c 0.50, CH2Cl2). 
 
An analytical sample of alcohol 318 was obtained by flash column chromatography (silica, 
hexanes:EtOAc = 16:1) as a colorless oil: 
 
Rf = 0.16 (Hexanes:EtOAc = 16:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.80 (ddt, 3J20/21A = 16.9 Hz, 3J20/21B = 10.3 Hz, 3J20/19 = 6.6 Hz, 1H, 
20-H), 5.14 (mC, 1H, 16-H), 5.00 (mC, 1H, 21-HA), 4.93 (mC, 1H, 21-HB), 4.10 (mC, 1H, 6-H), 
3.44 (dd, 3J1/2 = 8.9, 7.4 Hz, 1H, 1-H), 2.18−2.12 (m, 2H, 19-H), 2.09−2.01 (m, 3H, 15-HA, 18-H), 
1.98−1.88 (m, 2H, 2-HA, 15-HB), 1.70−1.62 (m, 3H, 4-H, 5-HA, 8-HA), 1.60 (br s, 3H, 23-H), 
1.59−1.55 (m, 1H, 14-HA), 1.52−1.41 (m, 4H, 2-HB, 3-HA, 5-HB, 13-H), 1.37−1.31 (m, 1H, 7-H), 
1.30−1.24 (m, 1H, 3-HB), 1.23−1.15 (m, 2H, 14-HB, OH), 1.14 (s, 9H, 12-H), 1.02 (dd, 2J8B/8A = 3J8B/7 
= 12.9 Hz, 1H, 8-HB), 0.92 (d, 3J22/13 = 6.6 Hz, 3H, 22-H), 0.71 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 138.9 (C-20), 134.7 (C-17), 125.2 (C-16), 114.4 (C-21), 80.8 (C-1), 
72.4 (C-11), 68.4 (C-6), 42.8 (C-9), 42.0 (C-7), 39.2 (C-18), 37.6 (C-4), 36.0 (C-8), 35.6 (C-14), 
34.0 (C-5), 33.8 (C-13), 32.5 (C-19), 31.4 (C-2), 28.9 (C-12), 25.6 (C-3), 25.3 (C-15), 17.7 (C-22), 
16.2 (C-23), 11.0 (C-10) ppm.  
 
EI-MS for C25H44O2+ [M+]: calcd. 376.3336 
 found 376.3328. 
 
IR (ATR): ῦ/cm−1 = 3432 (br s), 3078 (w), 2973 (s), 2929 (s), 2913 (s), 2873 (s), 1461 (w), 1378 (w), 
1361 (m), 1254 (w), 1197 (m), 1063 (m), 1046 (m), 1004 (w), 907 (w), 880 (w), 861 (w). 
2 Experimental Procedures  185 
[ ]20Dα  = +27.6 (c 0.50, CH2Cl2). 
 
 
Synthesis of Alcohol 320 
 
 
In a Schlenk-tube was added t-BuLi (1.86 mL of a 1.7M solution in pentane, 3.16 mmol, 11.8 eq.) to 
Et2O (8 mL) at −78 °C followed by dropwise addition of 2-bromopropene (142 μL, 1.60 mmol, 
6.0 eq.). The resulting mixture was allowed to warm to 0 °C and was stirred for 30 min before being 
cooled to −78 °C. Then, a solution of ketone 319 (100 mg, 267 μmol, 1.0 eq.) in Et2O (2 mL) was 
added dropwise and the mixture was stirred for an additional 15 min. The reaction was quenched by 
addition of saturated aqueous NH4Cl (10 mL) at −78 °C and the mixture was allowed to warm to room 
temperature. The phases were separated and the aqueous layer was extracted with Et2O (3 x 20 mL). 
The combined organic layers were washed with saturated aqueous NaCl (15 mL) and dried over 
MgSO4. The solvents were evaporated under reduced pressure and the crude product was purified by 
flash column chromatography (silica, hexanes:EtOAc = 50:1) to yield alcohol 320 (102 mg, 245 μmol, 
92%) as a colorless oil and single diastereomer. 
 
Rf = 0.13 (Hexanes:EtOAc = 30:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.81 (ddt, 3J20/21A = 17.0 Hz, 3J20/21B = 10.1 Hz, 3J20/19 = 6.7 Hz, 1H, 
20-H), 5.14 (mC, 1H, 16-H), 5.09 (mC, 1H, 25-HA), 5.01 (mC, 1H, 21-HA), 4.94 (mC, 1H, 21-HB), 
4.88 (mC, 1H, 25-HB), 3.51 (dd, 3J1/2 = 9.0, 7.3 Hz, 1H, 1-H), 2.17−2.13 (m, 2H, 19-H), 2.07−2.03 (m, 
2H, 18-H), 1.96−1.89 (m, 3H, 2-HA, 15-H), 1.80−1.72 (m, 2H, 4-H, 7-H), 1.76 (br s, 3H, 26-H), 
1.65 (mC, 1H, 13-H), 1.59 (s, 3H, 23-H), 1.55 (br s, 1H, OH), 1.50−1.42 (m, 3H, 2-HB, 3-HA, 8-HA), 
1.31−1.17 (m, 6H, 3-HB, 5-H, 8-HB, 14-H), 1.15 (s, 9H, 12-H), 0.86 (d, 3J22/13 = 6.8 Hz, 3H, 22-H), 
0.76 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 151.7 (C-24), 138.9 (C-20), 134.7 (C-17), 125.0 (C-16), 
114.4 (C-21), 109.9 (C-25), 80.9 (C-1), 80.1 (C-6), 72.4 (C-11), 42.6 (C-9), 40.7 (C-7), 39.3 (C-4)*, 
39.2 (C-18)*, 39.1 (C-5)*, 38.0 (C-14), 32.9 (C-8), 32.6 (C-19), 31.5 (C-2), 31.2 (C-13), 29.0 (C-12), 
26.1 (C-15), 25.8 (C-3), 19.8 (C-26), 16.6 (C-22), 16.1 (C-23), 11.1 (C-10) ppm.  
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EI-MS for C28H48O2+ [M+]: calcd. 416.3649 
 found 416.3642. 
 
IR (ATR): ῦ/cm−1 = 3598 (br w), 3077 (w), 2973 (s), 2954 (s), 2932 (s), 2875 (s), 1401 (w), 1388 (w), 
1362 (w), 1254 (w), 1198 (m), 1125 (w), 1095 (w), 1063 (m), 991 (w), 903 (w). 
 
[ ]20Dα  = +26.4 (c 0.25, CH2Cl2). 
 
 
Synthesis of Vinyl Iodide 330 
 
 
To a solution of Cp2ZrCl2 (5.85 g, 20.0 mmol, 2.0 eq.) in THF (50 mL) at 0 °C was added 
DIBAL-H (20.0 mL of a 1.0M solution in toluene, 20.0 mmol, 2.0 eq.) within 1 h forming a white 
suspension. After stirring an additional 1.5 h at this temperature, a solution of alkyne 329[219] (2.19 g, 
10.0 mmol, 1.0 eq.) in THF (10 + 2 mL rinse) was added and the resulting mixture was heated to 
50 °C for 1.5 h at which point TLC analysis showed complete consumption of the starting material. 
The mixture was cooled to −78 °C and a solution of I2 (3.81 g, 15.0 mmol, 1.5 eq.) in THF (20 mL) 
was slowly added. The cold bath was exchanged with an ice/water bath and the solution was stirred for 
an additional 30 min at 0 °C. The reaction was quenched by addition of saturated aqueous 
Na2S2O3 (30 mL) and the mixture was diluted with half-saturated aqueous Rochelle salt (100 mL). 
After stirring vigorously at room temperature for 2.5 h, the layers were separated and the aqueous 
layer was extracted with Et2O (3 x 100 mL). The combined organic layers were washed with saturated 
aqueous NaCl (100 mL) and dried over MgSO4. Having evaporated the solvents under reduced 
pressure, the crude product was purified by flash column chromatography (silica, hexanes:EtOAc = 
30:1) to yield vinyl iodide 330 (2.08 g, 6.01 mmol, 60%) as a pale yellow liquid and as a 10:1 mixture 
of regioisomers as determined by 1H NMR spectroscopy. Further careful flash column 
chromatography (silica, hexanes:EtOAc = 60:1) yielded vinyl iodide 330 (1.48 g, 4.28 mmol, 43%) as 
a light yellow oil. 
 
Rf = 0.47 (Hexanes:EtOAc = 7:1). 
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1H NMR (CDCl3, 400 MHz): δ = 7.29−7.22 (m, 2H, 9-H), 6.91−6.84 (m, 2H, 10-H), 6.14 (tq, 3J2/3 = 
7.6 Hz, 4J2/6 = 1.6 Hz, 1H, 2-H), 4.42 (s, 2H, 7-H), 3.81 (s, 3H, 12-H), 3.42 (t, 3J 5/4 = 6.2 Hz, 2H, 5-H), 
2.37−2.35 (m, 3H, 6-H), 2.12 (mC, 2H, 3-H), 1.70−1.62 (m, 2H, 4-H) ppm. 
  
13C NMR (CDCl3, 100 MHz): δ = 159.3 (C-8), 140.7 (C-2), 130.7 (C-11), 129.4 (C-9), 113.9 (C-10), 
94.2 (C-1), 72.8 (C-7), 69.0 (C-5), 55.4 (C-12), 29.0 (C-4), 27.6 (C-6), 27.4 (C-3) ppm.  
 
EI-MS for C14H19IO2+ [M+]: calcd. 346.0424 
 found 346.0427. 
 
IR (ATR): ῦ/cm–1 = 2934 (m), 2854 (m), 1586 (w), 1512 (s), 1463 (w), 1363 (w), 1302 (w), 1245 (s), 
1098 (s), 1036 (m), 820 (w). 
 
The analytical data matched those reported previously.[219] 
 
 
Synthesis of Ketone 332 
 
 
To a solution of silyl ether 299 (300 mg, 761 μmol, 1.0 eq.) in CH2Cl2/MeOH (7:1, 8 mL) was added 
(1R)-(−)-camphorsulfonic acid (35 mg, 0.15 mmol, 20 mol-%) and the mixture was stirred for 4 h at 
room temperature. The reaction was diluted with CH2Cl2 (5 mL) and quenched by addition of 
saturated aqueous NaHCO3 (5 mL). The phases were separated and the aqueous layer was extracted 
with CH2Cl2 (3 x 5 mL). The combined organic layers were washed with saturated aqueous 
NaCl (5 mL) and dried over MgSO4. The solvents were evaporated under reduced pressure to yield 
crude alcohol 331 which was used without further purification. 
To a suspension of crude alcohol 331 (assumed 761 μmol, 1.0 eq.) and NaHCO3 (192 mg, 2.28 mmol, 
3.0 eq.) in CH2Cl2 at room temperature was added DMP (483 mg, 1.14 mmol, 1.5 eq.). The mixture 
was stirred for 2 h and the reaction was quenched by addition of saturated aqueous NaHCO3/saturated 
aqueous Na2S2O3/H2O (1:1:1, 8 mL). After extracting the mixture with CH2Cl2 (3 x 15 mL), the 
combined organic layers were washed with saturated aqueous NaCl (10 mL) and dried over MgSO4. 
The solvent was evaporated under reduced pressure and the crude product was purified by flash 
column chromatography (silica, hexanes:EtOAc = 40:1) to yield ketone 332 (191 mg, 687 μmol, 90% 
over two steps) as a colorless oil. 
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Rf = 0.47 (Hexanes:EtOAc = 10:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.82 (mC, 1H, 14-H), 5.02−4.96 (m, 2H, 15-H), 3.46 (dd, 3J1/2 = 8.9, 
7.8 Hz, 1H, 1-H), 2.87 (mC, 1H, 13-H), 2.42 (ddd, 3J7/8B = 12.9 Hz, 3J7/8A = 6.3 Hz, 3J7/13 = 3.5 Hz, 1H, 
7-H), 2.34−2.25 (m, 2H, 5-H), 2.02−1.94 (m, 1H, 2-HA), 1.88 (dd, 2J8A/8B = 12.8 Hz, 3J8A/7 = 6.3 Hz, 
1H, 8-HA), 1.65 (mC, 1H, 4-H), 1.61−1.54 (m, 2H, 2-HB, 3-HA), 1.43−1.36 (m, 1H, 3-HB), 1.21 (dd, 
2J8B/8A = 3J8B/7 = 12.8 Hz, 1H, 8-HB), 1.14 (s, 9H, 12-H), 0.97 (s, 3H, 10-H), 0.95 (d, 3J16/13 = 6.9 Hz, 
3H, 16-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 211.6 (C-6), 142.7 (C-14), 113.8 (C-15), 79.9 (C-1), 72.7 (C-11), 
49.9 (C-7), 45.0 (C-4), 43.4 (C-5), 42.4 (C-9), 36.8 (C-8), 35.7 (C-13), 31.9 (C-2), 28.8 (C-12), 
25.9 (C-3), 15.2 (C-16), 11.2 (C-10) ppm.  
 
EI-MS for C18H30O2+ [M+]: calcd. 278.2240 
 found 278.2241. 
 
IR (ATR): ῦ/cm−1 = 3073 (w), 2972 (s), 2874 (m), 1706 (s), 1461 (w), 1389 (w), 1362 (m), 1251 (w), 
1192 (m), 1122 (w), 1061 (m), 1001 (w), 901 (w). 
 
[ ]20Dα  = +43.1 (c 1.00, CH2Cl2). 
 
An analytical sample of alcohol 331 was obtained by flash column chromatography (silica, 
hexanes:EtOAc = 30:1) as a colorless wax:  
 
Rf = 0.31 (Hexanes:EtOAc = 10:1). 
 
1H NMR (CDCl3, 300 MHz): δ = 5.82 (ddd, 3J14/15A = 17.1 Hz, 3J14/15B = 10.2 Hz, 3J14/13 = 9.1 Hz, 1H, 
14-H), 5.07 (ddd, 3J15A/14 = 17.1 Hz, 2J15A/15B = 2.0 Hz, 4J15A/13 = 0.8 Hz, 1H, 15-HA), 4.98 (dd, 3J15B/14 = 
10.2 Hz, 2J15B/15A = 1.9 Hz, 1H, 15-HB), 3.98 (br s, 1H, 6-H), 3.45 (dd, 3J1/2 = 8.9, 7.7 Hz, 1H, 1-H), 
2.12 (mC, 1H, 13-H), 1.98−1.84 (m, 1H, 2-HA), 1.76−1.59 (m, 3H, 4-H, 5-HA, 8-HA), 1.55−1.23 (m, 
5H, 2-HB, 3-H, 5-HB, 7-H), 1.14 (s, 9H, 12-H), 1.07 (mC, 1H, 8-HB), 1.02 (d, 3J16/13 = 6.6 Hz, 3H, 
16-H), 0.71 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 75 MHz): δ = 144.5 (C-14), 113.5 (C-15), 80.7 (C-1), 72.4 (C-11), 68.0 (C-6), 
42.8 (2C, C-7, C-9), 40.8 (C-13), 37.6 (C-4), 36.3 (C-8), 33.3 (C-5), 31.4 (C-2), 28.9 (C-12), 
25.6 (C-3), 19.1 (C-16), 11.0 (C-10) ppm.  
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EI-MS for C18H32O2+ [M+]: calcd. 280.2397 
 found 280.2389. 
 
IR (ATR): ῦ/cm−1 = 3428 (br s), 3312 (br s), 3073 (w), 2973 (s), 2934 (s), 2902 (s), 1460 (w), 1389 
(w), 1361 (w), 1198 (w), 1168 (w), 1127 (w), 1071 (w), 1002 (w), 906 (w). 
 
[ ]20Dα  = +50.4 (c 0.5, CH2Cl2). 
 
 
Synthesis of Alcohol 333 
 
 
To a solution of vinyl iodide 330 (546 mg, 1.57 mmol, 3.0 eq.) in Et2O (15 mL) at −78 °C was added 
dropwise t-BuLi (1.79 mL of a 1.7M solution in pentane, 3.04 mmol, 5.8 eq.) and the mixture was 
stirred for 30 min at this temperature. Then, a solution of ketone 332 (145 mg, 520 μmol, 1.0 eq.) in 
Et2O (3 mL + 1 mL rinse) was added dropwise. After 15 min, the reaction was quenched by addition 
of saturated aqueous NH4Cl (10 mL). The mixture was allowed to warm to room temperature and was 
diluted with H2O (10 mL) and Et2O (20 mL). The phases were separated and the aqueous layer was 
extracted with Et2O (3 x 20 mL). The combined organic layers were washed with saturated aqueous 
NaCl (30 mL) and dried over MgSO4. Having evaporated the solvents under reduced pressure, the 
crude product was purified by flash column chromatography (silica, hexanes:EtOAc = 24:1) to yield 
title compound 333 (226 mg, 453 μmol, 87%) as a highly viscous colorless oil. 
 
The relative stereochemistry at C-6 was established by key NOE 
correlations as depicted aside.  
 
Rf = 0.15 (hexanes:EtOAc = 10:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.27−7.24 (m, 2H, 25-H), 6.87 (mC, 2H, 26-H), 5.78 (ddd, 3J14/15A = 
16.7 Hz, 3J14/15B = 10.9 Hz, 3J14/13 = 6.9 Hz, 1H, 14-H), 5.57 (mC, 1H, 18-H), 4.91−4.84 (m, 2H, 15-H), 
4.42 (mC, 2H, 23-H), 3.80 (s, 3H, 28-H), 3.50 (dd, 3J1/2 = 9.1, 7.4 Hz, 1H, 1-H), 3.44 (t, 3J21/20 = 
6.5 Hz, 2H, 21-H), 2.28 (mC, 1H, 13-H), 2.14 (mC, 2H, 19-H), 1.95−1.89 (m, 1H, 2-HA), 1.86 (ddd, 
3J7/8B = 12.7 Hz, 3J7/8A = 3.7 Hz, 3J7/13 = 2.3 Hz, 1H, 7-H), 1.78−1.64 (m, 4H, 4-H, 5-HA, 20-H), 
1.61 (s, 3H, 22-H), 1.49 (dd, 2J8A/8B = 12.4 Hz, 3J8A/7 = 3.7 Hz, 1H, 8-HA), 1.48−1.42 (m, 2H, 2-HB, 
H
MeH
OH
Ot-Bu
HH
OPMB
Me
H H
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3-HA), 1.30−1.22 (m, 2H, 3-HB, 8-HB), 1.17−1.09 (m, 1H, 5-HB), 1.15 (s, 9H, 12-H), 0.95 (d, 3J16/13 = 
6.8 Hz, 3H, 16-H), 0.74 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 159.3 (C-27), 145.5 (C-14), 141.4 (C-17), 130.9 (C-24), 
129.4 (C-25), 122.9 (C-18), 113.9 (C-26), 112.0 (C-15), 80.9 (C-1), 79.7 (C-6), 72.8 (C-23), 
72.4 (C-11), 69.7 (C-21), 55.4 (C-28), 42.6 (C-9), 40.2 (C-7), 39.3 (C-4), 39.2 (C-5), 36.5 (C-13), 
33.9 (C-8), 31.5 (C-2), 29.9 (C-20), 28.9 (C-12), 25.7 (C-3), 24.7 (C-19), 15.0 (C-16), 13.7 (C-22), 
10.9 (C-10) ppm.  
 
ESI-MS for C32H49O4− [(M−H)−]: calcd. 497.3636 
 found 497.3633. 
 
IR (ATR): ῦ/cm−1 = 3484 (br w), 3074 (w), 2971 (s), 2954 (s), 2869 (m), 1634 (w), 1587 (w), 
1513 (m), 1388 (w), 1362 (m), 1248 (m), 1196 (w), 1097 (m), 1061 (m), 1048 (m), 905 (w), 821 (w). 
 
[ ]20Dα  = +23.4 (c 0.50, CH2Cl2). 
 
 
Synthesis of Diol 334 
 
 
To a solution of PMB ether 333 (175 mg, 351 μmol, 1.0 eq.) in CH2Cl2/H2O (10:1, 22 mL) at 0 °C was 
added DDQ (159 mg, 708 μmol, 2.0 eq.) in one portion and the biphasic mixture was stirred 
vigorously for 2 h. The mixture was filtered over a pad of Celite® (washings with CH2Cl2) and the 
resulting solution was sequentially washed with saturated aqueous NaHCO3 (3 x 25 mL), H2O 
(20 mL) and saturated aqueous NaCl (20 mL), and dried over MgSO4. The solvents were evaporated 
under reduced pressure and the crude product was purified by flash column chromatography (silica, 
CH2Cl2:MeOH = 100:1) to yield diol 334 (99 mg, 262 μmol, 75%) as a pale yellow oil. 
 
Rf = 0.19 (hexanes:EtOAc = 4:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.79 (ddd, 3J14/15A = 16.7 Hz, 3J14/15B = 10.7 Hz, 3J14/13 = 7.0 Hz, 1H, 
14-H), 5.61 (mC, 1H, 18-H), 4.91−4.85 (m, 2H, 15-H), 3.67 (t, 3J21/20 = 6.5 Hz, 2H, 21-H), 3.50 (dd, 
3J1/2 = 9.1, 7.4 Hz, 1H, 1-H), 2.28 (mC, 1H, 13-H), 2.15 (mC, 2H, 19-H), 1.95−1.89 (m, 1H, 2-HA), 
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1.87 (ddd, 3J = 12.8, 3.7, 2.3 Hz, 1H, 7-H), 1.78−1.70 (m, 2H, 4-H, 5-HA), 1.70−1.64 (m, 2H, 20-H), 
1.63 (s, 3H, 22-H), 1.52−1.39 (m, 5H, 2-HB, 3-HA, 8-HA, OH), 1.30−1.22 (m, 2H, 3-HB, 8-HB), 
1.17−1.10 (m, 1H, 5-HB), 1.15 (s, 9H, 12-H), 0.96 (d, 3J16/13 = 7.0 Hz, 3H, 16-H), 0.74 (s, 3H, 
10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 145.4 (C-14), 141.6 (C-17), 122.7 (C-18), 112.1 (C-15), 80.9 (C-1), 
79.7 (C-6), 72.4 (C-11), 62.9 (C-21), 42.6 (C-9), 40.2 (C-7), 39.3 (C-4), 39.2 (C-5), 36.6 (C-13), 
34.0 (C-8), 32.8 (C-20), 31.5 (C-2), 28.9 (C-12), 25.7 (C-3), 24.4 (C-19), 15.1 (C-16), 13.7 (C-22), 
10.9 (C-10) ppm.  
 
ESI-MS for C24H42O3+ [M+]: calcd. 378.3128 
 found 378.3121. 
 
IR (ATR): ῦ/cm−1 = 3416 (br m), 3074 (w), 2972 (s), 2954 (s), 2946 (s), 2872 (s), 1461 (w), 1388 (w), 
1362 (m), 1254 (w), 1196 (m), 1129 (w), 1096 (w), 1061 (m), 905 (w). 
 
[ ]20Dα  = +34.7 (c 0.15, CH2Cl2). 
 
 
Synthesis of Alkyne 337 
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H
H
Me
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Et3N (6.0 eq.)
CH2Cl2, 78 °C, 30 min;
78 °C to 0 °C, 30 min
(5.0 eq.)
K2CO3 (7.5 eq.)
MeOH, 0 °C
to rt, 1 h
(78% over two
steps)
N2
O
(MeO)2P
O
334 335
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C25H40O2
M = 372.58 g/mol
H
336
 
To a solution of DMSO (55 μL, 0.78 mmol, 3.0 eq.) in CH2Cl2 (5 mL) at −78 °C was added dropwise 
(COCl)2 (195 μL of a 2.0M solution in CH2Cl2, 390 μmol, 1.5 eq.) and the mixture was stirred for 
30 min. Then, a solution of diol 334 (99 mg, 0.26 mmol, 1.0 eq.) in CH2Cl2 (2 mL) was added slowly 
and the reaction was stirred for an additional 30 min at −78 °C. After addition of Et3N (220 μL, 
1.56 mmol, 6.0 eq.), the cold bath was replaced by an ice/water bath and the mixture was stirred for 
30 min. The reaction was partitioned between H2O (10 mL) and CH2Cl2 (10 mL), and the aqueous 
layer was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were washed with 
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saturated aqueous NaCl (15 mL) and dried over MgSO4. The solvents were removed under reduced 
pressure and the crude product was purified by flash column chromatography (silica, hexanes:EtOAc 
= 7:1) to yield aldehyde 335, which was immediately used in the next step. 
To a solution of aldehyde 335 (assumed 0.26 mmol, 1.0 eq.) in MeOH (7 mL) at 0 °C was 
consecutively added K2CO3 (259 mg, 1.88 mmol, 7.5 eq.) and a solution of Ohira-Bestmann 
reagent (336, 243 mg, 1.25 mmol, 5.0 eq.) in MeOH (2 mL). The mixture was allowed to warm to 
room temperature and stirred for 1 h. The reaction was diluted with H2O (15 mL) and the mixture was 
extracted with Et2O (5 x 10 mL). The combined organic layers were washed with saturated aqueous 
NaCl (10 mL) and dried over MgSO4. The solvents were removed under reduced pressure and the 
crude product was purified by flash column chromatography (silica, hexanes:EtOAc = 40:1) to yield 
alkyne 337 (75 mg, 0.20 mmol, 78% over two steps) as a colorless oil. 
 
Rf = 0.13 (hexanes:EtOAc = 30:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.79 (ddd, 3J14/15A = 17.6 Hz, 3J14/15B = 9.8 Hz, 3J14/13 = 7.0 Hz, 1H, 
14-H), 5.63 (mC, 1H, 18-H), 4.91−4.85 (m, 2H, 15-H), 3.50 (dd, 3J1/2 = 9.2, 7.4 Hz, 1H, 1-H), 
2.36−2.22 (m, 5H, 13-H, 19-H, 20-H), 1.95−1.84 (m, 1H, 2-HA), 1.93 (t, 4J22/20 = 2.5 Hz, 1H, 22-H), 
1.87 (ddd, 3J = 12.7, 3.8, 2.3 Hz, 1H, 7-H), 1.78−1.70 (m, 2H, 4-H, 5-HA), 1.65 (s, 3H, 23-H), 
1.56 (br s, 1H, OH), 1.50 (dd, 2J8A/8B = 12.6 Hz, 3J8A/7 = 3.9 Hz, 1H, 8-HA), 1.48−1.41 (m, 2H, 2-HB, 
3-HA), 1.32−1.19 (m, 2H, 3-HB, 8-HB), 1.18−1.10 (m, 1H, 5-HB), 1.15 (s, 9H, 12-H), 0.96 (d, 3J16/13 = 
7.1 Hz, 3H, 16-H), 0.74 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 145.5 (C-14), 142.6 (C-17), 121.6 (C-18), 112.1 (C-15), 
84.5 (C-21), 80.9 (C-1), 79.8 (C-6), 72.4 (C-11), 68.4 (C-22), 42.6 (C-9), 40.2 (C-7), 39.3 (C-4), 
39.1 (C-5), 36.5 (C-13), 34.0 (C-8), 31.5 (C-2), 28.9 (C-12), 27.3 (C-19), 25.7 (C-3), 18.9 (C-20), 
16.1 (C-16), 13.8 (C-23), 10.9 (C-10) ppm. 
 
EI-MS for C25H39O2+ [(M−H)+]: calcd. 371.2945 
 found 371.2943. 
 
IR (ATR): ῦ/cm−1 = 3545 (br w), 3309 (m), 3076 (w), 2971 (s), 2871 (s), 1462 (w), 1388 (w), 
1361 (m), 1253 (w), 1196 (m), 1127 (w), 1095 (w), 1061 (m), 995 (w), 904 (w). 
 
[ ]20Dα  = +41.7 (c 0.33, CH2Cl2). 
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Synthesis of Vinyl Stannane 340 
 
 
To a solution of alkyne 337 (52 mg, 0.14 mmol, 1.0 eq.) in THF (5 mL) was added trimethyl(tri-n-
butylstannyl)silane (244 μL, 700 μmol, 5.0 eq.) and Pd(PPh3)4 (32 mg, 28 μmol, 20 mol-%). The 
yellow solution was heated to reflux for 5 h changing its color to dark brown. The reaction mixture 
was allowed to cool to room temperature and was diluted with hexanes (15 mL). The mixture was 
filtered over a pad of silica (washings with Et2O) and the solvents were removed under reduced 
pressure. The thus obtained orange crude oil was purified by flash column chromatography (silica, 
hexanes:EtOAc = 1:0 to 80:1) to yield stannane 340 (77 mg, 105 μmol, 75%) as a colorless oil. 
 
Rf = 0.18 (hexanes:EtOAc = 30:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 6.37 (br s, 1H, 22-H), 5.79 (mC, 1H, 14-H), 5.55 (mC, 1H, 18-H), 
4.91−4.85 (m, 2H, 15-H), 3.50 (dd, 3J1/2 = 9.0, 7.3 Hz, 1H, 1-H), 2.38−2.24 (m 3H, 13-H, 20-H), 
2.11−2.02 (m, 2H, 19-H), 1.95−1.89 (m, 1H, 2-HA), 1.87 (mC, 1H, 7-H), 1.79−1.69 (m, 2H, 4-H, 
5-HA), 1.63 (s, 3H, 23-H), 1.54−1.41 (m, 9H, 2-HB, 3-HA, 8-HA, 26-H), 1.32 (mC, 6H, 27-H), 
1.28−1.22, (m, 2H, 3-HB, 8-HB), 1.18−1.12 (m, 1H, 5-HB), 1.15 (s, 9H, 12-H), 1.01−0.83 (m, 18H, 
16-H, 25-H, 28-H), 0.74 (s, 3H, 10-H), 0.09 (s, 9H, 24-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 165.2 (C-21), 145.6 (C-14), 143.7 (C-22), 141.0 (C-17), 
122.8 (C-18), 112.0 (C-15), 80.9 (C-1), 79.7 (C-6), 72.4 (C-11), 47.2 (C-20), 42.6 (C-9), 40.3 (C-7), 
39.3 (2C, C-4, C-5), 36.6 (C-13), 34.1 (C-8), 31.5 (C-2), 29.4 (C-26), 28.9 (C-12), 28.6 (C-19), 
27.7 (C-27), 25.7 (C-3), 16.1 (C-16), 13.8 (2C, C-23, C-28), 11.4 (C-25), 10.9 (C-10), 0.4 (C-24) ppm. 
 
ESI-MS for C40H76O2SiSnCl− [(M+Cl)−]: calcd. 771.4331 
 found 771.4325. 
 
IR (ATR): ῦ/cm−1 = 3599 (br w), 3071 (w), 2953 (s), 2929 (s), 2871 (s), 2855 (m), 1463 (w), 1375 (w), 
1361 (w), 1246 (w), 1196 (w), 1128 (w), 1063 (w), 905 (w), 861 (w), 835 (w). 
 
[ ]20Dα  = +11.4 (c 0.33, CH2Cl2). 
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Synthesis of Vinyl Iodide 342 
 
 
 
To a solution of stannane 340 (74 mg, 0.10 mmol, 1.0 eq.) in CH2Cl2 (6 mL) at −40 °C was added 2,6-
di-tert-butyl-4-methylpyridine (341, 62 mg, 0.30 mmol, 3.0 eq.) followed by I2 (26 mg, 0.10 mmol, 
1.0 eq.). The yellow mixture was stirred at this temperature for 1.5 h and the reaction was then 
quenched by addition of saturated aqueous Na2S2O3 (7 mL). The mixture was diluted with H2O (7 mL) 
and CH2Cl2 (10 mL), and the phases were separated. The aqueous layer was extracted with 
CH2Cl2 (3 x 10 mL) and the combined organic layers were dried over Na2SO4. The solvents were 
evaporated under reduced pressure and the crude product was purified by flash column 
chromatography (silica, hexanes:EtOAc = 80:1 to 60:1) to yield vinyl iodide 342 (55 mg, 95 μmol, 
95%) as a colorless oil. 
 
Rf = 0.09 (hexanes:EtOAc = 30:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 6.33 (t, 4J22/20 = 1.0 Hz, 1H, 22-H), 5.79 (mC, 1H, 14-H), 5.55 (mC, 
1H, 18-H), 4.91−4.86 (m, 2H, 15-H), 3.50 (dd, 3J1/2= 8.9, 7.4 Hz, 1H, 1-H), 2.61 (mC, 2H, 20-H), 
2.33−2.23 (m, 3H, 13-H, 19-H), 1.95−1.90 (m, 1H, 2-HA), 1.87 (mC, 1H, 7-H), 1.76−1.70 (m, 2H, 4-H, 
5-HA), 1.66 (s, 3H, 23-H), 1.50 (dd, 2J8A/8B = 12.7 Hz, 3J8A/7 = 3.7 Hz, 1H, 8-HA), 1.48−1.41 (m, 2H, 
2-HB, 3-HA), 1.32−1.21 (m, 2H, 3-HB, 8-HB), 1.17−1.11 (m, 1H, 5-HB), 1.15 (s, 9H, 12-H), 0.96 (d, 
3J16/13 = 6.9 Hz, 3H, 16-H), 0.74 (s, 3H, 10-H), 0.18 (s, 9H, 24-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 145.4 (C-14), 142.4 (C-17), 137.4 (C-22), 122.8 (C-21), 
121.2 (C-18), 112.1 (C-15), 80.9 (C-1), 79.8 (C-6), 72.4 (C-11), 50.9 (C-20), 42.6 (C-9), 40.3 (C-7), 
39.4 (C-4)*, 39.3 (C-5)*, 36.5 (C-13), 34.0 (C-8), 31.4 (C-2), 28.9 (C-12), 28.0 (C-19), 25.7 (C-3), 
16.1 (C-16), 13.9 (C-23), 10.9 (C-10), −1.0 (C-24) ppm. 
 
ESI-MS for C28H48IOSi+ [(M−OH)+]: calcd. 555.2514 
 found 555.2510. 
 
IR (ATR): ῦ/cm−1 = 3560 (br w), 3072 (w), 2972 (s), 2955 (s), 2873 (m), 1595 (m), 1461 (w), 
1388 (w), 1361 (w), 1248 (m), 1196 (m), 1127(w), 1062 (w), 905 (w), 863 (w), 841 (m). 
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[ ]20Dα  = +32.0 (c 0.25, CH2Cl2). 
 
 
Synthesis of Vinyl Silane 343 
 
 
To a suspension of CuI (87 mg, 0.45 mmol, 5.0 eq.) in Et2O (5 mL) at −20 °C was added dropwise 
MeLi (0.57 mL of a 1.6M solution in Et2O, 0.91 mmol, 10 eq.) and the resulting pale yellow solution 
was stirred for an additional 15 min. Then, a solution of vinyl iodide 342 (52 mg, 91 μmol, 1.0 eq.) in 
Et2O (1.5 mL) was added dropwise and the reaction mixture was allowed to slowly warm to 0 °C. 
After stirring for an additional 60 min at 0 °C, the reaction was quenched by addition of saturated 
aqueous NH4Cl (5 mL) and the biphasic mixture was filtered over a pad of Celite® (washings with 
Et2O). The phases were separated and the aqueous layer was extracted with Et2O (3 x 10 mL). The 
combined organic layers were washed with saturated aqueous NaCl (10 mL) and dried over MgSO4. 
The solvents were evaporated under reduced pressure and the crude product was purified by flash 
column chromatography (silica, hexanes:EtOAc = 70:1 to 60:1) to yield vinyl silane 343 (36 mg, 
78 μmol, 86%) as a colorless oil. 
 
The C-21/C-22 double bond geometry has been verified to be (E) by 2D NOESY experiments, 
indicating a proximity between 24-H and 25-H. 
 
Rf = 0.18 (hexanes:EtOAc = 30:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.79 (mC, 1H, 14-H), 5.55 (mC, 1H, 18-H), 5.20 (mC, 1H, 22-H), 
4.91−4.84 (m, 2H, 15-H), 3.50 (dd, 3J1/2 = 9.0, 7.4 Hz, 1H, 1-H), 2.31−2.26 (m, 1H, 13-H), 
2.26−2.09 (m, 4H, 19-H, 20-H), 1.95−1.85 (m, 1H, 2-HA), 1.87 (ddd, 3J7/8B = 12.8 Hz, 3J7/8A = 3.6 Hz, 
3J7/13 = 2.3 Hz, 1H, 7-H), 1.78 (d, 4J24/22 = 0.8 Hz, 3H, 24-H), 1.77−1.69 (m, 2H, 4-H, 5-HA), 1.63 (s, 
3H, 23-H), 1.49 (dd, 2J8A/8B = 12.6 Hz, 3J8A/7 = 3.8 Hz, 1H, 8-HA), 1.48−1.41 (m, 2H, 2-HB, 3-HA), 
1.30−1.22 (m, 1H, 3-HB), 1.24 (dd, 2J8B/8A = 3J8B/7 = 12.7 Hz, 1H, 8-HB), 1.18−1.11 (m, 1H, 5-HB), 
1.15 (s, 9H, 12-H), 0.96 (d, 3J16/13 = 6.9 Hz, 3H, 16-H), 0.74 (s, 3H, 10-H), 0.09 (s, 9H, 25-H) ppm. 
 
13C NMR (CDCl3, 150 MHz): δ = 154.9 (C-21), 145.4 (C-14), 140.9 (C-17), 123.1 (C-22), 
122.8 (C-18), 111.8 (C-15), 80.7 (C-1), 79.5 (C-6), 72.3 (C-11), 42.4 (C-9), 42.2 (C-20), 40.1 (C-7), 
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39.1 (2C, C-4, C-5), 36.3 (C-13), 33.8 (C-8), 31.3 (C-2), 28.7 (C-12), 26.4 (C-19), 25.5 (C-3), 
21.6 (C-24), 15.9 (C-16), 13.5 (C-23), 10-7 (C-10), 0.1 (C-25) ppm. 
 
ESI-MS for C30H53O4Si− [(M+HCOO)−]: calcd. 505.3719 
 found 505.3719. 
 
IR (ATR): ῦ/cm−1 = 3598 (br w), 3073 (w), 2972 (s), 2955 (s), 2876 (m), 1618 (w), 1461 (w), 
1376 (w), 1362 (w), 1248 (m), 1197 (m), 1128 (w), 1062 (w), 906 (w), 866 (w), 838 (m). 
 
[ ]20Dα  = +28.4 (c 0.25, CH2Cl2). 
 
 
Synthesis of Alcohol 346 
 
 
To a solution of alcohol 300 (330 mg, 801 μmol, 1.0 eq.) in DMF (8 mL) was sequentially added 
imidazole (163 mg, 2.40 mmol, 3.0 eq.) and TBDPSCl (239 μL, 921 μmol, 1.1 eq.), and the mixture 
was stirred for 2 h at room temperature. The reaction was quenched by addition of H2O (8 mL) and the 
mixture was extracted with Et2O (4 x 15 mL). The combined organic layers were washed with 10% 
aqueous NaCl (3 x 8 mL) and subsequently dried over MgSO4. Having evaporated the solvents under 
reduced pressure, the crude product was subjected to a short flash column chromatography (silica, 
hexanes:EtOAc = 60:1) to yield bissilyl ether 462 (Rf = 0.37, hexanes:EtOAc = 16:1) as a colorless oil, 
which was directly used in the next step. 
To a solution of crude bissilyl ether 462 (assumed 801 μmol, 1.0 eq.) in CH2Cl2/MeOH (7:1, 12 mL) 
was added (1R)-(−)-camphorsulfonic acid (35 mg, 0.15 mmol, 20 mol-%) and the mixture was stirred 
for 3.5 h at room temperature. The reaction was quenched by addition of saturated aqueous 
NaHCO3 (8 mL) and the mixture was extracted with CH2Cl2 (3 x 15 mL). The combined organic 
layers were washed with saturated aqueous NaCl (10 mL) and dried over MgSO4. Having evaporated 
the solvents under reduced pressure, the crude product was purified by flash column 
chromatography (silica, n-pentane:Et2O = 8:1) to yield silyl ether 346 (345 mg, 644 μmol, 87% over 
two steps) as a colorless honey.  
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Rf = 0.30 (hexanes:EtOAc = 7:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.69−7.65 (m, 4H, 20-H)*, 7.44−7.40 (m, 2H, 22-H), 7.40−7.37 (m, 
4H, 21-H)*, 4.05 (mC, 1H, 6-H), 3.76−3.70 (m, 1H, 15-HA), 3.69−3.64 (m, 1H, 15-HB), 3.45 (mC, 1H, 
1-H), 1.93−1.84 (m, 2H, 2-HA, 14-HA), 1.73−1.58 (m, 4H, 4-H, 5-HA, 8-HA, 13-H), 1.51−1.40 (m, 4H, 
2-HB, 3-HA, 5-HB, OH), 1.34−1.23 (m, 3H, 3-HB, 7-H, 14-HB), 1.14 (s, 9H, 12-H), 1.05 (s, 9H, 18-H), 
1.04−0.99 (m, 1H, 8-HB), 0.85 (d, 3J16/13 = 6.8 Hz, 3H, 16-H), 0.68 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 135.8 (C-20)*, 134.0 (C-19), 129.7 (C-22), 127.8 (C-21)*, 
80.8 (C-1), 72.4 (C-11), 67.9 (C-6), 62.5 (C-15), 42.8 (C-9), 42.1 (C-7), 37.5 (C-4), 37.1 (C-14), 
36.2 (C-8), 33.7 (C-5), 31.5 (C-2), 3.1 (C-13), 28.9 (C-12), 27.1 (C-18), 25.6 (C-3), 19.3 (C-17), 
18.2 (C-16), 11.0 (C-10) ppm. 
 
ESI-MS for C34H53O3Si+ [(M+H)+]: calcd. 537.3758 
 found 537.3761. 
 
IR (ATR): ῦ/cm−1 = 3480 (br w), 3071 (w), 2981 (s), 2932 (s), 1472 (w), 1428 (w), 1389 (w), 
1361 (w), 1197 (w), 1112 (m), 1086 (m), 1063 (m), 702 (m). 
 
[ ]20Dα  = +22.8 (c 0.50, CH2Cl2). 
 
 
Synthesis of Ketone 347 
 
 
To a solution of DMSO (120 μL, 1.68 mmol, 3.0 eq.) in CH2Cl2 (15 mL) at −78 °C was added 
(COCl)2 (420 μL of a 2.0M solution in CH2Cl2, 840 μmol, 1.5 eq.) within 5 min and the mixture was 
stirred for 15 min. Then, a solution of alcohol 346 (300 mg, 560 μmol, 1.0 eq.) in CH2Cl2 (3 mL) was 
added slowly and the mixture was stirred for an additional 45 min prior to adding Et3N (470 μL, 3.36 
mmol, 6.0 eq.). The cold bath was replaced with an ice/water bath and the mixture was stirred at 0 °C 
for 30 min. The reaction was quenched by addition of H2O (20 mL) and the phases were separated. 
The aqueous layer was extracted with CH2Cl2 (3 x 20 mL) and the combined organic layers were 
washed with saturated aqueous NaCl (15 mL), and were dried over MgSO4. Having evaporated the 
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solvents under reduced pressure, the crude product was purified by flash column 
chromatography (silica, hexanes:EtOAc = 16:1) to yield ketone 347 as a colorless oil.  
Purification was carried out combined with a smaller reaction batch. Overall, alcohol 346 (320 mg, 
596 μmol) was converted to ketone 347 (305 mg, 571 μmol) in 96% yield. 
 
Rf = 0.47 (hexanes:EtOAc = 7:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.69−7.63 (m, 4H, 20-H)*, 7.43−7.40 (m, 2H, 22-H), 7.40−7.35 (m, 
4H, 21-H)*, 3.69−3.62 (m, 2H, 15-H), 3.45 (mC, 1H, 1-H), 2.40 (mC, 1H, 13-H), 2.01−1.95 (m, 3H, 
5-H, 7-H), 2.01−1.95 (m, 1H, 2-HA), 1.82 (dd, 2J8A/8B = 12.4 Hz, 3J8A/7 = 6.4 Hz, 1H, 8-HA), 
1.67−1.52 (m, 3H, 2-HB, 3-HA, 4-H), 1.51−1.47 (m, 2H, 14-H), 1.40−1.36 (m, 1H, 3-HB), 
1.20−1.14 (m, 1H, 8-HB), 1.15 (s, 9H, 12-H), 1.04 (s, 9H, 18-H), 0.89 (s, 3H, 10-H), 0.76 (d, 3J16/13 = 
6.8 Hz, 3H, 16-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 212.1 (C-6), 135.7 (C-20)*, 134.1 (C-19), 129.7 (C-22), 
127.7 (C-21)*, 80.0 (C-1), 72.7 (C-11), 62.5 (C-15), 49.2 (C-7), 44.7 (C-4), 43.2 (C-5), 42.3 (C-9), 
37.2 (C-14), 35.8 (C-8), 31.8 (C-2), 28.9 (C-12), 27.8 (C-13), 27.1 (C-18), 25.9 (C-3), 19.3 (C-17), 
16.4 (C-16), 11.2 (C-10) ppm. 
 
EI-MS for C33H47O3Si+ [(M−Me)+]: calcd. 519.3289 
 found 519.3283. 
 
IR (ATR): ῦ/cm–1 = 3072 (w), 2960 (s), 2931 (s), 2859 (s), 1705 (s), 1472 (m), 1428 (m), 1389 (w), 
1362 (m), 1253 (w), 1192 (m), 1109 (s), 1061 (s), 899 (w), 738 (w), 701 (s). 
 
[ ]20Dα  = +14.4 (c 1.00, CH2Cl2). 
 
 
Synthesis of Alcohol 348 
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330 (2.5 eq.)
t-BuLi (4.8 eq.)
Et2O, 78 °C
60 min
(60%)347 348
C48H70O5Si
M = 755.15 g/mol  
To a solution of vinyl iodide 330 (494 mg, 2.74 mmol, 2.5 eq.) in Et2O (15 mL) at −78 °C was added 
t-BuLi (1.61 mL of a 1.7M solution in pentane, 1.43 mmol, 4.8 eq.) and the resulting solution was 
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stirred for 30 min at this temperature. Then, a solution of ketone 347 (305 mg, 571 μmol, 1.0 eq.) in 
Et2O (4 mL) was added dropwise and the mixture was stirred for 60 min prior to quenching the 
reaction by addition of saturated aqueous NH4Cl (10 mL). The mixture was allowed to warm to room 
temperature and was diluted with H2O (10 mL) and Et2O (15 mL). The phases were separated and the 
aqueous layer was extracted with Et2O (3 x 20 mL). The combined organic layers were dried over 
MgSO4 and the solvents were evaporated under reduced pressure. The crude product was purified by 
flash column chromatography (silica, hexanes:EtOAc = 12:1 to 7:1) to yield alcohol 348 (260 mg, 
345 μmol, 60%) as a colorless oil and single isomer. 
 
Rf = 0.29 (hexanes:EtOAc = 7:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.67−7.63 (m, 4H, 32-H)*, 7.42−7.38 (m, 2H, 34-H), 7.38−7.34 (m, 
4H, 33-H)*, 7.24 (mC, 2H, 25-H), 6.86 (mC, 2H, 26-H), 5.54 (mC, 1H, 18-H), 4.40 (mC, 2H, 23-H), 
3.79 (s, 3H, 28-H), 3.65−3.58 (m, 2H, 15-H), 3.49 (dd, 3J1/2 = 9.0, 7.4 Hz, 1H, 1-H), 3.40 (t, 3J21/20 = 
6.5 Hz, 2H, 21-H), 2.14−2.02 (m, 2H, 19-H), 1.95−1.88 (m, 1H, 2-HA), 1.83−1.77 (m, 1H, 13-H), 
1.76−1.59 (m, 5H, 4-H, 5-HA, 7-H, 20-H), 1.55 (s, 3H, 22-H), 1.51−1.36 (m, 5H, 2-HB, 3-HA, 8-HA, 
14-H), 1.30−1.20 (m, 2H, 3-HB, 8-HB), 1.15 (s, 9H, 12-H), 1.09−1.01 (m, 1H, 5-HB), 1.03 (s, 9H, 
30-H), 0.77 (d, 3J16/13 = 6.9 Hz, 3H, 16-H), 0.71 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 159.2 (C-27), 141.3 (C-17), 135.7 (C-32)*, 134.2 (C-31), 
130.9 (C-24), 129.7 (C-34), 129.4 (C-25), 127.7 (C-33)*, 122.6 (C-18), 113.9 (C-26), 80.9 (C-1), 
80.1 (C-6), 72.7 (C-23), 72.4 (C-11), 69.8 (C-21), 62.4 (C-15), 55.4 (C-28), 42.6 (C-9), 40.6 (C-14), 
40.4 (C-7), 39.3 (C-4), 39.1 (C-5), 33.0 (C-8), 31.5 (C-2), 29.9 (C-20), 28.9 (C-12), 27.8 (C-13), 
27.0 (C-30), 25.8 (C-3), 24.7 (C-19), 19.3 (C-29), 16.4 (C-16), 13.6 (C-22), 11.0 (C-10) ppm. 
 
ESI-MS for C48H74O5NSi+ [(M+NH4)+]: calcd. 772.5331 
 found 772.5330. 
 
IR (ATR): ῦ/cm−1 = 3481 (br w), 3071 (w), 2933 (s), 2858 (s), 1513 (w), 1302 (w), 1248 (m), 
1196 (w), 1111 (m), 1093 (m), 1063 (w), 823 (w), 703 (w).  
 
[ ]20Dα  = +16.8 (c 0.33, CH2Cl2). 
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Synthesis of Diol 349 
 
 
To a solution of PMB ether 348 (260 mg, 345 μmol, 1.0 eq.) in CH2Cl2 (24 mL) and aqueous pH 7 
buffer (3 mL) at 0 °C was added DDQ (157 mg, 690 μmol, 2.0 eq.) in one portion. The biphasic 
mixture was allowed to warm to room temperature and was stirred for an additional 5 h prior to 
filtering over a pad of Celite® (washings with CH2Cl2, ca. 50 mL). The organic layer was washed with 
saturated aqueous NaHCO3 (3 x 20 mL) and the combined aqueous layers were re-extracted with 
CH2Cl2 (2 x 20 mL). The combined organic layers were washed with H2O (20 mL) and saturated 
aqueous NaCl (20 mL), and were dried over MgSO4. Having evaporated the solvents under reduced 
pressure, the crude product was purified by flash column chromatography (silica, CH2Cl2:MeOH = 
50:1) to yield diol 349 (204 mg, 321 μmol, 93%) as a colorless foam. 
 
Rf = 0.39 (hexanes:EtOAc = 7:3). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.66−7.62 (m, 4H, 26-H)*, 7.43−7.38 (m, 2H, 28-H), 7.38−7.34 (m, 
4H, 27-H)*, 5.56 (mC, 1H, 18-H), 3.65−3.55 (m, 4H, 15-H, 21-H), 3.48 (dd, 3J1/2 = 9.0, 7.3 Hz, 1H, 
1-H), 2.12−2.00 (m, 2H, 19-H), 1.93−1.87 (m, 1H, 2-HA), 1.83−1.77 (m, 1H, 13-H), 1.76−1.69 (m, 
2H, 4-H, 5-HA) 1.66 (mC, 1H, 7-H) 1.59 (mC, 2H, 20-H), 1.56 (s, 3H, 22-H), 1.51−1.35 (m, 5H, 2-HB, 
3-HA, 8-HA, 14-H), 1.29−1.19 (m, 3H, 3-HB, 8-HB, OH), 1.14 (s, 9H, 12-H), 1.10−1.07 (m, 1H, 5-HB), 
1.03 (s, 9H, 30-H), 0.77 (d, 3J16/13 = 6.9 Hz, 3H, 16-H), 0.71 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 141.5 (C-17), 136.7 (C-26)*, 134.2 (C-25), 129.7 (C-28), 
122.7 (C-27)*, 122.4 (C-18), 80.9 (C-1), 80.1 (C-6), 72.4 (C-11), 62.8 (C-21), 62.4 (C-15), 42.6 (C-9), 
40.6 (C-14), 40.5 (C-7), 39.3 (C-4), 39.1 (C-5), 33.0 (C-8), 32.8 (C-20), 31.5 (C-2), 28.9 (C-12), 
27.8 (C-13), 27.0 (C-24), 25.8 (C-3), 24.3 (C-19), 19.3 (C-23), 16.4 (C-16), 13.6 (C-22), 
11.0 (C-10) ppm. 
 
ESI-MS for C40H62O4NaSi+ [(M+Na)+]: calcd. 657.4310 
 found 657.4307. 
 
IR (ATR): ῦ/cm−1 = 3433 (br m), 3071 (w), 2932 (s), 2859 (s), 1472 (w), 1428 (w), 1389 (w), 
1362 (w), 1196 (w), 1112 (m), 1092 (m), 1062 (w), 901 (w), 824 (w).  
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[ ]20Dα  = +9.2 (c 0.50, CH2Cl2). 
 
 
Synthesis of Alkyne 350 
 
 
To a solution of DMSO (87 μL, 1.2 mmol, 4.0 eq.) in CH2Cl2 (7 mL) at −78 °C was added dropwise 
(COCl)2 (310 μL of a 2.0M solution in CH2Cl2, 620 μmol, 2.0 eq.) and the mixture was stirred for 
20 min. Then, a solution of diol 349 (195 mg, 308 μmol, 1.0 eq.) in CH2Cl2 (3 mL) was added within 
5 min and the reaction was stirred for an additional 2 h at −78 °C. After addition of Et3N (343 μL, 
2.46 mmol, 8.0 eq.), the cold bath was replaced by an ice/water bath and the mixture was stirred for 
60 min. The reaction mixture was partitioned between H2O (10 mL) and CH2Cl2 (15 mL), and the 
aqueous layer was extracted with CH2Cl2 (3 x 15 mL). The combined organic layers were washed with 
saturated aqueous NaCl (20 mL) and dried over MgSO4. The solvents were removed under reduced 
pressure and the crude product was purified by flash column chromatography (silica, hexanes:EtOAc 
= 5:1) to yield aldehyde 463 (176 mg, 278 μmol, 91%, Rf = 0.48, hexanes:EtOAc = 4:1) as a light 
yellow oil, which was immediately used in the next step. 
To a solution of aldehyde 463 (176 mg, 278 μmol, 1.0 eq.) in MeOH (7 mL) at 0 °C was sequentially 
added K2CO3 (345 mg, 2.50 mmol, 9.0 eq.) and a solution of Ohira-Bestmann reagent (336, 320 mg, 
1.67 mmol, 6.0 eq.) in MeOH (3 mL). The mixture was allowed to warm to room temperature and was 
stirred for 4 h prior to being diluted with H2O (10 mL). The biphasic mixture was extracted with 
Et2O (5 x 20 mL) and the combined organic layers were washed with saturated aqueous 
NaCl (15 mL), and dried over MgSO4. The solvents were removed under reduced pressure and the 
crude product was purified by flash column chromatography (silica, n-pentane:Et2O = 16:1 to 12:1) to 
yield alkyne 350 (141 mg, 230 μmol, 75% over two steps) as a colorless oil. 
 
Rf = 0.53 (hexanes:EtOAc = 7:1). 
 
202  EXPERIMENTAL SECTION 
1H NMR (CDCl3, 600 MHz): δ = 7.67−7.63 (m, 4H, 26-H)*, 7.44−7.40 (m, 2H, 27-H), 7.40−7.35 (m, 
4H, 25-H)*, 5.60 (mC, 1H, 18-H), 3.65−3.56 (m, 2H, 15-H), 3.49 (mC, 1H, 1-H), 2.29−2.15 (m, 4H, 
19-H, 20-H), 1.95−1.89 (m, 1H, 2-HA), 1.87 (t, 4J22/20 = 2.4 Hz, 1H, 22-H), 1.82 (mC, 1H, 13-H), 
1.77−1.69 (m, 2H, 4-H, 5-HA), 1.67 (mC, 1H, 7-H), 1.58 (s, 3H, 23-H), 1.50−1.38 (m, 5H, 2-HB, 3-HA, 
8-HA, 14-H), 1.33−1.19 (m, 2H, 3-HB, 8-HB), 1.15 (s, 9H, 12-H), 1.11 (mC, 1H, 5-HB), 1.04 (s, 9H, 
29-H), 0.78 (d, 3J16/13 = 7.0 Hz, 3H, 16-H), 0.72 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 142.5 (C-17), 135.7 (C-25)*, 134.2 (C-24), 129.7 (C-27), 
127.7 (C-26)*, 121.3 (C-18), 84.5 (C-21), 80.9 (C-1), 80.1 (C-6), 72.4 (C-11), 68.4 (C-22), 
62.4 (C-15), 42.6 (C-9), 40.6 (C-14), 40.4 (C-7), 39.3 (C-4), 39.1 (C-5), 33.0 (C-8), 31.5 (C-2), 
28.9 (C-12), 27.8 (C-13), 27.3 (C-19), 27.0 (C-29), 25.8 (C-3), 19.3 (C-28), 19.0 (C-20), 16.4 (C-16), 
13.7 (C-23), 11.0 (C-10) ppm. 
 
ESI-MS for C42H61O5Si− [(M+HCOO)−]: calcd. 673.4294 
 found 673.4304. 
 
IR (ATR): ῦ/cm−1 = 3311 (w), 3072 (w), 2957 (s), 2931 (s), 2857 (m), 1472 (w), 1428 (w), 1389 (w), 
1362 (w), 1259 (w), 1196 (w), 1111 (m), 1063 (w), 738 (w), 702 (w). 
 
[ ]20Dα  = +7.0 (c 0.25, CH2Cl2). 
 
 
Synthesis of Vinyl Iodide 357 
 
 
To a solution of vinyl iodide 356[238] (700 mg, 3.53 mmol, 1.0 eq.) in DMF (7 mL) was added 
imidazole (626 mg, 9.20 mmol, 2.6 eq.) and Et3SiCl (770 μL, 4.60 mmol, 1.3 eq.). The mixture was 
stirred for 2 h at room temperature before the reaction was quenched by addition of H2O (7 mL). The 
mixture was diluted with n-pentane (15 mL), the phases were separated and the aqueous layer was 
extracted with n-pentane (3 x 15 mL). The combined organic layers were washed with 10% aqueous 
NaCl (2 x 10 mL) and dried over MgSO4. Having evaporated the solvents under reduced pressure, the 
crude product was purified by flash column chromatography (silica, n-pentane:Et2O = 1:0 to 30:1) to 
yield vinyl iodide 357 (1.04 g, 3.33 mmol, 94%) as a colorless liquid. 
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Rf = 0.47 (hexanes:EtOAc = 30:1). 
 
1H NMR (CDCl3, 300 MHz): δ = 6.24−6.21 (m, 1H, 1-H), 4.11 (mC, 2H, 3-H), 1.79 (mC, 3H, 4-H), 
1.00−0.93 (m, 9H, 6-H), 0.66−0.56 (m, 6H, 5-H) ppm. 
  
13C NMR (CDCl3, 75 MHz): δ = 146.9 (C-2), 76.2 (C-1), 66.9 (C-3), 21.3 (C-4), 6.9 (C-6), 
4.6 (C-5) ppm. 
 
EI-MS for C10H21IOSi+ [M+]: calcd. 312.0401 
 found 312.0406. 
 
IR (ATR): ῦ/cm−1 = 2955 (s), 2910 (s), 2876 (s), 1458 (w), 1413 (w), 1377 (w), 1280 (w), 1250 (w), 
1143 (w), 1106 (m), 1007 (w), 815 (w), 744 (w). 
 
 
Synthesis of Diol 359 
 
 
To a solution of alkene 299 (624 mg, 1.58 mmol, 1.0 eq.) in THF (9.5 mL) was added 9-BBN (237, 
6.35 mL of a 0.5M solution in THF, 3.16 mmol, 2.0 eq.) and the resulting mixture was stirred at 40 °C 
for 3 h. The solution was cooled to 0 °C and degassed aqueous Cs2CO3 (3N, 1.9 mL, 5.53 mmol, 
3.5 eq.) was added. The mixture was stirred vigorously for 45 min at room temperature and a solution 
of vinyl iodide 357 (740 mg, 2.37 mmol, 1.5 eq.) and AsPh3 (193 mg, 632 μmol, 40 mol-%) in 
degassed DMF (15.8 mL) was added. The mixture was degassed (N2 bubbling for 5 min) and 
Pd(dppf)Cl2 (complex with CH2Cl2, 128 mg, 158 μmol, 10 mol-%) was added. The reaction mixture 
was stirred for 20 h at room temperature and was then diluted with H2O (20 mL) and Et2O (20 mL). 
The layers were separated and the aqueous layer was extracted with Et2O (4 x 20 mL). The combined 
organic layers were washed with 10% aqueous NaCl (3 x 20 mL) and the aqueous layers were re-
extracted with Et2O (2 x 20 mL). The combined organic layers were dried over MgSO4 and the 
solvents were evaporated under reduced pressure. The crude product was purified by flash column 
chromatography (silica, hexanes:EtOAc = 100:1 to 60:1) to yield bissilyl ether 358 (Rf = 0.2, 
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hexanes:EtOAc = 30:1, 700 mg, ~1.21 mmol, ~77%) as a yellow liquid, which was contaminated by 
some impurities and used without further purification in the next step. 
To a solution of crude bissilyl ether 358 (700 mg, 1.21 mmol, 1.0 eq.) in CH2Cl2/MeOH (5:1, 24 mL) 
was added (1R)-(−)-camphorsulfonic acid (112 mg, 480 μmol, 40 mol-%) and the solution was stirred 
for 6 h at room temperature. The reaction was quenched by addition of saturated aqueous 
NaHCO3 (15 mL) and the aqueous layer was extracted with CH2Cl2 (4 x 15 mL). The combined 
organic layers were washed with saturated aqueous NaCl (20 mL) and dried over MgSO4. Having 
evaporated the solvents under reduced pressure, the crude product was purified by flash column 
chromatography (silica, CH2Cl2:MeOH = 100:1 to 50:1) to yield diol 359 (350 mg, 994 μmol, 63% 
over two steps) as a pale yellow highly viscous oil. 
 
Rf = 0.19 (hexanes:EtOAc = 7:3). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.42 (mC, 1H, 16-H), 4.09 (mC, 1H, 6-H), 3.99 (s, 2H, 18-H), 
3.44 (dd, 3J1/2 = 8.8, 7.5 Hz, 1H, 1-H), 2.15−2.05 (m, 1H, 15-HA), 2.04−1.96 (m, 1H, 15-HB), 
1.95−1.85 (m, 1H, 2-HA), 1.70−1.56 (m, 4H, 4-H, 5-HA, 8-HA, 14-HA), 1.67 (s, 3H, 20-H), 
1.54−1.30 (m, 7H, 2-HB, 3-HA, 7-H, 13-H, 14-HB, OH), 1.30−1.18 (m, 2H, 3-HB, 5-HB), 1.13 (s, 9H, 
12-H), 1.02 (dd, 2J8A/8B = 3J8A/7 = 12.7 Hz, 1H, 8-HA), 0.92 (d, 3J19/13 = 6.7 Hz, 3H, 19-H), 0.71 (s, 3H, 
10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 134.9 (C-17), 126.8 (C-16), 80.8 (C-1), 72.4 (C-11), 69.2 (C-18), 
68.3 (C-6), 42.8 (C-9), 42.0 (C-7), 37.6 (C-4), 36.0 (C-8), 34.3 (C-5), 34.1 (C-14), 33.7 (C-13), 
31.4 (C-2), 28.9 (C-12), 25.6 (C-3), 25.1 (C-15), 17.6 (C-19), 13.9 (C-20), 11.0 (C-10) ppm. 
 
EI-MS for C22H38O2+ [(M−H2O)+]: calcd. 334.2866 
 found 334.2875. 
 
IR (ATR): ῦ/cm−1 = 3360 (br s), 2973 (s), 2930 (s), 2871 (s), 1461 (w), 1388 (w), 1361 (w), 1197 (w), 
1128 (w), 1063 (w), 1007 (w). 
 
[ ]20Dα  = +33.9 (c 0.50, CH2Cl2). 
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Synthesis of Alcohol 360 
 
 
To a solution of diol 359 (358 mg, 1.02 mmol, 1.0 eq.) in pyridine (10 mL) at 0 °C was added 
PivCl (213 μL, 1.73 mmol, 1.7 eq.). The mixture was allowed to warm to room temperature and was 
stirred for 4 h prior to being diluted with CH2Cl2 (60 mL). The solution was washed with HCl (2N, 
2 x 25 mL) and the combined aqueous layers were re-extracted with CH2Cl2 (3 x 25 mL). The 
combined organic layers were washed with saturated aqueous NaCl (20 mL) and dried over MgSO4. 
After evaporation of the solvents under reduced pressure, purification of the crude product by flash 
column chromatography (silica, hexanes:EtOAc = 10:1) afforded alcohol 360 (394 mg, 904 μmol, 
89%) as a colorless oil. 
 
Rf = 0.19 (hexanes:EtOAc = 10:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.44 (mC, 1H, 16-H), 4.44 (s, 2H, 18-H), 4.08 (mC, 1H, 6-H), 
3.44 (mC, 1H, 1-H), 2.15−2.07 (m, 1H, 15-HA), 2.04−1.96 (m, 1H, 15-HB), 1.95−1.87 (m, 1H, 2-HA), 
1.72−1.56 (m, 4H, 4-H, 5-HA, 8-HA, 14-HA), 1.64 (s, 3H, 20-H), 1.55−1.36 (m, 4H, 2-HB, 3-HA, 13-H, 
14-HB*), 1.36−1.32 (m, 1H, 7-H), 1.32−1.18 (m, 2H, 3-HB, 5-HB*), 1.21 (s, 9H, 23-H), 1.14 (s, 9H, 
12-H), 1.03 (dd, 2J8A/8B = 3J8A/7 = 12.7 Hz, 1H, 8-HA), 0.92 (d, 3J19/13 = 6.7 Hz, 3H, 19-H), 0.71 (s, 3H, 
10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 178.6 (C-21), 130.3 (C-17), 129.5 (C-16), 80.8 (C-1), 72.4 (C-11), 
70.2 (C-18), 68.3 (C-6), 42.9 (C-9), 42.0 (C-7), 39.0 (C-22), 37.5 (C-4), 35.9 (C-8), 34.2 (C-5)*, 
34.1 (C-14)*, 33.8 (C-13), 31.4 (C-2), 28.9 (C-12), 27.4 (C-23), 25.6 (C-3), 25.2 (C-15), 17.6 (C-19), 
14.0 (C-20), 11.0 (C-10) ppm. 
 
ESI-MS for C27H48O4Na+ [(M+Na)+]: calcd. 459.3445 
 found 459.3444. 
 
IR (ATR): ῦ/cm−1 = 3520 (br w), 2972 (s), 2933 (s), 2873 (m), 1730 (m), 1480 (w), 1461 (w), 
1388 (w), 1362 (w), 1284 (w), 1197 (w), 1156 (m), 1063 (w).  
 
[ ]20Dα  = +27.0 (c 1.00, CH2Cl2). 
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Synthesis of Ketone 361 
 
 
To a suspension of alcohol 360 (390 mg, 894 μmol, 1.0 eq.) and NaHCO3 (225 mg, 2.68 mmol, 
3.0 eq.) in CH2Cl2 (15 mL) was added DMP (568 mg, 1.34 mmol, 1.5 eq.) in one portion. The 
resulting mixture was stirred for 3 h at room temperature prior to quenching the reaction by addition of 
saturated aqueous NaHCO3/saturated aqueous Na2S2O3/H2O (1:1:1, 10 mL). The biphasic mixture was 
stirred vigorously at room temperature until two clear layers were obtained. The mixture was then 
diluted with CH2Cl2 (10 mL) and the aqueous layer was extracted with CH2Cl2 (3 x 15 mL). The 
combined organic layers were washed with saturated aqueous NaCl (20 mL) and were dried over 
MgSO4. Having evaporated the solvents under reduced pressure, the crude product was purified by 
flash column chromatography (silica, n-pentane:Et2O = 8:1 to 4:1) to yield ketone 361 (326 mg, 
751 μmol, 84%) as a colorless oil.  
 
Rf = 0.19 (hexanes:EtOAc = 10:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.44 (mC, 1H, 16-H), 4.44 (s, 2H, 18-H), 3.47 (dd, 3J1/2 = 9.0, 7.7 Hz, 
1H, 1-H), 2.37−2.19 (m, 4H, 5-H, 7-H, 13-H), 2.08−1.94 (m, 3H, 2-HA, 15-H), 1.87 (dd, 2J8A/8B = 
12.6 Hz, 3J8A/7 = 6.5 Hz, 1H, 8-HA), 1.68−1.50 (m, 3H, 2-HB, 3-HA, 4-H), 1.63 (s, 3H, 20-H), 
1.43−1.35 (m, 1H, 3-HB), 1.26 (mC, 2H, 14-H), 1.22−1.16 (m, 1H, 8-HB), 1.21 (s, 9H, 23-H), 1.15 (s, 
9H, 12-H), 0.97 (s, 3H, 10-H), 0.79 (d, 3J19/13 = 6.8 Hz, 3H, 19-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 212.4 (C-6), 178.5 (C-21), 130.5 (C-17), 129.0 (C-16), 80.0 (C-1), 
72.7 (C-11), 70.1 (C-18), 49.4 (C-7), 44.6 (C-4), 43.2 (C-5), 42.3 (C-9), 39.0 (C-22), 35.7 (C-8), 
34.4 (C-14), 31.9 (C-2), 30.8 (C-13), 28.9 (C-12), 27.5 (C-23), 26.0 (C-15)*, 25.9 (C-3)*, 16.0 (C-14), 
13.9 (C-20), 11.2 (C-10) ppm. 
 
ESI-MS for C27H46O4Na+ [(M+Na)+]: calcd. 457.3288 
 found 457.3287. 
 
IR (ATR): ῦ/cm−1 = 2970 (s), 2933 (s), 2872 (s), 1727 (s), 1705 (s), 1479 (w), 1460 (w), 1389 (w), 
1362 (m), 1282 (m), 1192 (m), 1151 (s), 1061 (m), 1031 (w), 901 (w).  
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[ ]20Dα  = +6.0 (c 0.50, CH2Cl2). 
 
 
Synthesis of Vinyl Iodide 364 
 
 
To a solution of alcohol 363[240] (297 mg, 1.50 mmol, 1.0 eq.) in DMF (3 mL) was consecutively 
added imidazole (265 mg, 3.90 mmol, 2.6 eq.) and TBSCl (271 mg, 1.80 mmol, 1.2 eq.), and the 
mixture was stirred for 2.5 h at room temperature. The reaction was quenched by addition of 
H2O (7 mL) and the mixture was diluted with n-pentane (15 mL). The phases were separated and the 
aqueous layer was extracted with n-pentane (3 x 10 mL). The combined organic layers were washed 
with 10% aqueous NaCl (2 x 7 mL) and dried over MgSO4. Having evaporated the solvents under 
reduced pressure, the crude product was purified by flash column chromatography (silica, 
n-pentane:Et2O = 1:0 to 30:1) to yield vinyl iodide 364 (413 mg, 1.32 mmol, 88%) as a pale yellow 
liquid. 
The double bond configuration was verified to be (E) by 2D NOESY experiments indicating a 
proximity between 3-H and 4-H. 
 
Rf = 0.43 (hexanes:EtOAc = 30:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 6.29 (tq, 3J2/3 = 6.5 Hz, 4J2/4 = 1.4 Hz, 1H, 2-H), 4.12 (d, 3J3/2 = 
6.4 Hz, 2H, 3-H), 2.41 (br s, 3H, 4-H), 0.90 (s, 9H, 6-H), 0.07 (s, 6H, 7-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 140.8 (C-2), 96.1 (C-1), 60.8 (C-3), 28.2 (C-4), 26.0 (C-6), 
18.5 (C-5), −5.1 (C-7) ppm. 
 
EI-MS for C10H21IOSi+ [M+]: calcd. 312.0401 
 found 312.0382. 
 
IR (ATR): ῦ/cm−1 = 2954 (s), 2929 (s), 2885 (m), 2857 (s), 1472 (w), 1463 (w), 1380 (w), 1256 (m), 
1089 (s), 1042 (m), 836 (s), 776 (m). 
 
The analytical data matched those reported previously.[241] 
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Synthesis of Alcohol 365 
 
 
To a solution of vinyl iodide 364 (350 mg, 1.12 mmol, 1.6 eq.) in Et2O (7 mL) at −78 °C was slowly 
added t-BuLi (1.27 mL of a 1.7M solution in pentane, 2.16 mmol, 3.1 eq.) and the mixture was stirred 
for 30 min at this temperature. The thus obtained solution of the corresponding vinyl lithium species 
was added dropwise via cannula to a solution of ketone 361 (318 mg, 696 μmol, 1.0 eq.) in 
Et2O (14 mL) at −78 °C. The mixture was stirred for an additional 2 h and the reaction was quenched 
by addition of half-saturated aqueous NH4Cl (25 mL). The phases were separated and the aqueous 
layer was extracted with Et2O (3 x 25 mL). The combined organic layers were washed with saturated 
aqueous NaCl (15 mL) and dried over MgSO4. Having evaporated the solvents under reduced 
pressure, the crude product was purified by flash column chromatography (silica, hexanes:EtOAc = 
30:1) to yield tertiary alcohol 365 (330 mg, 539 μmol, 77%) as a colorless oil and single isomer. 
 
Rf = 0.14 (hexanes:EtOAc = 16:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.73 (mC, 1H, 22-H), 5.41 (mC, 1H, 16-H), 4.43 (s, 2H, 18-H), 
4.27 (mC, 2H, 23-H), 3.50 (dd, 3J1/2 = 9.0, 7.5 Hz, 1H, 1-H), 1.99−1.88 (m, 3H, 2-HA, 15-H), 
1.79−1.71 (m, 3H, 4-H, 5-HA, 7-H), 1.68−1.53 (m, 1H, 13-H), 1.62 (s, 3H, 20-H), 1.60 (s, 3H, 24-H), 
1.50−1.41 (m, 3H, 2-HB, 3-HB, 8-HA), 1.31−1.18 (m, 4H, 3-HB, 8-HB, 14-H), 1.21 (s, 9H, 30-H), 
1.18−1.10 (m, 1H, 5-HB), 1.15 (s, 9H, 12-H), 1.09 (br s, 1H OH), 0.91 (s, 9H, 27-H), 0.85 (d, 3J19/13 = 
6.9 Hz, 3H, 19-H), 0.75 (s, 3H, 10-H), 0.08 (s, 6H, 25-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 178.5 (C-28), 141.6 (C-21), 130.3 (C-17), 129.4 (C-16), 
124.1 (C-22), 80.9 (C-1), 79.9 (C-6), 72.4 (C-11), 70.2 (C-18), 60.9 (C-23), 42.6 (C-9), 39.8 (C-7), 
39.2 (C-29)*, 39.0 (C-4)*, 38.8 (C-5), 37.4, (C-14), 32.9 (C-8), 31.5 (2C, C-2, C-13), 28.9 (C-12), 
27.4 (C-30), 26.2 (C-27), 26.1 (C-15), 25.8 (C-3), 18.5 (C-26), 16.7, (C-19), 13.9 (C-20), 13.8 (C-24), 
11.1 (C-10), −4.9 (C-25) ppm. 
 
ESI-MS for C37H72O5NSi+ [(M+NH4)+]: calcd. 638.5174 
 found 638.5173. 
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IR (ATR): ῦ/cm−1 = 3529 (br w), 2956 (s), 2932 (s), 2878 (m), 1730 (m), 1462 (w), 1388 (w), 
1283 (w), 1254 (w), 1196 (w), 1155 (m), 1062 (m), 836 (w).  
 
[ ]20Dα  = +19.8 (c 0.50, CH2Cl2). 
 
 
Synthesis of Diol 366 
 
 
To a solution of pivalate 365 (330 mg, 531 μmol, 1.0 eq.) in CH2Cl2 (25 mL) at −78 °C was slowly 
added DIBAL-H (1.86 mL of a 1.0M solution in toluene, 1.86 mmol, 3.5 eq.) and the resulting mixture 
was stirred for 30 min. Due to incomplete conversion, another aliquot of DIBAL-H (400 μL of a 1.0M 
solution in toluene, 400 μmol, 0.75 eq.) was added and the mixture was stirred for an additional 
15 min. The reaction was quenched by addition of half-saturated aqueous Rochelle salt (25 mL) and 
the biphasic mixture was vigorously stirred at room temperature for 2 h. The layers were separated and 
the aqueous layer was extracted with CH2Cl2 (4 x 20 mL). The combined organic layers were washed 
with saturated aqueous NaCl (20 mL) and were dried over MgSO4, Having evaporated the solvents 
under reduced pressure, the crude product was purified by flash column chromatography (silica, 
n-pentane:Et2O = 4:1) to yield diol 366 (241 mg, 449 μmol, 85%) as a colorless oil. 
 
Rf = 0.42 (hexanes:EtOAc = 4:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.72 (mC, 1H, 22-H), 5.37 (mC, 1H, 16-H), 4.27 (mC, 2H, 23-H), 
3.98 (mC, 2H, 18-H), 3.50 (dd, 3J1/2 = 9.0, 7.4 Hz, 1H, 1-H), 1.98−1.89 (m, 3H, 2-HA, 15-H), 
1.79−1.70 (m, 3H, 4-H, 5-HA, 7-H), 1.65 (s, 3H, 20-H), 1.64−1.59 (m, 1H, 13-H), 1.60 (s, 3H, 24-H), 
1.50−1.41 (m, 4H, 2-HB, 3-HB, 8-HA OH), 1.32−1.17 (m, 5H, 3-HB, 8-HB, 14-H, OH), 1.17−1.10 (m, 
1H, 5-HB), 1.15 (s, 9H, 12-H), 0.91 (s, 9H, 28-H), 0.85 (d, 3J19/13 = 6.8 Hz, 3H, 19-H), 0.75 (s, 3H, 
10-H), 0.08(2) (s, 3H, 25-H)*, 0.08(0) (s, 3H, 26-H)* ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 141.7 (C-21), 134.8 (C-17), 126.5 (C-16), 124.0 (C-22), 80.9 (C-1), 
79.9 (C-6), 72.4 (C-11), 69.1 (C-18), 61.0 (C-23), 42.6 (C-9), 39.8 (C-7), 39.2 (C-4), 38.8 (C-5), 
37.6 (C-14), 32.9 (C-8), 31.5 (C-2), 31.2 (C-13), 28.9 (C-12), 26.2 (C-28), 25.8 (2C, C-3, C-15), 
18.6 (C-27), 16.7 (C-19), 13.8 (2C, C-20, C-24), 11.0 (C-10), −4.8 (C-25)*, −4.9 (C-26)* ppm. 
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ESI-MS for C32H60O4NaSi+ [(M+Na)+]: calcd. 559.4153 
 found 559.4152. 
 
IR (ATR): ῦ/cm−1 = 3410 (br m), 2954 (s), 2931 (s), 2858 (s), 1472 (w), 1463 (w), 1388 (w), 1362 (w), 
1255 (w), 1196 (w), 1062 (m), 836 (w) 776 (w). 
  
[ ]20Dα  = +18.4 (c 0.50, CH2Cl2). 
 
 
Synthesis of Sulfone 367 
 
 
To a solution of diol 366 (14 mg, 26 μmol, 1.0 eq.) in CH2Cl2 at 0 °C was sequentially added 
imidazole (4.6 mg, 68 μmol, 2.6 eq.), PPh3 (14 mg, 52 μmol, 2.0 eq.) and I2 (13 mg, 52 μmol, 2.0 eq.) 
and the reaction was stirred for 30 min. The mixture was diluted with n-pentane (10 mL) and filtered 
over a short plug of silica (eluted with n-pentane:Et2O = 4:1). The product containing fractions were 
carefully evaporated under reduced pressure (water bath temperature: 30 °C) to yield an intermediate 
allylic iodide (Rf = 0.68, hexanes:EtOAc = 7:1) which was used without further purification. 
To a solution of crude allylic iodide (assumed 26 μmol, 1.0 eq.) in DMF (2 mL) was added 
NaSO2p-tol (14 mg, 78 μmol, 3.0 eq.) in one portion and the mixture was stirred for 2.5 h in the dark. 
The reaction was quenched by addition of H2O (3 mL) and the biphasic mixture was extracted with 
Et2O (4 x 5 mL). The combined organic layers were washed with 10% aqueous NaCl (3 x 3 mL) and 
dried over MgSO4. The solvents were removed under reduced pressure and the crude product was 
purified by flash column chromatography (silica, n-pentane:Et2O = 7:1 to 5:1) to yield allylic 
sulfone 367 (8 mg, 12 μmol, 46% over two steps) as a colorless oil.  
 
The product was contaminated by ca. 25% of an unknown impurity. Based on the 13C NMR spectrum, 
this compound is presumably a diastereomer, the structure of which needs to be elucidated in future 
experiments. 
 
Rf = 0.53 (hexanes:EtOAc = 4:1). 
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1H NMR (CDCl3, 600 MHz, major isomer quoted): δ = 7.72 (mC, 2H), 7.33 (mC, 2H), 5.71 (mC, 1H) 
5.09 (mC, 1H), 4.26 (mC, 2H), 3.76 (s, 2H), 3.50 (dd, J = 9.0, 7.4 Hz, 1H), 2.45 (s, 3H), 1.99−1.80 (m, 
3H), 1.78−1.64 (m, 6H), 1.63−1.33 (m, 7H), 1.29−1.22 (m, 2H), 1.18−1.08 (m, 1H), 1.16 (s, 9H), 
1.06 (br s, 1H), 1.03−0.97 (m, 2H), 0.90 (s, 9H), 0.80 (d, J = 6.8 Hz, 3H), 0.75 (s, 3H), 
0.07 (s, 6H) ppm. 
  
13C NMR (CDCl3, 150 MHz, major isomer quoted): δ = 144.5 (Cq), 141.5 (Cq), 136.5 (CH), 
135.7 (Cq), 129.6 (CH), 128.7 (CH), 124.1 (CH), 123.3 (Cq), 80.9 (CH), 79.8 (Cq), 72.5 (Cq), 
66.5 (CH2), 60.9 (CH2), 42.6 (Cq), 39.8 (CH), 39.1 (CH), 38.8 (CH2), 37.0 (CH2), 32.9 (CH2), 
31.6 (CH2)*, 31.5 (CH)*, 29.0 (CH3), 26.9 (CH2), 26.2 (CH3), 25.8 (CH2), 21.8 (CH3), 18.5 (Cq), 
16.8 (CH3), 16.6 (CH3), 13.8 (CH3), 11.1 (CH3), −4.8(5) (CH3), −4.9(0) (CH3) ppm. 
 
ESI-MS for C39H70O5NSSi+ [(M+NH4)+]: calcd. 692.4738 
 found 692.4733. 
 
IR (ATR): ῦ/cm−1 = 3518 (br w), 2951 (s), 2857 (m), 1463 (w), 1361 (w), 1315 (w), 1256 (w), 
1197 (w), 1132 (w), 1088 (w), 1062 (w), 835 (w).  
 
Since the product had been obtained as a mixture of isomers, the specific optical rotation was not 
determined. 
 
 
Synthesis of Vinyl Iodide 378 
 
 
To a solution of vinyl iodide 377[249] (630 mg, 3.00 mmol, 1.0 eq.) in THF/DMF (2:1, 12 mL) at 0 °C 
was added NaH (60% in mineral oil, 228 mg, 5.70 mmol, 1.9 eq.) in one portion and the resulting 
suspension was stirred for 20 min at this temperature. Then, PMBCl (560 μL, 4.13 mmol, 1.4 eq.) was 
slowly added and the mixture was allowed to warm to room temperature. After stirring for an 
additional 3 h, the reaction was carefully quenched with saturated aqueous NH4Cl (15 mL) and the 
biphasic mixture was stirred for 30 min prior to diluting with H2O (10 mL). The layers were separated 
and the aqueous layer was extracted with Et2O (3 x 30 mL). The combined organic layers were 
sequentially washed with saturated aqueous CuSO4 (10 mL), saturated aqueous NaHCO3 (10 mL) and 
saturated aqueous NaCl (10 mL), and dried over MgSO4. After evaporation of the solvents under 
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reduced pressure, the crude product was purified by flash column chromatography (silica, 
hexanes:EtOAc = 20:1) to yield vinyl iodide 378 (810 mg, 2.46 mmol, 82%) as a colorless oil. 
 
Rf = 0.58 (hexanes:EtOAc = 4:1). 
 
1H NMR (CDCl3, 300 MHz): δ = 7.34 (mC, 2H, 8-H), 6.89 (mC, 2H, 9-H), 6.35 (mC, 1H, 2-H), 
4.58−4.49 (m, 3H, 5-H, 6-H), 3.81 (s, 3H, 11-H), 2.54−2.43 (m, 1H, 3-HA), 2.34−2.10 (m, 2H, 3-HB, 
4-HA), 2.00−1.89 (m, 1H, 4-HB) ppm. 
 
13C NMR (CDCl3, 75 MHz): δ = 159.4 (C-10), 143.7 (C-2), 130.6 (C-7), 129.6 (C-8), 113.8 (C-9), 
96.7 (C-1), 88.2 (C-5), 70.5 (C-6), 55.4 (C-11), 33.1 (C-3), 29.1 (C-4) ppm. 
 
EI-MS for C13H15IO2+ [M+]: calcd. 330.0111 
 found 330.0113. 
 
IR (ATR): ῦ/cm–1 = 2998 (w), 2934 (m), 2848 (m), 1612 (m), 1586 (w), 1512 (s), 1463 (w), 1339 (w), 
1302 (w), 1245 (s), 1172 (m), 1158 (w), 1075 (m), 1034 (s), 922 (w), 889 (w), 821 (m). 
 
[ ]20Dα  = +2.2 (c 1.00, CHCl3). 
 
The analytical data matched those reported previously.[251] 
 
 
Synthesis of PMB Ether 379 
 
9-BBN (237, 2.0 eq.)
THF, 40 °C, 3 h;
Cs2CO3 (3.5 eq.)
THF/H2O, rt, 40 min;
378 (1.3 eq.)
AsPh3 (40 mol-%)
Pd(dppf)Cl2 (10 mol-%)
DMF, rt, 24 h
H
Me O
O
O Me
H
379
C37H62O4Si
M = 598.97 g/mol
O
1
2
34
9
5
6
7
8
11
12
10
13
14
15
16
17
18
19
20
22
2324
25
26
27
21
Si
28
29
Me
H
Ot-Bu
Et3SiO
Me
H
299
(88%)
 
To a solution of alkene 299 (600 mg, 1.50 mmol, 1.0 eq.) in THF (9 mL) was added 9-BBN (237, 
6.00 mL of 0.5M solution in THF, 3.00 mmol, 2.0 eq.) and the resulting solution was heated to 40 °C 
for 3 h. The mixture was cooled to 0 °C and degassed aqueous Cs2CO3 (3N, 1.75 mL, 5.25 mmol, 
3.5 eq.) was added. The reaction was stirred vigorously at room temperature for 40 min prior to adding 
a solution of vinyl iodide 378 (643 mg, 1.95 mmol, 1.3 eq.) and AsPh3 (184 mg, 600 μmol, 40 mol-%) 
in degassed DMF (15 mL). The reaction mixture was degassed (N2 bubbling) and Pd(dppf)Cl2 
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(complex with CH2Cl2, 122 mg, 150 μmol, 10 mol-%) was added in one portion. The mixture was 
stirred for 24 h, at which time the reaction was partitioned between H2O (20 mL) and Et2O (30 mL). 
The aqueous layer was extracted with Et2O (3 x 30 mL), the combined organic layers were washed 
with 10% aqueous NaCl (2 x 30 mL) and saturated aqueous NaCl (30 mL), and dried over MgSO4. 
Having evaporated the solvents under reduced pressure, the crude product was purified by flash 
column chromatography (silica, hexanes:EtOAc = 50:1) to yield silyl ether 379 (793 mg, 1.32 mmol, 
88%) as a colorless oil.  
 
Rf = 0.34 (hexanes:EtOAc = 16:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.28 (mC, 2H, 24-H), 6.87 (mC, 2H, 25-H), 5.56 (mC, 1H, 17-H), 
4.50 (d, 2J22A/22B = 11.3 Hz, 1H, 22-HA), 4.48 (mC, 1H, 20-H), 4.38 (d, 2J22B/22A = 11.3 Hz, 1H, 22-HB), 
4.02 (mC, 1H, 6-H), 3.80 (s, 3H, 27-H), 3.42 (dd, 3J1/2 = 8.9, 7.5 Hz, 1H, 1-H), 2.45−2.39 (m, 1H, 
18-HA), 2.23−2.17 (m, 1H, 18-HB), 2.17−2.04 (m, 3H, 15-H, 19-HA), 1.94−1.83 (m, 2H, 2-HA, 19-HB), 
1.73 (mC, 1H, 4-H), 1.60−1.47 (m, 4H, 5-HA, 8-HA, 13-H, 14-HA), 1.47−1.35 (m, 3H, 2-HB, 3-HA, 
5-HB), 1.32−1.21 (m, 3H, 3-HB, 7-H, 14-HB), 1.15 (s, 9H, 12-H), 1.10 (dd, 2J8B/8A = 3J8B/7 = 12.5 Hz, 
1H, 8-HB), 0.95 (t, 3J29/28 = 8.0 Hz, 9H, 29-H), 0.87 (d, 3J21/13 = 6.8 Hz, 3H, 21-H), 0.69 (s, 3H, 10-H), 
0.62−0.52 (m, 6H, 28-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ  = 159.2 (C-26), 145.4 (C-16), 131.4 (C-23), 129.3 (C-24), 
127.4 (C-17), 113.8 (C-25), 85.0 (C-20), 81.0 (C-1), 72.3 (C-11), 70.0 (2C, C-6, C-22), 55.4 (C-27), 
42.7 (C-9), 42.5 (C-7), 37.4 (C-4), 35.4 (C-8), 34.7 (C-5), 34.2 (C-13), 33.3 (C-14), 31.6 (C-2), 
30.3 (C-18), 30.0 (C-19), 29.0 (C-12), 25.9 (C-15), 25.5 (C-3), 17.2 (C-21), 11.1 (C-10), 7.2 (C-29), 
5.5 (C-28) ppm. 
 
ESI-MS for C37H62O4NaSi+ [(M+Na)+]: calcd. 621.4310 
 found 621.4314. 
 
IR (ATR): ῦ/cm–1 = 2952 (s), 2933 (s), 2911 (s), 2874 (s), 1612 (w), 1513 (m), 1462 (w), 1361 (w), 
1247 (m), 1195 (w), 1062 (m), 1042 (m), 976 (w), 798 (w), 741 (w)  
 
[ ]20Dα  = +36.6 (c 0.50, CH2Cl2). 
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Synthesis of Ketone 382 and Methyl Ether 380 
 
 
To a solution of silyl ether 378 (710 mg, 1.18 mmol, 1.0 eq.) in CH2Cl2/MeOH (3:1, 20 mL) was 
added (1R)-(−)-camphorsulfonic acid (110 mg, 470 μmol, 40 mol-%) in one portion and the mixture 
was stirred for 1 h prior to being partitioned between saturated aqueous NaHCO3 (20 mL) and 
CH2Cl2 (20 mL). The phases were separated and the aqueous layer was extracted with CH2Cl2 (3 x 
20 mL). The combined organic layers were washed with saturated aqueous NaCl (20 mL) and were 
dried over MgSO4. Having evaporated the solvents under reduced pressure, the crude product was 
purified by flash column chromatography (silica, hexanes:EtOAc = 8:1) to yield methyl 
ether 380 (172 mg, 454 μmol, 38%) along with PMB ether 381 (Rf = 0.43, hexanes:EtOAc = 4:1, 
264 mg, 540 μmol, 46%), which was immediately used in the next step. 
To a suspension of crude alcohol 381 (264 mg, 540 μmol, 1.0 eq.) and NaHCO3 (136 mg, 1.62 mmol, 
3.0 eq.) in CH2Cl2 (10 mL) was added DMP (343 mg, 810 μmol, 1.5 eq.) in one portion and the 
mixture was stirred for 2 h at room temperature. The reaction was quenched by addition of saturated 
aqueous Na2S2O3/saturated aqueous NaHCO3/H2O (1:1:1, 10 mL) and the biphasic mixture was stirred 
vigorously for 30 min. The phases were separated and the aqueous layer was extracted with 
CH2Cl2 (3 x 15 mL). The combined organic layers were washed with saturated aqueous NaCl (10 mL), 
dried over MgSO4 and the solvents were evaporated under reduced pressure. Purification by flash 
column chromatography (silica, pentane:Et2O = 5:1) yielded ketone 382 (195 mg, 405 μmol, 34% over 
two steps) as a colorless oil. 
 
Rf = 0.59 (hexanes:EtOAc = 4:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.26 (mC, 2H, 24-H), 6.87 (mC, 2H, 25-H), 5.58 (mC, 1H, 17-H), 
4.51 (d, 2J22A/22B = 11.3 Hz, 1H, 22-HA), 4.46 (mC, 1H, 20-H), 4.36 (d, 2J22B/22A = 11.5 Hz, 1H, 22-HB), 
3.80 (s, 3H, 27-H), 3.45 (dd, 3J1/2 = 8.9, 7.8 Hz, 1H, 1-H), 2.42 (mC, 1H, 18-HA), 2.34−2.28 (m, 2H, 
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5-HA, 7-H), 2.28−2.05 (m, 6H, 5-HB, 13-H, 15-H, 18-HB, 19-HA), 2.02−1.95 (m, 1H, 2-HA), 
1.89−1.81 (m, 2H, 8-HA, 19-HB), 1.67−1.53 (m, 3H, 2-HB, 3-HA, 4-H), 1.44−1.32 (m, 3H, 3-HB, 14-H), 
1.22−1.12 (m, 1H, 8-HB), 1.15 (s, 9H, 12-H), 0.96 (s, 3H, 10-H), 0.79 (d, 3J21/13 = 6.8 Hz, 3H, 
21-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ  = 212.5 (C-6), 159.2 (C-26), 144.6 (C-16), 131.3 (C-23), 
129.3 (C-24), 127.9 (C-17), 113.9 (C-25), 85.1 (C-20), 80.0 (C-1), 72.7 (C-11), 70.2 (C-22), 
55.4 (C-27), 49.6 (C-7), 44.7 (C-4), 43.3 (C-5), 42.3 (C-9), 35.8 (C-8), 32.6 (C-14), 31.9 (C-2), 
31.0 (C-13), 30.3 (C-18), 30.0 (C-19), 28.9 (C-12), 26.6 (C-15), 25.9 (C-3), 16.0 (C-21), 
11.2 (C-10) ppm. 
 
ESI-MS for C31H46O4Na+ [(M+Na)+]: calcd. 505.3288 
 found 505.3287. 
 
IR (ATR): ῦ/cm–1 = 2970 (s), 2931 (s), 2854 (m), 1704 (m), 1612 (s), 1513 (m), 1462 (w), 1361 (w), 
1301 (w), 1248 (m), 1192 (w), 1062 (m), 1038 (w), 820 (w).  
 
[ ]20Dα  = +15.6 (c 0.50, CH2Cl2). 
 
Methyl ether 380 was obtained as colorless oil and as a single diastereomer. The relative configuration 
at C-20 could not be assigned by 2D NMR spectroscopy. 
 
Rf = 0.48 (hexanes:EtOAc = 4:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.59 (mC, 1H, 17-H), 4.27 (mC, 1H, 20-H), 4.08 (ddd, 3J6/5A = 3J6/5B = 
3J6/7 = 2.8 Hz, 1H, 6-H), 3.45 (dd, 3J1/2 = 8.8, 7.4 Hz, 1H, 1-H), 3.30 (s, 3H, 22-H), 2.44−2.37 (m, 1H, 
18-HA), 2.28−2.14 (m, 3H, 15-H, 18-HB), 2.13−2.07 (m, 1H, 19-HA), 1.97−1.85 (m, 2H, 2-HA, 14-HA), 
1.80 (mC, 1H, 19-HB), 1.73−1.60 (m, 3H, 4-H, 5-HA, 8-HA), 1.53−1.38 (m, 4H, 2-HB, 3-HA, 5-HB, 
13-H), 1.32−1.21 (m, 2H, 3-HB, 7-H), 1.19−1.07 (m, 1H, 14-HB), 1.13 (s, 9H, 12-H), 1.00 (mC, 1H, 
8-HB), 0.89 (d, 3J21/13 = 6.7 Hz, 3H, 21-H), 0.70 (s, 3H, 10-H) ppm. 
  
13C NMR (CDCl3, 150 MHz): δ  = 143.4 (C-16), 129.9 (C-17), 89.1 (C-20), 80.9 (C-1), 72.3 (C-11), 
67.2 (C-6), 56.3 (C-22), 42.8 (C-9), 42.4 (C-7), 37.5 (C-4), 36.4 (C-8), 33.5 (C-5), 32.4 (C-13), 
31.7 (C-14), 31.5 (C-2), 30.1 (C-18), 29.7 (C-19), 28.9 (C-12), 26.8 (C-15), 25.6 (C-3), 17.2 (C-21), 
11.0 (C-10) ppm. 
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EI-MS for C24H42O3+ [M+]: calcd. 378.3128 
 found 378.3120. 
 
IR (ATR): ῦ/cm–1 = 3462 (br m), 2971 (s), 2929 (s), 2870 (s), 1461 (w), 1387 (w), 1361 (m), 1253 (w), 
1196 (m), 1127 (w), 1062 (m), 1025 (w), 1008 (w).  
 
[ ]20Dα  = +32.6 (c 0.50, CH2Cl2). 
 
 
Synthesis of Ketone 385 
 
 
To a solution of DMSO (97.0 μL, 1.38 mmol, 4.0 eq.) in CH2Cl2 (5 mL) at −78 °C was added 
dropwise (COCl)2 (344 μL of a 2.0M solution in CH2Cl2, 688 μmol, 2.0 eq.) and the mixture was 
stirred for 30 min prior to adding slowly a solution of alcohol 380 (130 mg, 344 μmol, 1.0 eq.) in 
CH2Cl2 (1 mL). The reaction was stirred for an additional 1 h at −78 °C and Et3N (380 μL, 2.75 mmol, 
8.0 eq.) was added in one portion. The cold bath was replaced by an ice/water bath and the mixture 
was stirred for 1 h at 0 °C. The reaction was partitioned between H2O (5 mL) and CH2Cl2 (5 mL) and 
the layers were separated. The aqueous layer was extracted with CH2Cl2 (3 x 5 mL), and the combined 
organic layers were washed with saturated aqueous NaCl (5 mL) and dried over MgSO4. Having 
evaporated the solvents under reduced pressure, the crude product was purified by flash column 
chromatography (silica, hexanes:EtOAc = 8:1) to yield ketone 385 (106 mg, 281 μmol, 82%) as a 
colorless oil. 
 
Rf = 0.59 (hexanes:EtOAc = 4:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.56 (mC, 1H, 17-H), 4.30 (mC, 1H, 20-H), 3.47 (mC, 1H, 1-H), 
3.30 (s, 3H, 22-H), 2.43−2.34 (m, 2H, 7-H 18-HA), 2.31 (dd, 2J5A/5B = 14.9 Hz, 3J5A/4 = 4.9 Hz, 1H, 
5-HA), 2.29−2.07 (m, 5H, 5-HB, 13-H, 15-HA, 18-HB, 19-HA), 2.04−1.95 (m, 2H, 2-HA, 15-HB), 
1.88 (dd, 2J8A/8B = 12.8 Hz, 3J8A/7 = 6.3 Hz, 1H, 8-HA), 1.78 (mC, 1H, 19-HB), 1.68−1.54 (m, 3H, 2-HB, 
3-HA, 4-H), 1.45−1.32 (m, 3H, 3-HB, 14-H), 1.19 (mC, 1H, 8-HB), 1.15 (s, 9H, 12-H), 0.97 (s, 3H, 
10-H), 0.89 (d, 3J21/13 = 6.6 Hz, 3H, 21-H) ppm. 
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13C NMR (CDCl3, 150 MHz): δ  = 212.5 (C-6), 144.5 (C-16), 127.7 (C-17), 87.3 (C-20), 80.0 (C-1), 
72.7 (C-11), 55.9 (C-22), 49.0 (C-7), 44.6 (C-4), 43.3 (C-5), 42.2 (C-9), 35.4 (C-8), 32.6 (C-14), 
31.9 (C-2), 30.9 (C-13), 30.2 (C-18), 29.3 (C-19), 28.9 (C-12), 26.5 (C-15), 25.9 (C-3), 16.2 (C-21), 
11.2 (C-10) ppm. 
 
EI-MS for C24H40O3+ [M+]: calcd. 376.2972 
 found 376.2971. 
 
IR (ATR): ῦ/cm–1 = 3376 (br w), 2969 (s), 2931 (s), 2873 (m), 1704 (s), 1461 (w), 1388 (w), 1361 (m), 
1251 (w), 1192 (m), 1103 (w), 1061 (m), 1026 (w).  
 
[ ]20Dα  = +1.6 (c 0.50, CH2Cl2). 
 
 
2.3 Experimental Procedures for Chapter 4: ‘Synthetic Studies 
toward Nitiol’ 
 
Synthesis of Oxazolidinone 399  
 
 
To a solution of Evans auxiliary 397[264] (4.71 g, 28.9 mmol, 1.0 eq.) in THF (120 mL) at −78 °C was 
added dropwise n-BuLi (12.7 mL of a 2.5M solution in hexanes, 31.8 mmol, 1.1 eq.) and the mixture 
was stirred for 30 min at this temperature before adding dropwise a solution of crotonyl chloride (398, 
3.04 mL, 31.8 mmol, 1.1 eq.) in THF (10 mL). The mixture was stirred for an additional 60 min at 
−78 °C and was allowed to warm to 0 °C. The reaction was quenched by addition of saturated aqueous 
NH4Cl (15 mL) and the mixture was freed of THF under reduced pressure. The resulting suspension 
was partitioned between Et2O (100 mL) and H2O (30 mL) and the layers were separated. The aqueous 
phase was extracted with Et2O (30 mL) and the combined organic layers were washed with saturated 
aqueous NaHCO3 (2 x 30 mL) and saturated aqueous NaCl (30 mL). Having dried the organic layer 
over Na2SO4 and evaporated the solvents under reduced pressure, the crude product was purified by 
flash column chromatography (hexanes:EtOAc = 5:1 to 1:1) to yield oxazolidinone 399 (5.16 g, 
22.3 mmol, 78%) as a pale yellow solid.  
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Rf = 0.50 (hexanes:EtOAc = 7:3). 
 
1H NMR (CDCl3, 400 MHz): δ = 7.41−7.24 (m, 6H, 2-H, 9-H, 10-H, 11-H), 7.09 (dq, 3J2/3 = 15.3 Hz, 
3J3/4 = 6.8 Hz, 1H, 3-H), 5.48 (dd, 3J7/6A = 8.7 Hz, 3J7/6B = 3.8 Hz, 1H, 7-H), 4.69 (dd, 2J6A/6B = 3J6A/6B = 
8.8 Hz, 1H, 6-HA), 4.27 (dd, 2J6B/6A = 8.9 Hz, 3J6B/7 = 3.9 Hz, 1H, 6-HB), 1.93 (dd, 3J4/3 = 6.9 Hz, 4J4/2 = 
1.6 Hz, 3H, 4-H) ppm. 
   
13C NMR (CDCl3, 100 MHz): δ = 164.4 (C-1), 153.8 (C-5), 147.4 (C-3), 139.2 (C-8), 129.3 (C-10), 
128.7 (C-11), 126.1 (C-9), 121.8 (C-2), 70.1 (C-7), 57.8 (C-6), 18.6 (C-4) ppm. 
 
ESI-MS for C13H13NNaO3+ [(M+Na)+]: calcd. 254.0788 
 found 254.0788. 
 
IR (ATR): ῦ/cm−1 = 3034 (w), 2977 (w), 1774 (s), 1618 (w), 1495 (w), 1338 (m), 1234 (m), 1197 (m), 
1126 (w), 1024 (w), 968 (w), 924 (w), 830 (w), 762 (w).  
 
[ ]20Dα  = −113.6 (c 1.00, CHCl3). 
 
The analytical data matched those reported previously.[265] 
 
 
Synthesis of Michael Adduct 400  
 
 
To a slurry of CuBr·SMe2 (115 mg, 560 μmol, 1.3 eq.) in THF (5 mL) at −40 °C was added 
allylmagnesium bromide (560 μL mL of a 1.0M solution in Et2O, 560 μmol, 1.3 eq.) within 10 min. 
The solution was stirred for an additional 30 min at this temperature before being cooled to −78 °C. To 
the resulting black reaction mixture was sequentially added BF3·OEt2 (70 μL, mmol, 1.3 eq.) and a 
solution of oxazolidinone 399 (100 mg, 430 μmol, 1.0 eq.) in THF (2 mL). The mixture was stirred for 
an additional 90 min and the reaction was quenched by addition of saturated aqueous NH4Cl (5 mL). 
The biphasic mixture was diluted with Et2O (5 mL), filtered over a pad of Celite® and the layers were 
separated. The aqueous layer was extracted with Et2O (4 x 5 mL) and the combined organic layers 
were dried over MgSO4. The solvents were removed under reduced pressure and the crude product 
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was purified by flash column chromatography (hexanes:EtOAc = 5:1) to yield 
oxazolidinone 400 (93 mg, 0.34 mmol, 79%, d.r. > 95:5) as a colorless solid. 
 
Rf = 0.29 (hexanes:EtOAc = 4:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 7.43−7.26 (m, 5H, 12-H, 13-H, 14-H), 5.72 (mC, 1H, 5-H), 5.43 (dd, 
3J10/9A = 8.8 Hz, 3J10/9B = 3.8 Hz, 1H, 10-H), 5.01−4.93 (m, 2H, 6-H), 4.68 (dd, 2J9A/9B = 3J9A/10 = 
8.8 Hz, 1H, 9-HA), 4.27 (dd, 2J9B/9A = 8.9 Hz, 3J9B/10 = 3.8 Hz, 1H, 10-HB), 2.99 (dd, 2J2A/2B = 16.5 Hz, 
3J2A/3 = 5.9 Hz, 1H, 2-HA), 2.71 (dd, 2J2B/2A = 16.4 Hz, 3J2B/3 = 8.2 Hz, 1H, 2-HB), 2.16−1.93 (m, 3H, 
3-H, 4-H), 0.88 (d, 3J7/3 = 6.6 Hz, 3H, 7-H) ppm. 
   
13C NMR (CDCl3, 100 MHz): δ = 172.3 (C-1), 153.8 (C-8), 139.3 (C-11), 136.6 (C-5), 129.3 (C-13), 
128.8 (C-14), 126.1 (C-12), 116.7 (C-6), 70.0 (C-10), 57.7 (C-9), 42.0 (C-2), 41.1 (C-4), 29.4 (C-3), 
19.6 (C-7) ppm. 
 
ESI-MS for C16H19NNaO3+ [(M+Na)+]: calcd. 296.1257 
 found 296.1255. 
 
IR (ATR): ῦ/cm−1 = 2962 (w), 2917 (w), 1778 (s), 1703 (m), 1495 (w), 1458 (w), 1384 (m), 1322 (m), 
1196 (m), 1044 (w), 1001 (w), 916 (w), 762 (w), 710 (w).  
 
[ ]20Dα  = −59.6 (c 0.50, CHCl3), lit. for ent-400, [ ]20Dα  = +53.8 (c 2.12, CHCl3).[263] 
 
On a larger scale, the yield dropped dramatically. Beside recovered starting 
material, side product 401 was isolated in 10% yield as colorless foam, which 
was contaminated by some minor impurities. The relative stereochemistry of this 
single diastereomer could not be determined.  
 
Rf = 0.09 (hexanes:EtOAc = 4:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 7.40−7.27 (m, 8H), 7.25−7.20 (m, 2H), 5.75 (mC, 1H), 5.43 (dd, 
J = 8.6, 3.3 Hz, 1H), 5.32 (dd, J = 8.7, 3.8 Hz, 1H), 5.05−4.96 (m, 2H), 4.61 (mC, 2H), 4.22 (dd, J = 
8.9, 3.2 Hz, 1H), 4.20 (dd, J = 8.9, 3.9 Hz, 1H), 4.09 (t, J = 7.5 Hz, 1H), 2.81 (dd, J = 17.7, 10.3 Hz, 
1H), 2.71 (dd, J = 17.8, 3.0 Hz, 1H), 2.49−2.41 (m, 1H), 2.33−2.25 (m, 1H), 2.01−1.94 (m, 1H), 
1.91−1.83 (m, 1H), 0.92 (d, J = 6.3 Hz, 3H), 0.75 (d, J = 6.4 Hz, 3H) ppm. 
   
OMe
N
O
O
Ph
ONO
O
Ph
Me
401
C29H32N2O6
M = 504.57 g/mol
*
*
*
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13C NMR (CDCl3, 100 MHz): δ = 174.7 (Cq), 171.8 (Cq) 153.7 (Cq), 153.5 (Cq), 139.5 (Cq), 139.2 (Cq), 
136.5 (CH), 129.2 (2C, CH), 128.7 (2C, CH), 126.3 (CH), 125.9 (CH), 116.6 (CH2), 69.9 (CH2), 
69.5 (CH2), 58.0 (CH), 57.7 (CH), 50.1 (CH), 38.9 (CH2), 38.6 (CH2), 33.1 (CH), 29.8 (CH), 
17.8 (CH3), 15.6 (CH3) ppm. 
 
ESI-MS for C29H33N2O6+ [(M+H)+]: calcd. 505.2339 
 found 505.2334. 
 
 
Synthesis of Weinreb Amide 402 
 
 
To a suspension of (MeO)NHMe·HCl (92 mg, 0.94 mmol, 3.6 eq.) in THF (2.5 mL) at 0 °C was 
slowly added AlMe3 (245 μL of a 2.0M solution in toluene, 490 μmol, 1.9 eq.) and the mixture was 
stirred for 1 h at room temperature. After cooling to 0 °C, a solution of oxazolidinone 400 (72 mg, 
0.26 mmol, 1.0 eq.) in THF (2 mL) was added and the mixture was stirred for 30 min at 0 °C and an 
additional 16 h at room temperature. The reaction was quenched by addition of saturated aqueous 
Rochelle salt (4 mL) and the mixture was diluted with H2O (2 mL) and CH2Cl2 (4 mL). The layers 
were separated and the aqueous phase was extracted with CH2Cl2 (2 x 5 mL). The combined organic 
layers were dried over MgSO4 and the solvents were evaporated under reduced pressure. Purification 
of the obtained crude product by flash column chromatography (silica, hexanes:EtOAc = 4:1) yielded 
the desired Weinreb amide 402 (12 mg, 70 mmol, 26%) as a volatile colorless liquid. 
 
Rf = 0.19 (hexanes:EtOAc = 4:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 5.78 (mC, 1H, 5-H), 5.05−4.99 (m, 2H, 6-H), 3.67 (s, 3H, 9-H), 
3.18 (s, 3H, 8-H), 2.42 (dd, 2J2A/2B = 15.0 Hz, 3J2/3 = 5.4 Hz, 1H, 2-HA), 2.28−2.05 (m, 3H, 2-HB, 3-H, 
4-HA), 2.04−1.95 (m, 1H, 4-HB), 0.95 (d, 3J7/3 = 6.4 Hz, 3H, 7-H) ppm. 
   
13C NMR (CDCl3, 100 MHz): δ = 137.0 (C-5), 116.4 (C-6), 61.3 (C-9), 41.4 (C-4), 38.5 (C-2), 
32.3 (br, C-8), 29.7 (C-3), 20.0 (C-7) ppm (C1 obscured). 
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FAB-MS for C9H18NO2+ [(M+H)+]: calcd. 172.1338 
 found 172.1333. 
 
IR (ATR): ῦ/cm−1 = 3093 (w), 2928 (w), 2873 (w), 1524 (s), 1481 (w), 1349 (s), 1266 (m), 1202 (w), 
1041 (m), 919 (w), 893 (w).  
 
[ ]20Dα  = −18.0 (c 0.30, CHCl3), Lit.: [ ]20Dα  = −13.1 (c 0.23, CHCl3).[266] 
 
 
Synthesis of Carboxylic Acid 404 
 
 
To a solution of oxazolidinone 403[266] (400 mg, 1.46 mmol, 1.0 eq.) in THF/H2O (4:1, 8 mL) at 0 °C 
was consecutively added H2O2 (30% in H2O, 660 μL, 5.84 mmol, 4.0 eq.) and a solution of 
LiOH (56.0 mg, 2.34 mmol, 1.6 eq.) in H2O (4 mL). The mixture was stirred for an additional 90 min 
at 0 °C before quenching the reaction by adding a solution of Na2SO3 (736 mg, 5.84 mmol, 4.0 eq.) in 
H2O (6 mL). Most of the THF was removed under reduced pressure (water bath temperature: 30 °C) 
and the resulting basic phase was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers 
were dried over MgSO4 and the solvents were removed under reduced pressure to yield recovered 
Evans auxiliary. 
The pH of the aqueous phase was adjusted at 0 °C to pH = 1 by addition of HCl (2N). The aqueous 
phase was extracted with CH2Cl2 (4 x 10 mL), the combined organic layers were dried over MgSO4 
and the solvent was carefully removed under reduced pressure (water bath temperature: 30 °C) to yield 
acid 404 (159 mg, 1.24 mmol, 85%) as a colorless liquid judged to be pure by 1H NMR spectroscopy. 
 
Rf = 0.23 (hexanes:EtOAc = 10:1, 1% AcOH). 
 
1H NMR (CD2Cl2, 400 MHz): δ = 5.79 (mC, 1H, 5-H), 5.06−5.00 (m, 2H, 6-H), 2.39 (dd, 2J2A/2B = 
15.1 Hz, 3J2A/3 = 5.3 Hz, 1H, 2-HA), 2.18−2.00 (m, 4H, 2-HB, 3-H, 4-H), 0.98 (d, 3J7/3 = 6.6 Hz, 3H, 
7-H) ppm. 
   
13C NMR (CD2Cl2, 100 MHz): δ = 179.8 (C-1), 137.0 (C-5), 117.0 (C-6), 41.4 (C-4), 41.2 (C-2), 
30.5 (C-3), 19.8 (C-7) ppm. 
 
222  EXPERIMENTAL SECTION 
ESI-MS for C14H23O4− [(2M−H)−]: calcd. 255.1602 
 found 255.1610. 
 
IR (ATR): ῦ/cm−1 = 3079 (w), 2962 (w), 1703 (s), 1642 (m), 1541 (w), 1411 (m), 1380 (w), 1284 (w), 
1196 (m), 1032 (w), 995 (w), 913 (w).  
 
[ ]20Dα  = +1.6 (c 0.53, CHCl3), lit. for ent-404: [ ]20Dα  = −0.71 (c 1.13, CHCl3),[269] −2.8 (c 1.00, 
CHCl3).[262] 
 
 
Synthesis of Western Fragment 392* 
 
 
To a solution of acid 404 (100 mg, 780 μmol, 1.0 eq.), EDCI (180 mg, 940 μmol, 1.2 eq.), 
Et3N (390 μL, 2.81 mmol, 4.2 eq.) and DMAP (20 mg, 0.160 mmol, 30 mol-%) in CH2Cl2 (7 mL) was 
added (1R,2R)-pseudoephedrine (405, 135 mg, 820 μmol, 1.05 eq.) and the mixture was stirred for 15 
h at room temperature. The mixture was quenched by addition of saturated aqueous NH4Cl (5 mL) and 
the aqueous phase was extracted with CH2Cl2 (2 x 5 mL). The combined organic layers were washed 
with saturated aqueous NaCl (5 mL), dried over Na2SO4 and the solvents were removed under reduced 
pressure. The crude product was purified by flash column chromatography (silica, CH2Cl2:MeOH = 
97:3) to yield amide 392 (190 mg, 691 μmol, 89%) as a highly viscous colorless oil. 
 
Rf = 0.23 (hexanes:EtOAc = 1:1). 
 
1H NMR (CDCl3, 300 MHz, 3.6:1 mixture of rotamers, asterix denotes minor rotamer): δ = 
7.41−7.22 (m, 5H, 11-H, 12-H, 13-H), 5.86−5.69 (m, 1H, 5-H), 5.10−4.93 (m, 2H, 6-H), 
4.64−4.52 (m, 1H, 8-H), 4.51−4.38 (m, 1H, 9-H), 4.07−3.96 (m, 1H, 9-H)*, 2.91 (s, 3H, 14-H)*, 
2.81 (s, 3H, 14-H), 2.49−1.87 (m, 5H, 2-H, 3-H, 4-H), 1.11 (d, 3J15/8 = 7.1 Hz, 3H, 15-H), 0.98 (d, 
3J15/8 = 6.8 Hz, 3H, 15-H)*, 0.95 (d, 3J7/3 = 5.8 Hz, 3H, 7-H)*, 0.94 (d, 3J7/3 = 6.0 Hz, 3H, 7-H) ppm. 
   
                                                 
* The analytical data was obtained from a sample assumed to be >90% ee pure. This assumption is based on the 
fact that acid 404 had been prepared utilizing highly diastereomerically enriched oxazolidinone 400. 
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13C NMR (CDCl3, 75 MHz, asterix denotes minor rotamer): δ = 175.0 (C-1), 173.7 (C-1)*, 
142.7 (C-10), 141.3 (C-10)*, 137.2 (C-5)*, 136.9 (C-5), 128.9 (C-11)*, 128.6 (C-13)*, 128.5 (C-11), 
127.8 (C-13), 127.1 (C-12)*, 126.5 (C-12), 116.5 (C-6), 116.3 (C-6)*, 76.7 (C-9), 75.7 (C-9)*, 
58.5 (C-8), 58.1 (C-8)*, 41.5 (C-4)*, 41.3 (C-4), 40.8 (C-2), 40.3 (C-2)*, 33.4 (C-14), 30.2 (C-3)*, 
30.1 (C-3), 26.9 (C-14)*, 20.1 (C-7)*, 19.9 (C-7), 15.5 (C-15)*, 14.7 (C-15) ppm. 
 
ESI-MS for C17H26NO2+ [(M+H)+]: calcd. 276.1958 
 found 276.1956. 
 
IR (ATR): ῦ/cm−1 = 3376 (br m), 3065 (w), 2972 (m), 2930 (m), 1617 (s), 1454 (m), 1405 (m), 
1377 (w), 1260 (w), 1200 (w), 1111 (w), 1052 (w), 912 (w), 701 (w). 
 
[ ]20Dα  = −96.8 (c 0.50, CHCl3). 
 
 
Synthesis of Acid 409 and Lactone 408 
 
 
To a solution of ketone ent-141 (500 mg, 2.57 mmol, 1.0 eq.) in THF (25 mL) at −78 °C was added 
dropwise KHMDS (7.20 mL of a 0.5M solution in toluene, 3.60 mmol, 1.4 eq.) and the mixture was 
stirred for 30 min at this temperature. Then Et3N (1.79 mL, 12.9 mmol, 4.0 eq.) and Et3SiCl (1.94 mL, 
11.6 mmol, 4.5 eq.) were added dropwise and the reaction was stirred for an additional 30 min. The 
reaction was quenched by addition of saturated aqueous NH4Cl (10 mL) and the mixture was diluted 
with n-pentane (50 mL). The mixture was allowed to warm to room temperature and the phases were 
separated. The aqueous layer was extracted with n-pentane (2 x 20 mL) and the combined organic 
layers were dried over Na2SO4. The solvents were removed under reduced pressure (water bath 
temperature: 30 °C) to yield silylenol ether 406 as a colorless oil, which was used without further 
purification. 
224  EXPERIMENTAL SECTION 
Through a solution of crude enol ether 406 in MeOH (15 mL) and CH2Cl2 (15 mL) at −78 °C was 
bubbled O3 until the solution turned blue. After bubbling N2 through the solution for 10 min, 
Me2S (5.6 mL, 77.1 mmol, 30 eq.) was added and the mixture was allowed to warm to room 
temperature within 1 h. The solution was stirred for an additional 1 h at this temperature before the 
solvents were removed under reduced pressure. The residue was purified by flash column 
chromatography (silica, CH2Cl2:MeOH = 10:1) to yield labile acid 407 (594 mg, quantitative) as a pale 
yellow oil, which was immediately used in the next step. 
To a solution of aldehyde 407 (assumed 2.57 mmol, 1.0 eq.) in THF (30 mL) at 0 °C was slowly added 
isopropenylmagnesium bromide (219, 15.0 mL of a 0.5M in THF, 7.50 mmol, 3.0 eq.). The mixture 
was stirred an additional 10 min at this temperature and then for 1 h at room temperature. The mixture 
was quenched by addition of saturated aqueous NH4Cl (15 mL) and the aqueous phase was acidified 
with HCl (2N). The biphasic mixture was extracted with Et2O (3 x 30 mL) and the combined organic 
layers were dried over MgSO4. Evaporation of the solvents under reduced pressure and purification of 
the crude product by flash column chromatography (hexanes:EtOAc = 5:1, 1% AcOH) yielded labile 
seco acid 409 (290 mg, 1.08 mmol, 42% over three steps) as an inseparable, approximately 1:1 
mixture of diastereomers, which was immediately used in the next step.  
Additionally, lactone 408 (80 mg, 0.32 mmol, 12% over three steps) was isolated as a single 
diastereoisomer, the relative configuration of which was not be determined. This compound was 
contaminated by Et3SiOH and was characterized by 1H NMR, 13C NMR and low resolution mass 
spectrometry. 
 
Analytical data for acid 407: 
 
Rf = 0.39 (CH2Cl2:MeOH = 10:1). 
 
1H NMR (CDCl3, 400 MHz): δ = 9.81 (dd, 3J9/8A = 3.2 Hz, 3J9/8B = 2.6 Hz, 1H, 9-H), 2.46 (dd, 2J8A/8B = 
14.9 Hz, 3J8A/9 = 3.2 Hz, 1H, 8-HA), 2.39−2.25 (m, 3H, 2-H, 8-HB), 1.94 (mC, 1H, 3-H) 1.74−1.54 (m, 
5H, 4-H, 5-HA, 6-H, 11-H), 1.49−1.41 (m, 1H, 5-HB), 0.98 (s, 3H, 10-H), 0.91 (d, 3J12/11 = 6.8 Hz, 3H, 
12-H)*, 0.82 (d, 3J13/11 = 6.6 Hz, 3H, 13-H)* ppm.  
 
13C NMR (CDCl3, 100 MHz): δ = 203.3 (C-9), 179.4 (C-1), 54.8 (C-8), 49.6 (C-4), 47.6 (C-3), 
43.6 (C-7), 38.4 (C-6), 35.1 (C-2), 29.3 (C-11), 23.2 (C-5), 22.5 (C-12)*, 21.0 (C-10), 
16.8 (C-13)* ppm. 
 
ESI-MS for C26H43O6− [(2M−H)−]: calcd. 451.3065 
 found 451.3064. 
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IR (ATR): ῦ/cm−1 = 2951 (s), 2870 (m), 1703 (s), 1467 (w), 1412 (w), 1387 (w), 1367 (w), 1301 (w), 
1278 (w), 1240 (w), 1141 (w), 1079 (w).  
 
Analytical data for allylic alcohol 409: 
 
Rf = 0.49 (CH2Cl2:MeOH = 10:1). 
 
1H NMR (CDCl3, 600 MHz, both diastereomers quoted): δ = 4.95 (mC, 0.5H, 11-HA), 4.94 (mC, 0.5H, 
11-HA), 4.78 (mC, 0.5H, 11-HB), 4.77 (mC, 0.5H, 11-H)B, 4.23 (d, J = 8.5 Hz, 0.5H, 9-H), 4.22 (d, J = 
4.22 Hz, 0.5H, 9-H), 2.42 (dd, 2J2A/2B = 15.5 Hz, 3J2A/3 = 6.3 Hz, 0.5H, 2-HA), 2.40 (dd, 2J2A/2B = 
15.3 Hz, 3J2A/3 = 5.7 Hz, 0.5H, 2-HA), 2.18 (dd, 2J2B/2A = 15.2 Hz, 3J2B/3 = 7.0 Hz, 0.5H, 2-HB), 
2.17 (dd, 2J2B/2A = 15.4 Hz, 3J2B/3 = 6.8 Hz, 0.5H, 2-HB), 1.97 (mC, 0.5H, 3-H), 1.90 (mC, 0.5H, 3-H), 
1.73 (s, 3H, 12-H), 1.72−1.55 (m, 5H, 4-H, 5-HA, 6-HA, 8-HA, 14-H), 1.54−1.33 (m, 4H, 5-HB, 6-HB, 
8-HB, OH), 0.94 (s, 1.5H, 13-H), 0.96 (d, 3J15/14 = 6.7 Hz, 3H, 15-H)*, 0.86 (s, 1.5H, 13-H), 0.82 (d, 
3J16/14 = 6.4 Hz, 1.5H, 16-H)*, 0.81 (d, 3J16/14 = 6.5 Hz, 1.5H, 16-H)* ppm.  
 
13C NMR (CDCl3, 150 MHz, both diastereomers quoted): δ = 179.6 (C-1), 179.3 (C-1), 149.2 (C-10), 
149.1 (C-10), 110.5 (C-11), 110.3 (C-11), 74.2 (C-9), 73.4 (C-9), 50.8 (C-4), 50.1 (C-4), 47.3 (C-3), 
47.1 (C-8), 46.4 (C-3), 45.9 (C-8), 44.3 (C-7), 44.2 (C-7), 39.0 (C-6), 38.2 (C-6), 35.8 (C-2), 
35.6 (C-2), 29.5 (C-14), 29.2 (C-14), 23.1 (C-5), 22.9 (C-5), 22.6 (2C, C-15)*, 21.3 (C-13), 
20.9 (C-13), 18.0 (C-12), 17.8 (C-12), 16.8 (C-16)*, 16.5 (C-16)* ppm. 
 
ESI-MS for C16H27O3− [(M−H)−]: calcd. 267.1966 
 found 267.1970. 
 
IR (ATR): ῦ/ cm−1 = 3401 (br w), 2957 (s), 2929 (s), 2876 (m), 1708 (s), 1454 (w), 1438 (w), 
1388 (w), 1235 (w), 1015 (w). 
 
Since this compound had been obtained as a mixture of diastereomers, the specific optical rotation was 
not determined. 
 
Analytical data for lactone 408: 
 
Rf = 0.14 (hexanes:EtOAc = 16:1). 
 
226  EXPERIMENTAL SECTION 
1H NMR (CDCl3, 600 MHz): δ  = 5.01 (mC, 1H), 4.86 (mC, 1H), 4.27 (d, J = 10.3 Hz, 1H), 
2.57−2.47 (m, 2H), 1.83−1.59 (m, 5H), 1.79 (s, 3H), 1.58−1.54 (m, 1H), 1.49−1.40 (m, 2H), 
1.27−1.20 (m, 1H), 0.99 (s, 3H), 0.92 (d, J = 6.8 Hz, 3H), 0.81 (d, J = 7.2 Hz, 3H) ppm.  
 
13C NMR (CDCl3, 150 MHz): δ = 174.8, 144.0, 112.6, 79.5, 46.8, 46.7, 46.0, 42.9, 40.0, 33.2, 28.5, 
22.3, 22.1, 18.2, 18.1, 16.8 ppm. 
 
LRESI-MS for C16H27O2+ [(M+H)+]: calcd. 251.4 
 found 251.3. 
 
 
Synthesis of Ester 412 
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To solution of seco acid 409 (220 mg, 820 μmol, 1.0 eq.) in THF (10 mL) at 0 °C was added 
LiAlH4 (3.30 mL of a 1.0M solution in THF, 3.30 mmol, 4.0 eq.) dropwise. The mixture was allowed 
to warm to room temperature and stirred for 4 h before being quenched by addition of NaOH (3M, 
2 mL). The mixture was diluted with Et2O (20 mL) and water (5 mL) and filtered over a pad of 
Celite® (washings with Et2O). The aqueous phase was extracted with Et2O (2 x 10 mL) and the 
combined organic layers were dried over MgSO4. The solvents were evaporated under reduced 
pressure and the crude product was purified by flash column chromatography (hexanes:EtOAc = 2:1) 
to yield diol 415 (195 mg, 768 μmol, 96%) as a mixture of diastereomers, which was immediately 
used in the next step. 
To a solution of diol 415 (165 mg, 650 μmol, 1.0 eq.) in CH2Cl2 (10 mL) at 0 °C was added 
subsequently Et3N (498 μL, 3.58 mmol, 5.0 eq.), TBDPSCl (850 μL, 3.25 mmol, 5.0 eq.) and 
DMAP (4.3 mg, 30 μmol, 5.0 mol-%). The mixture was allowed to warm to room temperature and 
stirred for an additional 5 h. The mixture was diluted with CH2Cl2 (10 mL) and the reaction was 
quenched by addition of saturated aqueous NH4Cl (10 mL). The aqueous layer was extracted with 
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CH2Cl2 (3 x 15 mL) and the combined organic layers were washed with saturated aqueous 
NaCl (20 mL) and dried over MgSO4. The solvents were evaporated under reduced pressure and the 
crude product was purified by flash column chromatography (hexanes:EtOAc = 24:1) to yield 
alcohol 410 as mixture of diastereomers. Due to silanol impurities, this material was directly used in 
the next step. 
The crude alcohol 410 (assumed 650 μmol, 1.0 eq.) was dissolved in triethyl orthoacetate (411, 5 mL, 
27.3 mmol, 42 eq.) and one drop of propionic acid was added. The mixture was heated to 130 °C for 
1 h, distilling off generated EtOH. The reaction was allowed to cool to room temperature and excess 
orthoacetate 411 was removed under reduced pressure. The residue was dissolved in Et2O (50 mL) and 
was sequentially washed with saturated aqueous NaHCO3 (2 x 10 mL) and saturated aqueous 
NaCl (10 mL). The organic layer was dried over MgSO4, the solvent was removed under reduced 
pressure and the crude product was purified by flash column chromatography (hexanes:EtOAc = 39:1) 
to yield ester 412 (330 mg, 587 μmol, 86% over three steps) as a highly viscous colorless oil. 
 
The configuration of the double bond was determined to be (E) by 2D NOESY NMR spectroscopy 
showing the proximity of 3-H and 5-H. 
 
Rf = 0.48 (hexanes:EtOAc = 7:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.69−7.65 (m, 4H, 25-H)*, 7.43−7.35 (m, 6H, 24-H*, 26-H), 
5.19 (mC, 1H, 5-H), 4.11 (q, 3J19/20 = 7.1 Hz, 2H, 19-H), 3.66 (dd, 3J13/12A = 3J13/12B = 7.3 Hz, 2H, 
13-H), 2.40−2.33 (m, 2H, 2-H), 2.32−2.26 (m, 2H, 3-H), 2.02 (dd, 2J6A/6B = 14.3 Hz, 3J6A/5 = 8.2 Hz, 
1H, 6-HA), 1.76 (dd, 2J6B/6A = 14.2 Hz, 3J6B/5 = 7.0 Hz, 1H, 6-HB), 1.70−1.63 (m, 1H, 12-HA), 
1.61−1.56 (m, 1H, 16-H), 1.54 (s, 3H, 14-H), 1.53−1.40 (m, 3H, 9-HA, 10-H, 12-HB), 1.36−1.22 (m, 
4H, 8-H, 9-HB, 11-H), 1.24 (t, 3J20/19 = 7.1 Hz, 3H, 20-H), 1.05 (s, 9H, 22-H), 0.82 (d, 3J17/16 = 7.0 Hz, 
3H, 18-H)**, 0.72 (d, 3J18/16 = 6.8 Hz, 3H, 16-H)**, 0.69 (s, 3H, 15-H) ppm.  
 
13C NMR (CDCl3, 150 MHz): δ = 173.7 (C-1), 135.7 (C-25)*, 134.4 (C-4), 132.2 (C-23), 
129.6 (C-26), 127.7 (C-24)*, 122.8 (C-5), 64.8 (C-13), 60.4 (C-19), 50.8 (C-10), 46.5 (C-11), 
45.5 (C-7), 39.9 (C-6), 38.6 (C-8), 35.2 (C-3), 34.3 (C-12), 33.6 (C-2), 29.8 (C-16), 27.1 (C-22), 
22.9 (C-17)**, 22.8 (C-9), 20.7 (C-15), 19.3 (C-21), 16.4 (C-18)**, 16.3 (C-14), 14.4 (C-20) ppm. 
  
ESI-MS for C36H58O3NSi+ [(M+NH4)+]: calcd. 580.4180 
 found 580.4179. 
 
228  EXPERIMENTAL SECTION 
IR (ATR): ῦ/cm−1 = 3072 (w), 3051 (w), 2957 (s), 2932 (s), 2860 (s), 1737 (s), 1472 (w), 1464 (w), 
1428 (w), 1386 (w), 1368 (w), 1300 (w), 1254 (w), 1177 (w), 1560 (w), 1112 (m), 1093 (m), 941 (w) 
823 (w), 702 (m), 614 (w).  
 
[ ]20Dα  = −0.8 (c 0.50, CH2Cl2). 
 
 
Synthesis of Carboxylic Acid 417 
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To a suspension of NaH (60 wt% in mineral oil, 5.73 g, 144 mmol, 2.5 eq.) in THF (75 mL) was 
carefully added bromoacetic acid (464, 7.90 g, 57.4 mmol, 1.0 eq.) and the mixture was stirred at room 
temperature until H2 evolution had ceased. After cooling to 0 °C, a solution of PMBOH (7.10 mL, 
58.0 mmol, 1.05 eq.) in THF (150 mL) was carefully added via cannula. The mixture was allowed to 
warm to room temperature and stirred for an additional 1 h at this temperature before adding 
Bu4NBr (1.00 g, 3.00 mmol, 5.2 mol-%) and heating the suspension to reflux for 4 h. The reaction was 
cooled to 0 °C and EtOH (20 mL) was carefully added. The white precipitate was filtered off and 
dissolved in H2O (50 mL). This solution was acidified with aqueous HCl (2N, 20 mL) to pH = 1 
precipitating a colorless solid. The aqueous phase was extracted with Et2O (3 x 50 mL) and the 
combined organic layers were dried over MgSO4. Evaporation of the solvent under reduced pressure 
yielded carboxylic acid 417 (8.10 g, 41.3 mmol, 72%) as a colorless solid. 
 
Rf = 0.31 (hexanes:EtOAc = 1:1, 1% AcOH). 
 
Melting point = 53.5−55.0 °C (Et2O). 
 
1H NMR (CDCl3, 300 MHz): δ = 10.86 (brs, 1H, OH), 7.29 (mC, 2H, 5-H), 6.89 (mC, 2H, 6-H), 
4.58 (s, 2H, 3-H), 4.11 (s, 2H, 2-H), 3.81 (s, 3H, 8-H) ppm. 
   
13C NMR (CDCl3, 75 MHz): δ = 175.5 (C-1), 159.8 (C-7), 130.0 (C-5), 128.8 (C-4), 114.1 (C-6), 
73.2 (C-3), 66.4 (C-2), 55.4 (C-8) ppm. 
 
ESI-MS for C10H11O4− [(M−H)−]: calcd. 195.0663 
 found 195.0669. 
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IR (ATR): ῦ/cm−1 = 3125 (br m), 2960 (m), 2840 (w), 1756 (s), 1724 (s), 1611 (m), 1583 (w), 1511 
(s), 1461 (m), 1429 (m), 1374 (w), 1301 (w), 1249 (s), 1214 (m), 1174 (s), 1094 (m), 1026 (m), 
999 (m), 952 (m), 933 (w), 903 (w), 816 (s), 758 (w).  
 
The analytical data matched those reported previously.[279] 
 
 
Synthesis of Ester 418 
 
 
To a solution of lactone 408 (50 mg, 0.20 mmol, 1.0 eq.) in Et2O (4 mL) at 0 °C was added 
LiAlH4 (23 mg, 0.60 mmol, 3.0 eq.) in one portion and the mixture was stirred at room temperature for 
4 h. The reaction was quenched at 0 °C by carefully adding half-saturated aqueous Rochelle 
salt (4 mL) and the biphasic mixture was stirred vigorously for 1 h at room temperature. The phases 
were separated and the aqueous layer was extracted with Et2O (3 x 10 mL). The combined organic 
layers were dried over MgSO4 and the solvents were evaporated under reduced pressure. The crude 
product was purified by a short flash column chromatography (silica, hexanes:EtOAc = 2:1 to 1:1) to 
yield diol 415 (37 mg, 0.15 mmol, 73%, Rf = 0.18, CH2Cl2:MeOH = 100:5) as a colorless solid, which 
was used without further characterization. 
To a solution of diol 415 (30 mg, 0.12 mmol, 1.0 eq.) in CH2Cl2 (2 mL) at 0 °C was added 
Et3N (18 μL, 0.13 mmol, 1.1 eq.), TBSCl (20 mg, 0.13 mmol, 1.1 eq.) and DMAP (spatula tip). The 
mixture was allowed to warm to room temperature and was stirred an additional 16 h prior to being 
diluted with CH2Cl2 (10 mL). The reaction was quenched by addition of saturated aqueous 
NH4Cl (5 mL) and the phases were separated. The aqueous layer was extracted with CH2Cl2 (3 x 
5 mL) and the combined organic layers were dried over Na2SO4. The solvents were evaporated under 
reduced pressure and the crude product was purified by flash column chromatography (silica, 
hexanes:EtOAc = 16:1) to yield allylic alcohol 416 (34 mg, 92 μmol, 78%, Rf = 0.12, hexanes:EtOAc 
= 30:1) as a highly viscous colorless oil, which was used in the next step without further 
characterization.  
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To a solution of allylic alcohol 416 (30 mg, 82 μmol, 1.0 eq.), carboxylic acid 417 (80 mg, 0.41 mmol, 
5.0 eq.) and DMAP (55 mg, 0.45 mmol, 5.50 eq.) in CH2Cl2 (5 mL) at 0 °C was added 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (78 mg, 0.41 mmol, 5.0 eq.). The mixture 
was allowed to warm to room temperature and stirred for an additional 30 min before being stirred at 
35 °C for 16 h. The reaction was cooled to room temperature, diluted with CH2Cl2 (5 mL) and 
quenched by addition of H2O (5 mL). The organic phase was extracted with CH2Cl2 (3 x 5 mL) and 
the combined organic layers were sequentially washed with saturated aqueous NaHCO3 (4 mL) and 
saturated aqueous NH4Cl (4 mL), and dried over MgSO4. Having evaporated the solvents under 
reduced pressure, the crude product was purified by flash column chromatography (silica, 
hexanes:EtOAc = 20:1) to yield ester 418 (40 mg, 73 μmol, 90%) as a colorless oil. 
Note: the intermediate allylic alcohol 416 and ester 418 are co-polar on TLC. 
 
Rf = 0.12 (hexanes:EtOAc = 30:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.29 (mC, 2H, 24-H), 6.88 (mC, 2H, 25-H), 5.37 (dd, 3J3/4A = 8.4 Hz, 
3J3/4B = 3.0 Hz, 1H, 3-H), 4.95 (br s, 1H, 1-HA), 4.83 (mC, 1H, 1-HB), 4.56 (s, 2H, 22-H), 4.03 (s, 2H, 
21-H), 3.80 (s, 3H, 27-H), 3.64 (ddd,2J11A/11B = 9.8 Hz, 3J11A/10B = 8.4 Hz, 3J11A/10A = 5.4 Hz, 1H, 
11-HA), 3.58 (ddd, 2J11B/11A = 9.9 Hz, 3J11B/10A = 8.1 Hz, 3J11B/10B = 6.9 Hz, 1H, 11-HB), 1.89 (dd, 2J4A/4B 
= 14.9 Hz, 3J4A/3 = 8.5 Hz, 1H, 4-HA), 1.72 (s, 3H, 12-H), 1.70 (mC, 1H, 14-H), 1.64−1.59 (m, 2H, 8-H, 
10-HA), 1.57−1.48 (m, 2H, 6-HA, 7-HA), 1.45−1.40 (m, 2H, 4-HB, 10-HB), 1.48−1.33 (m, 1H, 7-HB), 
1.31−1.26 (m, 2H, 6-HB, 9-H), 0.91−0.87 (m, 3H, 15-H)*, 0.89 (s, 9H, 19-H), 0.81 (s, 3H, 13-H), 
0.77 (d, 3J16/15 = 6.9 Hz, 3H, 16-H)*, 0.04 (s, 6H, 17-H) ppm.  
 
13C NMR (CDCl3, 150 MHz): δ = 169.8 (C-20), 159.6 (C-26), 144.6 (C-2), 129.9 (C-24), 
129.5 (C-23), 114.0 (C-25), 112.4 (C-1), 76.6 (C-3), 73.0 (C-22), 67.2 (C-21), 62.9 (C-11), 
55.4 (C-27), 50.1 (C-8), 48.0 (C-9), 45.0 (C-4), 44.3 (C-5), 38.8 (C-6), 34.2 (C-10), 29.7 (C-14), 
26.1 (C-19), 22.8 (2C, C-7, C-15*), 20.4 (C-13), 18.5 (C-18), 18.3 (C-12), 16.3 (C-16)*, 
−5.1 (C-17) ppm. 
 
ESI-MS for C32H58NO5Si+ [(M+NH4)+]: calcd. 564.4079 
 found 564.4078. 
 
IR (ATR): ῦ/cm−1 = 2954 (s), 2959 (m), 1755 (m), 1613 (w), 1514 (m), 1463 (w), 1386 (w), 1250 (m), 
1197 (w), 1108 (m), 1039 (w), 940 (w), 835 (w), 775 (w). 
 
[ ]20Dα  = +4.0 (c 0.50, CH2Cl2). 
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2.4 Experimental Procedures for Chapter 5: ‘Synthetic Studies 
toward YW 3548’ 
 
Synthesis of Oxazolidinone 434 
 
 
To a solution of Evans auxiliary 436[296] (1.58 g, 12.2 mmol, 1.0 eq.) in THF (30 mL) at −78 °C was 
added n-BuLi (5.60 mL of a 2.4M solution in hexanes, 13.4 mmol, 1.0 eq.) and the mixture was stirred 
for 30 min. Then, a solution of 4-pentenoyl chloride (437, 1.50 mL, 13.6 mmol, 1.1 eq.) in 
THF (1.5 mL) was added dropwise and the reaction mixture was stirred for 30 min at −78 °C prior to 
removing the cold bath. After stirring for an additional 30 min at room temperature, the reaction was 
quenched by addition of saturated aqueous NH4Cl (15 mL) and the aqueous phase was extracted with 
EtOAc (3 x 30 mL). The combined organic layers were dried over MgSO4 and the solvents were 
removed under reduced pressure. The crude product was purified by flash column 
chromatography (silica, hexanes:EtOAc = 7:1) to yield oxazolidinone 434 (1.87 g, 8.83 mmol, 72%) 
as a colorless oil. 
 
Rf = 0.34 (hexanes:EtOAc = 4:1). 
 
1H NMR (CDCl3, 300 MHz): δ = 5.85 (ddt, 3J4/5A = 16.9 Hz, 3J4/5B = 10.2 Hz, 3J4/3 = 6.6 Hz, 1H, 4-H), 
5.07 (ddt, 3J5A/4 = 17.1 Hz, 2J5A/5B = 4J5A/3 = 1.6 Hz, 1H, 5-HA), 5.00 (ddt, 3J5B/4 = 10.3 Hz, 2J5B/5A = 
4J5B/3 = 1.4 Hz, 1H, 5-HB), 4.43 (mC, 1H, 8-H), 4.26 (dd, 2J7A/7B = 9.2 Hz, 3J7A/8 = 8.1 Hz, 1H, 7-HA), 
4.19 (dd, 2J7B/7A = 9.2 Hz, 3J7B/8 = 3.4 Hz, 1H, 7-HB), 3.10 (ddd, 2J2A/2B = 17.0 Hz, 3J2A/3 = 7.8 Hz, 
3J2A/3 = 7.0 Hz, 1H, 2-HA), 2.97 (ddd, 2J2B/2A = 17.1 Hz, 3J2B/3 = 7.5, 7.5 Hz, 1H, 2-HB), 2.49−2.28 (m, 
3H, 3-H, 11-H), 0.90 (d, 3J10/9 = 7.0 Hz, 3H, 10-H)*, 0.86 (d, 3J11/9 = 6.9 Hz, 3H, 11-H)* ppm.  
  
13C NMR (CDCl3, 75 MHz): δ = 172.6 (C-1), 154.2 (C-6), 136.8 (C-4), 115.8 (C-5), 63.5 (C-7), 
58.5 (C-8), 34.9 (C-2), 28.5 (2C, C-3, C-9), 18.1 (C-10)*, 14.8 (C-11)* ppm. 
 
EI-MS for C11H17NO3+ [M+]: calcd. 211.1203 
 found 211.1201. 
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IR (ATR): ῦ/cm−1 = 3079 (w), 2965 (w), 2877 (w), 1776 (s), 1706 (s), 1641 (w), 1487 (w), 1439 (w), 
1389 (s), 1302 (m), 1204 (s), 1061 (m), 916 (w).  
 
[ ]20Dα  = +50.2 (c 1.00, CHCl3). 
 
The analytical data matched those reported previously.[297] 
 
 
Synthesis of Aldol Product 439 
 
 
To a solution of oxazolidinone 434 (1.45 g, 6.85 mmol, 1.0 eq.) in Et2O (20 mL) at 0 °C was 
consecutively added Bu2BOTf (3.32 mL, 13.7 mmol, 2.0 eq.) and DIPEA (1.40 mL, 8.09 mmol, 
1.2 eq.). The resulting suspension was stirred for an additional 30 min at 0 °C and then cooled to 
−78 °C before adding a solution of acetaldehyde (432, 482 μL, 8.56 mmol, 1.25 eq.) in Et2O (6.8 mL) 
within 10 min. The reaction mixture was stirred for an additional 1 h at −78 °C and was then quenched 
by addition of tartaric acid (5.13 g, 34.0 mmol, 5.0 eq.). The mixture was allowed to warm to room 
temperature and stirred for 2 h at this temperature, forming a dark brown solution. The acid was 
filtered off, the filter cake was rinsed with Et2O (30 mL) and the organic layer was washed with 
H2O (30 mL). The aqueous phase was extracted with Et2O (2 x 40 mL) and the combined organic 
layers were washed with saturated aqueous NaHCO3 (2 x 80 mL). The aqueous phases were re-
extracted with Et2O (3 x 80 mL) and the combined organic layers were washed with saturated aqueous 
NaCl (100 mL). The volume of the Et2O phase was reduced to ca. 180 mL, before the solution was 
cooled to 0 °C and a mixture of MeOH/H2O2 (3:1, 35 mL) was added dropwise. The biphasic mixture 
was stirred for 1 h at room temperature changing its color from orange to yellow. The mixture was 
diluted with Et2O (100 mL) and the organic phase was washed with saturated aqueous 
NaHCO3 (75 mL) and saturated aqueous NaCl (75 mL). Having dried the organic layer over Na2SO4 
and having evaporated the solvent under reduced pressure, the crude product was purified by flash 
column chromatography (silica, hexanes:EtOAc = 5:1 to 4:1 to 3:1) to yield alcohol 439 (1.48 g, 
5.8 mmol, 85%, d.r. = 94:6) as an inseparable mixture of diastereomers as a colorless oil. 
The diastereomeric ratio was determined by 1H NMR spectroscopy by integration of the baseline 
separated doublet signals of 4-H at 1.29 ppm (major) and 1.22 ppm (minor). 
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Rf = 0.29 (hexanes:EtOAc = 3:1). 
 
1H NMR (CDCl3, 600 MHz, only major isomer quoted): δ = 5.75 (mC, 1H, 6-H), 5.06 (ddt, 3J7A/6 = 
17.1 Hz, 2J7A/7B = 4J7A/5 = 1.6 Hz, 1H, 7-HA), 5.00 (mC, 1H, 7-HB), 4.42 (ddd, 3J10/9A = 7.9 Hz, 3J10/11 = 
3.9 Hz, 3J10/9B = 3.0 Hz, 1H, 10-H), 4.23 (dd, 2J9A/9B = 9.0 Hz, 3J9A/10 = 7.8 Hz, 1H, 9-HA), 4.20 (dd, 
2J9B/9A = 9.0 Hz, 3J9B/10 = 3.0 Hz, 1H, 9-HB), 4.02 (ddd, 3J2/3 = 9.0 Hz, 3J2/5A = 6.0 Hz, 3J2/5B = 5.6 Hz, 
1H, 2-H), 3.93 (ddq, 3J3/2 = 3J3/OH = 8.9 Hz, 3J3/4 = 6.3 Hz, 1H, 3-H), 2.60 (d, 3JOH/3 = 9.1 Hz, 1H, OH), 
2.54−2.26 (m, 3H, 5-H, 11-H), 1.27 (d, 3J4/3 = 6.4 Hz, 3H, 4-H), 0.92 (d, 3J12/11 = 7.1 Hz, 3H, 12-H)*, 
0.88 (d, 3J13/11 = 7.0 Hz, 3H, 13-H)* ppm. 
  
13C NMR (CDCl3, 75 MHz, only major isomer quoted): δ = 175.5 (C-1), 154.4 (C-8), 135.1 (C-6), 
117.4 (C-3), 69.4 (C-3), 63.5 (C-9), 59.0 (C-10), 49.5 (C-2), 33.8 (C-5), 28.7 (C-11), 21.8 (C-4), 18.1 
(C-12)*, 14.8 (C-13)* ppm. 
 
EI-MS for C13H21NO4+ [M+]: calcd. 255.1465 
 found 255.1455. 
 
IR (ATR): ῦ/cm−1 = 3508 (br s), 3078 (w), 2967 (m), 2932 (m), 2876 (w), 1776 (s), 1696 (m), 1641 
(w), 1489 (w), 1439 (w), 1385 (m), 1300 (w), 1202 (m), 1119 (w), 1057 (w).  
 
[ ]20Dα  = +61.2 (c 1.00, d.r. = 94:6, CH2Cl2). 
 
 
Synthesis of Carbamate 443 
 
 
To a solution of alcohol 439 (d.r. = 94:6, 28 mg, 0.11 mmol, 1.0 eq.) in CH2Cl2 (3 mL) at 0 °C was 
added DMAP (28 mg, 0.35 mmol, 3.4 eq.) and 4-bromophenyl isocyanate (442, 65 mg, 0.33 mmol, 
3.0 eq.). The thus formed yellow solution was allowed to warm to room temperature and stirred for 
1.5 h precipitating a white solid. The reaction was quenched by addition of saturated aqueous 
NaHCO3 (5 mL) and the mixture was extracted with Et2O (2 x 15 mL). The combined organic layers 
were washed with saturated aqueous NaCl (10 mL) and dried over Na2SO4. After evaporation of the 
solvents under reduced pressure, the crude product was purified by flash column 
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chromatography (silica, hexanes:EtOAc = 7:1 to 5:1) to yield carbamate 443 (43 mg, 95 μmol, 86%) 
as a colorless solid. The minor diastereomer was separable by flash column chromatography, but not 
isolated. 
 
Crystals suitable for X-ray analysis were obtained by slow evaporation of a solution of carbamate 443 
in Et2O/n-pentane (1:1). 
 
Rf = 0.36 (hexanes:EtOAc = 3:1). 
 
Melting point = 106.0−108.0 °C (hexanes/EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.41−7.37 (m, 2H, 17-H), 7.29−7.23 (m, 2H, 16-H), 6.65 (br s, 1H, 
NH), 5.75 (mC, 1H, 6-H), 5.22 (mC, 1H, 3-H), 5.07 (dd, 3J7A/6 = 17.1 Hz, 4J7A/5 = 1.3 Hz, 1H, 7-HA), 
5.03 (d, 3J7B/6 = 10.1 Hz, 1H, 7-HB), 4.44 (mC, 1H, 10-H), 4.37 (mC, 1H, 2-H), 4.23 (dd, 2J9A/9B = 
9.0 Hz, 3J9A/10 = 8.3 Hz, 1H, 9-HA), 4.18 (dd, 2J9B/9A = 9.1 Hz, 3J9B/10 = 3.0 Hz, 1H, 9-HB), 
2.45−2.28 (m, 3H, 5-H, 11-H), 1.29 (d, 3J4/3 = 6.5 Hz, 3H, 4-H), 0.87 (d, 3J12/11 = 7.2 Hz, 3H, 12-H)*, 
0.84 (d, 3J13/11 = 7.0 Hz, 3H, 13-H)* ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 173.2 (C-1), 154.0 (C-8), 152.3 (C-14), 137.1 (C-15) 134.2 (C-6), 
132.1 (C-17), 120.2 (C-16), 118.0 (C-7), 116.0 (C-18), 72.8 (C-3), 63.4 (C-9), 58.9 (C-10), 47.4 (C-2), 
33.5 (C-5), 28.7, (C-11), 18.2 (C-4), 18.1 (C-12)*, 14.8 (C-13)* ppm. 
 
ESI-MS for C20H25BrN2NaO5+ [(M+Na)+]: calcd. 475.0839 
 found 475.0838. 
 
IR (ATR): ῦ/cm−1 = 3334 (br w), 3077 (w), 2965 (w), 2875 (w), 1775 (s), 1702 (s), 1593 (m), 1527 (s), 
1489 (m), 1396 (s), 1386 (s), 1305 (m), 1219 (s), 1118 (w), 1099 (w), 1073 (m), 1055 (m), 1007 (w), 
977 (w), 922 (w), 825 (w), 767 (w), 707 (w).  
 
[ ]20Dα  = +38.8 (c 1.00, CH2Cl2). 
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Synthesis of Acetates 444 and 445 
 
 
To a solution of alcohol 439 (d.r. = 94:6, 950 mg, 3.72 mmol, 1.0 eq.) in CH2Cl2 (35 mL) was added 
Et3N (780 μL, 5.62 mmol, 1.5 eq.), DMAP (129 mg, 1.06 mmol, 28 mol-%) and Ac2O (433, 560 μL, 
5.50 mmol, 1.5 eq.). The resulting solution was heated to reflux for 2 h and, after cooling to room 
temperature, the mixture was diluted with CH2Cl2 (35 mL). The organic phase was washed with 1N 
HCl (30 mL), saturated aqueous NaHCO3 (40 mL) and saturated aqueous NaCl (50 mL). Having dried 
the organic layer over Na2SO4 and evaporated the solvent under reduced pressure, the crude product 
was purified by flash column chromatography (silica, hexanes:EtOAc = 5:1) to yield 
acetate 445 (940 mg, 3.16 mmol, 85%) as a colorless solid along with the 
syn-diastereomer 444 (30 mg, 0.10 mmol, 3%) from the previous reaction as a colorless oil. 
 
Analytical data for anti-diastereomer 445: 
 
Rf = 0.30 (hexanes:EtOAc = 3:1). 
 
Melting point = 65.0−67.0 °C (hexanes/EtOAc). 
 
1H NMR (CDCl3, 600 MHz): δ = 5.78−5.70 (m, 1H, 6-H), 5.17 (dq, 3J3/2 = 8.5 Hz, 3J3/4 = 6.3 Hz, 1H, 
3-H), 5.05 (ddt, 3J7A/6 = 17.1 Hz, 2J7A/7B = 4J7A/5 = 1.6 Hz, 1H, 7-HA), 5.01 (mC, 1H, 7-HB), 4.43 (ddd, 
3J10/9A = 8.2 Hz, 3J10/11 = 4.0 Hz, 3J10/9B = 3.2 Hz, 1H, 10-H), 4.31 (dt, 3J2/3 = 8.5 Hz, 3J2/5 = 5.6 Hz, 1H, 
2-H), 4.22 (dd, 2J9A/9B = 9.1 Hz, 3J9A/10 = 8.2 Hz, 1H, 9-HA), 4.18 (dd, 2J9B/9A = 9.2 Hz, 3J9B/10 = 3.2 Hz, 
1H, 9-HB), 2.40−2.27 (m, 3H, 5-H, 11-H), 1.96 (s, 3H, 15-H), 1.29 (d, 3J4/3 = 6.3 Hz, 3H, 4-H), 
0.90 (d, 3J12/11 = 7.1 Hz, 3H, 12-H)*, 0.88 (d, 3J13/11 = 7.0 Hz, 3H, 13-H)* ppm. 
  
13C NMR (CDCl3, 150 MHz): δ = 173.2 (C-1), 170.0 (C-14), 153.9 (C-8), 134.2 (C-6), 117.9 (C-7), 
71.7 (C-3), 63.3 (C-9), 58.7 (C-10), 47.3 (C-2), 33.4 (C-5), 28.7 (C-11), 21.2 (C-15), 18.1 (C-12)*, 
17.6 (C-4), 14.9 (C-13)* ppm. 
 
FAB-MS for C15H24NO5+ [(M+H)+]: calcd. 298.1649 
 found 298.1653. 
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IR (ATR): ῦ/cm−1 = 3274 (br w), 2975 (w), 1776 (s), 1733 (s), 1697 (s), 1386 (s), 1372 (s), 1300 (m), 
1231 (s), 1201 (s), 1120 (m), 1098 (m), 1056 (m), 978 (w), 950 (w), 927 (w).  
 
[ ]20Dα  = +54.0 (c 1.00, CH2Cl2). 
 
Analytical data for syn-diastereomer 444: 
 
Rf = 0.38 (hexanes:EtOAc = 3:1). 
 
1H NMR (CDCl3, 300 MHz): δ = 5.73 (mC, 1H, 6-H), 5.26 (mC, 1H, 3-H), 5.11−4.95 (m, 2H, 7-H), 
4.44 (mC, 1H, 10-H), 4.28−4.14 (m, 3H, 2-H, 9-H), 2.56−2.44 (m, 1H, 5-HA), 2.39−2.24 (m, 2H, 5-HB, 
11-H), 2.00 (s, 3H, 14-H), 1.27 (d, 3J4/3 = 6.3 Hz, 3H, 4-H), 0.91 (d, 3J12/11 = 7.1 Hz, 3H, 12-H)*, 
0.90 (d, 3J13/11 = 7.0 Hz, 3H, 13-H)* ppm. 
  
13C NMR (CDCl3, 75 MHz): δ = 172.7 (C-1), 170.2 (C-14), 154.0 (C-8), 135.2 (C-6), 117.3 (C-7), 
70.6 (C-3), 63.3 (C-9), 58.7 (C-10), 46.8 (C-2), 31.9 (C-5), 28.5 (C-11), 21.2 (C-15), 18.1 (C-12)*, 
17.7 (C-4), 14.6 (C-13)* ppm. 
 
FAB-MS for C15H24NO5+ [(M+H)+]: calcd. 298.1649 
 found 298.1666. 
 
IR (ATR): ῦ/cm−1 = 3080 (w), 2967 (m), 1777 (s), 1739 (s), 1697 (m), 1387 (m), 1371 (m), 1301 (w), 
1236 (s), 1203 (m), 1122 (w), 1098 (w), 1058 (w), 1020 (w). 
 
[ ]20Dα  = +41.4 (c 1.00, CH2Cl2). 
 
 
Synthesis of Enol Triflate 446 
 
 
To a solution of acetate 445 (750 mg, 2.52 mmol, 1.0 eq.) in THF (40 mL) at −78 °C was added 
dropwise KHMDS (20.0 mL of a 0.5M solution in toluene, 10.0 mmol, 4.0 eq.) and the pale yellow 
solution was stirred for 2.5 h at −78 °C prior to quenching the reaction by addition of MeOH/saturated 
2 Experimental Procedures  237 
aqueous NH4Cl/H2O (1:1:1, 40 mL). After warming to room temperature, the pH was adjusted to 2−3 
by adding 1N HCl and the biphasic mixture was extracted with EtOAc (3 x 50 mL). The combined 
organic layers were dried over MgSO4 and evaporation of the solvents under reduced pressure yielded 
crude ketone 465 as an orange oil, which was used without further purification. 
The crude oil 465 (assumed 2.52 mmol, 1.0 eq.) was redissolved in CH2Cl2 (13 mL) and the solution 
was cooled to −78 °C. Then Et3N (1.10 mL, 7.94 mmol, 3.2 eq.) and Tf2O (6.00 mL of a 1.0M solution 
in CH2Cl2, 6.00 mmol, 2.4 eq.) were sequentially added and the solution was stirred for an additional 
90 min at this temperature. The reaction was quenched by addition of saturated aqueous 
NaHCO3 (25mL) and the mixture was allowed to warm to room temperature before being extracted 
with CH2Cl2 (3 x 50 mL). The combined organic layers were dried over MgSO4 and the solvents were 
removed under reduced pressure. The crude product was purified by flash column 
chromatography (silica, hexanes:EtOAc = 7:1) to yield enol triflate 446 (566 mg, 1.89 mmol, 75% 
over two steps) as a pale yellow oil 
 
Rf = 0.32 (hexanes:EtOAc = 9:1). 
 
1H NMR (CDCl3, 300 MHz): δ = 6.08 (s, 1H, 2-H), 5.72 (dddd, 3J7/8B = 17.1 Hz, 3J7/8A = 10.3 Hz, 
3J7/6 = 7.5, 6.7 Hz, 1H, 7-H), 5.22 (mC, 1H, 8-HA), 5.19 (ddt, 3J8B/7 = 16.9 Hz, 2J8B/8A = 4J8B/6 = 1.4 Hz, 
1H, 8-HB), 4.65 (qd, 3J4/9 = 6.7 Hz, 3J4/5 = 3.2 Hz, 1H, 4-H), 2.57 (ddd, 3J5/6A = 7.6 Hz, 3J5/6B = 4.8 Hz, 
3J5/4 = 3.2 Hz, 1H, 5-H), 2.55−2.41 (m, 2H, 6-H), 1.47 (d, 3J9/4 = 6.6 Hz, 1H, 9-H) ppm. 
  
13C NMR (CDCl3, 75 MHz): δ = 163.6 (C-1), 161.9 (C-3), 131.9 (C-7), 120.4 (C-8), 118.4 (q, 
1J10/F = 321 Hz, C-10), 109.7 (q, 5J2/F = 0.8 Hz, C-2), 75.8 (C-5), 42.8 (C-4), 34.5 (C-6), 
19.8 (C-9) ppm. 
 
19F NMR (CDCl3, 377 MHz): δ = −73.2 ppm. 
 
FAB-MS for C10H12F3O5S+ [(M+H)+]: calcd. 301.0352 
 found 301.0345. 
 
IR (ATR): ῦ/cm−1 = 3085 (w), 2987 (w), 1730 (s), 1659 (w), 1429 (s), 1366 (w), 1305 (m), 1246 (m), 
1213 (s), 1136 (s), 1078 (m), 1042 (w), 980 (w), 916 (w), 884 (m), 797 (w), 762 (w).  
 
[ ]20Dα  = +95.0 (c 1.00, CH2Cl2). 
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Synthesis of Dimer 447 
 
 
To a degassed solution of enol triflate 446 (30 mg, 0.10 mmol, 1.0 eq.) and Me6Sn2 (47 mg, 
0.15 mmol, 1.5 eq.) in DMF (2.5 mL) was added CuI (6.0 mg, 32 μmol, 32 mol-%) followed by 
Pd2dba3 (16 mg, 17 μmol, 17 mol-%) and the resulting suspension was stirred at 60 °C for 1 h. After 
cooling to room temperature, the reaction was quenched by addition of H2O (3 mL) and the mixture 
was extracted with Et2O (3 x 7 mL). The combined organic layers were washed with 10% aqueous 
NaCl (2 x 10 mL) and dried over MgSO4. The solvent was evaporated under reduced pressure and the 
crude product was purified by flash column chromatography (silica, hexanes:EtOAc = 5:1 to 3:1) to 
yield dimer 447 (11 mg, 36 μmol, 72%) as a colorless amorphous solid. 
 
Rf = 0.12 (hexanes:EtOAc = 3:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 6.24 (s, 2H, 2-H), 5.75 (mC, 2H, 7-H), 5.20 (mC, 2H, 8-HA), 5.16 
(mC, 2H, 8-HB), 4.84 (mC, 2H, 5-H), 2.53 (mC, 2H, 4-H), 2.34−2.24 (m, 4H, 6-H), 1.39 (d, 3J9/5 = 
6.8 Hz, 6H, 9-H) ppm. 
   
13C NMR (CDCl3, 150 MHz): δ = 162.6 (C-1), 151.6 (C-3), 133.5 (C-7), 119.8 (C-2)*, 119.4 (C-8)*, 
75.7 (C-5), 38.8 (C-4), 36.9 (C-6), 20.0 (C-9) ppm. 
 
FAB-MS for C18H23O4+ [(M+H)+]: calcd. 303.1591 
 found 303.1577. 
 
IR (ATR): ῦ/cm−1 = 3078 (w), 2979 (w), 1704 (s), 1437 (w), 1380 (w), 1350 (w), 1224 (m), 1135 (w), 
1039 (m), 994 (w), 917 (w), 885 (w). 
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Synthesis of Lactone 448 
 
 
To a suspension of enol triflate 446 (24 mg, 80 μmol, 1.0 eq.), Pd(PPh3)4 (12 mg, 10 μmol, 0.13 eq.), 
CuI (8.8 mg, 88 μmol, 1.1 eq.) and Na2CO3 (59 mg, 0.56 mmol, 7.0 eq.) in degassed benzene (5 mL) 
was added a solution of phenylboronic acid (29 mg, 0.24 mmol, 3.0 eq.) in EtOH (1.5 mL) and the 
reaction mixture was heated to reflux for 1 h changing its color from pale yellow to deep red. The 
mixture was allowed to cool to room temperature and quenched by addition of saturated aqueous 
NaHCO3 (4 mL). The mixture was diluted with EtOAc (5 mL) and the organic layer was washed with 
H2O (2 x 10 mL) and saturated aqueous NaHCO3 (3 x 10 mL). The combined aqueous phases were re-
extracted with EtOAc (2 x 10 mL) and the combined organic layers were washed with saturated 
aqueous NaCl (30 mL). After drying the organic layer over MgSO4 and evaporation of the solvent 
under reduced pressure, the crude product was purified by flash column chromatography (silica, 
hexanes:EtOAc = 1:0 to 9:1) to yield lactone 448 (16 mg, 70 μmol, 88%) as a highly viscous colorless 
oil. 
 
Rf = 0.42 (hexanes:EtOAc = 3:1). 
 
1H NMR (CDCl3, 600 MHz): δ = 7.54−7.50 (m, 2H, 11-H), 7.48−7.43 (m, 3H, 12-H, 13-H), 6.31 (s, 
1H, 2-H), 5.74 (mC, 1H, 8-H), 5.14−5.09 (m, 2H, 9-H), 4.83 (qd, 3J5/6 = 6.8 Hz, 3J5/4 = 1.1 Hz, 1H, 
5-H), 2.78 (mC 1H, 4-H), 2.34 (mC, 2H, 7-H), 1.47 (d, 3J6/5 = 6.7 Hz, 3H, 6-H) ppm. 
   
13C NMR (CDCl3, 150 MHz): δ = 164.0 (C-1), 156.9 (C-3), 136.2 (C-10), 134.4 (C-8), 130.7 (C-13), 
129.3 (C-12), 126.5 (C-11), 118.8 (C-9), 114.8 (C-2), 75.5 (C-5), 41.9 (C-4), 36.7 (C-7), 
20.0 (C-6) ppm. 
 
EI-MS for C14H16O+ [(M−CO)+]: calcd. 200.1196 
 found 200.1191. 
 
IR (ATR): ῦ/cm−1 = 3077 (w), 2979 (w), 1707 (s), 1640 (w), 1618 (w), 1446 (w), 1363 (m), 1258 (w), 
1225 (m), 1135 (w), 1043 (m), 996 (w), 961 (w), 920 (w), 874 (m), 771 (m).  
 
[ ]20Dα  = +241.6 (c 0.25, CH2Cl2). 
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A1 X-RAY CRYSTALLOGRAPHIC DATA 
 
The data collections were performed on an Oxford Diffraction Xcalibur diffractometer or on a Nonius 
KappaCCD diffractometer at 100K or 173 K using MoK -radiation (  = 0.71073 Å, graphite 
monochromator). The CrysAlisPro software (version 1.171.33.41)[318] was applied for the integration, 
scaling and multi-scan absorption correction of the data. The structures were solved by direct methods 
with SIR97[319] and refined by least-squares methods against F2 with SHELXL-97.[320] All non-
hydrogen atoms were refined anisotropically. The hydrogen atoms were placed in ideal geometry 
riding on their parent atoms. More details are provided in tables A1.1 A1.12 at the different sections.  
 
 
A1.1 Diketone 116 
 
CCDC 934941 contains the supplementary crystallographic data for diketone 116. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table A1.1 Crystallographic Data for Diketone 116. 
net formula C10H12O2 
Mr/g mol 1 164.201 
crystal size/mm 0.43 × 0.37 × 0.28 
T/K 100(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system orthorhombic 
space group P212121 
a/Å 7.3464(3) 
b/Å 10.3828(4) 
c/Å 11.4263(4) 
/° 90 
/° 90 
/° 90 
V/Å3 871.56(5) 
Z 4 
calc. density/g cm 3 1.25139(7) 
/mm 1 0.086 
absorption correction 'multi-scan' 
transmission factor range 0.99380 1.00000 
refls. measured 6290 
Rint 0.0282 
mean σ(I)/I 0.0327 
θ range 4.31 28.28 
observed refls. 1942 
x, y (weighting scheme) 0.0370, 0.1077 
hydrogen refinement constr 
Flack parameter 0.4(13) 
refls in refinement 2149 
parameters 110 
restraints 0 
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R(Fobs) 0.0350 
Rw(F2) 0.0834 
S 1.056 
shift/errormax 0.001 
max electron density/e Å 3 0.184 
min electron density/e Å 3 0.126 
 
Flack test meaningless (Mo radiation, no anomalous scatterer), correct structure derived from synthesis. 
 
 
 
 
A1.2 Acid 205 
 
CCDC 934940 contains the supplementary crystallographic data for acid 205. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table A1.2 Crystallographic data for acid 205. 
net formula C15H22O4 
Mr/g mol 1 266.333 
crystal size/mm 0.25 × 0.17 × 0.12 
T/K 100(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system orthorhombic 
space group P212121 
a/Å 6.3678(7) 
b/Å 9.2177(8) 
c/Å 24.664(3) 
/° 90 
/° 90 
/° 90 
V/Å3 1447.7(3) 
Z 4 
calc. density/g cm 3 1.2220(3) 
/mm 1 0.087 
absorption correction 'multi-scan' 
transmission factor range 0.98476 1.00000 
refls. measured 7632 
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Rint 0.0350 
mean σ(I)/I 0.0423 
θ range 4.23 25.34 
observed refls. 2316 
x, y (weighting scheme) 0.0262, 0.3919 
hydrogen refinement mixed 
Flack parameter 0.0(12) 
refls in refinement 2641 
parameters 180 
restraints 0 
R(Fobs) 0.0389 
Rw(F2) 0.0832 
S 1.022 
shift/errormax 0.001 
max electron density/e Å 3 0.152 
min electron density/e Å 3 −0.159 
 
Flack test meaningless (no anomalous scatterer, Mo radiation), correct structure derived from synthesis. C-bound 
H: constr, O-bound H: refall. 
 
 
 
 
A1.3 Ketone 195 
 
CCDC 865613 contains the supplementary crystallographic data for ketone 195. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table A1.3 Crystallographic data for ketone 195 
net formula C12H18O3 
Mr/g mol 1 210.270 
crystal size/mm 0.31 × 0.28 × 0.12 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
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crystal system orthorhombic 
space group P212121 
a/Å 9.2588(5) 
b/Å 9.4467(5) 
c/Å 12.5446(7) 
/° 90 
/° 90 
/° 90 
V/Å3 1097.21(10) 
Z 4 
calc. density/g cm 3 1.27292(12) 
/mm 1 0.090 
absorption correction 'multi-scan' 
transmission factor range 0.89301 1.00000 
refls. measured 8113 
Rint 0.0310 
mean σ(I)/I 0.0270 
θ range 4.31 26.33 
observed refls. 1051 
x, y (weighting scheme) 0.0500, 0 
hydrogen refinement Constr 
Flack parameter 3.1(15) 
refls in refinement 1301 
parameters 137 
restraints 0 
R(Fobs) 0.0320 
Rw(F2) 0.0784 
S 0.969 
shift/errormax 0.001 
max electron density/e Å 3 0.166 
min electron density/e Å 3 0.136 
 
Flack parameter meaningless. 933 Friedel pairs merged. 
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A1.4 Enone 194 
 
CCDC 865618 contains the supplementary crystallographic data for enone 194. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table A1.4 Crystallographic data for enone 194 
net formula C12H16O3 
Mr/g mol 1 208.254 
crystal size/mm 0.49 × 0.16 × 0.03 
T/K 173(2) 
Radiation MoKα 
diffractometer 'KappaCCD' 
crystal system monoclinic 
space group P21 
a/Å 6.4233(5) 
b/Å 9.7999(7) 
c/Å 8.5116(7) 
/° 90 
/° 100.147(4) 
/° 90 
V/Å3 527.41(7) 
Z 2 
calc. density/g cm 3 1.31138(17) 
/mm 1 0.093 
absorption correction none 
refls. measured 3526 
Rint 0.0515 
mean σ(I)/I 0.0365 
θ range 3.84–25.32 
observed refls. 874 
x, y (weighting scheme) 0.0496, 0.0788 
hydrogen refinement constr 
Flack parameter 1.7(19) 
refls in refinement 1016 
parameters 137 
restraints 1 
R(Fobs) 0.0379 
Rw(F2) 0.0953 
S 1.081 
shift/errormax 0.001 
max electron density/e Å 3 0.166 
min electron density/e Å 3 0.185 
 
Flack parameter meaningless, absolute structure deduced from synthesis, 845 Friedel pairs merged. 
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A1.5 Ketone 220 
 
CCDC 865615 contains the supplementary crystallographic data for ketone 220. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table A1.5 Crystallographic data for ketone 220. 
net formula C15H22O3 
Mr/g mol 1 250.333 
crystal size/mm 0.29 × 0.17 × 0.07 
T/K 173(2) 
Radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system monoclinic 
space group P21 
a/Å 9.6490(5) 
b/Å 5.8746(3) 
c/Å 12.3783(7) 
/° 90 
/° 107.487(6) 
/° 90 
V/Å3 669.22(6) 
Z 2 
calc. density/g cm 3 1.24233(11) 
/mm 1 0.085 
absorption correction 'multi-scan' 
transmission factor range 0.96533 1.00000 
refls. measured 4829 
Rint 0.0299 
mean σ(I)/I 0.0419 
θ range 4.20 26.33 
observed refls. 1167 
x, y (weighting scheme) 0.0412, 0 
hydrogen refinement constr 
Flack parameter 2.5(13) 
refls in refinement 1488 
parameters 165 
restraints 1 
R(Fobs) 0.0344 
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Rw(F2) 0.0732 
S 0.926 
shift/errormax 0.001 
max electron density/e Å 3 0.169 
min electron density/e Å 3 0.118 
 
Flack parameter meaningless. 741 Friedel pairs merged. Absolute structure deduced from synthesis. 
 
C2
C1
O1
O2
C3
C4
C5
C12
C6
C7
O3
C8
C14
C13
C15
C10
C11
C9
 
 
 
A1.6 Ketone ent-141 
 
CCDC 865614 contains the supplementary crystallographic data for ketone ent-141. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table A1.6 Crystallographic data for ketone ent-141. 
net formula C13H22O 
Mr/g mol 1 194.313 
crystal size/mm 0.15 × 0.14 × 0.04 
T/K 173(2) 
Radiation MoKα 
Diffractometer 'KappaCCD' 
crystal system monoclinic 
space group P21 
a/Å 7.2906(10) 
b/Å 6.4842(11) 
c/Å 13.310(2) 
α/° 90 
β/° 104.680(10) 
γ/° 90 
V/Å3 608.67(17) 
Z 2 
calc. density/g cm 3 1.0602(3) 
/mm 1 0.064 
absorption correction none 
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refls. Measured 2730 
Rint 0.0901 
mean σ(I)/I 0.0727 
θ range 3.63 23.63 
observed refls. 715 
x, y (weighting scheme) 0.0964, 0.0251 
hydrogen refinement constr 
Flack parameter 1(5) 
refls in refinement 974 
Parameters 130 
Restraints 1 
R(Fobs) 0.0686 
Rw(F2) 0.1868 
S 1.180 
shift/errormax 0.001 
max electron density/e Å3 0.190 
min electron density/e Å3 0.185 
 
Flack parameter meaningless, 589 Friedel pairs merged. Investigated crystal had poor scattering strength leading 
to reduced resolution. 
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A1.7 Ketone 222 
 
CCDC 865619 contains the supplementary crystallographic data for ketone 222. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table A1.7 Crystallographic data for ketone 222. 
net formula C15H24O3 
Mr/g mol 1 252.349 
crystal size/mm 0.23 × 0.20 × 0.11 
T/K 173(2) 
Radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system Orthorhombic 
space group P212121 
a/Å 5.8846(4) 
b/Å 9.0415(5) 
c/Å 26.2051(14) 
/° 90 
/° 90 
/° 90 
V/Å3 1394.26(14) 
Z 4 
calc. density/g cm 3 1.20219(12) 
/mm−1 0.082 
absorption correction 'multi-scan' 
transmission factor range 0.98145 1.00000 
refls. Measured 5778 
Rint 0.0359 
mean σ(I)/I 0.0470 
θ range 4.20 26.24 
observed refls. 1215 
x, y (weighting scheme) 0.0388, 0 
hydrogen refinement constr 
Flack parameter 1.5(14) 
refls in refinement 1665 
Parameters 166 
Restraints 0 
R(Fobs) 0.0361 
Rw(F2) 0.0738 
S 0.894 
shift/errormax 0.001 
max electron density/e Å 3 0.177 
min electron density/e Å 3 0.124 
 
Flack Parameter meaningless, 1256 Friedel pairs merged. Absolute structure derived from synthesis. 
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A1.8 Ketone 246 
 
CCDC 865616 contains the supplementary crystallographic data for ketone 246. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table A1.8 Crystallographic data for ketone 246. 
net formula C15H24O3 
Mr/g mol 1 252.349 
crystal size/mm 0.26 × 0.11 × 0.06 
T/K 173(2) 
Radiation MoKα 
Diffractometer 'KappaCCD' 
crystal system monoclinic 
space group P21 
a/Å 10.0211(5) 
b/Å 5.8555(2) 
c/Å 11.9154(6) 
/° 90 
/° 93.215(2) 
/° 90 
V/Å3 698.08(5) 
Z 2 
calc. density/g cm 3 1.20056(9) 
/mm 1 0.082 
absorption correction None 
refls. Measured 4457 
Rint 0.0240 
mean σ(I)/I 0.0351 
θ range 3.89 25.31 
observed refls. 2167 
x, y (weighting scheme) 0.0396, 0.1213 
hydrogen refinement Constr 
Flack parameter 0.7(12) 
refls in refinement 2417 
252  APPENDICES 
 
Parameters 185 
Restraints 2 
R(Fobs) 0.0392 
Rw(F2) 0.0970 
S 1.148 
shift/errormax 0.001 
max electron density/e Å 3 0.143 
min electron density/e Å 3 0.152 
 
Flack test results meaningless, no anomalous scatterer in structure. C14 and C15 are disordered, split model 
applied, sof ratio 0.58/0.42. Only the main part of the disordered group C14/C15 is shown is the figure: 
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A1.9 Epoxide 250 
 
CCDC 934938 contains the supplementary crystallographic data for epoxide 250. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table A1.9 Crystallographic data for epoxide 250. 
net formula C15H24O3 
Mr/g mol 1 252.349 
crystal size/mm 0.33 × 0.09 × 0.07 
T/K 173(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system orthorhombic 
space group P212121 
a/Å 5.88880(10) 
b/Å 14.6273(4) 
c/Å 16.5099(4) 
/° 90 
/° 90 
/° 90 
V/Å3 1422.12(6) 
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Z 4 
calc. density/g cm 3 1.17864(5) 
/mm 1 0.080 
absorption correction None 
refls. Measured 9872 
Rint 0.0312 
mean σ(I)/I 0.0265 
θ range 3.72 26.00 
observed refls. 2449 
x, y (weighting scheme) 0.0613, 0.3685 
hydrogen refinement constr 
Flack parameter 0.2(13) 
refls in refinement 2785 
parameters 166 
restraints 0 
R(Fobs) 0.0450 
Rw(F2) 0.1169 
S 1.047 
shift/errormax 0.001 
max electron density/e Å 3 0.368 
min electron density/e Å 3 0.258 
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A1.10 Ketone 191 
 
CCDC 865617 contains the supplementary crystallographic data for ketone 191. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table A1.10 Crystallographic data for ketone 191. 
net formula C19H36O2Si 
Mr/g mol 1 324.573 
crystal size/mm 0.31 × 0.29 × 0.15 
T/K 173(2) 
Radiation MoKα 
Diffractometer 'Oxford XCalibur' 
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crystal system orthorhombic 
space group P212121 
a/Å 6.1373(2) 
b/Å 10.5263(4) 
c/Å 30.6532(13) 
/° 90 
/° 90 
/° 90 
V/Å3 1980.29(13) 
Z 4 
calc. density/g cm 3 1.08868(7) 
 /mm 1 0.124 
absorption correction 'multi-scan' 
transmission factor range 0.93992 1.00000 
refls. Measured 15263 
Rint 0.0421 
mean σ(I)/I 0.0564 
θ range 4.25–26.35 
observed refls. 3138 
x, y (weighting scheme) 0.0376, 0 
hydrogen refinement constr 
Flack parameter 0.00(11) 
refls in refinement 3991 
parameters 207 
restraints 0 
R(Fobs) 0.0344 
Rw(F2) 0.0720 
S 0.920 
shift/errormax 0.001 
max electron density/e Å 3 0.200 
min electron density/e Å 3 0.170 
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A1.11 Lactone 291 
 
CCDC 934939 contains the supplementary crystallographic data for lactone 291. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table A.11 Crystallographic data for lactone 291. 
net formula C17H28O3 
Mr/g mol−1 280.402 
crystal size/mm 0.33 × 0.20 × 0.15 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system orthorhombic 
space group P212121 
a/Å 9.1321(9) 
b/Å 11.8589(12) 
c/Å 15.1809(15) 
/° 90 
/° 90 
/° 90 
V/Å3 1644.0(3) 
Z 4 
calc. density/g cm 3 1.1329(2) 
/mm 1 0.076 
absorption correction 'multi-scan' 
transmission factor range 0.75017 1.00000 
refls. Measured 5560 
Rint 0.0337 
mean σ(I)/I 0.0342 
θ range 4.31–26.10 
observed refls. 1655 
x, y (weighting scheme) 0.0545, 0.1445 
hydrogen refinement Constr 
Flack parameter 1.1(15) 
refls in refinement 1869 
Parameters 186 
Restraints 0 
R(Fobs) 0.0400 
Rw(F2) 0.1031 
S 1.060 
shift/errormax 0.001 
max electron density/e Å 3 0.167 
min electron density/e Å 3 0.199 
 
Flack parameter meaningless, 1386 Friedel pairs merged, correct structure deduced from synthesis. 
 
256  APPENDICES 
 
 
 
A1.12 Carbamate 443 
 
CCDC 934937 contains the supplementary crystallographic data for carbamate 443. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Table A1.12 Crystallographic data for carbamte 443. 
net formula C20H25BrN2O5 
Mr/g mol 1 453.327 
crystal size/mm 0.31 × 0.22 × 0.16 
T/K 173(2) 
Radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system orthorhombic 
space group P212121 
a/Å 5.9917(2) 
b/Å 9.7824(4) 
c/Å 36.0498(14) 
/° 90 
/° 90 
/° 90 
V/Å3 2112.99(14) 
Z 4 
calc. density/g cm 3 1.42505(9) 
/mm 1 1.978 
absorption correction 'multi-scan' 
transmission factor range 0.93697–1.00000 
refls. Measured 8750 
Rint 0.0340 
mean σ(I)/I 0.0838 
θ range 4.17 26.33 
observed refls. 2799 
x, y (weighting scheme) 0.0131, 0 
hydrogen refinement mixed 
Flack parameter 0.013(6) 
refls in refinement 4003 
parameters 259 
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restraints 1 
R(Fobs) 0.0300 
Rw(F2) 0.0433 
S 0.800 
shift/errormax 0.001 
max electron density/e Å 3 0.469 
min electron density/e Å 3 0.329 
 
C-bound H: constr., N-bound H: distance fixed to 0.88(1) Å, U(H) = 1.2 U(N). 
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260  APPENDICES 
 1H NMR (CDCl3, 300 MHz): 
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13C NMR (CDCl3, 75 MHz): 
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1H NMR (CDCl3, 300 MHz):  
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13C NMR (CDCl3, 75 MHz): 
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1H NMR (CDCl3, 300 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 75 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot-Bu
O
Me
203
C14H22O2
M = 222.32 g/mol
A2 1H and 13C NMR Spectra  263 
1H NMR (CDCl3, 300 MHz): 
 
 
13C NMR (CDCl3, 75 MHz): 
 
Ot -Bu
O
Me
205
C15H22O4
M = 266.33 g/mol
COOH
264  APPENDICES 
1H NMR (CDCl3, 400 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
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00
 
 
13C NMR (CDCl3, 100 MHz): 
 
Ot-Bu
O
Me
207
C14H24O2
M = 224.34 g/mol
H
A2 1H and 13C NMR Spectra  265 
1H NMR (CDCl3, 300 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
 
13C NMR (CDCl3, 75 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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OH
O
Me
208
C10H16O2
M = 168.23 g/mol
H
266  APPENDICES 
1H NMR (CDCl3, 400 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 100 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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OHMe
210
C12H20O3
M = 212.29 g/mol
H
O
O
A2 1H and 13C NMR Spectra  267 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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OMe
195
C12H18O3
M = 210.27 g/mol
H
O
O
268  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220
f1 (ppm)
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OMe
194
C12H16O3
M = 208.25 g/mol
H
O
O
A2 1H and 13C NMR Spectra  269 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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O
H
O
O
O
Me
217
C12H16O4
M = 224.25 g/mol
270  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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OMe
220
C15H22O3
M = 250.33 g/mol
H
O
O
A2 1H and 13C NMR Spectra  271 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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OMe
222
C15H24O3
M = 252.35 g/mol
H
O
O
272  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Me
224
C15H26O3
M = 254.37 g/mol
H
O
O
OH
A2 1H and 13C NMR Spectra  273 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.012.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)  
Me
H
O
227
C22H30O4S
M = 390.54 g/mol
O
O
OPh
S
274  APPENDICES 
1H NMR (CD2Cl2, 400 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CD2Cl2, 100 MHz): 
0102030405060708090100110120130140150160170180190200210220
f1 (ppm)
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Me
225
C15H24O2
M = 236.35 g/mol
H
O
O
A2 1H and 13C NMR Spectra  275 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Me
232
C15H26O3
M = 254.37 g/mol
H
O
O
OH
276  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Me
H
O
O
OH
233
C15H26O3
M = 254.37 g/mol
A2 1H and 13C NMR Spectra  277 
1H NMR (CD2Cl2, 400 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CD2Cl2, 100 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)  
Me
H
239
C15H24O3
M = 252.35 g/mol
O
O
O
H
H
278  APPENDICES 
1H NMR (CDCl3, 400 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.012.513.013.514.0
f1 (ppm)  
 
13C NMR (CDCl3, 100 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Me
H
240
C15H26O4
M = 270.35 g/mol
O
O
OH
OH
A2 1H and 13C NMR Spectra  279 
1H NMR (C6D6, 400 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (C6D6, 100 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Me
H
242
C15H24O4S
M = 312.42 g/mol
O
O
O
O SH
H
280  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220
f1 (ppm)
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Me
ent-141
C13H22O
M = 194.31 g/mol
H
O
A2 1H and 13C NMR Spectra  281 
1H NMR (CD2Cl2, 400 MHz): 
0.51.01.52.02.53.03.54.04.55.05.56.06.5
f1 (ppm)  
 
13C NMR (CDCl2, 100 MHz): 
-100102030405060708090100110120130140150160170180190200210220
f1 (ppm)  
Me
245
C15H22O2
M = 234.33 g/mol
H
O
O
282  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220
f1 (ppm)
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OMe
246
C15H24O3
M = 252.35 g/mol
H
O
O
A2 1H and 13C NMR Spectra  283 
1H NMR (CD2Cl2, 400 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CD2Cl2, 100 MHz): 
0102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Me
221
C15H24O2
M = 236.35 g/mol
H
O
O
284  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
0102030405060708090100110120130140150160170180190200210220
f1 (ppm)
17
.3
5
21
.8
1
24
.2
4
31
.5
0
40
.0
7
47
.6
2
57
.7
0
62
.7
4
64
.3
3
64
.5
5
11
0.
06
 
Me
H
250
C15H24O3
M = 252.35 g/mol
O
O
O
H
H
A2 1H and 13C NMR Spectra  285 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
0102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Me
192
C15H26O3
M = 254.37 g/mol
H
O
O
OH
286  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3,150 MHz): 
-100102030405060708090100110120130140150160170180190200210220
f1 (ppm)
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Me
251
C15H26O3
M = 254.37 g/mol
H
O
O
OH Me
H
O
O
OH
7.1 : 1
192
A2 1H and 13C NMR Spectra  287 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Me
255
C13H22O2
M = 210.31 g/mol
H
OH
O
288  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220
f1 (ppm)
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Me
256
C13H22O2
M = 210.31 g/mol
H
O
OH
A2 1H and 13C NMR Spectra  289 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220
f1 (ppm)
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Me
191
C19H36O2Si
M = 324.57 g/mol
H
OTBS
O
290  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220
f1 (ppm)
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Me
257
C15H26O2
M = 238.37 g/mol
H
O
O
A2 1H and 13C NMR Spectra  291 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Me
190
C13H22O
M = 194.31 g/mol
H
O
292  APPENDICES 
1H NMR (CDCl3, 100 MHz): 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 75 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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273
C14H22O2
M = 222.32 g/mol
Ot -Bu
O
Me
H
A2 1H and 13C NMR Spectra  293 
1H NMR (CDCl3, 600 MHz): 
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.012.513.013.514.0
f1 (ppm)  
 
13 C NMR (CDCl3, 100 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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276
C16H26O4
M = 282.38 g/mol
Ot -Bu
HO
Me
H
MeO
O
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1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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280
C17H28O2
M = 264.40 g/mol
Ot -Bu
O
Me
H
H
A2 1H and 13C NMR Spectra  295 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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286
C17H30O2
M = 266.42 g/mol
Ot -Bu
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Me
H
H
296  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
0102030405060708090100110120130140150160170180190200210220
f1 (ppm)
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288
C17H30O2
M = 266.42 g/mol
Ot -Bu
HO
Me
H
H
A2 1H and 13C NMR Spectra  297 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot-BuMe
290
C16H26O3
M = 266.38 g/mol
H
O
H
H
O
298  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot-BuMe
291
C17H28O3
M = 280.40 g/mol
H
O
Me H
H
O
A2 1H and 13C NMR Spectra  299 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot-Bu
HO
Me
H
Me
H
EtOOC
295
C21H36O4
M = 352.51 g/mol
300  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
 
Ot-Bu
HO
Me
H
HO
Me
H
296
C17H32O3
M = 284.43 g/mol
A2 1H and 13C NMR Spectra  301 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot-Bu
Et3SiO
Me
H
Et3SiO
Me
H
297
C29H60O3Si2
M = 512.96 g/mol
302  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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298
C23H44O3Si
M = 296.68 g/mol
Ot -Bu
O
Me
H
O
Me
H
SiEt3
H
A2 1H and 13C NMR Spectra  303 
1H NMR (CDCl3, 600 MHz):  
 
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)  
Ot-Bu
Et3SiO
Me
H
Me
H
299
C24H46O2Si
M = 394.71 g/mol
304  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)  
Ot -BuMe
H
Et3SiO
H
Me
HO
300
C24H48O3Si
M = 412.72 g/mol
A2 1H and 13C NMR Spectra  305 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot-BuMe
H
HO
H
Me
HO
458
C18H34O3
M = 298.46 g/mol
306  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220
f1 (ppm)  
Ot-BuMe
H
O
H
Me
O
H
301
C18H30O3
M = 294.43 g/mol
A2 1H and 13C NMR Spectra  307 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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O
Me
H
H
OTBS
302
C22H40O2Si
M = 364.64 g/mol
308  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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HO
Me
H
H
OTBS
303
C22H42O2Si
M = 366.65 g/mol
A2 1H and 13C NMR Spectra  309 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220
f1 (ppm)
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Me
H
O
H
H
O
304
C21H38O3Si
M = 366.61 g/mol
OTBS
310  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
0102030405060708090100110120130140150160170180190200210220
f1 (ppm)
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Me
H
O
H
H
O
269
C22H40O3Si
M = 380.64 g/mol
OTBS
Me
A2 1H and 13C NMR Spectra  311 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220
f1 (ppm)
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Et3SiO
Me
H
Et3SiO
Me
H
OTBS
305
C34H72O3Si3
M = 613.19 g/mol
312  APPENDICES 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Et3SiO
Me
H
Me
H
OTBS
268
C29H58O2Si2
M = 494.94 g/mol
A2 1H and 13C NMR Spectra  313 
 
1H NMR (CDCl3, 300 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 75 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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IEt3SiO
308
C12H25IOSi
M = 340.32 g/mol
314      APPENDICES 
 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot-BuMe
H
O
H
Me
OSiEt3 311
C36H72O3Si2
M = 609.13 g/mol
SiEt3
A2 1H and 13C NMR Spectra  315 
 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
5.
48
7.
23
11
.1
4
16
.1
6
25
.5
3
31
.5
7
37
.3
9
42
.3
8
42
.5
6
42
.7
2
69
.9
2
72
.3
1
80
.9
9
12
6.
36
13
2.
50
20
2.
84
 
Ot-BuMe
H
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O
SiEt3H
312
C30H56O3Si
M = 492.85 g/mol
316      APPENDICES 
 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot-BuMe
H
O
H
Me
SiEt3
317
C31H58O2Si
M = 490.88 g/mol
A2 1H and 13C NMR Spectra  317 
 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot-BuMe
H
HO
H
Me
318
C25H44O2
M = 376.62 g/mol
318      APPENDICES 
 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot-BuMe
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Me
319
C25H42O2
M = 374.60 g/mol
A2 1H and 13C NMR Spectra  319 
 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot -BuMe
H
HO
H
Me
320
C28H48O2
M = 416.68 g/mol
320      APPENDICES 
 
1H NMR (CDCl3, 400 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 100 MHz): 
0102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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PMBO I
330
C14H19IO2
M = 346.20 g/mol
A2 1H and 13C NMR Spectra   321 
 
1H NMR (CDCl3, 300 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 75 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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331
C18H32O2
M = 280.45 g/mol
Ot-Bu
HO
Me
H
Me
H
322      APPENDICES 
 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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332
C18H30O2
M = 278.43 g/mol
Ot-Bu
O
Me
H
Me
H
A2 1H and 13C NMR Spectra   323 
 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
0102030405060708090100110120130140150160170180190200210220
f1 (ppm)
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333
C32H50O4
M = 498.74 g/mol
Ot-BuMe
H
Me
H
OH
PMBO
324      APPENDICES 
 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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334
C24H42O3
M = 378.59 g/mol
Ot-BuMe
H
Me
H
OH
HO
A2 1H and 13C NMR Spectra   325 
 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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337
C25H40O2
M = 372.58 g/mol
Ot-BuMe
H
Me
H
OH
326      APPENDICES 
 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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340
C40H76O2SiSn
M = 735.83 g/mol
Ot-BuMe
H
Me
H
TMS
SnBu3
OH
A2 1H and 13C NMR Spectra   327 
 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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342
C28H49IO2Si
M = 572.68 g/mol
Ot-BuMe
H
Me
H
TMS
I
OH
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1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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343
C29H52O2Si
M = 460.81 g/mol
Ot-BuMe
H
Me
H
TMS
OH
A2 1H and 13C NMR Spectra   329 
 
1H NMR (CDCl3, 600 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot -BuMe
H
HO
H
Me
TBDPSO
346
C34H52O3Si
M = 536.86 g/mol
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1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot -BuMe
H
O
H
Me
TBDPSO
347
C34H50O3Si
M = 534.85 g/mol
A2 1H and 13C NMR Spectra   331 
 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot-BuMe
H
H
Me
PMBO
OH
348
C48H70O5Si
M = 755.15 g/mol
TBDPSO
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1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot-BuMe
H
H
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HO
OH
TBDPSO
349
C40H62O4Si
M = 635.00 g/mol
A2 1H and 13C NMR Spectra   333 
 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ot-BuMe
H
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350
C41H60O3Si
M = 629.00 g/mol
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1H NMR (CDCl3, 300 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 75 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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IEt3SiO
357
C10H21IOSi
M = 312.26 g/mol
A2 1H and 13C NMR Spectra  335 
 
 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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359
C22H40O3
M = 352.55 g/mol
Me
HO
H
H
Me Ot -Bu
HO
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1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
102030405060708090100110120130140150160170180190
f1 (ppm)
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360
C27H48O4
M = 436.67 g/mol
Me
PivO
H
H
Me Ot-Bu
HO
A2 1H and 13C NMR Spectra  337 
 
 
1H NMR (CDCl3, 600 MHz):  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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361
C27H46O4
M = 434.65 g/mol
Me
PivO
H
H
Me Ot-Bu
O
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1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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ITBSO
364
C10H21IOSi
M = 312.26 g/mol
A2 1H and 13C NMR Spectra  339 
 
 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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365
C37H68O5Si
M = 621.02 g/mol
Me
OTBSPivO
H
OH H
Me Ot-Bu
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1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Me
OTBSHO
H
OH H
Me Ot-Bu
366
C32H60O4Si
M = 536.90 g/mol
A2 1H and 13C NMR Spectra  341 
 
 
1H NMR (CDCl3, 600 MHz): 
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Me
OTBSp-tolO2S
H
OH H
Me Ot-Bu
367
C39H66O5SSi
M = 675.09 g/mol
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1H NMR (CDCl3, 300 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 75 MHz): 
0102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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OPMB
I
378
C13H15IO2
M = 330.16 g/mol
A2 1H and 13C NMR Spectra   343 
 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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H
Me Ot-BuPMBO
Me
H
379
C37H62O4Si
M = 598.97 g/mol
Et3SiO
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1H NMR (CDCl3, 600 MHz): 
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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382
C31H46O4
M = 482.69 g/mol
A2 1H and 13C NMR Spectra   345 
 
1H NMR (CDCl3, 600 MHz): 
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)
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13C  NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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H
Me Ot-BuMeO
Me
H
HO
single diastereomer,
relative configuration
not assignable
380
C24H42O3
M = 378.59 g/mol
*
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1H NMR (CDCl3, 600 MHz): 
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)
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13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220
f1 (ppm)
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H
Me Ot-BuMeO
Me
H
O
single diastereomer,
relative configuration
not assignable
385
C24H40O3
M = 376.57 g/mol
*
A2 1H and 13C NMR Spectra  347 
 
1H NMR (CDCl3, 400 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 100 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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399
C13H13NO3
M = 231.25 g/mol
O
N
O
O
Ph
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1H NMR (CDCl3, 400 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 100 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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400
C7H19NO3
M = 273.33 g/mol
OMe
N
O
O
Ph
A2 1H and 13C NMR Spectra  349 
 
1H NMR (CDCl3, 400 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 100 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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Ph
ONO
O
Ph
Me
401
C29H32N2O6
M = 504.57 g/mol
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1H NMR (CDCl3, 400 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 100 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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OMe
402
C9H17NO2
M = 171.24 g/mol
N
O
A2 1H and 13C NMR Spectra  351 
 
1H NMR (CD2Cl2, 400 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CD2Cl2, 100 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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OMe
404
C7H12O2
M = 128.17 g/mol
OH
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1H NMR (CDCl3, 300 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 75 MHz): 
0102030405060708090100110120130140150160170180190200210220
f1 (ppm)
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N
O
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Me
OH
Me
392
C17H25NO2
M = 275.39 g/mol
3.6:1 mixture
of rotamers
A2 1H and 13C NMR Spectra  353 
 
1H NMR (CDCl3, 400 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)  
HO O
Me
H
407
C13H22O3
M = 226.31 g/mol
O
H
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1H NMR (CDCl3, 600 MHz):  
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
102030405060708090100110120130140150160170180190200210
f1 (ppm)
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HO O
OH
Me
H
408
C16H28O3
M = 268.39 g/mol
d.r. ≈ 1:1
A2 1H and 13C NMR Spectra  355 
 
1H NMR (CDCl3, 600 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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1H NMR (CDCl3, 600 MHz):  
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1H NMR (CDCl3, 300 MHz):  
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)  
 
13C NMR (CDCl3, 75 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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1H NMR (CDCl3, 600 MHz):  
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13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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1H NMR (CDCl3, 300 MHz):  
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)  
 
13C NMR (CDCl3, 75 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)  
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1H NMR (CDCl3, 600 MHz):  
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1H NMR (CDCl3, 600 MHz):  
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13C NMR (CDCl3, 150 MHz): 
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
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1H NMR (CDCl3, 600 MHz): 
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1H NMR (CDCl3, 300 MHz):  
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1H NMR (CDCl3, 300 MHz):  
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f1 (ppm)  
 
13C NMR (CDCl3, 75 MHz): 
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f1 (ppm)
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1H NMR (CDCl3, 600 MHz):  
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13C NMR (CDCl3, 150 MHz): 
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1H NMR (CDCl3, 600 MHz):  
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13C NMR (CDCl3, 150 MHz): 
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